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Background: Multiple sclerosis (MS) is a neurological disorder and the most frequent neurological 
cause of disability in young adults. 40-65% of MS patients experience cognitive difficulties 
(Bennedict et al., 2012), with problems in memory, attention and information processing speed being 
most frequently reported. However, visuoperceptual and language functions are much less studied in 
MS, but the few studies that looked into them (Vleugels, 2001; Grossman, 1995) have found 
prevalence of significant posterior deficits in MS.  Up to today no study has investigated the domain-
specificity of cognitive dysfunction in MS and its longitudinal progression.  
Aims: The primary aim of this project was to investigate the dimensionality of MS-related cognitive 
impairment longitudinally. The second aim was to determine the predictors of the observed 
longitudinal changes. The third aim was to investigate whether the participants themselves were 
aware of their cognitive changes, and what predicted the self-perception of change. 
Methods: To address these aims I followed a sample of MS patients and compared their performance 
on cognitive tests measuring five cognitive domains (verbal memory, visuospatial memory, 
processing speed, visuoperceptual and language) at baseline and at follow-up three years apart. Then 
I’ve composed separate models to explain the predictors first of the actual changes, and then of the 
perceived changes in performance. Moreover, as part of this project I have analysed pre-existing data 
to evaluate the instruments and optimized the baseline test battery for use in performing the follow-
up assessments.  
Findings: I have managed to collect follow-up data on 82 MS patients and 23 matching healthy 
controls, acquiring high (76% and 79% respectively) recruitment rates. My MS sample (24% PPMS, 
34% SPMS and 46% RRMS) was representable of the overall MS population. I found that deficits 
were seen in all cognitive domains (none were spared) and that new deficits were picked up 
sporadically, although with higher predisposition towards the information processing speed, 
visuoperceptual and memory domains. The new deficits showed the tendency to slowly accumulate, 
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leading to development of major problems with longer disease duration. Interestingly it was found 
that even though the factors that influenced cognitive decline were specific for each of the cognitive 
domains, however, neurological disability, MS type and levels of depression were the most common 
predictors of change in cognitive functioning. I found that in general MS patients perceived 
longitudinal changes on the BRBN battery more accurately than on visuoperceptual and language 
tests, and the factors that played a role in the self-perception of change were executive dysfunction, 
neurological disability and MS impact. 
Implications: The results of this study add significant contribution to the field of longitudinal change 
in cognition in MS. Not only I explored the dimensionality of MS-related cognitive deficits, but also 
examined the factors that led to poorer performance, and the patients’ own perspective of their 
cognitive change. Moreover, with this project I have addressed common problems in the field of 
longitudinal research in MS – definition of normal variation in performance; the sensitivity of 
cognitive tests to pick up MS-related deficits; and heterogeneity of cognitive impairments in MS; - 
and I have used the performance of my own controls in attempts to account for all of that. I believe 
that this study will be of interest not only to those who specialize in cognitive functioning in MS, but 
also to those who question the methods employed in clinical research to define impairments and to 
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Chapter One. Introduction - literature review and implications for 
the current study  
 
1.1. Multiple Sclerosis 
1.1.1. MS definition, causes, prevalence, life expectancy, and cost 
I. MS definition 
Multiple sclerosis (MS) is a chronic neurodegenerative disorder, caused mainly by autoimmune 
destruction of the myelin sheath around the neurons in the central nervous system. It is the most 
frequent demyelinating disease and a leading cause for permanent disability in young adults. MS is 
characterized by a variable disease course that causes problems with bodily functions, movement, 
and cognition. Most often MS symptoms follow a pattern of relapses with near-complete recovery, 
followed by gradual progressive accumulation of neurological deficits. 
II. MS causes 
The cause of MS is currently unknown, and is likely associated with genetics as well as multiple 
environmental factors, such as geographical latitude, sunlight exposure, vitamin D deficiency and 
certain viruses (Milo & Kahana, 2010). None of the causes by themselves appear to be sufficient for 
the development of MS, and MS is likely to be caused by the complex interaction of all of these 
factors (Pryse-Phillips, 2001).  
III. MS prevalence and life expectancy 
It is estimated that 2.5 million people globally have MS with a prevalence of 30 in 100 000 people; 
and Scotland is among the countries with the highest prevalence in the world with 188 in 100 000 
people in population (Kingwell et al., 2013). MS is 2.4 times more common in women than in men, 
with the prevalence reaching 285.5 per 100 000 in women and 113.1 per 100 000 in men in UK 
(Mackenzie, Morant, Bloomfield, MacDonald, & O'riordan, 2014). This gender discrepancy in 
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prevalence is greatest in patients with relapsing-remitting type of MS, and almost non-existent in 
primary progressive type (Noseworthy et al., 2000). 
MS is typically diagnosed between ages 20 and 60 with peak incidence occurring around age 40 
(Mackenzie, et al., 2014). The median survival is 35 to 42 years after diagnosis (Poser, Kurtzke, 
Poser, & Schlaf, 1989), leading patients with MS (pwMS) to have six to seven years shorter life 
expectancy than the general population (Sadovnick, Ebers, Wilson, & Paty, 1992).  
IV. MS cost 
MS has the tendency to strike during the prime employment years and is associated with great costs 
to the individual and society, ranging from 8 528 to 54 244 USD per patient per year in medical, non-
medical and indirect costs (Adelman, Rane, & Villa, 2013), such as the patient having to medically 
retire and the partner (or parent or child) having to take time off work to take care of the patient.  
1.1.2. Diagnosis of MS – pathology and symptoms 
Currently in clinical practice MS is diagnosed following the guidelines of the revised McDonald 
Criteria (Polman et al., 2011) that involves clinical examination of MS symptoms and MS pathology.  
I. MS pathology 
The examination of MS pathology consists of the analysis of Magnetic Resonance Imaging (MRI) 
and cerebrospinal fluid data.  
On MRI, pwMS exhibit multifocal lesions, most often in the white matter of periventricular, brain 
stem, cerebellum, and spinal cord areas. The distribution, as well as the rate of acquiring the lesions 
is very heterogeneous. On occasions when there is diagnostic uncertainty about the rate of MS 
activity, repeated MRI after several months can provide evidence that MS is active and the lesions 
are disseminated in time (Noseworthy et al., 2000). While MS is traditionally considered an 
inflammatory, white matter disease, degeneration of gray matter is increasingly recognized as a 
primary contributor to progressive cognitive decline (Trapp & Nave, 2008), and can occur 
independently (Frischer et al., 2009) 
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In MS diagnostics cerebrospinal fluid analysis is used to pick up increased intrathecal synthesis of 
immunoglobulins with moderate lymphocytic pleocytosis (Noseworthy et al., 2000), that indicate 
presence of auto-immune mechanisms. Presence of auto-immune reactions are considered to be the 
evidence of the immune system attacks on the nerve cells and the demyelinating processes that cause 
the MS symptoms. 
II. MS symptoms 
Besides the pathological markers, currently MS is diagnosed and classified based on the spontaneous 
presentation of symptoms that appear suddenly over the course of several days, last for usually short 
periods of time (from a few days to a few months), until complete or at least partial recovery, and 
remain symptom-free for months or years. These spontaneous attacks are defined as relapses and the 
recoveries as remissions (Miller, 2001). Each new relapse results from an attack on the white matter 
of the central nervous system, and depending on its location in the areas of the brain or the spinal 
cord, it can cause very different symptoms. During a relapse the patient may experience new 
symptoms or an increase in existing symptoms. 
The most common MS physical symptoms experienced by the patients consist of weakness; stiffness; 
paralysis; tremor; fatigue; disturbances in coordination, gait and vision; difficulties swallowing and 
speaking; disruption of bladder and bowel functions, and sexual dysfunction; sensory changes and 
heat sensitivity; and psychiatric and cognitive problems (Miller, 2001). The expression of MS 
symptoms is very heterogeneous, causing the patients to suffer from a very individual mixture of 
various symptoms that range in their order of accumulation and severity as well. 
1.1.3. MS subtypes 
Due to the heterogeneity and individual variation of MS symptoms, in clinical practice the patients 
are grouped based on their MS subtype rather than on their symptoms (Chelune, Stott, & Pinkston, 
2008). The classification of MS subtypes is based on consensus and relies on the clinical descriptors 
of the course of the disease based on current status and history. Nowadays MS is most often classified 
into relapsing-remitting (RRMS), secondary-progressive (SPMS), and primary progressive (PPMS) 
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(Lublin et al., 2014). The disease onset and clinical course are highly variable and mostly 
unpredictable.  
The majority of patients (around 80%) start with a RRMS course, which is characterised by a pattern 
of clinical attacks (relapses) from which the patient essentially recovers (remissions), and there’s 
relative stability between the attacks (Figure 1.1). Few patients with RRMS do extremely well, with 
seldom exacerbations and little deterioration, but the majority (around 60%) of people with RRMS 
after a while start accumulating symptoms progressively, either with or without occasional relapses. 
This subtype of MS is termed SPMS.  
Figure 1.1. An illustration of relapses and progression of MS symptoms in RRMS, SPMS and PPMS 
over time 
 
Note. Image adapted from Multiple Sclerosis Association of America website 




However, there’s a subgroup of patients (around 15%) who develop PPMS.  This course of MS is 
defined by continuous worsening of symptoms and progressing disability without distinct relapses. 
The beginning of PPMS is typically around age 40, which is around 10 years later than the start of 
RRMS, but around the same age as the transition from RRMS to SPMS happens (Thompson et al., 
2000). On occasions, PPMS progresses very rapidly, reducing a patient to helpless dependency or 
death soon after disease onset.  
Besides the relatively common RRMS, SPMS and PPMS, other type of MS exists, called 
progressive-relapsing MS (PRMS). PRMS is characterized by steadily progressing disease from the 
beginning and occasional exacerbations along the way. People with this form of MS may or may not 
experience some recovery following these attacks; the disease continues to progress without 
remissions (Lublin, et al., 2014). 
Another term commonly used in MS staging is the clinically isolated syndrome (CIS) (Lublin et al., 
2014). CIS is recognised as the first clinical presentation of the disease that shows characteristics of 
inflammatory demyelination that could be MS, but has yet to fulfil criteria of dissemination in time. 
However, PRMS and CIS are much less common and most research focuses on RRMS, SPMS and 
PPMS types only. 
1.2.    Cognitive dysfunction in MS 
In addition to the physical symptoms, around 45- to 65-percent of pwMS experience cognitive 
symptoms as well. These typically involve deficits of speed of information processing; attention and 
concentration; memory; and executive functions (DeSousa, Albert, & Kalman, 2002). Although 
cognitive dysfunction is one of the most prominent symptoms associated with MS as it occurs in 
over half of the patients, it is often less severe than those seen in other neurodegenerative disorders 
in which dementia is prominent (such as Alzheimer’s disease (AD) or Fronto-temporal dementia 
(FTD) (Filley, Heaton, Nelson, Burks, & Franklin, 1989). In MS cognitive dysfunction is probably 
the most important determinant of employment status and associated societal costs, and also 
adversely affects everyday tasks, such as driving safety; household task completion; social activity; 
physical independence; rehabilitation progress; coping; treatment adherence; and mental health 
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(Langdon, 2011). Furthermore, patients’ cognitive impairment is one of the leading sources of 
caregiver strain (Chipchase, 2001), making other MS symptoms more difficult to manage. 
Data on the prevalence of cognitive deficits in pwMS varies with MS subtypes and tests performed 
(Chelune, Stott, & Pinkston, 2008), and the basic constituents of cognitive dysfunction in multiple 
sclerosis are still under debate. The frequency and pattern of cognitive functions affected vary 
considerably between and within patients, since it is hypothesized to typically consist of differently 
intermingled domain-specific deficits rather than of a uniform overall cognitive decline. This could 
potentially be due primarily to the heterogeneity of the disease in its extent, its location and the 
dynamics of its pathological processes (Hoffmann, Tittgemeyer, & von Cramon, 2007). 
Because of the many ways in which the lesions can manifest in the brain, pwMS can have their 
cognition affected in many ways, therefore this is why a neuropsychological examination of these 
patients requires assessment of a variety of functions (Lezak, 2004). Due to the heterogeneity and 
lack of clear definition of cognitive deficits in MS, patients seen in MS clinics and neurologic 
practices are not routinely assessed neuropsychologically.  
1.2.1.       Information processing speed and attention 
Many pwMS report feeling mentally slowed down, and find it difficult to concentrate and keep up 
with the pace of normal conversations. Measures of information-processing speed appear to be the 
most robust and sensitive markers of cognitive impairment in multiple sclerosis patients. Recent 
studies demonstrate that single, predominantly speed-related cognitive tests may be superior to 
extensive and time-consuming test batteries in screening overall cognitive decline (Hoffmann et al., 
2007). 
Impaired processing speed is a classic finding in MS, irrespective to the modality of stimulus 
presentation (auditory or visual) (DeLuca, Chelune, Tulsky, Lengenfelder, & Chiaravalloti, 2004), 
and is considered to be independent of motor involvement (Rao, Aubin-Faubert, & Leo, 1989). 
Moreover, other studies have found that information processing speed deficits tend to be separate 
from attentional deficits as MS patients can often perform at the same level of accuracy as the 
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controls if the stimuli are presented at a sufficiently slow rate or if the task is self-paced (Demaree, 
DeLuca, Gaudino, & Diamond, 1999; Lengenfelder et al., 2006).  
Processing speed is often considered to be the initial symptom of MS-related cognitive deficit, that 
later with progression of the disease contributes to working memory and long-term memory 
impairment in pwMS (Archibald & Fisk, 2000; Litvan, Grafman, Vendrell, & Martinez, 1988). Some 
MS-type differences exist with general slowing appearing to be highest in the progressive types of 
MS (50%) and less prominent in the RRMS (24%) (De Sonneville et al., 2002). 
Regardless of disease status, most MS patients exhibit deficits on attention tasks with greater stimulus 
or response complexity, and those requiring inhibition of previously correct response (Paul, Beatty, 
Schneider, Blanco, & Hames, 1998), shifting attention back and forth from one stimulus to another 
(Grigsby, Kaye, & Busenbark, 1994) and dual-tasking (D'Esposito et al., 1996).  
1.2.2.       Memory and learning 
PwMS often report problems with explicit memory, such as remembering recent events, times of 
appointments, and names of people and objects. This deficit is more apparent for recent events rather 
than events from distant past and their semantic memory is often well preserved (Prakash, Snook, 
Lewis, Motl, & Kramer, 2008). Moreover, free recall is reported to tend to be poorer than cued recall, 
which in turn to be inferior to recognition (Thornton & Raz, 1997). Therefore the memory 
impairment among pwMS is argued to be a consequence of inadequate initial learning and not a 
function of impaired retrieval (Chiaravalloti, Balzano, Moore, & DeLuca, 2009; DeLuca, Barbieri-
Berger, & Johnson, 1994). As previous studies suggest, the impaired encoding capacity could be 
partly explained by poor ability to activate mnemonic strategies, such as semantic clustering (Arnett 
et al., 1997) or visual imagery (Canellopoulou & Richardson, 1998). 
1.2.3. Executive functions 
MS patients are repeatedly reported to have problems with tasks involving cognitive estimation, 
planning, sequencing and problem solving (Arnett, et al., 1997; Foong et al., 1997). These deficits 
detrimentally affect many aspects of daily life, such as the ability to run a household, participate in 
8 
 
social events, and maintain employment—factors that can all affect the overall quality of life of the 
patient. Disorders of executive functioning commonly are linked to behavioural problems, such as 
apathy or disinhibition, and are often more apparent to family members than they are to the affected 
individual, resulting in persons close to the patient erroneously attributing these behaviours to 
personality features, such as disorganization or stubbornness (Benedict et al., 2000; Chiaravalloti & 
DeLuca, 2003), causing even more issues in social interactions at home or at work. 
Verbal fluency is often disrupted in MS, whether by reductions in processing speed, flexibility, 
search strategy, or access to semantic storage, and suggesting that measures of verbal fluency may 
be amongst the most sensitive neuropsychological measures to cognitive impairment in MS (Henry 
& Beatty, 2006). In addition, some studies report that phonemic fluency tasks are more sensitive to 
impairment than semantic category fluency tasks (Connick, Kolappan, Bak, & Chandran, 2012), 
however, in MS samples semantic category fluency has been more widely studied. 
1.2.4. Visuoperceptual functions 
Eye problems such as blindness, partial vision, blurring, or decrease in visual acuity, visual fields 
and colour perception, are common in MS and they are often caused by damage to the optic nerve. 
Besides problems with the peripheral vision, pwMS tend to have complaints about their vision that 
relate to damage to the higher level processing of visuoperceptual information. Any aspect of 
visuoperception may be disrupted, including facial perception (“knowing who”), visual form 
perception (“knowing what”) and visuospatial perception (“knowing where”) (Rao, Leo, Bernardin, 
& Unverzagt, 1991; Vleugels et al., 2000). 
For example, pwMS often report problems with processing visual information from reading and 
watching the television where they report being able to see the images, but to have difficulties 
processing their meaning. A more dangerous example is from family members expressing concern 
about patients who have visuospatial difficulties and tend to drive too close to the side of the road 
and have some “near misses” on the highway (Fischer, 2001). 
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1.2.5. Language functions 
In MS language functions are considered to typically remain intact except for those dependent on 
rapid and efficient retrieval (Lezak, 2004). Deficits in confrontation naming have been reported in 
MS, however, those deficits could be argued to be caused by disruption in retrieval rather than 
semantic storage, as phonemic cuing often facilitates retrieval in MS (Prakash, et al., 2008). 
Dysarthrias (difficulties articulating) are rare in MS, and if such severe language disturbances occur, 
they tend to be associated with damage to the brainstem and inability to perform movements 
involving the mouth, such as swallowing (Kurtzke, 1983), rather than linguistic problems. However, 
subtle language problems do tend to occur in MS, such as difficulties with comprehension of complex 
or ambiguous grammatical structures, which causes problems with keeping up with conversations 
(Grossman et al., 1995). Moreover, pwMS have been reported to have the tendency to generate verbal 
output with fewer information units per sentence, and fewer complete and grammatically correct 
sentences (Wallace & Holmes, 1993). These small difficulties in sentence generation can cause 
frustration and have detrimental effects on inter-personal communication at home and on work 
performance where the job involves verbal communication. 
1.2.6. Prevalence of impairment on different cognitive domains 
Currently it is estimated that around 40% of pwMS in the community samples (Rao et al., 1991) and 
around 50-60% of pwMS in hospital samples (Ron, Callanan, & Warrington, 1991) have some level 




Table 1.1. Prevalence of MS-related impairment on cognitive functions 
 
Domain of cognitive function Prevalence of severe impairment 
a 
Most commonly impaired 
 
Episodic memory 22-31% 
Complex attention/ processing speed 22-25% 
Verbal fluency 22% 
  
Impaired moderately often  
Executive functions 13-19% 
Visual perception 12-19% 
  
Less frequently impaired  
Language/ semantic memory 8-10% 
Attention span 7-8% 
a Severe impairment – performance below the 5th centile of demographically matched healthy 
controls. Table taken from Fisher (2001), with its contents adapted from Rao et al. (1991) 
 
1.2.7. Consensus approach to domain-specificity of cognitive impairment in MS 
Since the reported deficits in cognitive functioning of pwMS are highly heterogeneous, there have 
been systematic approaches to generalize and simplify the concept of MS-related cognitive 
impairment. 
The first attempt to systematically review current studies into cognitive deficits in MS was published 
by Janis M. Peyser, Stephen M. Rao, Nicholas G. LaRocca and Edith Kaplan in 1990. In their seminal 
paper they identified a problem that part of the reason why it was so difficult to define MS-related 
cognitive impairment, was the heterogeneity of research methods and samples employed in the 
neuropsychological studies. Therefore they aimed to uniform the methods in the research area by 
proposing a battery comprising of seventeen tests to assess all of the cognitive functions considered 
to be related to MS (Peyser, Rao, LaRocca, & Kaplan, 1990), including information processing speed, 
attention/concentration, memory, language, visuoperceptual and executive functions. In his attempts 
to shorten this battery, Stephen Rao has chosen to leave only the tests which he found most sensitive 
to MS, resulting in a five item test battery measuring verbal and visuospatial learning and memory, 
information processing speed, sustained attention, and verbal fluency (Rao et al., 1991). He named 
11 
 
his battery Brief - Repeatable Battery of Neuropsychological tests (BRBN) (Rao, 1990) and since 
then this battery is considered to be the gold standard of cognitive assessment in MS.  
Due to the popularity of the BRBN and its subtests, the cognitive domains it measures have been 
well studied in MS. Much less is known about the cognitive domains not covered by the BRBN and 
its variants, such as language and visuoperceptual functions. 
The BRBN was comprised to be a compilation of the tests proven to be most sensitive to MS-related 
cognitive impairment, and to save time three of its components have been used as standalone 
assessments in many research studies. The Paced Auditory Serial Addition Test (PASAT), Symbol-
Digit Modalities Test (SDMT) and the verbal fluency tasks measure predominantly speed of 
information processing, but at the same time address other complex functions such as memory, 
attention, and executive functions. It is important to note that these most sensitive and the most often 
used tests are, in a way, ‘dirty tests’ as they assess a compound of various cognitive functions. In a 
clinical setting, such ‘dirty tests’ serve physicians as a valuable tool to differentiate patients with and 
without cognitive impairment, but not as much to identify which functions are impaired in individual 
patients in order to define starting points for individualized disease management (Hoffmann et al., 
2007). Since MS-related cognitive impairments are highly heterogeneous, it could be considered 
insufficient to administer solely the PASAT, SDMT and category fluency tasks in studies addressing 
cognitive deterioration. 
1.3.     Links between cognitive dysfunction and disease variables 
Depending on a study, cognitive dysfunction is considered to be partly explained by MS type, MS 
duration, neurological disability, brain tissue damage, levels of depression, and cognitive reserve. 
However, depending on their methodology, many studies tend to present discrepant findings. 
1.3.1.        MS type 
Even though the classification into RRMS, SPMS and PPMS is primarily based on progression of 
physical dysfunction, some courses of MS are more associated with cognitive difficulties than others. 
In general, patients with RRMS tend to outperform patients with PPMS and SPMS on cognitive 
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examinations (Grossman et al., 1994), and PPMS patients tend to perform better than those with 
SPMS (Camp et al., 1999; Gaudino, Chiaravalloti, DeLuca, & Diamond, 2001). RRMS patients may 
also have cognitive deficits when compared to healthy controls, albeit less obvious ones than those 
observed in SPMS and PPMS (Grossman et al., 1994; Ryan, Clark, Klonoff, Li, & Paty, 1996). 
However, keeping that in mind, the relationship between cognitive impairment and disease course is 
not strong enough to predict the cognitive status of individual MS patients (Beatty, Goodkin, 
Hertsgaard, & Monson, 1990), especially once the patients are equated for disease duration and 
disability (Foong et al., 2000).  
1.3.2.        Disease duration 
Among the factors playing a role in development of cognitive dysfunction in MS, disease duration 
is reported  not to play a significant role (Beatty, et al., 1990; Lynch, Parmenter, & Denney, 2005). 
In the course of a sufficiently long follow-up cognitive dysfunction is likely to emerge and progress 
in a sizable proportion of patients, however, it is likely to reflect the progression of disease and 
development of more neurologic symptoms and brain tissue damage. The number of years someone 
has had MS alone is not a sufficient predictor of cognitive symptom development (Amato, Ponziani, 
Siracusa, & Sorbi, 2001).  
1.3.3. Neurological disability 
The neurological disability as indicated by the score on the Expanded Disability Status Scale (EDSS) 
(Kurtzke, 1983) alone fails to account for the progression of cognitive deficits (Beatty, et al., 1990); 
however correlations are reported between measures of neurological disability and tests of 
information processing speed (Lynch et al., 2005).  
Studies show relapses to be associated with fluctuations in cognitive function, as during a relapse the 
patients tend to perform more poorly on cognitive tests, particularly on those involving attention and 
processing speed (Foong et al., 1998); and the total number of relapses since diagnosis  is shown to 
correlate with overall cognitive dysfunction (MacAllister et al., 2005). 
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1.3.4. Brain tissue damage 
Studies involving factors that contribute to the severity of cognitive impairment indicate, that the 
extent of tissue damage in white and grey matter tend to be among the best correlates. Brain atrophy 
has been reported to account for more variance than lesion burden in predicting cognitive impairment 
in MS (Filippi et al., 2010), and central atrophy in the thalamus in particular is strongly associated 
with neuropsychological morbidity, as it is believed to mediate cognitive function via cortical and 
subcortical pathways (Benedict et al., 2004).  
A considerable number of imaging studies have attempted to identify the relationship between the 
location of multiple sclerosis lesions and modality of cognitive dysfunction, but no conclusion was 
reached as the studies produced conflicting results, which can partially be explained by the 
heterogeneous pathological substrate of multiple sclerosis lesions and the fact that, besides the 
periventricular white matter, there is no preferred region where lesions aggregate (Hoffmann et al., 
2007).  
1.3.5. Depression 
Depressed mood in MS patients has been reported to be associated with poorer performance on 
processing speed, executive (Arnett, Higginson, & Randolph, 2001) and working memory tests 
(Arnett, Higginson, Voss, Bender et al., 1999). The authors argue, that the impaired performance on 
speeded attentional tasks of the depressed mood pwMS could be potentially caused by several factors, 
such as reduced working memory capacity, impaired deployment of executive strategies, or 
psychomotor slowing (Arnett et al., 1999). Furthermore, there is evidence that depression causes 
brain pathology (i.e. causes changes in hippocampal structure) (Videbech & Ravnkilde, 2004), which 
makes in turn it difficult to dissociate from MS-related pathology. 
However, it has been shown that the detrimental effects of depression on cognition could in part be 
reversible with exercise in interventional studies (Motl & Pilutti, 2012; Stroud & Minahan, 2009; 
Velikonja, Čurić, Ožura, & Jazbec, 2010), therefore it could be considered that the effects of 
depression may be mediated by individual differences and lifestyle variables. 
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1.3.6. Cognitive reserve  
Cognitive reserve is a relatively new and understudied concept in MS, however, successful models 
of cognitive reserve have been developed and studied in other neurodegenerative conditions, namely 
the Alzheimer’s Disease. The idea of reserve stems from the observed lack of direct relationship 
between the degree of brain pathology and its clinical manifestation (Stern, 2002). For example, the 
same magnitude of brain damage caused by neurodegeneration can result in varying levels of 
cognitive impairment in different individuals, depending on their level of reserve (Stern, 2009; Figure 
1.2). Specifically, the point of inflection, where the cognitive functioning begins to be affected by 
pathology, starts later in individuals with higher levels of reserve, and in result the clinical 
manifestation of cerebral pathology is reached later, when pathology is more severe. 
 
Figure 1.2. Theoretical illustration of how reserve may mediate between brain pathology and 
Alzheimer’s Disease clinical expression 
 
Note. This figure has been adapted from Stern, 2009. 
 
 
Literature into neurodegenerative disorders distinguishes between two types of reserve: passive and 
active. Brain reserve is an example of a passive model, where the protective resources derive from 
the brain size or neuronal count. Specifically, it has been shown that larger brains can sustain more 
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atrophy before the clinical deficits emerge, because sufficient neural substrate remains to support 
normal function (Katzman, 1993). On the other hand, active models, such as cognitive reserve, 
suggest that the brain actively attempts to cope with brain damage by using pre-existing cognitive 
processes or by enlisting compensatory processes (Stern, 2002). Therefore according to the reserve 
theory, although two patients may have the same amount of passive (brain) reserve capacity, the 
patient with more active (cognitive) reserve would better sustain brain damage and maintain function 
for longer. 
Previous work into cognitive reserve indicates that a set of life experiences, such as educational and 
occupational exposure and leisure activities, are associated with slower rate of cognitive decline and 
lower rates of developing dementia; and that each of these life experiences tend contribute to 
cognitive reserve independently (Stern et al., 1994).  Of the methods which could be used in research 
as proxies for cognitive reserve, educational exposure is the most commonly employed; however, 
even though less often studied, engagement in leisure activities has been shown to be a better 
indicator of protective factors associated with cognitive reserve (Valenzuela & Sachdev, 2005). 
Most of the work on cognitive reserve has been done on cognitive ageing and people with dementia, 
however, life experience proxies for higher cognitive reserve have also been reported to mediate 
cognitive changes associated with HIV dementia (Farinpour et al., 2003), schizophrenia, bipolar 
disorder and depression (Barnett, Salmond, Jones, & Sahakian, 2006), and traumatic brain injury 
(Kesler, Adams, Blasey, & Bigler, 2003). 
Previous work involving MS patients has shown that pwMS with higher reserve tend to be better 
able to withstand MS neuropathology without cognitive impairment (Sumowski, Chiaravalloti, 
Wylie, & DeLuca, 2009). Specifically, in pwMS higher premorbid ability and more years of 
education have been reported to account for slower deterioration of information processing speed 
(Benedict, Morrow, Weinstock Guttman, Cookfair, & Schretlen, 2010) and cerebral tissue 
destruction (Bonnet et al., 2006), which potentially is indicative of cognitive compensation in more 
educated patients. Cognitive reserve or lifestyle choices (indicated as early-life cognitive leisure) 
were shown to be protective against MS-related cognitive impairment independently of genetic 
factors outside of one’s control, and the effect of cognitive reserve was reported to be superior to 
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brain reserve (indicated as larger maximal lifetime brain volume) (Sumowski et al., 2013). 
Interestingly, cognitive reserve related compensation is reported to be most beneficial at earliest 
stages of MS and may, however, fail with progression of damage (Amato et al., 2013). 
1.3.7. Exercise 
Among health behaviours that have been shown to have a compensatory effect on progression of 
cognitive deficits, exercise is reported to exert a prophylactic effect for MS progression. Previous 
research from observational studies have reported a positive association between cardiorespiratory 
fitness and structural brain volumes and preservation of neuronal integrity (Prakash, Snook, Motl, & 
Kramer, 2010). In addition, observational studies have shown that pwMS who regularly exercise 
tend to maintain better affective overall mental health (Turner, Kivlahan, & Haselkorn, 2009), have 
less long-term disability and perform better on measures of processing speed (Prakash, et al., 2010). 
However, the results from interventional studies limit definite conclusions from the observational 
studies on the disease-modifying effect exercise has on clinical measures of MS, but the effect on 
MRI, animal model and patient self-reported feeling of well-being has been well supported (Dalgas 
& Stenager, 2012). 
1.4. Self-awareness of cognitive deficits in MS 
Much research has been done in order to identify and explain the course of MS progression and new 
cognitive deficit acquirement. However, less is known about the patients’ subjective perception of 
their deficit progression. Based on the previous literature into MS and into other neurodegenerative 
illnesses there are grounds to speculate that pwMS might have difficulties in their self-perception of 
cognitive deficit progression. 
Disordered awareness of cognitive and behavioural deficits, or anosognosia, is one of the leading 
factors determining the prognosis, the development of coping strategies and the efficacy of post-
diagnostic support (Robinson et al., 2011). Underestimation of existing deficits can have a negative 
impact on patients’ engagement with post-diagnostic support, and can lead to performing dangerous 
or difficult activities beyond one’s capabilities (Yokoi & Okamura, 2013). This could include taking 
part in such activities as cooking, driving or getting around independently, potentially leading to 
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accidents. If identified early, to some degree the awareness deficits can be managed, possibly 
avoiding some of the potential mishaps. 
Evidence from neuroimaging studies suggest an association between impairments in aspects of self-
awareness and insight and frontal and prefrontal lobe neural atrophy in neurodegenerative disorders 
(Rosen et al., 2011; Stuss et al., 2000). Loss of insight is considered to be one of the core features of 
frontal/behavioural variant of Fronto-Temporal Dementia (FTD) (Eslinger et al., 2005), however, 
due to many shared clinical and pathological features, it has also been reported and studied, although 
to a lesser extent, in other neurodegenerative conditions, such as Alzheimer’s Disease (AD) 
(Robertsson, Nordström, & Wijk, 2007), Parkinson’s Disease with dementia (PD) (Prigatano, Maier, 
& Burns, 2010), Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD) 
(O’Keefe et al., 2007). From studying insight in FTD, PSP, CBD and healthy controls, O’Keefe et 
al. (2007) concluded that awareness problems are caused by involvement of the frontal and prefrontal 
regions, and could be predicted by poorer performance on frontal-executive tests, such as set-shifting, 
planning and categorisation (Grafman & Litvan, 1999).  
Since pwMS tend to have more extensive cortical atrophy in superior frontal and parietal cortices 
than in other regions (Benedict et al., 2002), and, executive functions are reported to be impaired 
moderately often in pwMS (13-19%; Table 1.1.) (Rao et al., 1991), under the same reasoning it could 
be hypothesised that pwMS may be vulnerable to experiencing deficits in insight as well. 
And indeed, even though neuropsychological evaluations have estimated some degree of cognitive 
impairment to be prevalent in around half of pwMS, however, the outcomes of specialist assessments 
don’t always go hand in hand with patient self-reports of their cognitive deficits. In one study pwMS 
have been found to not be fully aware of their current cognitive deficits (or not report them reliably) 
when examined cross-sectionally, however, when examined longitudinally, pwMS were found to be 
accurate in their reports of perceived levels of cognitive change (Christodoulou et al., 2005). 
Another study that investigated the self-perception of cognitive deficits in MS has shown that the 
pwMS could be classified according to whether they overestimated or underestimated their cognitive 
ability. However, instead of comparing the patients’ self-reports to their actual performance, this 
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study compared them to informant ratings (usually spouse or family member). In this study, 
compared to underestimations,  overestimations of performance were linked to lower levels of 
depression and conscientiousness, and greater degrees of cognitive impairment, euphoric behavioural 
disinhibition, and unemployment (Carone, Benedict, Fishman, & Weinstock-Guttman, 2005). This 
again highlights the behavioural consequences of insight deficits in pwMS.  
The exploration of awareness deficits is a relatively new and unexplored field of study in MS. Most 
research of awareness deficits in clinical samples have been performed on patients with dementia, 
brain injury, and stroke. Research into those samples has shown that metacognition can be affected 
differently for each cognitive domain (i.e. for example, the patient may be aware of disruption in 
memory, but not aware of disruption of executive functions), therefore the awareness of cognitive 
deficits in each cognitive domain should be assessed separately (Cosentino & Stern, 2005; Schoo, 
van Zandvoort, Biessels, Kappelle, & Postma, 2013).   
1.5. Prognosis and cognitive symptom progression in MS. Longitudinal studies 
Great variability in longitudinal changes in cognitive performance in pwMS exists with some patients 
performing at the same level with controls even after many years with MS, and other patients’ 
cognitive symptoms progressing rapidly from the very start of their MS (Benedict & Zivadinov, 2011; 
Staff, Lucchinetti, & Keegan, 2009). Predicting the probability and course of cognitive impairment 
in an MS patient is difficult, as it may depend on many different variables, such as genetics, male 
sex, progressive disease course, MRI metrics and comorbid neuropsychiatric illnesses (Benedict & 
Zivadinov, 2011; de Groot et al., 2009). Furthermore, slowed progression of neuropsychological 
deficits is also reported to be linked to health behaviours and cognitive reserve (i.e. higher level of 
premorbid cognitive functioning) (Benedict et al., 2010; Sumowski et al., 2009).  
Since around half of people with MS suffer from some degree of cognitive problems, there’s a 
number of longitudinal cohort studies that investigate how the cognitive symptoms develop and 
progress in a sample of pwMS. Most longitudinal studies in MS were developed to have a 
retrospective design, where the neuropsychological evaluation is performed only at follow-up with 
only the predictor variables, such as MRI or clinical course, collected at baseline. In order to 
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investigate the heterogeneous progression of cognitive deficits in pwMS, the cohort approach where 
the same individuals undergo neuropsychological assessments at baseline and at follow-up, separated 
by a time period, can be deemed superior to retrospective research. Therefore for the purposes of this 
study it was chosen to review only the adult cohort longitudinal studies where the cognitive 
evaluation was performed at least twice by a specialist researcher, and the baseline and follow-up 
phases are clearly defined and separated by a time interval. Studies using survey design or self-
reported measures of cognitive dysfunction, or longitudinal studies designed to validate cognitive 
assessment tools or interventions, rather than investigate naturally occurring cognitive changes, were 
not deemed suitable for the purposes of this project and therefore were not reviewed.  
To the best of my knowledge 23 existing longitudinal cohort studies investigating cognitive changes 
in pwMS can be identified (Table 1.2.). However, the results from these studies are difficult to 
compare, since these studies differ substantially in their methodologies; clinical characteristics of the 
patients; follow-up intervals; cognitive domains assessed and the neuropsychological measurements 
employed per domain; cut-off points in the definition of cognitive impairment; follow-up rates; and 
methods of statistical analyses (Table 1.2.). In addition, the majority of longitudinal studies do not 
employ a control sample (or if they do they only assess them once as a cut-off reference point without 
following them up longitudinally), therefore they do not account for the longitudinal changes in 
cognitive abilities that are related to normal variability in performance, cognitive ageing, practice 
effect, or systematic differences in administration, rather than being caused by MS. High drop-out 
rates in some studies are also problematic as they indicate poor representation of the sample and the 
population and in turn make the findings difficult to interpret and generalize. 
In addition to differing methodologies, some studies present discrepant findings, especially on the 
modest effect that the MS type, disease duration and neurological disability have on cognitive 
deterioration. Strongest correlations were found in the studies where pwMS were classified into 
‘cognitively impaired’ and ‘cognitively unimpaired’ at baseline. The ‘cognitively impaired’ tend to 
have higher WML load and more brain atrophy and poor cognitive performance at baseline, and their 
cognitive symptoms progress more rapidly, irrespective of the MS type. These people can be 
identified early in their MS by poorer performance on information processing speed tasks, which 
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later leads to moderately worsening performance in memory and executive domains, and this process 
occurs at a faster pace than for the ‘cognitively unimpaired’ group, and is considered to be 
independent of progression of neurological disability. 
The reason why some pwMS fall into ‘cognitively impaired’ and ‘cognitively unimpaired’ groups at 
baseline is unclear, and could potentially have to do with general intellectual ability or cognitive 
reserve at baseline, and the rate of cognitive symptom progression could be mediated by certain 
health behaviours.  
Currently in the MS literature the research on the progression of deficits measured by the BRBN 
battery (verbal and visuospatial memory, processing speed, attention/concentration, and verbal 
fluency) is overrepresented, thus lacking a systematic approach to cognitive deterioration in temporal 
and posterior regions, such as language and visuoperceptual abilities. All (100%) of previous studies 
included at least one measurement of memory, 87% included measures of attention, 65% included 
information processing speed or executive functioning, and only 30% of studies have looked into 
visuoperceptual functions or language (Table 1.2.). I found only one study that looked into all 
cognitive functions (Strober et al., 2014), but this study had an extremely low follow-up rate 
(29.34%), therefore their findings can be considered unfit for generalizations. 
The heterogeneity of methodologies employed and cognitive tests used make the dimensionality of 
cognitive impairment in MS difficult to establish. Some studies treat cognitive impairments as one 
entity and do not dissociate between the mechanisms that cause deterioration in separate functions, 
while other studies claim that MS causes disruptions in information processing speed, which later 




Table 1.2. Summary of prospective non-interventional longitudinal studies of cognition in MS 
arranged by total follow-up interval 
Study Sample 
size with 




Cognitive functions assessed Follow-
up rate  
Predictors/correlates 
of cognitive decline 




17 SPMS,  
1 PPMS,  
70 
controls 
1.5 year ✓ ✓ ✓ ✓ ✓  25% Cognitive impairment 
starts with visuo-
perceptual deficits, 
and then with disease 
progression spreads 
into memory, 
executive deficits and  
processing speed  
(Mariani et 
al., 1991) 










2 years  ✓ ✓ ✓  ✓ N / A Early axonal loss and 
brain atrophy, but not 
clinical variables, 





99 PPMS 2 years ✓ ✓ ✓ ✓   67.3% Lower baseline 
cognitive status and 




6 CIS,  
22 RRMS,  
7 SPMS,  







✓ ✓ ✓    89% Information 
processing speed 
deficits correlate with 
disease progression 
and disability, but 
memory problems 
occur after 2 years 




70 RRMS 2.1 
years 
 ✓ ✓ ✓   64% Decline in decision 
making appears as an 
isolated deficit early in 
MS and is not related 
















(Patti et al., 
1998) 
34 SPMS,  
23 RRMS 







31 RRMS,  
15 SPMS,  
6 PPMS,  
1 PRMS 
3 years ✓ ✓ ✓ ✓   69% Self-reported 
depression predicts 





24 PPMS,  
25 
controls 




Table 1.2. (continued)          
Study Sample 
size with 




Cognitive functions assessed Follow-
up rate 
Predictors/correlates 
of cognitive decline 
I A M E V L 
(de Groot, 
et al., 2009) 
146 
pwMS 
0.5, 1, 2 
and 3 
years 
✓ ✓ ✓    93.6% Older age, male sex, 
perceived ability to 




13 RRMS,  
20 PMS,  
18 
controls 









1 and 4 
years 
✓ ✓ ✓    64% WML volume in 




24 CIS,  
13 
controls 
5 years ✓ ✓ ✓ ✓  ✓ N / A WML load at baseline 
(Glanz et 
al., 2012) 
90 pwMS 1, 2, 3, 
4 and 5 
years 




et al., 2012) 











7 years  ✓ ✓ ✓ ✓ ✓ 74% Cognitive dysfunction 
correlates to disease 







1, 2, 5 
and 7 
years 




and diffused brain 
damage at baseline; 
and progressive 
central brain atrophy 






10 RRMS,  
17 SPMS,  
4 PPMS 
8 years ✓ ✓   ✓  97 % Slowed processing 
speed and high 
disability in SPMS 
patients at follow-up 
(Piras et al., 
2003) 
12 RRMS 8.5 
years 
 ✓ ✓ ✓   37.5% Slowed processing 









✓ ✓ ✓    69% Rate of deterioration 
in first two years was 











 ✓ ✓ ✓  ✓ 90% Neurological 
disability, progressive 




22 pwMS 17.9 
years 
✓ ✓ ✓ ✓ ✓ ✓ 29.34% Drop in processing 
speed 
 I A M E V L  
% of longitudinal studies with at 
least one test per that cognitive 
domain 
65 87 100 65 30 30 
 
Abbreviations: RRMS - Relapsing-Remitting MS, SPMS - Secondary Progressive MS, PPMS -  Primary Progressive MS, PMS - 
progressive MS, PRMS - Progressive Relapsing MS, CIS - Clinically Isolated Syndrome. I - Information processing speed, A - 




To the best of my knowledge no study up to date has analysed the dimensionality of cognitive 
impairment to investigate the pattern of how MS-related cognitive decline starts and spreads, while 
accounting for inter-personal variation that pwMS exhibit: MS course and levels of disability, 
baseline intellectual ability, cognitive reserve and exercise, levels of depression and various 
medication. In addition, no study so far has systematically examined the patients’ perception of 
cognitive decline in MS samples, and related their self-perception of change to the actual longitudinal 
changes in performance on neuropsychological tests. I hope that with such study the discrepancies 
in findings from previous research could be merged and explained and if a sufficiently large and 
heterogeneous sample is collected. Such investigation could also broaden the current understanding 
of MS-related progression of cognitive deficits whilst accounting for individual variation, which 
normally causes problems when trying to compare findings from different longitudinal studies. 
1.6. Gaps of knowledge and predictions 
1.6.1. Development of the scientific framework for the longitudinal study 
This project aimed to set up the scientific framework through which a sample of pwMS could be 
followed in order to study the MS-related longitudinal change between the baseline and follow-up 
assessments. The scientific framework for this project was developed based on the previously 
published literature that addresses longitudinal cognitive assessment in MS. During this process 
several gaps of knowledge were identified, and predictions were made about the development and 
progression of cognitive impairment in pwMS, its dimensionality, and clinical and non-clinical 
correlates. This project was devised to fill these identified gaps of knowledge and to test the following 
informed predictions. 
1.6.2. Predictions for dimensionality of cognitive impairment in MS 
The first identified gap of knowledge revolved around the dimensionality of MS related cognitive 




I. Cross-sectional predictions 
The first goal of this project was to investigate whether MS affects all of the cognitive functions or 
only some of them. It was predicted that due to heterogeneity of brain lesion locations, MS has the 
potential to affect all cognitive domains, although independently and not necessarily at the same 
frequency. Based on the small body of existing literature the cognitive deficits are predicted to occur 
in recognizable patterns, and potentially groups of pwMS who have shared patterns of cognitive test 
failure can be identified.  
II. Longitudinal predictions 
The next step was to identify the longitudinal change in the dimensionality of cognitive deficits in 
pwMS. If we accept the premise that pwMS have impaired cognition because they have pathology 
affecting their brains, and that the extent (burden) of this randomly distributed pathology will 
increase over time, then we can predict that the pattern of cognitive deficits will become more 
homogeneous (and unidimensional / ‘global’) over time at the population level, reflecting increasing 
multidimensionality at the individual level. 
1.6.3. Predictors of longitudinal change in cognition  
The second aim of this project was to investigate what causes longitudinal change in cognitive 
functioning.  
A number of predictions can potentially be made about the effects of clinical and non-clinical 
variables. Based on the review of the previous literature, the following model can be regarded as 
plausible: 
Longitudinal change in cognition= α + β1 (clinical factors) + β2 (demographic factors) + β3 
(cognitive reserve factors) + β4 (error) 
Clinical variables were considered to be those that are caused by MS (such as MS type, disease 
duration, level of neurological disability, number of relapses, and taking disease modifying treatment 
(DMT)) and those related to MS but not necessarily caused by MS alone (levels of depressiveness 
and antidepressant uptake). MS-unrelated predictors include demographic characteristics (age and 
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gender) and cognitive reserve factors (involving educational exposure, pre-morbid IQ and premorbid 
cognitive leisure, number of languages spoken, engagement in physical fitness, and employment 
status). The total amount of variance left unexplained by such a model would include measurement 
error, genetic variability in CNS plasticity / repair capacity, and potentially other unspecified 
moderator variables. 
It is predicted that this model (or some of its components) would explain why some individuals 
experience more longitudinal changes in cognition than others. 
1.6.4. Predictions for self-perception of cognitive change 
After having measured the extent, dimensionality and causes of longitudinal changes in cognitive 
functioning, the third aim of the project was to investigate to what extent the patients themselves are 
aware of their deficit progression. Based on the analysis of previous literature I raised the assumption 
that pwMS may not be entirely accurate in their evaluations of their cognitive performance, and if 
that’s true, I wanted to know what causes the patients to perceive the changes in cognition. 
Based on the review of previous literature, the self-perception of longitudinal change in cognition 
could potentially be explained by the following model: 
 
Self-perception of longitudinal change = α + β1 (executive functioning) + β2 (depressive 
symptomology) + β3 (neurological disability) + β4 (Number of relapses in-between assessments) + 
β5 (MS impact) 
When building this model it was considered that the patients’ perception of longitudinal change in 
cognitive functioning could be influenced by their abilities to make judgements (executive 
functioning), whether they can be identified as being more depressed, or whether they feel more 
affected by MS (either having a higher neurological disability score, a higher MS impact score or 
experiencing more relapses). 
However, since heterogeneity in cognitive domains affected is expected, it can be that this model 
may have a better fit for self-perception of changes in cognitive functioning for some cognitive 
domains but not the others.  
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1.6.5. Concluding remarks 
With this project I hope that by testing these predictions I will help fill the indicated gaps of 
knowledge. In this project both the factors that have positive and detrimental effects on cognition 
will be accounted for, and it is hoped that these analyses will be able to account for the individuality 
and heterogeneity in prevalence and rate of progression of cognitive impairment in MS. 
The analyses carried out throughout this thesis were devised to combine the findings from previous 
studies into one multidimensional model that will potentially encompass and help explain the 
heterogeneity of trajectories of MS, and this way will add benefit the existing body of literature. 
Besides the theoretical value, throughout this project I also attempt to critically evaluate the existing 
methods of cognitive assessment and result analysis, therefore the findings from this project have the 
potential to benefit work in everyday clinical practice.  
1.7. Structure of this thesis 
This thesis begins with a presentation of the methodology of the phase I (baseline) assessment 
(Chapter Two). Chapter Three contains characterization of the phase I study, and the procedure 
behind the optimization of the phase II (follow-up) battery. Chapter Four contains characteristics of 
the phase II cohort. Chapter Five includes the analyses of the dimensionality of cognitive impairment 
in MS. Chapter Six addresses the trajectory, extent, and predictors of cognitive change in pwMS. In 
Chapter Seven I analyse the patients’ self-perceptions of cognitive change and compare them to the 
actual change in performance. 
Since the majority of the experimental chapters included overlapping themes (definition of 
impairment, comparison of patients to controls, and clinical implications) to avoid redundancy all 





Chapter Two. Phase I battery 
2.1. Chapter overview 
This chapter describes the methodology of the phase I of the longitudinal study. It starts with a 
description of the design and the recruitment procedure, followed by a detailed presentation of the 
materials and the administration procedure. The chapter ends with an outline of the strengths and 
weaknesses of the phase I test battery. 
2.2. Phase I design 
The phase I study was started as a PhD research project at The University of Edinburgh by Mara 
Sittampalam in 2010 and was supervised by Dr Thomas Bak and Prof Siddharthan Chandran. The 
phase I study had a cross-sectional between groups design and its aim was to gain a better 
understanding of the prevalence and underlying mechanisms of cognitive dysfunction in MS, and 
then to relate them to MS subtype, disease duration and motor disability scales.  
2.3. Phase I study recruitment 
For the phase I study the patient participants were recruited from secondary care in the Lothian area 
of Scotland, referred by local neurologists and specialist nurses between August 2010 and August 
2012. Potential participants were screened against the following eligibility criteria: revised (2010) 
MacDonald criteria MS (Polman, et al., 2011), ages 18-65 years inclusive and absence of psychiatric 
or physical comorbidity (including major affective disorder, significant dementia or other significant 
comorbidities). Subjects showing any non-MS related ophthalmological condition that might 
interfere with neuropsychological testing were excluded too. For this purpose subjects having a 
Snellen acuity worse than 20/70 (0.25) (criterion for visuoperceptual testing proposed by McCarthy 
and Warrington (McCarthy & Warrington, 1990)) were excluded. Furthermore, it was chosen to 
restrict the phase I study to MS patients not residing permanently in a nursing home or other 
institutional setting. Of 972 pwMS screened, 108 patients fulfilled the eligibility criteria and agreed 
to participate. It was projected to accomplish a sample with the prevalence of PPMS, SPMS and 
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RRMS similar to the natural prevalence in the population. Based on that at phase one Mara 
Sittampalam has recruited 21 patients with PPMS, 34 SPMS and 53 RRMS totalling to 108 people 
in the MS sample.  
To enable definition of appropriate normal ranges a matched control cohort was then achieved 
through stratified sampling by age, gender and educational level. Exclusion criteria were a disease 
of the central nervous system, major psychiatric illness, history of alcohol or drug abuse, serious 
head injury, learning disability and recent heart attack or other major medical illness. All persons 
needed to have adequate vision to complete testing, and if participants required hearing or visual aid, 
they were used during all assessments. A parallel group of 33 healthy controls included patients’ 
spouses, family members and friends, as well as selection from the Psychology Department of The 
Edinburgh University volunteer panel. 
2.4. Phase I study methods 
This section includes a description of the tools employed to collect data on demographic, disease, 
disability and neuropsychological variables. The information about the validity of the assessment 
tools was reported only for the items that were included in the optimized phase II battery, and that 
information can be found in Appendix D. 
2.4.1. Demographic and disease information 
The demographic data collected about participants included age, gender and years of education. For 
the patient participants the history of MS, including, diagnostic criteria, disease onset and disease 
duration, medication, motor and sensory symptoms past and present relevant to Kurtzke disability 
score in MS Expanded Disability Status Scale (EDSS) was collected.  
2.4.2. Assessments of disability 
It has been shown that disability has a large impact on ability to perform certain cognitive tasks. This 
may be due to the nature of standard cognitive batteries that are problematic for patients with speech 
or upper limb weakness. Even though this was not considered to be a problem with the majority of 
tests being used in this study, physical disability was measured to control for this confounder.  
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EDSS: The Expanded Disability Status Scale (EDSS) (Kurtzke, 1983) combines an assessment of 
seven different neurological domains and an ambulatory score. These domains are referred to as 
Functional Systems (FS) and include pyramidal, cerebellar, brainstem, sensory, bowel and bladder, 
visual, and cerebral (or mental) functions. The patient’s experiences of symptoms are not included, 
merely the findings from physical examination and direct questions related to mood, cognitive and 
bladder and bowel symptoms. The EDSS scale is 20 half steps from ‘0’ to ‘10’, with ‘0’ 
corresponding to a completely normal examination, and ‘10’ to death due to MS. The scores from 
‘0’ to ‘4’ depend on individual FS scores, and over ‘4’ the score is based on assessment of ambulation 
using distance and dependence on aids. Since its introduction, it has become standard practice to use 
the EDSS score in MS research and clinical assessments. As part of EDSS visual domain visual 
acuity data for right and left eyes and binocular vision with correction was collected using a 2m 
Snellen acuity chart in order to exclude participants with visual problems that might interfere with 
neuropsychological evaluations. 
MSIS 29: The Multiple Sclerosis Impact Scale (MSIS-29) (Hobart, Lamping, Fitzpatrick, Riazi, & 
Thompson, 2001) comprises of 20 physical and 9 psychological questions based on a 1-5 Likert scale. 
Unlike other patient based questionnaires, MSIS-29 was developed using psychometric methods. 
129 items gained from patient interviews, literature review and expert opinion, were then 
systematically reduced after analysing protocols from 1530 patients, and a 29-item scale was 
developed. Item descriptive statistics, item convergent and discriminant validity, and factor analysis 
indicated that it was legitimate to generate scores for MSIS-29 scales by summing items. These 
results indicate the MSIS-29 is a clinically useful and scientifically sound patient-based outcome 
measure of the impact of MS suitable for clinical trials and epidemiological studies.  
BDI - II: Beck’s Depression Inventory – II (BDI - II) (Beck, Steer, & Brown, 1996) is a questionnaire 
that is used in research and clinical practice, in a wide range of medical diseases and is composed of 
items relating to symptoms of depression such as hopelessness and irritability, feelings of guilt or 
being punished, as well as physical symptoms such as fatigue, weight loss, and lack of interest in sex. 
The scale takes 5 minutes to complete and can be self-administered or verbally by a trained 
administrator. BDI-II contains 21 questions, each answer being scored on a scale value of 0 to 3. 
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Higher total scores indicate more severe depressive symptoms. The test was also shown to be robust 
to daily variations in mood (Beck et al., 1996).  
2.4.3. Assessments of general cognitive ability 
ACE-R: Addenbrooke’s Cognitive Examination – Revised (ACE-R) (Mioshi, Dawson, Mitchell, 
Arnold, & Hodges, 2006) is a screening battery for dementia that incorporates the Mini-Mental State 
Examination (MMSE) with the addition of verbal fluency, visuospatial tasks and expansion of the 
memory and language components. It is a brief (takes around 15 minutes) bedside screening tool that 
is easy to conduct and score in routine clinical practice (Larner, 2007). The ACE-R it is widely used 
across the world, having been translated into over 30 languages and validated in different cultures 
(Bak & Mioshi, 2007). Importantly, it has been applied in a broad range of neurodegenerative 
diseases, including dementias (Mathuranath, 2000) and neurodegenerative movement disorders (Bak 
et al., 2005). The ACE-R assesses five cognitive domains, and each of their scores add to a composite 
score of 100: attention (18), verbal fluency (14), language (26), memory (26), and visuospatial skills 
(16). The ACE-R score ranges from 0 to 100, with higher values indicating better cognitive abilities. 
A score of 88 is reported to be a sensitive cut-off for detecting mild cognitive impairment and a score 
of 82 is an indicator of dementia (Mioshi, et al., 2006). 
NART–2: National Adult Reading Test, second edition (NART-2) (Nelson & Willison, 1991) is a 
test designed to provide an estimate of premorbid cognitive ability. The subjects are required to read 
a list of 50 irregularly spelled words (e.g. heir, banal, zealot) and assuming that the patient is familiar 
with the irregular word, accuracy of pronunciation is used to predict IQ, and is argued to depend 
more on previous knowledge than on current cognitive capacity, as the ability to pronounce irregular 
words is generally retained in mildly demented individuals (Stebbins, Wilson, Gilley, Bernard, & 
Fox, 1990). The NART-2 reading scores can further be used to predict pre-morbid WAIS-R IQ. In 
this study the predicted WAIS-R IQ scores (accounting for demographic differences) were used 





2.4.4. Assessments of memory, attention, processing speed and verbal fluency 
BRB-N: Brief Repeatable Battery of Neuropsychological tests (Rao, 1990) is a sensitive measure of 
cognitive impairment in pwMS. BRBN provides measures of sustained attention/concentration, 
information processing speed, verbal and visuospatial learning and delayed recall and semantic 
retrieval (fluency). Such functions are reported to be most often disrupted in pwMS (Peyser et al., 
1990). Administration of the total test battery takes about 20-30 mins and it consists of the Selective 
Reminding Test (SRT) (8mins), the 10/36 Spatial Recall Test (SPART) (5mins), the Symbol Digit 
Modalities Test (SDMT) (3mins), the Paced Auditory Serial Addition Test (PASAT) (10mins) and 
the Word List Generation Test (WLGT) (2mins). The test battery is administered in the following 
order: SRT, SPART, SDMT, PASAT, Delayed Recall of the SRT, Delayed Recall of the SPART 
and the WLG.  
The Selective Reminding Test (SRT) is a test used to measure verbal learning and memory during a 
list learning task of six trials. The list consists of 12 words which the examiner reads at a rate of one 
word per two seconds. The subject is instructed to recall all 12 words in any order. Every consecutive 
trial only the words that are missed on the preceding trial are given. After 15 min (following the 
administration of the PASAT) the subject is asked to recall the word list. The SRT distinguishes 
between short-term and long-term components of memory and examines also the consistency of 
retrieval from long-term memory. The scoring is according to published rules (Buschke & Fuld, 
1974). Three SRT indices were used in our study. A word recalled on two consecutive trials is 
considered to have entered long-term storage (LTS) on the first of these trials and scored as LTS on 
all following trials regardless of subsequent recall. The total sum of the words in LTS of all six trials 
is taken (SRTL). If a word in LTS is consistently recalled on all subsequent trials then it is scored as 
in Consistent Long Term Retrieval (CLTR). The total sum of the words in CLTR of all six trials is 
taken (SRTC). As per Rao’s instruction manual (Rao, 1990) we used corrected SRT LTS and SRT 
CLTR values for every male participant, where we added four points to their scores. The Delayed 
Recall (SRTD) is the total number of words recalled after the delayed period.  
The 10/36 Spatial Recall Test (SPART) was developed to assess visuospatial learning and delayed 
recall. The test consists of a 6X6 checkerboard with ten checkers randomly placed, this is an adapted 
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version of the 24X7 Barbizet memory test (Barbizet & Cany, 1967). The board is put in front of the 
subject for 10 seconds. After presentation the subjects attempt to reproduce the original design on an 
empty board. This process is repeated twice and after 15 minutes (following the SRTD) the subject 
is asked to recall the design again. The score is the total number of correct responses for the three 
trials (SPART) and the delayed recall trial (SPARTD).  
The Symbol Digit Modalities Test (SDMT) examines information processing speed by primarily 
assessing complex visual scanning and tracking (Smith, 2002). The subject examines a series of nine 
meaningless geometric symbols which are labelled 1 to 9. During 90 seconds the subject substitutes 
symbols in a row by the corresponding number and responds verbally. The score is the number of 
correct substitutions (SDMT).  
The Paced Auditory Serial Addition Test (PASAT) is a measure of sustained auditory attention and 
information processing speed (Gronwall, 1977). The subject is instructed to add 60 pairs of digits 
such that each number is added to the one that immediately precedes it and report the outcome 
verbally. The digits are presented by tape, with a speed of every 3 seconds one digit. The subject is 
required to respond verbally quickly, inhibit encoding of his own response while attending to the 
next stimulus in a series, and perform at an externally determined pace. The score is the number of 
correct responses per trial (PASAT).  
The Word List Generation (WLG) is a semantic verbal fluency test evaluating the spontaneous 
production of names of a given category within a limited amount of time (Rao, 1990). The subject is 
asked to give as many names of vegetables and fruits (version A) or animals (version B) as possible 
during the time given. The score is the number of correct names produced (WLGT). Since we 
administered version B, to avoid redundancy, we used the animal fluency scores from the ACE-R 
battery. That task took 60 seconds to complete and we used the scoring norms as in the ACE-R 
administration protocol (Mioshi et al., 2006).  
Operational definition for failing the BRBN battery was chosen to be performance below cut-off for 




2.4.5. Assessments of visuoperceptual functions 
All of the stimuli in the visuoperceptual tests were administered binocularly, printed in black and 
white and the assessments were not timed. The visuoperceptual assessment was restricted to 
operations on non-moving stimulus configurations, and tasks requiring rapid verbal or motor 
responses were avoided. The subjects who were uncertain were urged to guess.  
VOSP: Visual Object and Space and Perception battery (VOSP) (Warrington & James, 1991) is a 
collection of eight tests based on the theory proposed by the authors that object and space perception 
is functionally and anatomically independent. Each of the eight VOSP test was devised to focus on 
one component of visual perception, while minimising the involvement of other cognitive skills. The 
VOSP consists of four tests of object perception (VOSP1, VOSP2, VOSP3 and VOSP4) and four 
tests of space perception (VOSP5, VOSP6, VOSP7 and VOSP8). In the phase I of this study we only 
used VOSP2, VOSP3, VOSP5, VOSP6, VOSP7 and VOSP8.  
In the Silhouette test (VOSP2) the subject is shown an outline of an object and asked to identify by 
naming them. The test consists of 15 silhouette drawings of animals and 15 silhouette drawings of 
inanimate objects and was constructed to be of graded difficulty ranging from very easy silhouettes 
that could be identified by all subjects to difficult silhouettes that only a proportion of the control 
sample identified.  
The Object Decision (VOSP3) test requires the participants to look at four figures of which one is a 
silhouette of an object and other three are distractor items, object-like shapes that are entirely 
imaginary, and to identify which one of them is a silhouette of a real object.  
In the Dot Counting Test (VOSP5) the test stimuli consists of arrays of black dots on a white card 
and the subject is asked to count them.  
The Position Discrimination test (VOSP6) stimulus consists of two adjacent horizontal squares, one 
with a black dot printed exactly in the centre and one with a black dot just ‘off’ centre. The subjects 
are asked to identify the dot which is in the centre of the square. 
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 In the Number Location task (VOSP7) the subjects are presented with two squares, the top one 
contains randomly placed numbers (1-9) and the bottom square contains a single black dot 
corresponding to the position of one of the numbers. The task is to identify the number that 
corresponds with the position of the dot.  
In the Cube Analysis test (VOSP8) the participants are presented with drawings of 3D arrangements 
of square bricks and are asked to count how many solid bricks are represented in each of the drawings. 
This test provides a measure of the perception of complex spatial relationships. 
BORB: Birmingham Object Recognition Battery (BORB) (Riddoch & Humphreys, 1993) consists 
of 14 separate subtests designed to assess particular aspects of visual processing and visual object 
recognition. In this study only the four BORB subtests dealing with the processing of ‘pre-categorical’ 
properties of objects (i.e. properties not tied to stored knowledge about the particular objects involved) 
were included. These tests are directed solely at the perception of basic properties and object forms 
– those include their size, orientation, location and length. In these four tests two items per trial are 
presented. The items are either the “same” (i.e. match in length, size, etc.) or they are different. There 
are equal numbers of “same” and “different” trials which are mixed together randomly. The patient 
is to indicate which stimuli are the same and which are different. Test 2 (BORB2) requires the 
matching of the line length, Test 3 (BORB3) the matching of the stimulus size, Test 4 (BORB4) the 
matching of line orientation and Test 5 (BORB5) the matching of the positions of gaps in two circles. 
2.4.6. Assessments of language functions 
Tests were chosen with consideration to the abilities and challenges of people with MS, therefore 
none of the tests chosen are timed, and the physical strain was kept to a minimum, with limited 
written and oral responses (many of the tasks involve only pointing). All computer-based tests were 
presented using a Toshiba laptop computer with a 10-inch touchscreen. 
TROG: Test of Reception of Grammar (TROG) (Bishop, 1982) is a receptive language test, designed 
to assess understanding of English grammatical contrasts marked by inflections, function words and 
word order. In this test the participants hear an orally presented sentence, then point to one of four 
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pictures which illustrates the content of the sentence. Additionally, this test has the practical 
advantage of being widely used and standardized in both child and, increasingly, brain damaged 
populations, and is frequently used to assess adults with aphasia. TROG enables the tester to discover 
not only how a person’s grammatical comprehension compares with that of other people of the same 
age, but also to pinpoint specific areas of difficulty. In order to focus on the syntactic properties of 
the examined structures, the vocabulary utilized and the visual form of the pictures is kept as simple 
as possible. In addition, the sentence length is kept constant for tasks of different syntactic complexity, 
minimizing the effect of possible attentional and short-term memory impairment. These two aspects 
are of particular importance when investigating patients with neurodegenerative diseases affecting 
several cognitive domains (Croot, Hodges, & Patterson, 1999). A multiple choice test requiring no 
verbal output, the original version comprises of 80 test items divided into 20 blocks of four test items 
with each block testing a particular grammatical construct, arranged in order of increasing 
complexity. In order to decrease the time taken, only the second 40 items of the tests were used, 
blocks K to T, as they were shown to be more sensitive to impairment in neurodegenerative diseases 
(Bak, O'Donovan, Xuereb, Boniface, & Hodges, 2001) and enabled us to shorten the overall testing 
time.  
All sentences were presented to the participants regardless of previous correct or incorrect responses, 
and each question was scored according to pass/fail system, with a maximum score of 40. 
BCT: Boston Cookie Theft test (BCT) (Goodglass & Kaplan, 1983) is a picture description and 
spontaneous language production task that measures expressive syntax. The participants are shown 
a picture of an eventful family kitchen scene that contains many details of surroundings familiar to 
most people and may be described with a simple vocabulary acquired early in life (Giles, Patterson, 
& Hodges, 1996) (Figure 2.1). The participants were asked to write their descriptions down rather 
than saying them aloud in order to promote grammatical production, and only for those patients who 
had severe upper limb disabilities or tremor the test was administered orally. The text was analysed 
according to a protocol developed by Friedel M. Reischies research group in Berlin (Bschor, Kühl, 
& Reischies, 2001), where the number of words and the number of picture variables (correctly named 
persons and objects, localizations, actions and features) was interpreted.  
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Figure 2.1. Boston Cookie Theft test stimulus. BCT test assesses spontaneous speech as the 
participants are asked to describe the scene from the stimulus picture 
 
PPT, KDT and TTT: are computer generated tasks that assess different aspects of understanding of 
semantic relationships. The test employed for receptive semantics was a shortened version of the 
Pyramids and Palm Trees Test (PPT) (Howard & Patterson, 1992), the Kissing and Dancing Test 
(KDT) (Bak & Hodges, 2003), and the Tomatoes and Tuna Test (TTT) (Danek et al., 2013). The 
PPT is concerned with the relationships between nouns, the KDT deals with verbs, and the TTT, 
sequential events and cause-effect scenarios. All of these tests involve making decisions about sets 
of pictures (Figure 2.2).  
Figure 2.2. An example of a word and picture triplets from the three semantic tasks.  
PPT KDT TTT 
   
Abbreviations: PPT – Pyramids and palm trees test; KDT – Kissing and dancing test; TTT –Tomato 
and tuna test.  
Participants must choose which of two alternatives at the bottom is best associated with the image at 
the top. For instance, in PPT, which assesses perceived relationships between nouns, palm trees are 
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associated with pyramids according to geography, but the other option, pine trees, has no such 
connection. In KDT, which assesses perceived relationships between verbs, writing is associated 
with typing, but not stirring coffee. In TTT, which assesses sequential events and cause-effect 
scenarios, the top picture of peeled banana is the goal state, and only the bottom picture of peeling 
the banana will be the action preceding the goal state and therefore correct.  
In this study we used the abbreviated computerised version of these three tests where each test 
contains 25 tasks of similar difficulty (Hulst, 2012). The tests required only touching the correct 
image on the computer screen and were simple and straightforward to perform. These tests did not 
require any verbal response and thus could be regarded as a more ‘pure’ measure of semantic function 
than, for example, regular picture naming tasks. 
GNT: The Graded Naming Test (GNT) (McKenna & Warrington, 1983) is a naming test that assesses 
expressive semantics and was chosen due to its popularity and the range of difficulty it provides. 
Given the variability other researchers have observed in naming tests, it was important to prepare for 
the possibility of different levels of naming ability. This confrontation naming test comprises of 30 
black and white drawings with items decreasing in frequency from item 1 ‘kangaroo’, to item 30 
‘retort’. Items were presented one at a time and participants were asked to give the name for each 
item. Responses were marked as correct only if named exactly as the target, except for item 25 
‘yashmak’ where ‘hijab’ was also accepted. 
Minimal Pairs Non-Words: Minimal pairs non-words (MPNWDS) discrimination task is a test of 
receptive phonology. Words that differ by only one phoneme are spoken aloud by recorded voices 
in a powerpoint slideshow developed by Philippa Jane Rewaj (Rewaj, 2013). In the minimal pairs 
test, participants needed to respond if the words they hear are the same or different (e.g. deg – ged). 
The nonword test comprised of 48 pairs, with 24 ‘same’ pairs and 24 ‘different’ pairs. There were 
two voices in the recorded stimulus, one male and one female – from the East and West of Scotland, 
respectively – but both words of a given minimal pair were spoken by the same speaker. There was 
a one-second delay between the words, and participants were asked to give their judgement aloud 
immediately after hearing the stimuli. The non-words were of comparable length and syllabic 
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complexity to real English words, never violating the rules of English phonology (eg. tusset, tuzzet). 
The phoneme that differed between the two words was always a consonant, and would vary only by 
one feature (place, manner or voicing).  
2.4.7. Assessments of audio-visual integration 
The Orchard task: The Orchard task is a relatively difficult test of audio-visual non-semantic 
information processing that was developed by Professor John Hodges and Dr Thomas Bak in 2007 
in Cambridge. During this task the participants are presented with a string of tones followed by four 
pictures with different numbers of dots inside the squares. The participants are required to listen to 
the recording and count how many tones they hear to determine which one of the four dot pictures 
matches the number of tones they have heard. This test is comprised of ten trials that are arranged in 
increasing difficulty. 
Sound picture matching: Sound picture matching task (SPMT) is a test developed for testing the 
ability to integrate auditory and semantic visual information (Hulst, 2012). Unlike the Orchard task, 
the SPMT requires access to previous knowledge of how everyday objects and animals sound. The 
participants were presented with a sound, for example, a recording of a song played on the piano, 
and were shown four pictures of musical instruments, namely French horn, piano, harmonica and a 
saxophone. Then the participants were asked to identify which one of the four objects could be 
associated with that sound. The test included 30 trials starting of increasing difficulty, and the sounds 
represented everyday man-made objects and living animals. 
2.5. Phase I procedure 
To minimise the effect of fatigue, at phase I the neuropsychological testing was conducted over at 
least two sessions where the patients were asked to come in to undergo clinical and 
neuropsychological assessments.  In combination both visits took at least four hours to complete, 
with additional sessions being scheduled for participants who couldn’t manage to go through the 
tests in the designated time, or for participants that got tired quickly and it was decided to continue 
over the third visit a few weeks later. For those participants the total testing time could go up to six 
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hours to complete. The order of the assessments was that during the first visit the clinical information 
was collected first, followed by tests of general cognition, memory, attention, processing speed and 
verbal fluency, and in the second visit tests of visuoperceptual cognition and language were 
administered in the same order as they have been presented in this chapter. 
2.6. Phase I battery strengths and weaknesses 
The test battery developed by Mara Sittampalam has been devised to be a comprehensive set of tools 
designed to pick up and identify domain-specific MS-related cognitive impairment. To our 
knowledge this investigation conducted by Mara Sittampalam has been the most in-depth and 
detailed analysis of multi-domain MS-related cognitive impairment. No other study to date has 
assessed so many cognitive functions in such great detail on a large number of MS patients. Therefore 
with all this information collected on the clinical history, cognitive and physical abilities, and 
demographical information, this study contained vast amounts of information about possible 
predictors of MS-related disease progression and cognitive decline, thus formed a rich foundation 
for future longitudinal follow-ups. To our knowledge, to date no other longitudinal study including 
pwMS had such a vast baseline assessment incorporating multi-domain cognitive data which could 
be analysed and used in follow-up assessments as an indicator or biomarker of future MS-related 
cognitive decline. Therefore the work conducted at phase I represented a great foundation for a multi-
domain longitudinal study of cognitive changes in MS. 
Although the test battery presented above had superior coverage to any of the assessments in MS to-
date, it was considered to be substantially too long. At the time between the phase I and phase II 
assessments some of the patients’ MS had substantially progressed and five to six hours over three 
days would become unbearable for them to endure. Therefore for this reason only, the otherwise 
willing participants had the potential to end up declining the offer to participate. Since one of the 
most important aspects indicating the quality of a longitudinal study is its follow-up recruitment rate, 
we aimed to make sure that everything possible was done to ensure that high turn-up rates at the 
follow-up assessment were obtained. Thus one of the main objectives of the phase II protocol 
development was to create the test battery as short as possible so that more participants would be 
willing to come back; but at the same time to retain its informativeness and wide coverage of 
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cognitive domains. The protocol behind the optimization procedure of the phase II battery is 
presented in the next chapter, Chapter Three. 
2.7. Chapter summary 
In Chapter Two the methodology behind the data collection for the phase I assessment was presented. 
In this chapter the design, recruitment, materials and administration procedure of the phase I study 
were covered.  
The phase I study had a cross-sectional between-groups design comparing the cognitive performance 
of pwMS with that of healthy controls. The aim of the phase I study was to gain a better understanding 
of the prevalence and underlying mechanisms of cognitive dysfunction in MS, and then to relate 
them to MS subtype, disease duration and motor disability scales. 
During the phase I study 108 pwMS and 33 healthy gender and education-matched controls have 
been recruited. The participants have underwent extensive cognitive and clinical examinations that 
took four to six hours to complete and had been administered through two to three research visits. In 
this chapter the assessment battery employed for the phase I study has been presented in detail 
including the information collected regarding the demographic and disease variables, measures of 
disability (EDSS, MSIS 29, BDI-II), assessments of general cognitive ability (ACE-R, NART), 
memory, attention, processing speed and verbal fluency (BRBN), visuoperceptual functions (VOSP, 
BORB), language functions (TROG, BCT, PPT, KDT, TTT, GNT, Minimal Pairs Non-Words), and 
audio-visual integration (The Orchard task, Sound Picture Matching). 
The test battery developed for phase I assessment has been devised to be a comprehensive set of tools 
designed to pick up and identify domain-specific cognitive impairment. No study to date had assessed 
so many cognitive functions in such great detail on a large number of MS patients, therefore the 
phase I study contained vast amounts of information regarding possible predictors of MS-related 
disease progression and cognitive decline, forming a rich foundation for longitudinal follow-ups. 
However, in order to proceed with reformatting the study design into a longitudinal cohort study, it 




Chapter Three. Protocol development for the phase II study 
3.1.     Chapter overview 
This chapter describes the theoretical and practical considerations that influenced the development 
of the phase II protocol. Standard study design issues were addressed, and a detailed account was 
given of revisions to the phase I cognitive assessment battery to ensure optimisation with respect to 
the phase II study aims. 
3.2.     Rationale for the development of a bespoke phase II protocol  
The overarching principal for phase II protocol development was to ensure that the longitudinal study 
aims could be addressed. The ability to make valid linkage and comparisons between the phase I and 
phase II datasets was therefore essential. This requirement could be superficially achieved through 
simple repetition of the phase I study protocol. However, revision of the phase I protocol was 
necessary due to:  
 International ethical standards for medical research involving human subjects as 
outlined in the World Medical Association (WMA) Declaration of Helsinki (WMA, 
2013). 
“The design and performance of each research study involving human subjects must 
be clearly described and justified in a research protocol.” 
Given the differing objectives of the phase I and phase II studies, independent 
development and justification of the phase II assessment schedule was necessary. In 
particular, justification of the phase II study assessment schedule required identification 
and inclusion of the metrics from phase I that were relevant and necessary to answer 
the specific questions being addressed at phase II, and removal of those that were 
irrelevant and/or unnecessary. 
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 Pragmatic considerations identified through feedback from phase I participants on the 
tolerability of the assessment schedule. The participants have found the phase I study 
to be too long and an unchanged assessment schedule was likely to impact negatively 
on recruitment to phase II. 
 Advances in the understanding of cognitive impairment due to MS that have emerged 
since the phase I study was designed in 2010. 
3.3.    Phase II study design – general considerations 
The phase I study was designed by a PhD student Mara Sittampalam and her supervisor Thomas Bak 
to be an independent piece of observational research. Phase I was therefore configured as a cross-
sectional study without specific consideration to the possibility of longitudinal follow-up. An initial 
challenge was therefore to design a protocol that would enable conversion to a longitudinal study 
design, with phase II representing the first ‘wave’ of review and enabling the potential for subsequent 
‘waves’ as independent follow-on projects.  
3.3.1.    Study aims 
This study was designed to answer the research questions raised in the introduction and to evaluate 
the predictions made based on the review of previous literature.  
The first aim was to evaluate the dimensionality of cognitive impairment in MS. We questioned the 
popular view that MS affects only frontal functions: complex attention, information processing speed, 
(episodic) memory, and executive functions (Jongen, Ter Horst, & Brands, 2012). We postulated that 
an underappreciated subgroup of patients exists in whom pathology affecting ‘posterior’ brain 
regions results in detectable impairment(s) of posterior cognitive functions such as visuoperceptual 
and language abilities. We parsed this as two linked but separate questions: (i) what is the 
dimensionality of impairments in terms of cognitive abilities (test performance), and (ii) what is the 
dimensionality of our cohort with respect to recognisable profiles (clusters) of impairment (i.e. are 
there subgroups of the population with recognisable impairment profiles). These questions are 
separately addressed with respect to the phase I and phase II datasets in Chapter Five – The 
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Dimensionality of Cognitive Impairment in MS. We predicted that the pattern of cognitive deficits 
would become more homogeneous over time at the population level (as individuals accumulate an 
increasing number of distinct cognitive deficits). 
The second aim was to evaluate the predictors of longitudinal change in cognitive performance. We 
predicted that there would be a range of ‘within subject, within domain’ changes in the severity of 
cognitive impairment at the level of individual subjects – cognitive impairments could worsen, 
remain static or even improve over time; and that these possible trajectories could be seen within the 
same individual across cognitive domains. We then sought to explore the extent to which longitudinal 
changes in cognition could be explained by clinical, demographic and cognitive reserve variables. 
This aim is addressed in Chapter Six - The Trajectory, Extent, and Predictors of Cognitive Change 
in People with MS. 
The third aim of the project was to determine whether the participants themselves were able to 
perceive the longitudinal changes in their abilities in each cognitive domain, and to explore the 
factors associated with self-perception of cognitive change. This is addressed in Chapter Seven – 
Self-perceptions of Cognitive Impairment in MS. 
3.3.2.  Study population 
Consistent with a longitudinal study design, all phase II participants were drawn from the cohort who 
participated in the phase I study, comprising 108 pwMS and 33 healthy controls. 
3.3.3. Study environment 
All phase I assessments of participants with MS were conducted in a The University of Edinburgh 
hospital-setting either at the Western General Hospital, the Royal Infirmary Edinburgh, or at the 
Princess Alexandria Eye Pavilion, depending on the stage of the recruitment and the date of the 
patient availability. All assessments were performed in uniform settings that comprised of a well-lit 
quiet room with a desk. However, given the inevitable progression of disability during the interval 
between assessment visits, and to ensure maximal recruitment without biasing phase II towards 
inclusion of participants with minimal change in disability, it was decided to offer phase II 
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assessment visits at the participant’s home. This was indicated to be a secondary option if the 
participant was unable / unwilling to be assessed in a hospital-setting.  
The phase II hospital-based assessments for patient participants were conducted solely at the Anne 
Rowling Regenerative Neurology Clinic at a desk in a quiet and well-lit room, with a research nurse 
on-site during the assessments. The Anne Rowling Clinic is a University of Edinburgh facility at the 
Royal Infirmary Edinburgh that provides out-patient care for people with a neurological condition 
who have been referred by their GP or neurologist, and all clinical activity is undertaken in 
partnership with the UK's National Health Service (NHS). For assessments undertaken at the 
participant’s home, the subjects were seen seated in a well-lit quiet room of their choice. The 
measures taken to ensure that these visits would capture comparable data to that collected at the Anne 
Rowling Clinic included removal of potential distractors (TV, radio, family members, pets etc) and 
administration of materials in the same order according to the study protocol. 
Phase I and phase II assessments of healthy controls were conducted at the research laboratories of 
The University of Edinburgh Psychology Department. These rooms were identical to the rooms at 
the Anne Rowling Clinic, as they have been specially designed for cognitive assessments, and were 
quiet and well-lit and had only a desk with chairs inside.  
To ensure comparability, all phase II assessments were administered by a single researcher (the 
author), in the exact same order as per study protocol. The influence of practice effects due to item 
familiarity was mitigated by employing alternate forms of the BRBN and ACE-R. Other tests did not 
have alternative versions available therefore had the same versions administered. Moreover, in order 
to control for any potential practice and other effects, when analysing the results the longitudinal 
changes in patient performance scores were standardized accounting for the variability of controls’ 
scores (explained in detail in Chapter Six).  
3.3.4. Time-interval between phase I and phase II assessments 
In order to maximise recruitment at phase II, a pragmatic view was taken to allow participants 
flexibility in the precise time-interval between phase I and phase II assessment. Phase I data was 
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captured between February 2011 and October 2012, and phase II data was projected to be captured 
between July 2014 and June 2015. The anticipated interval between assessments was therefore 
approximately three years. This interval is long-enough to support a reasonable belief that any 
observed changes in cognitive performance were likely to be caused by disease progression rather 
than the short-term variability in function that typifies MS, noting also that cognitive deficits 
exhibited following a relapse can be reversible (Foong, et al., 1998).  
3.3.5.  Ascertainment and recruitment 
Since the phase I study was designed to have a cross-sectional design, the phase I participants had 
not given prior consent for their details to be passed to additional investigators, nor to be re-contacted 
with respect to further research projects. These permissions were therefore sought as part of 
submissions for ethical approval. Permission was also sought to access medical records to screen 
against phase II eligibility criteria prior to sending invitations to participate. Invitations to participate 
were sent by post to those subjects fulfilling phase II eligibility criteria, and followed up after two 
weeks by a telephone call. Written informed consent was taken before any study-specific procedures 
were undertaken. 
3.3.6. Eligibility criteria for phase II recruitment 
 Participation in the phase I study 
 Current residence in Scotland 
 Not developed a medical or psychiatric disorder that would preclude comparable assessment 
of cognitive performance, and patients not currently being on a relapse 




3.4.     Scope of the phase II cognitive assessment battery 
3.4.1.   Overview of optimization strategy for the phase II cognitive battery 
Both empirical and theoretical justifications were employed to derive the optimised phase II 
neuropsychological test battery. Specifically, the following framework was applied: 
I. Responsiveness of phase I tests to clinically relevant changes in cognition 
I first identified the phase I tests with significant ceiling effects that would reduce their value in 
longitudinal research. I then evaluated the frequency of phase I test failure among pwMS compared 
to controls in order to identify those tests with evidence of sensitivity to MS-related cognitive 
difficulties. Although no tests were excluded purely on these criteria, this information was used to 
inform on test selection within a given cognitive domain.  
II. Adequate coverage of cognitive domains 
An empirical and data-driven approach (principal component analysis [PCA]) was used to evaluate 
the dimensionality of cognitive test performance, informing on the relationship between specific tests 
and the independent dimensions of MS-related cognitive impairment. This enabled identification of 
the most relevant tests from each principal component (dimension) to include into the follow-up 
battery. This approach established a core battery for coverage of all significant dimensions, while 
allowing to minimise redundancy (when appropriate) by ensuring that the participants didn’t perform 
multiple cognitive tests that evaluate the same cognitive function. Recognising the relatively limited 
sample size at phase I, and the exploratory nature of such analyses, this empirical evidence was 
regarded as informative but subordinate to a separate evaluation of dimensionality and coverage 
using theory-based definitions of cognitive domains. Some tests were therefore included from within 
the same empirically defined dimension if theory-based models of cognition identified them as 




3.4.2.    Responsiveness to clinically relevant changes in cognition 
Temporal responsiveness to change could not be directly assessed from the cross-sectional phase I 
dataset. However, useful insights were possible by considering: (I) sensitivity to detect variability in 
cognitive function (i.e. the absence of a significant ceiling effect), and (II) sensitivity to detect 
impairment defined through a binary present/absent categorisation (i.e. sensitivity with respect to 
deficits that are likely to be ‘clinically relevant’). 
I. Sensitivity to detect  variability in cognitive function at phase I 
Coefficients of variation (COV) were used to provide a standardised assessment of variability in 
phase I scores between cognitive tests with widely differing absolute ranges. The COVs were defined 
as the ratio of standardized deviation to the mean. Higher COVs represent a simultaneous assessment 
of variability attributable to the measurement error of each test (not independently assessed at phase 
I) and to ‘true’ variability in cognitive ability. The COV for pwMS and control performance at phase 





Table 3.1. Ranked coefficients of variation (COVs) in cognitive test performance of pwMS and 
controls 
 
Test item PwMS COVs Control COVs 
SRTC 69.56% 33.67% 
PASAT  52.73% 31.09% 
SRTD 51.16% 22.41% 
SRTL 47.25% 22.63% 
SPARTD 35.39% 25.93% 
SPART 32.57% 23.11% 
BC.Index 31.33% 11.64% 
SDMT 30.83% 13.57% 
WLGT 26.54% 18.88% 
VOSP2 20.39% 13.73% 
GNT 17.32% 14.75% 
VOSP3 11.40% 7.58% 
VOSP7  10.77% 4.09% 
BORB5 9.11% 6.84% 
BORB2 8.58% 5.62% 
VOSP6 8.20% 2.15% 
BORB4 8.18% 6.08% 
TTT 8.15% 4.49% 
BORB3 7.90% 6.39% 
KDT 7.89% 6.98% 
Orchard test 7.53% 4.45% 
VOSP8 7.53% 3.08% 
PPT 7.30% 6.51% 
SPMT 7.18% 4.20% 
MPNWDS 5.75% 2.14% 
TROG 5.22% 3.79% 
VOSP5 5.22% 1.86% 
 
Table 3.1. shows COVs for pwMS and control participants’ performance on the phase I cognitive 
tests. The COV was defined as the ratio of the standard deviation to the mean.  
 
Abbreviations: pwMS – people with MS, SRT – Selective Reminding Test (SRTL – Long Term Storage, 
SRTC – Consistent Long Term Retrieval, SRTD – delayed retrieval), SDMT – Symbol Digits Modalities 
Test, PASAT – Paced Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART – items 
correct at learning stage, SPARTD– items correct at delayed recall), WLGT – Category Animal 
Fluency task, VOSP – Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, 
VOSP3 – Object Decision Task, VOSP5 - Dot Counting Test, VOSP6 – Position Discrimination Task, 
VOSP7 – Number Location Task, VOSP8 – Cube Counting Task,) BORB – Birmingham Object 
Recognition Battery (BORB2 – Line Length Matching Task, BORB3 – Size Matching Task, BORB4 – 
Line Orientation Matching Task, BORB5 – Position of Gap Matching Task, GNT – Graded Naming 
Test, TROG – Test of Reception of Grammar, MPNWDS – Minimal Pairs Non-Words Task, TTT – 
Tomato and Tuna Test, PPT – Pyramids and Palm Trees Test, KDT – Kissing and Dancing Test, BC – 
Boston Cookie Test (BC.Index – Index of ratio of picture variables to number of words), SPMT – 




As it can be seen from the Table 3.1, the tests with the highest COVs were the items from the BRBN, 
BCT and the WLGT tests. As was expected, we have identified the same tests that in the previous 
literature have been defined as most suitable to detect MS-related cognitive impairment. However, 
it is important to note that we found these tests to have high coefficients of variation for the control 
performance as well, suggesting that non-pathological variability and/or measurement error were 
significant. Therefore, in order to dissect the component attributable to true differences (variability) 
in cognitive function due to MS, the ratio of COVs was derived (pwMS / controls) and is presented 
in descending rank in Table 3.2. 
As it can be seen from Table 3.2, the top six ranked tests were all visuoperceptual or language tasks. 
Although the COVs were small in absolute terms for these tests, the ratio suggested that a change in 




Table 3.2. Ranked relative variability in cognitive test performance between pwMS and controls 
 
Test PwMS COV Control COV Ratio (pwMS COV/ control COV) 
VOSP6 8.20% 2.15% 3.81 
VOSP5 5.22% 1.86% 2.81 
BC.Index 31.33% 11.64% 2.69 
MPNWDS 5.75% 2.14% 2.69 
VOSP7 10.77% 4.09% 2.63 
VOSP8 7.53% 3.08% 2.44 
SRTD 51.16% 22.41% 2.28 
SDMT 30.83% 13.57% 2.27 
SRTL 47.25% 22.63% 2.09 
SRTC 69.56% 33.67% 2.07 
TTT 8.15% 4.49% 1.82 
SPMT 7.18% 4.20% 1.71 
PASAT 52.73% 31.09% 1.70 
Orchard test 7.53% 4.45% 1.69 
BORB2 8.58% 5.62% 1.53 
VOSP3 11.40% 7.58% 1.50 
VOSP2 20.39% 13.73% 1.49 
SPART 32.57% 23.11% 1.41 
WLGT 26.54% 18.88% 1.41 
TROG 5.22% 3.79% 1.38 
SPARTD 35.39% 25.93% 1.36 
BORB4 8.18% 6.08% 1.35 
BORB5 9.11% 6.84% 1.33 
BORB3 7.90% 6.39% 1.24 
GNT 17.32% 14.75% 1.17 
KDT 7.89% 6.98% 1.13 
PPT 7.30% 6.51% 1.12 
  
Table 3.2. Coefficients of variation (COV) are shown for pwMS and control participants’ 
performance on the phase I cognitive tests. The COV was defined as the ratio of the standard 
deviation to the mean. The ratio of COVs is also shown, with ranking from highest (variability in the 
MS cohort scores greater than in controls) to lowest (variability in the MS cohort scores similar to 
that in controls).  
 
Abbreviations: pwMS – people with MS, SRT – Selective Reminding Test (SRTL – Long Term Storage, 
SRTC – Consistent Long Term Retrieval, SRTD – delayed retrieval), SDMT – Symbol Digits Modalities 
Test, PASAT – Paced Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART – items 
correct at learning stage, SPARTD– items correct at delayed recall), WLGT – Category Animal 
Fluency task, VOSP – Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, 
VOSP3 – Object Decision Task, VOSP5 - Dot Counting Test, VOSP6 – Position Discrimination Task, 
VOSP7 – Number Location Task, VOSP8 – Cube Counting Task,) BORB – Birmingham Object 
Recognition Battery (BORB2 – Line Length Matching Task, BORB3 – Size Matching Task, BORB4 – 
Line Orientation Matching Task, BORB5 – Position of Gap Matching Task, GNT – Graded Naming 
Test, TROG – Test of Reception of Grammar, MPNWDS – Minimal Pairs Non-Words Task, TTT – 
Tomato and Tuna Test, PPT – Pyramids and Palm Trees Test, KDT – Kissing and Dancing Test, BC – 
Boston Cookie Test (BC.Index – Index of ratio of picture variables to number of words), SPMT – 




II. Detection of Cognitive Impairment at Phase I 
In order to estimate the prevalence of cognitive impairment it was first necessary to define what a 
cognitive impairment is by establishing cut-off scores indicating a deviation from the norm. 
a) Definition of Impairment on Neuropsychological Tests at Phase I 
In order to define impairment on the cognitive tests used at phase I, the cut-off values from previously 
published test-validation studies were therefore reviewed. For the experimental tests which had not 
yet been validated and therefore lacked published cut-offs, we used the norms that the test authors 
have employed in their studies for other purposes. For cognitive tests where the authors suggest 
adjusting subject-specific thresholds based on age, gender, or years of education, these were 
reviewed separately. As it can be seen from the Appendix A, most of the cognitive tests included in 
the phase I battery did not have well-established cut-off values, and very few tests have had MS-
specific normative values. Moreover, for several tests different studies suggest discrepant normative 
values.  
Appendix A shows cut-offs at 1.5SD and 2SD below the validation control sample mean. In research 
concerning cognitive impairment in neurodegenerative diseases of older age it is a tradition to use a 
cut-off of 2SD or 5th centile below control performance (if the data’s sufficiently normally distributed) 
but, however, since MS develops early in the lifespan, some authors suggest to employ higher cut-
off values, such as 1.5SD below control mean (Amato et al., 2010; Borghi, et al., 2013). 
For many of the neuropsychological tasks employed, the previously published normal ranges of 
scores were either based on different reference groups, or not available (e.g. BORB), or not published 
in detail (e.g. TROG and BCT test). Therefore to ensure that the cut-off values for all the phase I 
tests were available, contemporaneous, and comparably valid, definitions of impairment were 
independently derived using the phase I control data. Three cut-off values were considered for each 
test: performance below the 5th percentile, and two based on standard deviations below our control 
sample mean (1.5SD and 2SD). These cut-off values produced on the dataset from phase I control 
cohort can be seen in Table 3.3. These values were then compared to published normative values 
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(Appendix A) to select the most appropriate cut-off values for our sample that would in turn provide 
consistency and therefore interpretability in the context of the existing literature.   
 
Table 3.3. Comparison of three common definitions for impairment on individual cognitive tasks. 
The 2SD, 5th centile and 1.5SD cut-off values were derived from the performance of the phase I 















SRTL 28 25 33 
SRTC 13 12 20 
SRTD 6 5 7 
SDMT 40 41 43 
PASAT 18 0 25 
SPART 12 14 14 
SPARTD 4 5 5 





VOSP2 17 17 19 
VOSP3 16 16 17 
VOSP5 10 10 10 
VOSP6 20 19 20 
VOSP7 10 9 10 





 BORB2 24 24 25 
BORB3 25 25 26 
BORB4 24 25 25 
BORB5 32 32 34 
 TROG 36 35 37 
 BC.Index 32% 35% 35% 
 PPT 21 21 22 
 KDT 20 19 21 
 TTT 23 22 23 
 GNT 18 16 20 
 MPNWDS 46 45 46 
 Orchard test 9 9 10 
 SPMT 27 26 27 
 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long Term 
Retrieval, SRTD – delayed retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced Auditory Serial 
Addition Test, SPART – 10/36 Spatial Recall Test (SPART – items correct at learning stage, SPARTD– items 
correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – Visual Object and Space Perception 
Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object Decision Task, VOSP5 - Dot Counting Test, VOSP6 – 
Position Discrimination Task, VOSP7 – Number Location Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB3 – Size Matching Task, 
BORB4 – Line Orientation Matching Task, BORB5 – Position of Gap Matching Task, GNT – Graded Naming Test, 
TROG – Test of Reception of Grammar, MPNWDS – Minimal Pairs Non-Words Task, TTT – Tomato and Tuna 
Test, PPT – Pyramids and Palm Trees Test, KDT – Kissing and Dancing Test, BC – Boston Cookie Test (BC.Index 




After comparing the 5th centile, 1.5SD and 2SD below control mean cut-off values with the published 
norms (Appendix A), it was decided that the cut-offs at 5th centile and 2SD below control mean were 
most compatible to the published norms therefore most suitable to proceed with and allow 
comparisons of our results to previous work. To avoid the risk of having too liberal cut-offs that 
include too many control participants thus making Type 1 error, it was decided not to proceed with 
the 1.5.SD cut-off values. The main difference between 5th centile and 2SD cut-off values were the 
values on the PASAT test. Specifically, from our sample two of thirty-three controls (6%) had found 
the PASAT instructions too difficult to understand and thus had failed to perform even the practice 
items resulting in a PASAT score of 0. Table 3.3. shows that the 5th centile value for the PASAT is 
0, but this problem could be avoided when using the cut-off value of 2SD.  
Therefore the impairment on the tests in the baseline battery was defined to be at 2SD below control 
mean. It is important to note, however, that due to the reference group we used, in our sample the 
cut-off values chosen were higher for the majority of BRBN and VOSP tasks than those proposed 
by the test authors. Therefore as a consequence these tests became more sensitive (and less specific) 
to detect cognitive problems in the MS sample.  
b) Defining normal performance at phase II 
2 SD thresholds were also applied to the phase II control cohort and gave differing values for the 
majority of phase II tests. The differences between phase I and phase II cut-off values are presented 
in Chapter Five. 
c) Frequency of impairment on neuropsychological tests 
The frequency of cognitive test-failure for the phase I cohort is shown in Figure 3.1. These figures 
account for missing observations and the prevalence of impairment is expressed as a percentage (the 







Figure 3.1. Frequency of cognitive impairment in pwMS by individual cognitive task at phase I 
 




3.1 B. True frequencies (%) of pwMS failing each cognitive task (percentage of pwMS failing 




Abbreviations: pwMS – people with MS, SRT – Selective Reminding Test (SRTL – Long Term Storage, 
SRTC – Consistent Long Term Retrieval, SRTD – delayed retrieval), SDMT – Symbol Digits Modalities 
Test, PASAT – Paced Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART – items 
correct at learning stage, SPARTD– items correct at delayed recall), WLGT – Category Animal 
Fluency task, VOSP – Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, 
VOSP3 – Object Decision Task, VOSP5 - Dot Counting Test, VOSP6 – Position Discrimination Task, 
VOSP7 – Number Location Task, VOSP8 – Cube Counting Task,) BORB – Birmingham Object 
Recognition Battery (BORB2 – Line Length Matching Task, BORB3 – Size Matching Task, BORB4 – 
Line Orientation Matching Task, BORB5 – Position of Gap Matching Task, GNT – Graded Naming 
Test, TROG – Test of Reception of Grammar, MPNWDS – Minimal Pairs Non-Words Task, TTT – 
Tomato and Tuna Test, PPT – Pyramids and Palm Trees Test, KDT – Kissing and Dancing Test, BC – 
Boston Cookie Test (BC.Index – Index of ratio of picture variables to number of words), SPMT – 












































































































































































































































Some tests had very few missing cases, for example the tests from the BRBN battery (105 to 107 of 
108 observations), but some other tests had a lot of missing cases, such as the BCT test (90 of 108 
observations). In the phase I assessment the missing data can be explained by which of the two or 
three study-appointments that particular individual has missed or at which point the fatigue became 
insurmountable. Missing data in the phase I dataset therefore could not be confirmed as missing at 
random, and under these circumstances imputation is unadvisable and thus was not performed. In the 
following result analyses the missing values were handled by exclusion. 
As it can be seen from Figure 3.1A, more pwMS fail tests of memory and information processing 
speed than tests of semantic processing and naming. This has been a consistent and widely reported 
finding since Rao’s seminal paper in 1991 (Rao et al., 1991).  
It initially appeared that the rates of impairment were very similar across all BRBN tests that assess 
attention/concentration, verbal and visuospatial learning and recall, whereas there were widely 
differing rates of impairment on the visuoperceptual and language tests at baseline. To understand 
this, it was necessary to account for the relative difficulty of the tests. We investigated the true 
frequencies of MS patients failing each task by calculating how many controls have failed each of 
the tests and subtracting the frequencies of control failure (Figure 3.1B). 
By investigating the true frequencies we have managed to identify the tasks that can be considered 
difficult to the patient participants only, from the tasks that are just challenging for everybody. This 
has helped in detecting the MS-related impairments.  
3.4.3.     Ensuring adequate coverage of cognitive domains and minimizing 
redundancy 
I. Empirical evaluation of dimensionality in phase I cognitive performance 
In order to evaluate the dimensionality of cognitive performance and the relationship of individual 
tests to identifiable dimensions, principal components analysis (PCA) was conducted using R-studio 
(version R 0.97.551) packages paran, princomp, GPArotation and rela. 
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Prior to running the PCA we checked whether our data met the relevant assumptions. First we 
checked each individual variable for normality of its distribution, and then separately we analysed to 
what extent the variables correlated with each other. Factorability was tested by analysing the 
sampling adequacy measures, and determining whether the sample size was sufficient. 
a) Testing assumptions of data distribution 
Prior to running the PCA the normality of distribution of test items was checked for using a Shapiro-
Wilk test and by analysing the distribution histograms. The results of initial exploration of univariate 
normality can be seen in Appendix B.  
The results from the initial exploration of normality with Shapiro-Wilk tests were discouraging. 
However, the Shapiro-Wilk test is often reported to be overly conservative, and individual histograms 
are typically considered to be more informative (see Appendix B for histograms for each variable). 
The normality of distributions of each groups of tests were discussed below: 
BRBN items: SRTL, SRTC and SRTD, SDMT, SPART, SPARTD, and WLGT items were 
sufficiently normal to allow ongoing inclusion in analyses. The PASAT was markedly platykurtotic. 
Transformation could not alter this, but platykurtosis is considered to allow responsiveness to the 
latent variable, thus judgment was taken that it is preferable to include the PASAT scores.   
Visuoperceptual items: All visuoperceptual items had significant negative-skew, which in this 
instance wasn’t much of a problem since it meant that all visual cognition items were similarly easy 
to the participants. It could be argued that VOSP2 and VOSP3 and all of the BORB items were 
sufficiently normally distributed since they had only one peak and no clear ceiling effect. However, 
due to problematic negative skew (obvious ceiling effect) on items VOSP5, VOSP6, VOSP7 and 
VOSP8, I further explored whether the negative skew could be in part mitigated by logarithmic 
transformation. 
Language items: The distribution of the language items faced similar problems as the 
visuoperceptual tests; they were also significantly negatively skewed. Only the BC.Index, PPT, KDT 
and GNT items could be argued to be not very different from normal distribution as they had only 
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one peak and less obvious ceiling effect. However, an obvious ceiling effect could be observed in 
the TROG, TTT, MPNWDS, SPMT and the Orchard tasks. It was therefore decided to attempt to 
logarithmically transform these items as well. Logarithmic transformations were employed for the 
non-normally distributed items, using the natural log (LN) function for each variable. As it can be 
seen from Table 2 in the Appendix B, the transformation did not improve the skewness of those 
variables.  
For this purpose it was decided to plot the logarithmically transformed distributions of those variables 
and upon visual inspection to estimate the level to which the ceiling effect was prominent. The 
histograms of the logarithmically transformed distributions of these variables have also been 
included in the Appendix B. I have also attempted the following transformations: Log10(x), Sqrt(x), 
1/x, where x was the variable to be transformed. I also tried running all of these transformations by 
replacing x with (k-x) where k was the highest observed value in each variable, but because the 
negative skew was so prominent, none of these attempts helped bring the distributions closer to 
normal. Since even after the transformation the ceiling effect was still very much prominent it was 
concluded that these variables had too much negative skew to be included into the PCA. Therefore 
it was decided to omit these items from the PCA.  
The items included into the PCA were all eight BRBN items (SRTL, SRTC, SRTD, SPART, 
SPARTD, SDMT, PASAT, WLGT), six visuoperceptual tests (VOSP2, VOSP3, BORB2, BORB3, 
BORB4, BORB5) and four language items (GNT, PPT, KDT and BC,Index).  
b) Testing assumptions of factorability 
Correlations between variables: Since a large number of items were non-normally distributed 
(Appendix B) I chose to employ the non-parametric Spearman’s test to measure the extent to which 
the items from the cognitive tests were inter-correlated (i.e. that there were at least some correlations 
amongst the variables so that coherent factors could be identified). All 18 items were entered to this 
analysis and I produced an 18x18 table of correlations (Table 3.4). From analysing the data presented 




Table 3.4. Correlations among cognitive test items performed as part of principal component 








































































SRTL                   
SRTC .888                  
SRTD .699 .752                 
SPART .319 .339 .380                
SPARTD .270 .280 .313 .721               
SDMT .373 .412 .515 .425 .435              
PASAT .318 .347 .253 .276 .293 .516             
VOSP2 .193 .198 .261 .274 .242 .364 .237            
VOSP3 .156 .148 .065 -.03 -.04 .186 .165 .353           
BORB2 .079 .138 .110 .024 .077 .110 .108 .048 .020          
BORB3 .151 .253 .286 -.01 .030 .169 .084 .310 .125 .418         
BORB4 .132 .124 .163 .081 .268 .065 .213 .218 .042 .150 .134        
BORB5 .175 .207 .194 .103 .185 .269 .180 .161 .057 .425 .254 .211       
GNT .260 .284 .261 .242 .187 .307 .363 .505 .385 .008 .189 .162 .234      
KDT .155 .245 .352 .133 .124 .294 .084 .303 .061 .029 -.03 -.07 .143 .117     
PPT .176 .229 .335 .034 .076 .341 .155 .396 .238 -.01 .229 .200 .165 .367 .455    
WLGT .327 .308 .344 .299 .369 .500 .437 .317 .254 .110 .022 .193 .226 .415 .131 .135   
BC.Index -.07 .023 -.04 .121 -.01 .075 -.06 .108 .217 -0.1 -0.1 -.04 -.01 .018 -.04 .053 .143  
 
The sections in bold represent statistically significant relationships (p < 0.05, unadjusted for multiple 
comparisons) 
 
Abbreviations: SRT – Selective Reminding Test (SRL – Long Term Storage, SRTC– Consistent Long Term 
Retrieval, SRTD – delayed retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced Auditory Serial 
Addition Test, SPART – 10/36 Spatial Recall Test (SPART – items correct at learning stage, SPARTD– items 
correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – Visual Object and Space 
Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object Decision Task) BORB – Birmingham 
Object Recognition Battery (BORB2 – Line Length Matching Task, BORB3 – Size Matching Task, BORB4 – 
Line Orientation Matching Task, BORB5 – Position of Gap Matching Task, GNT – Graded Naming Test, 
PPT – Pyramids and Palm Trees Test, KDT – Kissing and Dancing Test, BC – Boston Cookie Test (BC.Index 




Testing for sphericity: Bartlett test of sphericity was found to reach significance (X2(136) = 638.6, p 
< 0.001), therefore it was concluded that the sample intercorrelation matrix did not come from a 
population in which the intercorrelation matrix is an identity matrix, and it was safe to proceed with 
further analyses. 
Testing for sampling adequacy: I used the measures of sampling adequacy to investigate the degree 
of collinearity among the variables. The measures of sampling adequacy for individual items can be 
seen in Table 3.4. The BC.Index test item did not reach the minimum requirement for sampling 
adequacy and was therefore excluded from further analyses.  
 
Table 3.5. Values of measures of sampling adequacy (MSA) for items considered to include into 






















OVERALL MODEL 0.719 
 
Abbreviations: SRT – Selective Reminding Test (SRTL– Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – delayed retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART – items correct at learning 
stage, SPARTD– items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task) BORB – Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, 
BORB3 – Size Matching Task, BORB4 – Line Orientation Matching Task, BORB5 – Position of Gap 
Matching Task, GNT – Graded Naming Test, PPT – Pyramids and Palm Trees Test, KDT – Kissing and 




For our sample matrix the Kaiser-Meyer-Olkin (KMO) measure of sampling adequacy was 0.719, 
which met the minimum criteria of being higher that 0.5 and it was reasonable to conclude that if a 
PCA was conducted, the factors extracted would account for a sufficient amount of variance but 
although not a substantial amount (Cerny & Kaiser, 1977). 
Having removed all the missing observations, the following PCA was conducted on scores from 95 
patients that had full data from phase I assessment on all 17 variables included into the PCA. Ideally 
for a PCA, there should be a large ratio of N / k (Cases / Items), e.g., > ~20:1, but PCA is considered 
to still be reasonably done with ~5:1, with bare minimum for pilot study purposes as low as ~3:1 
(Fabrigar, Wegener, MacCallum, & Strahan, 1999). Since there were 17 variables in the PCA and 
95 patients with full data, this gave a ratio of 5.58, which was reasonably high to allow further 
investigations. 
c) Number of retained components from principal component analysis 
Scree plot: To determine the most appropriate number of factors to extract from the PCA I used 
Cattell’s Scree Plot. This is a plot of Eigenvalues associated with each of the factors extracted, against 
each factor. Principal components with Eigenvalues higher than 1 are typically regarded to be worthy 
of retention due to their contribution of explanatory value. As shown in Figure 3.2, a four-factor 
solution was supported.  




Table 3.6. Loadings from the first four factors from the Principal Component Analysis solution  
 
Item Factor 1 Factor 2 Factor 3 Factor 4 Communality Uniqueness 
SRTL 0.93 -0.03 0.00 -0.03 0.830 0.170 
SRTC 0.99 -0.04 -0.01 0.03 0.964 0.036 
SRTD 0.73 0.14 0.06 0.03 0.678 0.322 
SPART 0.12 0.04 0.70 -0.04 0.571 0.429 
SPARTD -0.02 -0.02 1.01 0.01 0.995 0.005 
SDMT 0.24 0.37 0.26 0.05 0.450 0.550 
PASAT -0.05 0.01 -0.11 0.16 0.036 0.964 
WLGT 0.08 0.41 0.24 0.04 0.348 0.652 
VOSP2 -0.08 0.82 0.07 0.02 0.675 0.325 
VOSP3 0.04 0.50 -0.13 0.01 0.240 0.760 
BORB2 0.00 -0.06 -0.02 0.82 0.658 0.342 
BORB3 0.08 0.29 -0.07 0.42 0.331 0.669 
BORB4 -0.06 0.21 0.22 0.19 0.157 0.843 
BORB5 0.10 0.15 0.10 0.44 0.314 0.686 
GNT 0.10 0.55 -0.10 -0.03 0.315 0.685 
KDT 0.19 0.24 0.00 -0.11 0.122 0.878 
PPT 0.16 0.49 -0.14 -0.08 0.273 0.727 
       
Proportion 
variance 






















Note. Loadings of 0.40 or higher are highlighted in each factor 
 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – delayed retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART – items correct at learning 
stage, SPARTD – items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task) BORB – Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, 
BORB3 – Size Matching Task, BORB4 – Line Orientation Matching Task, BORB5 – Position of Gap 




Model-level explanatory power vs. parsimony: Given the exploratory nature of the analysis, four-, 
three- and two-factor solutions were evaluated. The Bayesian information criterion (BIC) was -243, 
-276.59, and -269.35 respectively. Although this supported the three-factor model as an optimum 
balance between explanatory value and parsimony, the three-factor model explained only 38% of 
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variance whereas the four-factor model explained 44% of variance. Since coverage of a broad range 
of cognitive functions was central to the overall project’s success, the four-factor solution was 
preferred; and the factor loadings from the four-factor solution can be seen in Table 3.5. 
d) Interpretation of the identified dimensions (factors) 
The four-factor solution presented in Table 3.5 accounted for 44% of total variance. The most 
important factor (explaining 15% of the total variance) was related to verbal learning and memory, 
and consisted of the BRBN SRT task variables. The second factor (explaining 12% of the total 
variance) defined semantic object knowledge and consisted of the naming tasks. The third factor (10% 
total variance) was visuospatial learning and memory and was comprised of the SPART items. The 
fourth factor (7% total variance) comprised of items measuring pre-categorical properties of objects. 
This analysis was restricted to patients, however when repeated with the controls they resulted in no 
substantive changes for key findings. 
III.  A theory-based account of dimensionality in the phase I dataset 
Classical psychology (encompassing cognitive neuropsychology) posits a modular structure of 
cognitive abilities (Fodor, 1983). The coverage of the phase I battery with respect to conventionally 
understood cognitive functions (dimensions) was presented in Table 3.6. The phase I battery 
contained tests of memory domain, sustained attention and concentration and processing speed 
domain, visuoperceptual and language domains. It also included two tests of audio-visual integration 
that theoretically would fall into both visuoperceptual and language domains as they involved visual 
processing and semantic knowledge about objects.  
During the process of optimisation it was attempted to ensure that the phase II battery would retain 
the dimensionality and coverage of the phase I battery. This would therefore allow for valid 
comparisons between baseline and follow-up assessments to be made, and ensure that the 




Table 3.7. Theoretical account of the coverage of the phase I battery 
 
 
Test item Function Domain 
SRTL Verbal learning, long-term storage 
Verbal memory SRTC Verbal learning, consistent long-term retrieval 
SRTD Verbal memory, delayed recall 
SPART Visuospatial learning, long term storage Visuospatial memory 
SPARTD Visuospatial memory, delayed recall 




PASAT Auditory addition and inhibition 
WLGT Spontaneous production of names in a category 
VOSP5 Space perception, single point localization 
Visuoperceptual 
VOSP6 Space perception, position discrimination 
VOSP7 Space perception, position identification 
VOSP8 Space perception, complex spatial relationships 
BORB2 Apperceptive recognition of length 
BORB3 Apperceptive recognition of size 
BORB4 Apperceptive recognition of orientation 
BORB5 Apperceptive recognition of position 
VOSP2 Object perception, Silhouette recognition and naming 
VOSP3 Object perception, object identification 
Orchard test Audio-visual non-semantic processing Audio-visual 
integration SPMT Audio-visual semantic processing 
GNT Expressive semantics, object naming 
Language 
BC.Index Expressive syntax, spontaneous language production 
PPT Understanding semantic relationships between nouns 
KDT Understanding semantic relationships between verbs 
TTT 
Understanding semantic relationships between 
sequential events 
TROG Reception of grammatical constructs 
MPNWDS Receptive phonology, auditory non-semantic 
discrimination 
 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – delayed retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART – items correct at learning 
stage, SPARTD – items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task, VOSP5 - Dot Counting Test, VOSP6 – Position Discrimination Task, VOSP7 – Number 
Location Task, VOSP8 – Cube Counting Task,) BORB – Birmingham Object Recognition Battery 
(BORB2 – Line Length Matching Task, BORB3 – Size Matching Task, BORB4 – Line Orientation 
Matching Task, BORB5 – Position of Gap Matching Task, GNT – Graded Naming Test, TROG – Test 
of Reception of Grammar, MPNWDS – Minimal Pairs Non-Words Task, TTT – Tomato and Tuna Test, 
PPT – Pyramids and Palm Trees Test, KDT – Kissing and Dancing Test, BC – Boston Cookie Test 






3.5. Optimization of the phase II cognitive assessment battery: a 
synthesis 
 
In order to combine the preceding considerations and resolve a final phase II assessment battery, the 
following were prioritised (in order of importance): domain coverage (theoretical), domain coverage 
(data-driven), non-redundancy, detection of impairment, detection of variability, and practical 
considerations. 
3.5.1. Domain coverage 
The first PCA factor clustered together tasks that measure verbal learning and recall, and it consisted 
of three items and all of them were derived from the same SRT task. Since in order to collect the 
SRTL, SRTC and SRTD items it takes the same one administration procedure and they are all 
individually informative as they measure different aspects of verbal memory, it would be counter-
productive to remove any of them, as the battery wouldn’t become shorter to administer, but it would 
most definitely lose coverage. Therefore it was decided not to remove any of the first factor items. 
The second factor clustered together the neuropsychological tasks that measure picture naming 
ability and storage of semantic knowledge about objects, but not the semantic knowledge about 
actions, as KDT did not load highly on this factor. Even though all of the items in factor 2, including 
WLGT, VOSP2, VOSP3, GNT and PPT, are administered slightly differently, as in Animal fluency 
the participants are required to name animals from memory, in GNT they need to name pictures of 
objects, in VOSP items the participants name shadows of objects, and in PPT participants match two 
objects by their meaning; however, all of these tests are believed to measure the same semantic 
storage function. Therefore it is reasonable to conclude that these items could be considered 
redundant and that some of them could be removed in order to abbreviate the battery. 
The third factor clustered items from one test only, SPART, and included an item measuring the 
visuospatial learning, and an item measuring the delayed visuospatial recall. Similarly as with the 
items in factor 1, both of the items in factor 2 came from the same test and complement each other 
by measuring different components of visuospatial memory, and dropping one of them would have 
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only decrease the coverage of the battery without shortening its administration time. Therefore it was 
decided not to remove any of the third factor items. 
The fourth factor clustered three items from the BORB battery: BORB2, BORB3 and BORB5. 
Contrastingly to the items from the factor 2, the factor 4 item properties were not tied to stored 
knowledge about the particular objects involved. In this instance they were directed solely at the 
perception of basic properties and object forms – those include their size, orientation, location and 
length. Since all of these items measure similar functions, they cannot be said to be entirely 
overlapping, as matching for length involves not entirely the same neuropsychological functions as 
matching for orientation and location, therefore these items could not be argued to be redundant. 
Therefore it was decided not to remove any of the items from factor 4.  
From the PCA investigation of domain coverage I identified items that did not load on any of the 
factors, (i.e. all of the loadings for those items were below 0.35). Such items included SDMT, PASAT, 
BORB4 and KDT. Since SDMT was the only item assessing information processing speed, and the 
PASAT was the only item that assessed attention and concentration, it was decided to leave them in 
the battery. Furthermore, in the prevalence analysis SDMT proved to be a suitable test for picking 
up MS-related cognitive impairment, thus it would be unreasonable to exclude it based on the 
analysis of coverage only. However, the situation with the PASAT was not as clear – a moderate 
number of patients have failed it, but at the same time, it was too difficult for two of the controls as 
well. Since the PASAT is part of the BRBN battery and one of the most popular cognitive tests in 
MS research, it was decided to retain it for the phase II battery in order to be able to compare our 
results to other research studies. However, the same did not apply to the BORB4 and KDT tests. 
These tests have not been validated in MS and haven’t been used in other studies, thus I couldn’t 
even use them to compare our results to previous research. Therefore it was decided to exclude those 





 From the analysis of redundancy I found that the factor 2 items WLGT, VOSP2, VOSP3, GNT and 
PPT measured the same function. I used the prevalence of impairment analysis (presented earlier in 
this chapter, section 3.4.2.) to decide which of those items to drop. As the least patients have failed 
the GNT and PPT items, those tests have been decided to be less effective measures of the semantic 
knowledge and therefore were decided to be removed. 
3.5.3. Detection of impairment and variability 
Items that have true frequencies of failure for MS patients higher that 10% were regarded as 
important to retain. However, of those with a true frequency of failure below 10% (in decreasing 
order: BORB3, PPT, BORB5, VOSP8, VOSP5, GNT, Orchard test and KDT), I elected to include 
BORB5 and VOSP8 to demonstrate contrast, pick up the new emerging impairments, and ensure 
sufficient coverage of the visuoperceptual domain. 
3.5.4. Practical considerations 
It was decided to remove the Orchard task and the SPMT task based on practical grounds as they 
simultaneously measure both auditory and visual functions and are therefore challenging to interpret. 
MPNWDS, KDT, TTT and PPT tests were omitted as they were considered to be experimental in 
their nature and had not yet been validated in MS samples. So far to the best of my knowledge they 
have only been used with MND patients and on small numbers. In addition, the KDT, PPT, TTT, 
Orchard, SPMT, and MPNWDS tasks required two separate laptops to administer and since data 
collection included travelling to patient homes carrying all of the materials with the researcher, for 
practicality reasons it was decided to avoid including these items.  
The NART test was omitted from the phase II battery, as it was considered to be a measure of 
premorbid intelligence that (theoretically) should not change at re-assessment. Repeated 





3.6. Inclusion of additional assessments not performed in phase I 
Consideration was given to advances in the understanding of cognitive impairment in MS that have 
emerged in the time interval since design of the phase I study. Two principal areas were identified: 
cognitive reserve and self-perception of change. 
3.6.1.      Cognitive reserve 
Recent publications in cognitive epidemiology increasingly stress the role that cognitive reserve 
plays in susceptibility to cognitive impairment and in the rate of progression of cognitive symptoms 
in both healthy and clinical populations. It was therefore decided to include a short assessment of 
MS-specific cognitive reserve and cognitive leisure activities questionnaire developed by Sumowski 
and colleagues (Sumowski et al., 2010). 
3.6.2.       Other advances of relevance  
I also added a few questions that relate to factors that in the previous literature have been shown to 
have a positive effect on preventing cognitive decline. The first item related to bilingualism research, 
and I added a question that asks participants whether they speak any other languages besides English. 
The level of foreign language ability required to count the language as spoken is being able to ask 
for directions in the street and order a meal in the restaurant. The self-reported number of languages 
spoken was chosen to be recorded.  
The second item added was related to physical activities and relates to previous research on benefits 
of exercising on concentration. In this study we asked the participants to indicate whether they take 
part in physical activities. Walking was not considered as exercise. More strenuous physical activities, 
such as running, swimming, cycling or hiking were counted as exercise, as well as such activities as 
Yoga, Pilates, stretching or muscle toning.  
In the phase II study I’ve also chosen to collect data on participants’ employment status. All 
participants were asked to indicate if they were employed at the point of phase II assessment, and 
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whether they had been employed at the point of phase I assessment. No distinction was made between 
part-time and full-time employment, and volunteering was not regarded as employment  
3.6.3.     Self-perception of changes in cognitive performance 
Another type of evaluation added to the phase II battery was an assessment of the perceived 
progression of cognitive deficits. Performing this assessment allowed me to evaluate the cognitive 
change not only objectively, but also subjectively from the patient perspective. 
The self-evaluation of performance at phase II was measured by asking the participants to estimate 
their test performance on a 100-point scale from ‘very poor’ to ‘very good’ after completing the test 
(e.g. how well you think you performed on these tests?). Then the participants were asked to indicate 
on the same scale from 0 to 100 how they think they had performed on the same tests at the baseline 
(phase I) assessment. If the participant indicated that they estimate they’ve performed around 50th 
centile at the follow-up and then that they think that they’ve performed at 70th centile at the baseline, 
this would indicate that the subject perceived a 20% decrease in one’s cognitive ability in the time 
interval between the phase I and phase II assessments. The participants were informed that 
differences above 10% will be regarded as perceived change in their performance, so if they were 
unsure about whether they have changed or not they were asked to rate their performance at phase II 
in the range of -10 to +10 from their performance at phase I. 
Having included the additional assessments of cognitive reserve and insight, I devised the final 
version of the optimised phase II battery. The items included into the phase II battery assessed 
physical ability; memory, processing speed, attention, semantic fluency; visuoperceptual abilities; 
receptive and expressive language abilities; self-perception of deficit progression, and questionnaires 
on cognitive reserve, depression, and MS impact on life, as well as additional questions about 




3.7. Phase II assessment schedule 
All phase II assessments were administered by the author at a single visit. Since the assessments of 
phase I and phase II were administered by two different researchers as two separate PhD projects, 
several steps were taken to ensure inter-observer reliability and comparability of the results. Those 
steps included administering the assessments in the same sequence and by using the same test-
administration procedure and strictly following the test administration protocols developed by the 
test authors.  
Table 3.8. Items included into the phase II assessment battery 
 
Self-administered questionnaires Cognitive tests Clinical measures 
Beck’s Depression Inventory II (BDI-II) Addenbrooke’s Cognitive 
Examination – Revised (ACE-R) 
Snellen chart 
Multiple Sclerosis Impact Scale (MSIS-
29) 
Brief Repeatable Battery of 





7-question cognitive reserve and 
cognitive leisure activities 
questionnaire (based on Sumowski et 
al., 2010) 
Visual Object and Space 
Perception Battery (VOSP, only 
subtests 2, 3, 6 and 8) 
Questions on bilingualism and 
exercise 
Birmingham Object Recognition 
Batter (BORB, only subtests 2 and 
5) 
Self-Awareness of cognitive deficit 
scales 
Test of Reception of Grammar 
(TROG) 
 Boston Cookie Theft Test (BCT) 
 
 
The phase II battery included the items presented in Table 3.7 and they were to be administered in 
the following order. First the demographic information and medical history were collected, followed 
by physical examination including assessment of visual acuity (Snellen chart) and neurological 
functions (EDSS). Then the ACE-R was administered, noting the participants with severe global 
cognitive impairment. After ACE-R the remaining neuropsychological tests were administered.  
The first block of tests evaluated verbal and visuospatial memory, attention and concentration, 
information processing speed, semantic fluency, and was comprised of the BRBN items. The BRBN 
items were administered in the same order as in the baseline assessment:  SRT learning, SPART 
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learning, SDMT, PASAT, SRT delay and SPART delay.  The WLGT task again was used from the 
ACE-R battery. After having completed the BRBN the participants were asked to evaluate their 
performance on the BRBN tasks at phase II and at phase I retrospectively.  
The second block of tests included the visuoperceptual tasks which were then administered in the 
following order: VOSP2, VOSP3, VOSP6, VOSP8, BORB2 and BORB5. Having done that the 
participants were again asked to give estimates of their performance on the visuoperceptual tests at 
phase II and at phase I. 
The third block included the language tasks, administering the TROG first, followed by the BCT test. 
Having completed these two tasks, the participants were asked to provide estimates of their 
performance on the language tests at phase II and at phase I. This concluded the neuropsychological 
part of the evaluation. 
Lastly the participants were asked to fill out the self-administered questionnaires: cognitive reserve 
questionnaire (with additional questions on bilingualism, exercise and employment), MSIS-29, and 
BDI-II, with the experimenter still present in the room. Once the questionnaires were completed, 
participants were debriefed and the phase II assessment ended. 
3.8.     Chapter summary 
Chapter Three presents a description of the procedure behind the phase II protocol development. The 
rationale for optimizing the phase II battery had been identified through feedback from phase I 
participants who have found the phase I study to be too long and an unchanged assessment schedule 
was likely to impact negatively to phase II recruitment. Moreover, as advances in the understanding 
of cognitive impairment in MS have emerged since the phase I study was designed it was aimed to 
incorporate them into the phase II study schedule. 
The methodology behind the phase II cognitive battery optimisation was based on empirical and 
theoretical justifications. The empirical aspect of the optimisation procedure included removal of 
redundant or insensitive tests while maintaining the domain coverage unchanged. Firstly this has 
been achieved through an investigation of the test item responsiveness and sensitivity to detect 
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variability attributable to MS. Secondly, an empirical evaluation of the dimensionality of the phase 
I battery was done through the principal component analysis; and through the analysis of the four 
identified domains we identified the test items that ensured adequate coverage while minimizing 
redundancy of the phase II battery. The theoretical aspect of the optimization procedure included a 
synthesis of these empirical findings against the descriptions of the tests with respect to 
conventionally understood cognitive functions. This was performed in order to ensure that while 
incorporating the empirical findings the phase II battery would retain the dimensionality and 
coverage of the phase I battery, and therefore allow for valid comparisons between baseline and 
follow-up assessments to be made. Moreover, in that section the additional assessments were also 
incorporated into the phase II battery responding to advances in the field that have occurred since 
phase I, namely the items assessing cognitive reserve, protective factors against cognitive decline, 
and self-awareness measures of changes in the cognitive performance. 
Throughout the battery optimization procedure it was achieved that the changes made to the study 
battery did not affect any other test parameters, such as the test setting and sequence, and all attempts 
were undertaken to ensure that the results from the phase I and phase II would be comparable.  
The optimized phase II battery was considered suitable for follow-up investigations as it was reduced 
to three hours (making it manageable to be administered during a single visit) and it had good 








Chapter Four. Characterization of the phase II cohort 
4.1.       Chapter overview 
This chapter describes implementation of the phase II protocol, including characterisation of the 
cohort who consented to participation at phase II (follow up) and an evaluation of comparability with 
respect to the phase I cohort.  
4.2.       Implementation of the phase II study protocol 
4.2.1.  Approvals 
Approval for the phase II study was requested as minor amendment to the (phase I) Phenotypic 
Characterisation of Cognition in Multiple Sclerosis (MS) study (REC Reference number 
10/S1103/54, NHS R&D reference number: 2010/W/NEU/14) from the South East Scotland 
Research Ethics Committee II. Ethical approval was received on 3rd July, 2014. Approval from NHS 
R&D was received on 18th August, 2014.  
4.2.2.        Case ascertainment & recruitment 
The screening process was applied as described previously (Chapter Three, section 3.2.6). Of the 108 
pwMS and 33 controls in phase I, 82 pwMS and 23 controls were recruited to phase II (Figure 4.1). 
The raw recruitment rate was therefore 76% for patients and 70% for controls. Of those who fit the 
recruitment criteria and were invited to participate in phase II (98 pwMS & 28 controls), recruitment 
rates were 84% and 82% respectively.   
Notably, two phase I participants were excluded from phase II as they did not have the sufficient 
cognitive capacity to give consent to participate. That was considered to be evidence that those 
individuals had progressed cognitively even if their details were not collected at phase II. The issue 
of phase II sample representativeness with regards to the phase II non-participants will be addressed 























Excluded after medical  
records check 
 
2 patients deceased and 1 control developed chronic 
fatigue syndrome 
Excluded after  
discussion with  
MS nurse  
1 patient excluded due to terminal-phase illness; 2 patients 
had withdrawn consent to further contact  
Excluded due to insufficient  
contact details or no longer 
residing in Scotland 
4 patients and 3 controls had incomplete contact details; 1 
patient and 1 control were no longer resident in Scotland 
98 patients and 28 controls passed eligibility criteria and received phase II invitation letters 
Visits not  
arranged 
 
2 patients were excluded as they did not have the necessary cognitive 
capacity to arrange a visit over the phone 
Positive response 
 not received 
 
4 patients and 5 controls did not reply to the invitation letter;                   
10 patients declined to participate 
82 patients and 23 controls were seen at follow-up appointment at phase II 
108 patients and 33 controls were seen at phase I 
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4.2.3.      Systematic biases in recruitment to phase II 
Given that phase II participants were selected through a combination of pre-specified eligibility 
criteria and self-selection (informed consent), potential systematic (non-random) differences may 
have arisen between those who participated in phase II and those who did not. 
Comparison of these groups of pwMS is shown in Table 4.1. Those patients who did not participate 
in phase II were more likely to be female (X2= 5.356, p = 0.021) and exhibit higher levels of self-
reported depressive symptomatology (U = 670.00, p = 0.019) at baseline. 
 
Table 4.1. A comparison between demographic and disease variables at baseline for pwMS who 
were phase II participants and non-participants  
 
 





Age 48.38 (9.52) 46.00 (10.35) U=924.50, p=0.309 
Gender (% female) 52% 69% X2=5.356, p=0.021 
Years of education 12.83 (3.06) 11.96 (2.37) U=807.50, p=0.305 
Dementia  
(ACE-R <82) 
6% yes, 94% no 12%yes, 88% no X2 = 0.852, p=0.356 
BDI-II depression 
score 
14.62 (9.17) 21.68 (13.07) U=670.00, p=0.019 
MS disease course 
24% PP, 34% SP, 46% 
RR 
8% PP, 35% SP, 57% 
RR 
X2=3.057, p=0.217 
Disease duration 10.90 (8.08) 10.46 (7.53) U=1046.50, p=0.888 
EDSS score 4.53 (2.14) 4.73 (2.31) U=997.50, p=0.667 
MS modifying 
treatment 
22% 38% X2=2.572, p=0.109 
Antidepressant use 40% 58% X2 = 2.506, p=0.113 
 
Table 4.1 shows that women and those with higher levels of self-reported depressive 
symptomatology were less likely to participate in phase II. Comparisons were done using the Mann-
Whitney U test for interval and ordinal data, and Pearson’s chi square test for frequency data.  
Abbreviations: ACE-R – Addenbrooke’s Cognitive Examination – Revised, BDI-II – Beck’s Depression 
Inventory 2nd Ed., EDSS – Expanded Disability Status Scale 
 
Comparison of the groups of control individuals who participated in phase II assessments and those 
who did not is shown in Table 4.2. No statistically significant differences were found in age, gender, 
years of education, dementia or depressive symptomology between the controls who participated in 
the phase II and those who didn’t. 
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Table 4.2. A comparison between demographic variables at baseline for controls who were phase 
II participants and non-participants  
 
 





Age 48.87 (12.25) 41.70 (13.27) U=78.00, p=0.147 
Gender (% female) 65% 70% X2=0.072, p=0.789 
Years of education 12.43 (2.33) 12.60 (2.41) U=112.50, p=0.920 
Dementia  
(ACE-R <82) 
0 0  
BDI-II depression 
score 
3.27 (2.79) 4.50 (3.69) U=16.00, p=0.427 
 
Table 4.2 shows no statistically significant difference in the demographic characteristics of those 
who participated and did not participate in phase II. Comparisons were done using the Mann-
Whitney U test for interval and ordinal data, and Pearson’s chi square test for frequency data 
Abbreviations: ACE-R – Addenbrooke’s Cognitive Examination – Revised, BDI-II – Beck’s Depression 
Inventory 2nd Ed. 
 
4.2.4.     The phase II study environment 
The phase II assessment environment was considered to be comparable at all research locations 
(Anne Rowling Clinic, Psychology Department research laboratories and patient homes). In the Anne 
Rowling Clinic the study participants were seen in a quiet and well-lit room with a desk; a research 
nurse was present on-site during the assessments. At home, subjects were seen seated in their kitchens 
or living rooms at a desk; all potential distractors, such as pets, TV or family members, were removed, 
and lightening was adjusted. The conditions in the research laboratories were no different from the 
conditions at the Anne Rowling Clinic, as these rooms were quiet, well-lit and had no distractions. 
Two of the controls (partner and daughter of patients) were seen at home, and the remaining twenty-
one were seen at the research laboratories of The University of Edinburgh Psychology Department. 
Thirty-one patients were seen at the Anne Rowling Clinic and the remaining fifty-one were seen at 
home. As it can be seen from Table 4.3, the patients who preferred to be seen at home had more 
neurological disability (higher EDSS scores; U = 545.50, p=0.014) and longer MS duration (U = 
528.50, p = 0.020). The frequencies of MS courses was uneven (X2 = 10.089, p = 0.006), with more 
patients with SPMS preferring to be seen at home. In addition, the patients seen at home had much 
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more cognitive difficulties as 22% of them performed below the ACE-R cut-off for dementia (X2 = 
7.722, p = 0.005) and had fewer years of education (U = 510.50, p = 0.030) than those seen in the 
clinic.  
Table 4.3. A comparison between demographic and disease variables at phase II for patients who 
were assessed at the clinic vs. those assessed at their home 
 
 
Seen at the clinic 
(n=31) 
Seen at home (n=51) Difference 
Age 50.22 (8.11) 51.82 (10.31) U=718.50, p=0.491 
Gender (% female) 42% 59% X2=2.205, p=0.138 
Years of education 13.87 (3.46) 12.21 (2.65) U=510.50, p=0.030 
Dementia (ACE-R 
<82) 
0 22% X2=7.722, p=0.005 
BDI-II depression 
score 
13.74 (8.98) 16.22 (9.69) U=640.50, p=0.191 
MSIS-29 score 80.55 (27.16) 85.98 (26.29) U=691.00, p=0.414 
MS disease course 
32% PP, 13%SP, 55% 
RR 
18% PP, 47% SP, 35% 
RR 
X2=10.089, p=0.006 
Disease duration 10.96 (4.58) 15.92 (9.13) U=528.50, p=0.020 
EDSS 4.58 (2.04) 5.82 (1.79) U=545.50, p=0.014 
MS modifying 
treatment 
58% 62% X2=0.124, p=0.725 
Antidepressant use 35% 40% X2=0.134, p=0.714 
 
Table 4.3 shows that phase II participants with MS who were seen at home were less well-educated, 
had a higher rate of dementia-level cognitive impairment on the ACE-R, longer duration of disease, 
higher levels of physical disability, and were more likely to be in the secondary progressive phase 
than relapsing-remitting phase. Comparisons were done using the Mann-Whitney U test for interval 
and ordinal data, and Pearson’s chi square test for frequency data 
Abbreviations: ACE-R – Addenbrooke’s Cognitive Examination – Revised, BDI-II – Beck’s Depression 






4.2.5.     Tolerability of phase II assessment  
82 patients and 23 controls have completed the phase II assessments. Two patients did not manage 
to go through the phase II assessments in one appointment, and they were seen again to finish with 
the assessment one week later. Three patients could not take part in tasks that required upper limb 
movements due to severe neurological disability. One participant had moderate diplopia and could 
not perform some of the visuoperceptual tasks. Two patients had their cognitive deficits progressed 
to the level where they did not understand the requirements of some of the more difficult tasks, and 
those tasks were therefore not administered. All other tasks were performed to completion. 
4.2.6.      Time interval in-between phase I and phase II assessments 
82 patients and 23 controls completed both phase I and phase II assessments. The distribution of time 
intervals in-between assessments is shown in Figure 4.2. The mean time between phase I and phase 
II assessments for the patients was three years and two months (SD ± 4.5 months) and for the controls 
the mean time was two years and eleven months (SD + - 6.7 months).  
 
Figure 4.2. Time interval in years in-between phase I and phase II assessments. The data for patient 
(A) and control (B) participants is presented 
A       B 




The time duration in-between assessments was shorter for the control sample (t[26.42] = 2.193, p = 
0.037). This difference will be considered when comparing longitudinal changes in the patient 
sample with the control sample.  
4.3.      Characterisation of the phase II dataset & cohort  
4.3.1       Data completeness 
The phase II assessment data had high completeness with very few missing observations (Table 4.4). 
The completeness for the patient sample was 98.15% and for the control sample it was 100%.  
All the missing observations reflected patients with specific disabilities. The patients with upper limb 
paralysis were unable to perform the SPART test as the checkers needed to be moved. The VOSP6 
and BORB5 items were not administered to the patient with severe diplopia. 14 patients had found 
the PASAT rules too difficult to understand due to advanced cognitive impairment; they did not pass 
the practice, therefore this test was not performed on them. One patient was functioning so badly that 
she was able to understand only a small number of task requirements and couldn’t go beyond 
performing a few of the ACE-R tasks. She had profound physical impairments of all limb functions 
and severe head tremor (EDSS 9.5). Therefore all cases of missing data can be explained and thus 






Table 4.4. Phase II data completeness 
 
Variable 
Patient data completeness  
(% of 82) 
Control data completeness 
(% of 23) 
Demographical variables: 
  
Age 100% 100% 
Gender 100% 100% 
Years of education 95% 100% 
   
Covariates of interest:   
Pre-morbid cognitive leisure activity 
score 
99% 100% 
Employment 100% 100% 
Languages 99% 100% 
Exercise 100% 100% 
   
Disease variables:   
Disease duration 100% NA 
EDSS score 100% NA 
MS type 100% NA 
MSIS-29 score 99% NA 
BDI-II depression score 99% 100% 
Use of MS modifying treatment 99% NA 
Use of antidepressants 96% NA 
   
Cognitive test scores:   
ACE-R 100% 100% 
SRTL 99% 100% 
SRTC 99% 100% 
SRTD 99% 100% 
SPART 95% 100% 
SPARTD 95% 100% 
SDMT 99% 100% 
PASAT 83% 100% 
WLGT 100% 100% 
VOSP2 100% 100% 
VOSP3 99% 100% 
VOSP6 96% 100% 
VOSP8 99% 100% 
BORB2 99% 100% 
BORB5 96% 100% 
TROG 99% 100% 
BC.Index 98% 100% 
   
TOTAL DATASET 
98.15% 100% 
Abbreviations: ACE-R – Addenbrooke’s Cognitive Examination – Revised, BDI-II – Beck’s Depression Inventory 
2nd Ed., MSIS-29 – 29 item Multiple Sclerosis Impact Scale, EDSS – Expanded Disability Status Scale, SRT – 
Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long Term Retrieval, SRTD – delayed 
retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced Auditory Serial Addition Test, SPART – 10/36 
Spatial Recall Test (SPART– items correct at learning stage, SPARTD– items correct at delayed recall), WLGT – 
Category Animal Fluency task, VOSP – Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming 
Task, VOSP3 – Object Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) BORB 
– Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – Position of Gap 
Matching Task, TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – Index of ratio of 
picture variables to number of words), NA – not applicable 
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4.3.2.      Phase II participant characteristics 
82 patients and 23 controls had participated in both phases of the follow-up study. Summaries of the 
patient and control cohorts at each phase are shown in Table 4.5 and Table 4.6 respectively. 
Table 4.5. Demographic and disease characteristics of participants with MS from the follow-up 
sample at phases I & II  
 
 Phase I (n=82) Phase II (n=82) Difference 
Gender (% female) 43 (52%) 
43 (52%) p = 1.000 
Years of education 12.83 (3.06) 12.85 (3.07) Z = -1.000, p = 0.317 
Employed (%) 42 (51%) 27 (33%) p < 0.001 
Dementia (ACE-R <82) 5 (6%) 11 (13.4%) p = 0.031 
BDI-II depression score 14.62 (9.16) 15.27 (9.45) Z = -0.683, p = 0.495 
MS disease course 
19 (23%) PP, 
38 (46%) RR, 
25 (31%) SP 
19 (23%) PP, 
35 (43%) RR, 
28 (34%) SP 
X2 = 3.00, p = 0.083 
Disease duration 10.90 (8.08) 14.09 (8.09) Z = -8.275, p < 0.001 
EDSS 4.53 (2.14) 5.35 (1.97) Z = -4.006, p < 0.001 
MS modifying treatment 18 (23%) 49 (62%) p < 0.001 
Antidepressant use 27 (38%) 29 (41%) p = 0.815 
 
Table 4.5. shows that at phase II, patients were less likely to be in employment, but more likely to 
have a higher rate of dementia-level cognitive impairment on the ACE-R, and be on MS modifying 
treatment. Levels of physical disability (EDSS) were also higher at phase II 
Note: Wilcoxon Signed Ranks for interval and ordinal data, and 2x2 McNemar test and 3x3 
McNemar-Bowker’s test for frequency data employed 
Abbreviations: ACE-R – Addenbrooke’s Cognitive Examination – Revised, BDI – II – Beck’s 




Table 4.6. Demographic and other characteristics of control participants at phases I & II 
 
 Phase I (n=23) Phase II (n=23) Difference 
Gender (% female) 14 (61%) 14 (61%) 
 
p = 1.000 
Years of education 12.43 (2.33) 12.65 (2.35) Z = -1.342, p = 0.180 
Employed (%) 18 (78%) 17 (74%) p = 1.000 
Dementia (ACE-R <82) 0 0 p = 1.000 
BDI-II depression score 3.27 (2.79) 3.69 (3.20) Z = -1.929, p = 0.054 
 
Table 4.6. shows that there had been no significant changes in the characteristics of control sample. 
Note: Wilcoxon Signed Ranks for interval and ordinal data, and 2x2 McNemar for frequency data 
employed 
Abbreviations: ACE-R – Addenbrooke’s Cognitive Examination – Revised, BDI – II – Beck’s 




As expected, in the time period in-between phase I and phase II assessments there had been a general 
increase in measures associated with progression of MS. Three patients have progressed from RRMS 
to SPMS and an overall increase in disability (EDSS score) was observed. Thirty-one more patients 
started using disease modifying treatments. Six more patients had developed moderate cognitive 
impairment as indicated by the performance below the cut-off sensitive to dementia in a dementia-
screening tool (ACE-R < 82). The proportion of patients who were employed declined markedly 
between assessments from 51% at baseline to 33% at follow-up (X2(1) = 38.34, p < 0.001) with all 
of the retirements being due to medical reasons. There were no other changes related to the course 
of MS in our patient sample. Besides MS, at phase II thirty-one patients had additional illnesses, such 
as high cholesterol, osteoporosis, arthritis, joint hypermobility, thyroid problems, depression, sleep 
apnoea and diabetes. 
There had been no significant changes in the characteristics of the control sample. 
    4.3.3.      Phase II patient- and control-group matching for demographic and other 
variables 
The comparison of demographic and other characteristics in patient and control samples can be seen 
in Table 4.7.  
Table 4.7. Demographic and other characteristics of control participants and patient participants 
at phase II 
 
 Controls (n=23) Patients (n=82) Difference 
Age 51.39 (11.87) 51.22 (9.52) U=890.00, p=0.681 
Gender (% female) 14 (61%) 43 (52%) X2 = 0.514, p= 0.473 
Years of education 12.65 (2.35) 12.85 (3.07) U=888.50, p= 0.945 
Employed (%) 17 (74%) 27 (33%) X2 =12.394, p< 0.001 
Dementia (ACE-R <82) 0 11 (13.4%) X2 = 3.493, p = 0.062 
BDI-II depression score 3.69 (3.20) 15.27 (9.45) U=181.00, p< 0.001 
 
Table 4.7. shows that pwMS in phase II were more likely to be unemployed and report higher levels 
of depressive symptomatology than controls. Note: Mann Whitney U-test for interval and ordinal 
data, and Chi Square test for frequency data were employed. 
Abbreviations: ACE-R – Addenbrooke’s Cognitive Examination – Revised, BDI – II – Beck’s 





The phase II patient and control samples were well matched on demographic variables (age, gender, 
and years of education). The employment rate of control participants (74%) was more than two times 
higher than the patients’ (33%) (X2 = 12.394, p < 0.001), and the control employment rate at phase 
II was comparable to Scotland’s national employment rate (73.5%) (OECD, 2014). The patients were 
more prone to moderate cognitive impairment (ACE-R<82) (X2 = 3.493, p = 0.062) and had more 
depressive symptomology (U=181.00, p< 0.001) than the controls. 
4.4.      Chapter summary 
This chapter described the implementation of the phase II protocol, including the characterization of 
the phase II cohort and an evaluation of their comparability with respect to the phase I cohort. Even 
though the participants were seen in the Clinic as well as at home, the phase II environment was 
considered to be comparable at all research locations. The phase II battery was shown to be highly 
tolerable and 98% of patients and 100% of controls have managed to go through it in a single visit. 
The average time between phase I and phase II assessments was approximately three years. 
During the phase II of this study we managed to collect follow-up data on 82 pwMS and 23 controls 
ensuring high (over 70%) follow-up recruitment rates, and very high data completeness (over 98% 
for the patients and 100% for controls) at phase II.  
The patient and control samples were well-matched in terms of demographic and health variables, 
although not surprisingly, the patients had been more depressed and had higher chances of being 
unemployed. There were no major differences between the phase II control participants and non-
participants. However the phase II patient non-participants had a tendency to have slightly higher 
levels of depression, and more likely to be female. We have also compared the patients who had their 
phase II assessments performed in the clinic to those who had preferred to be seen at home. The 
patients who were seen at home had fewer years of education, were more neurologically and 
cognitively impaired, more often had a SPMS course and more years of MS duration. 
In the three years in-between assessments a tendency was observed for the patients to develop 
neurological and cognitive impairments, lose employment, and start MS modifying treatment. The 
controls, however, remained relatively unchanged. Therefore it can be concluded that the changes 
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observed between the phase I and phase II performance in-between the two groups could be 





Chapter Five. The Dimensionality of Cognitive Impairment in MS 
5.1. Chapter overview 
This chapter addresses the issue of disentangling whether cognitive impairment in pwMS should be 
considered a unidimensional or multidimensional construct, and the longitudinal pattern of changes 
in domain-specificity of cognitive impairments. 
This chapter starts with an attempt to investigate the domain-specificity of cognitive disturbances. 
The second but linked analysis revolved around identification of potential subgroups (clusters) of 
individuals (within the study population) who display distinct patterns of cognitive impairments 
and/or change. The dimensionality of the phase I and phase II datasets were analysed separately, then 
later the differences between phase I and phase II dimensionality were analysed as a third 
(longitudinal change) dataset. After each analysis I also explored clinical and demographic 
associations with the identified clusters of individuals.  
5.2. Methods 
The dimensionality of cognitive impairments within the study population was evaluated by examining 
both independence and overlap of domain-specific deficits. Cognitive domains (and the test items 
which evaluate them) were defined as:  
 Verbal memory (SRTL, SRTC, SRTD) 
 Visuospatial memory (SPART, SPARTD) 
 Processing speed (SDMT, PASAT, WLGT) 
 Visuoperceptual  (VOSP 2, 3, 6 & 8; BORB 2 & 5) 
 Language (TROG, BC.Index) 
Even though the items in the processing speed domain (SDMT, PASAT, WLGT) measure a spectrum 
of cognitive functions: attention and concentration, executive functions and information processing 
speed; for practical purposes these three items were grouped together and analysed as one entity. It 
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was considered not to be a major mistake to group these tests under the name ‘processing speed’ as 
these were the only items in the phase I and phase II test batteries where the participants had to 
produce responses under the time pressure. 
To evaluate the dimensionality of the study population with respect to cognitive impairments, a 
multivariate ‘data driven’ approach was used. Specifically, cluster analysis with cognitive tests as 
statistical units and subjects as variables listing the observations was employed. 
5.2.1.   Data format 
In order to identify the cognitive dysfunction of potential clinical significance to pwMS, only discrete 
cognitive impairments (performance below a reference threshold – as discussed below) have been 
considered in this chapter. Quantitative cognitive performance (including normal range) is addressed 
in Chapter Six. 
Cognitive performance data was coded ordinal binary into ‘0’s and ‘1’s. ‘0’s represented 
performance above the cut-off score and ‘1’s represented performance below the cut-off score for 
each subtest. 
I. Defining normal cognitive performance 
The lack of robust external normative data has already been noted (Appendix A). In order to 
determine the need for separate definitions (thresholds) of cognitive impairment at phases I and II, I 
therefore compared performance of 23 control subjects with both phase I and phase II data on the 
same cognitive tests using related measures non-parametric tests (Wilcoxon matched-pairs test) 
(Table 5.1). A non-parametric test was chosen as the controls tend to perform near ceiling on a 
number of tests with little variation, with item distribution being significantly negatively skewed.  
On the majority (9/16 = 56%) of tests the controls showed no statistically significant difference in 
performance between phase I and phase II assessments. However, the controls have showed 
improvement on visuospatial learning, information processing speed and semantic naming items; 
and deterioration on spatial orientation and expressive syntax items. 
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Table 5.1. Analysis of difference in control performance on the same tests at phase I and phase II 
of the longitudinal assessment.  
 Phase I (n=23) Phase II (n=23) Difference 
ACE-R 96.96 (2.72) 96.96 (1.82) Z = -0.066, p = 0.947 
SRTL 49.78 (12.10) 49.78 (11.42) Z =-0.293, p = 0.770 
SRTC 39.96 (14.25) 40.09 (13.48) Z = -0.228, p = 0.819 
SRTD 9.91 (2.13) 9.26 (2.32) Z = -1.256, p = 0.127 
SPART 20.94 (4.95) 22.91 (4.21) Z = -2.198, p = 0.028 
SPARTD 7.30 (1.82) 8.04 (2.46) Z = -1.576, p = 0.115 
SDMT 54.32 (6.93) 57.61 (7.26) Z = -2.808, p = 0.005 
PASAT 47.59 (12.70) 50.70 (6.55) Z = -1.114, p = 0.265 
WLGT 22.00 (4.28) 24.04 (5.10) Z = -2.096, p = 0.036 
VOSP2 23.22 (3.20) 24.91 (3.30) Z = -2.630, p = 0.009 
VOSP3 18.70 (1.26) 18.48 (1.47) Z = -0.408, p = 0.683 
VOSP6 19.83 (0.49) 18.30 (1.18) Z = -3.668, p < 0.001 
VOSP8 9.91 (0.28) 9.65 (0.57) Z = -1.897, p = 0.058 
BORB2 27.39 (1.30) 27.35 (1.85) Z = -0.029, p = 0.977 
BORB5 37.13 (2.34) 36.22 (2.23) Z = -2.070, p = 0.038 
TROG 38.81 (1.50) 38.52 (1.47) Z = -1.493, p = 0.135 
BC.Index 41.68 (4.57) 34.06 (7.56) Z = -3.847, p < 0.001 
 
Table 5.1. shows that the controls have showed improvement on visuospatial learning, information 
processing speed and semantic naming items; and deterioration on spatial orientation and 
expressive syntax items. 
Note. All comparisons were performed using the Wilcoxon matched-pairs test  
Abbreviations: ACE-R – Addenbrooke’s Cognitive Examination – Revised, SRT – Selective Reminding 
Test (SRTL – Long Term Storage, SRTC – Consistent Long Term Retrieval, SRTD– Delayed Retrieval), 
SDMT – Symbol Digits Modalities Test, PASAT – Paced Auditory Serial Addition Test, SPART – 10/36 
Spatial Recall Test (SPART – items correct at learning stage, SPARTD – items correct at delayed 
recall), WLGT – Category Animal Fluency task, VOSP – Visual Object and Space Perception Battery 
(VOSP2 – Silhouette Naming Task, VOSP3 – Object Decision Task, VOSP6 – Position Discrimination 
Task, VOSP8 – Cube Counting Task,) BORB – Birmingham Object Recognition Battery (BORB2 – Line 
Length Matching Task, BORB5 – Position of Gap Matching Task, TROG – Test of Reception of 
Grammar, BC – Boston Cookie Test (BC.Index – Index of ratio of picture variables to number of 
words). 
 
The substantial heterogeneity of normative (control) performance between phase I and II confirmed 
the need to define separate normal ranges for all tests at phases I and II so that valid attribution of 
changes in the MS population could be made to disease rather than experimental variation, practice, 
or aging effects. 
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II. Thresholds for impairment at phase I 
As previously described (Chapter Three, Table 3.3.), the definition of cognitive impairment at phase 
I was based on the performance of 29 controls, and was further defined as performance below 2 SD 
below phase I control mean. 
III. Thresholds for impairment at phase II 
Two SD thresholds were also applied to the phase II control cohort (n=23), and gave differing values 
for eleven (of sixteen) tests (Table 5.2). 
Table 5.2. Cut-off values used for definition of the range of normative performance for phases I 
and II. These values were calculated based on 2SD below phase I and phase II control means  
Test Phase I (n=29) Phase II (n=23) 
SRTL 28 27 
SRTC 13 14 
SRTD 6 5 
SDMT 40 44 
PASAT 18 38 
SPART 12 15 
SPARTD 4 4 
WLGT 15 14 
VOSP2 17 19 
VOSP3 16 16 
VOSP6 20 16 
VOSP8 10 9 
BORB2 24 24 
BORB5 32 32 
TROG 36 36 
BC.Index 32 % 19 % 
 
Abbreviations: ACE-R – Addenbrooke’s Cognitive Examination – Revised, SRT – Selective Reminding 
Test (SRTL – Long Term Storage, SRTC – Consistent Long Term Retrieval, SRTD– Delayed Retrieval), 
SDMT – Symbol Digits Modalities Test, PASAT – Paced Auditory Serial Addition Test, SPART – 10/36 
Spatial Recall Test (SPART – items correct at learning stage, SPARTD – items correct at delayed 
recall), WLGT – Category Animal Fluency task, VOSP – Visual Object and Space Perception Battery 
(VOSP2 – Silhouette Naming Task, VOSP3 – Object Decision Task, VOSP6 – Position Discrimination 
Task, VOSP8 – Cube Counting Task,) BORB – Birmingham Object Recognition Battery (BORB2 – Line 
Length Matching Task, BORB5 – Position of Gap Matching Task, TROG – Test of Reception of 





Six (6/16 = 38%) tests (SRTL, SRD, WLGT, VOSP6, VOSP8, BC.Index) had a lower threshold for 
impairment – i.e. the controls deteriorated or the test administration procedure made them more 
challenging. Five (5/16 = 31%) tests (SRTC, SDMT, PASAT, SPART, VOSP2) had a higher 
threshold to define impairment – i.e. the controls improved (practice effect?) or the test 
administration procedure have made them simpler.  
5.2.2.    The method of cluster analysis 
 
All cluster analyses were performed using Stata/SE 9.2 for Macintosh (Stata Corp, TX, USA). 
Guidelines by Aldenderfer and Blashfield (Aldenderfer & Blashfield, 1984) for performing cluster 
analysis were followed. The Jaccard similarity measure was chosen as it has been shown to be 
suitable for working with binary data due to its ability to classify correctly not only the observations 
with the trait visible, but also the observations where the trait is not expressed1. This is particularly 
important in this study as not only we were interested in grouping patients with certain cognitive 
impairments together, but also we wanted to identify a subgroup of ‘cognitively intact’ patients.  
Hierarchical clustering was chosen to use since it has been shown to be suitable for dichotomous 
data2, smaller sample sizes, and to be less sensitive to outliers and non-normality3. In addition, 
hierarchical method has been recommended to be performed first in all analyses to determine the 
number of clusters (Milligan, 1980). 
In this analysis the average linkage agglomeration method was chosen to employ instead of Ward’s 
method, since the latter has been reported to struggle with clusters of different sizes (Kaufman & 
Rousseeuw, 2009). Since I expected language and visuoperceptual impairments to be less prevalent 
in our sample than information processing speed or memory impairments, it was presumed that the 
clusters would differ in their size. 
                                                          
1 ("Similarity Coefficients for binary data: Why choose Jaccard over Russell and Rao?," 2013) 
2 ("Hierarchical or Two-step cluster analysis for binary data?," 2014) 




The cluster analysis method tends to assume the absence of missing data and is only able to include 
the observations for which every variable was measured.  
26 of 108 individuals with phase I data were removed from the following analyses as they did not 
have follow-up phase II data, as it was considered necessary to ensure that the same individuals were 
included into all analyses. Of the 82 patients with both phase I and phase II data, 21 had missing 
observations on at least one of the variables at either phase I or at phase II, and those individuals with 
incomplete data were therefore removed. Since the following analyses investigated the 
dimensionality of cognitive impairments, it was necessary to ensure that all participants had complete 
data in all assessments.  
The dimensionality analyses were conducted on 61 individuals that had full data on the following 
items: SRTL, SRTC, SRTD, SPART, SPARTD, SDMT, PASAT, WLGT, VOSP2, VOSP3, VOSP6, 
VOSP8, BOR 2, BORB5, TROG and BC.Index.  
However, in order to investigate the robustness of results from the complete case analysis, all 
analyses were repeated on the full dataset (n=82) after performing multiple imputations (Appendix 
E). 
5.2.3.  Number of clusters 
 
In order to select the best suited number of clusters for our data it was chosen to employ the dendrite 
method. Since the optimal classification of objects occurs when the variances of between clusters to 
within clusters changes drastically between the levels of cluster analysis (Sneath & Sokal, 1973), we 
chose to utilize the F-statistic proposed by Caliński and Harabasz (Caliński & Harabasz, 1974); as it 
has been shown to be most fit for this task (Milligan & Cooper, 1985). The number of clusters is 
considered to provide more distinct clustering for the data when the Caliński and Harabasz F-statistic 




5.2.4.    Identifying what the clusters represent  
 
In order to determine what the clusters represent it was chosen to count how many of each type of 
cognitive assessments the individuals in each cluster have failed, and then based on that to make 
assumptions about the dimensionality of cognitive impairment for the individuals in each cluster. 
5.2.5.    Characteristics of individuals in each cluster 
 
In this section for each analysis the demographic and clinical variables were explored in the attempts 
to explain the cluster groupings. The purpose of this section was purely explorative, hence no 
predictions were made. 
5.3. The dimensionality of cognitive impairments  
The result analysis of this chapter begins with an attempt to investigate the pattern in which the 
cognitive functions are affected by MS. First the dimensionality of cognitive impairments of phase I 
and phase II datasets is analysed separately, then later the dimensionality of emerging and resolving 
deficits as a third longitudinal dataset is studied. 
5.3.1.    Domain-specificity of impairments at phase I 
The first step was to investigate the pattern of domain deficits at phase I. This analysis of 
dimensionality allowed to explore two elements – the cumulative burden of impairments (i.e. were 
they predominantly single-domain, or multi-domain), and the pattern of impairments (i.e. was there 
obvious over-representation of certain combinations of cognitive domain failure). 
 The definition of a threshold for domain impairment was arbitrary and represented a trade-off 
between sensitivity and specificity, especially since the domains had an unequal number of cognitive 
tests in them. An approach was chosen to define cognitive impairment on a domain when a patient 
failed at least two test items within a domain. The motivation behind this approach was that it was 
less sensitive but more specific than failing at least one item, while allowing comparable application 
across all tested domains. This approach was also considered to minimize the chances of picking up 
false positives, where the patients might have failed one test in a domain because they didn’t 
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understand the task or due to fatigue. Being more conservative and avoiding such false positives was 
considered to be an important methodological aspect, since this study could be argued to be 
experimental in its nature as some of the tests employed here (e.g. majority of visuoperceptual and 






Table 5.3. The pattern of domain deficits for pwMS at phase I.  
Cognitive domain Number of items in each domain 
Minimum number of tests 
to fail to be considered 
impaired on each domain 
Verbal memory 3 (SRTL, SRTC, SRTD) 2 / 3 
Visuospatial memory 2 (SPART, SPARTD) 2 / 2 
Processing speed 3 (SDMT, PASAT, WLGT) 2 / 3 
Visuoperceptual 6 (VOSP2, VOSP3, VOSP6, VOSP8, BORB2, BORB5) 2 / 6 




Domain unaffected. Represents performance below cut-off on one or less tests in that domain. 
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No impairments 0 0 0 0 0 33 
Impairment on 
only one domain 
1 0 0 0 0 8 
0 1 0 0 0 2 
0 0 1 0 0 1 
0 0 0 1 0 4 
0 0 0 0 1   
Impairment on 
two domains 
1 1 0 0 0   
1 0 1 0 0 4 
1 0 0 1 0 4 
1 0 0 0 1 1 
0 1 1 0 0   
0 1 0 1 0   
0 1 0 0 1   
0 0 1 1 0 1 
0 0 1 0 1   
0 0 0 1 1 1 
Impairment on 
three domains 
1 1 1 0 0   
1 1 0 1 0   
1 1 0 0 1   
1 0 1 1 0   
1 0 1 0 1 1 
1 0 0 1 1   
0 1 1 1 0   
0 1 1 0 1   
0 1 0 1 1   
0 0 1 1 1   
Impairment of 
four domains 
1 1 1 1 0 1 
1 1 1 0 1   
1 1 0 1 1   
1 0 1 1 1   
0 1 1 1 1   
Global 
impairment 





As it can be seen from Table 5.3, at phase I the patients tend to fail all of the cognitive domains, 
although the impairments on verbal memory items were the most common. This could be because 
the SRTL and SRTC variables have been highly inter-correlated, and failing one of them in most 
cases went together with failing another. Besides that there seemed to be no over-representation of a 
particular combination, suggesting that cognitive deficits at phase I could indeed be considered 
multidimensional. At phase I fifteen patients failed only one cognitive domain, eleven patients failed 
two cognitive domains, and two patients could be considered more globally impaired with one of 
them failing three, and another one failing four cognitive domains. 
Another interesting aspect was that around half of patients at phase I could be considered cognitively 
spared, i.e. none of their impairments (if any) had qualified for failing a cognitive domain. However, 
it can be acknowledged that the impairment definition employed in these analyses was very 
conservative. In fact of those 33 patients, ten failed BC.Index, eight failed VOSP6, six failed SRTD, 
with smaller frequencies of them failing other tests. In addition, some of these patients in the ‘no 
impairments’ group had actually failed more than one item, although on different domains, thus still 
didn’t qualify for a domain impairment. Two of those ‘unimpaired’ pwMS had failed four (of sixteen) 
tests; four failed three tests; five failed two tests, and eleven failed one test. 
5.3.2.    Domain-specificity of impairments at phase II 
Now that I’ve investigated the phase I, the next step was to check whether the dimensionality of 
cognitive impairments has changed at phase II. Indeed, even with such conservative definition of 
domain-impairment, more patients have developed multi-dimensional deficits, as in phase II ten 
patients have failed three or more cognitive domains. Another interesting finding was that eight 
patients with impairments on three cognitive domains had identical patterns – they all have failed 
verbal memory, processing speed and visuoperceptual groups of tests. The one patient who had failed 







Table 5.4. The pattern of domain deficits for pwMS at phase II 
Cognitive domain Number of items in each domain 
Minimum number of tests 
to fail to be considered 
impaired on each domain 
Verbal memory 3 (SRTL, SRTC, SRTD) 2 / 3 
Visuospatial memory 2 (SPART, SPARTD) 2 / 2 
Processing speed 3 (SDMT, PASAT, WLGT) 2 / 3 
Visuoperceptual 6 (VOSP2, VOSP3, VOSP6, VOSP8, BORB2, BORB5) 2 / 6 




Domain unaffected. Represents performance below cut-off on one or less tests in that domain. 
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No impairments 0 0 0 0 0 27 
Impairment on 
only one domain 
1 0 0 0 0 3 
0 1 0 0 0 3 
0 0 1 0 0 7 
0 0 0 1 0 2 
0 0 0 0 1   
Impairment on 
two domains 
1 1 0 0 0   
1 0 1 0 0 3 
1 0 0 1 0 2 
1 0 0 0 1   
0 1 1 0 0   
0 1 0 1 0 1 
0 1 0 0 1   
0 0 1 1 0 3 
0 0 1 0 1   
0 0 0 1 1   
Impairment on 
three domains 
1 1 1 0 0 1 
1 1 0 1 0   
1 1 0 0 1   
1 0 1 1 0 8 
1 0 1 0 1   
1 0 0 1 1   
0 1 1 1 0   
0 1 1 0 1   
0 1 0 1 1   
0 0 1 1 1   
Impairment of 
four domains 
1 1 1 1 0 1 
1 1 1 0 1   
1 1 0 1 1   
1 0 1 1 1   
0 1 1 1 1   
Global 
impairment 
1 1 1 1 1   
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This finding has raised a question of whether these individuals could be considered to represent a 
pattern of MS progression – it could be hypothesized that globalization of MS cognitive deficits starts 
with problems in either verbal memory, processing speed or visuoperceptual cognition; then with 
longer disease duration spreads into all three domains; and with even more progression and longer 
MS duration impairments spread into visuospatial memory. 
In order to address this question I looked into the MS types, disease duration and neurological 
disability scores of these nine patients. The patient with 4-domain impairments was a 52-year-old 
female with SPMS and 9.4 years MS duration. Of the eight patients who had failed three cognitive 
domains the majority (five) had SPMS, one had PPMS, and two had RRMS. In addition, all of these 
patients have had long MS duration (18.63 (± 11.25) years), and most of them were older (54.66 (± 
10.39) years) and had more neurological disability (5.72 (± 1.46) EDSS score).  
One particular finding that can be noted was that at phase II none of the patients had failed the 
language domain, even though eight patients had failed the TROG and two patients failed the 
BC.Index.  
In addition, at phase II the impairments on the processing speed domain became more evident, and 
among the single-domain cognitive deficits, processing speed impairments became around twice 
more frequent than any other cognitive domain impairments.  
5.3.3.    Dimensionality of temporal change in cognitive impairments  
In the previous analyses the patterns were shown of how cognitive impairments group in pwMS at 
two separate phases of the assessment. However, what was left unexplained was how stable those 
impairments were, and what was the pattern of their longitudinal development. 
The dimensionality of change was analysed in two ways and separate steps were taken to investigate 
the impairments that emerge, and the impairments that resolve. This was done in order to explore 
whether any patterns of domain-specificity of evolving or resolving impairments could be observed.  
Several measures were undertaken in order to avoid the effect of potential artefacts in the 
dimensionality analysis that could potentially limit the generalizability of the findings. I identified a 
possibility that there could also be individuals that show patterns of both emerging and resolving 
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impairments in the same domain, but on different tests. Because of this reason it was chosen to define 
longitudinal change on a cognitive domain when there were at least two observations on two separate 
tests in the same direction, following the same reasoning as per definition of impairment in Table 5.3 
and Table 5.4. This adjustment made the analyses of longitudinal change more conservative, 
especially on the domains that have fewer tests in them. This method has made the chances of making 
Type I error smaller, but at the same time inflated the chances of the Type II error. 
I. Dimensionality of emerging impairments 
The first part of longitudinal analyses of changes in dimensionality of cognitive impairment revolved 
around identification of evolving impairments. These were the instances where a patient has 
performed at norm at phase I, but below the cut-off at phase II (Table 5.5). The majority of patients 
did not develop any new domain impairments, at least none that could get picked up by this 
conservative definition. Almost all of the newly developed domain impairments were uni-
dimensional, with emerging impairments in processing speed and visuoperception most prominent. 
The high frequency of new impairments in the visual cognition domain could be potentially an 
artefact arising from the fact that this domain contained the highest number of cognitive tests, 
therefore the probability of acquiring new deficits in two of them was the highest. In addition, none 






Table 5.5. Dimensionality of developing impairments. The pattern of acquired deficits for pwMS 
(n=61) in each domain between phase I and phase II is presented.  
Domain Number of tests in each domain 
Minimum number of items 
to develop new 
impairments on to be 
considered having emerging 
impairments on each 
domain 
Verbal memory 3 (SRTL, SRTC, SRTD) 2 / 3 
Visuospatial memory 2 (SPART, SPARTD) 2 / 2 
Processing speed 3 (SDMT, PASAT, WLGT) 2 / 3 
Visuoperceptual 6 (VOSP2, VOSP3, VOSP6, VOSP8, BORB2, BORB5) 2 / 6 




Impairments resolved or remained stable. 
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New impairments that emerged. 
 















0 0 0 0 0 39 
New impairment 
on only one 
domain 
1 0 0 0 0 2 
0 1 0 0 0 2 
0 0 1 0 0 6 
0 0 0 1 0 7 
0 0 0 0 1   
New impairment 
on two domains 
1 1 0 0 0   
1 0 1 0 0 1 
1 0 0 1 0 3 
1 0 0 0 1   
0 1 1 0 0   
0 1 0 1 0   
0 1 0 0 1   
0 0 1 1 0 1 
0 0 1 0 1   
0 0 0 1 1   
New impairment 
on three domains 
1 1 1 0 0   
1 1 0 1 0   
1 1 0 0 1   
1 0 1 1 0   
1 0 1 0 1   
1 0 0 1 1   
0 1 1 1 0   
0 1 1 0 1   
0 1 0 1 1   
0 0 1 1 1   
New impairment 
on four domains 
1 1 1 1 0   
1 1 1 0 1   
1 1 0 1 1   
1 0 1 1 1   
0 1 1 1 1   
Sudden global 
impairment 
1 1 1 1 1   
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Table 5.6. Dimensionality of resolving impairments. The pattern of resolving deficits for pwMS 
(n=61) in each domain between phase I and phase II is presented.  
Domain Number of tests in each domain 
Minimum number of tests to improve 
on to be considered having resolving 
impairments on each domain 
Verbal memory 3 (SRTL, SRTC, SRTD) 2 / 3 
Visuospatial memory 2 (SPART, SPARTD) 2 / 2 
Processing speed 3 (SDMT, PASAT, WLGT) 2 / 3 
Visuoperceptual 
6 (VOSP2, VOSP3, VOSP6, VOSP8, 
BORB2, BORB5) 
2 / 6 




Impairments resolve. I.e. impaired at phase I and non-impaired at phase II 
0 
 



















1 0 0 0 0  4 
0 1 0 0 0  1 
0 0 1 0 0   
0 0 0 1 0  2 
0 0 0 0 1  1 
Recovery on 
two domains 
1 1 0 0 0   
1 0 1 0 0   
1 0 0 1 0  2 
1 0 0 0 1   
0 1 1 0 0   
0 1 0 1 0   
0 1 0 0 1   
0 0 1 1 0   
0 0 1 0 1   
0 0 0 1 1   
Recovery on 
three domains 
1 1 1 0 0   
1 1 0 1 0   
1 1 0 0 1   
1 0 1 1 0   
1 0 1 0 1   
1 0 0 1 1   
0 1 1 1 0   
0 1 1 0 1   
0 1 0 1 1   
0 0 1 1 1   
Recovery on 
four domains 
1 1 1 1 0   
1 1 1 0 1   
1 1 0 1 1   
1 0 1 1 1   
0 1 1 1 1   
Global 
recovery 




5.3.4.   Dimensionality of resolving impairments 
 
The vast majority of patients did not improve on any of the cognitive domains, and if they did, they 
mostly improved on only one domain (Table 5.6.). Therefore it could be considered, that in general, 
the changes between phases I and II were not random, instead, a trend for acquiring new impairments 
was observed, with most of new problems emerging on visuoperceptual and information processing 
speed tests. 
5.3.5.   Dimensionality of cognitive impairments. Summary 
From analysing the domain-specificity of cognitive impairments it was found that all cognitive 
domains can be affected in MS, although not at the same frequencies. The majority of individuals 
from the observed MS sample had deficits only on one cognitive domain, however, with when re-
assessed three years later they became impaired on more cognitive domains, with emerging deficits 
on visuoperceptual and information processing speed tests being most prominent. 
5.4. The dimensionality of the study cohort  
After having analysed how the impairments of different cognitive domains group together, the next 
step was to investigate the pattern of how the pwMS from our sample could be grouped according to 
their cognitive performance. In this section it was aimed to examine, without making any predictions, 
whether any patterns could be observed between the emerging groups of patients in respect to their 
cognitive difficulties. 
5.4.1.  The dimensionality of the phase I study population 
It was chosen to run a cluster analysis in order to address the emerging patterns of grouping the 
pwMS based on their performance. The investigation of dimensionality of the phase I cohort was 
started by determining the most appropriate number of clusters for the following classifications.  
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I. Number of subject-clusters in the phase I dataset 
Based on the Caliński & Harabasz F-values (Table 5.7) a ten-cluster solution provided the best 
summary of the dataset. As it can be seen from the dendrogram (Figure 5.1), the ten clusters vary 
greatly in their sizes. The raw data of performance of individuals in each cluster can be seen in 
Appendix F.  
 
Table 5.7. Determination of the optimal number of clusters in the hierarchical cluster analysis of 
patient data at phase I 
 





















Figure 5.1. Dendrogram of hierarchical cluster analysis using average linkage model of patient data 
at phase I 
 
Note. The horizontal line is shown to represent where the 10-cluster cut falls in this analysis 
 
II. Neuropsychological characteristics of pwMS in each subject-cluster in phase I 
 
The frequency of cognitive impairments for each test by subject-cluster is shown in Table 5.8. An 
interpretative view of the cluster solution follows: 
The largest cluster (C1: 35/61 = 57.4%) showed impairments that appear to occur scattered across 
cognitive abilities, consistent with the classic pathological view of a widely distributed multifocal 








Table 5.8. Frequencies (%) of patients failing each test in each cluster at phase I 
 






























































































                   
C1 35 0 6 14 6 9 6 6 3 0 3 29 9 3 3 6 31 
C2 2 50 0 0 0 0 100 0 50 0 50 0 0 0 0 100 0 
C3 2 0 0 100 50 0 100 0 0 100 0 0 50 0 0 0 50 
C4 7 100 100 71 43 0 43 0 0 0 14 57 0 29 0 0 14 
C5 5 80 40 100 0 40 20 0 20 0 20 0 100 0 0 20 40 
C6 1 0 0 0 0 0 0 0 100 100 100 0 0 0 0 100 100 
C7 4 75 100 50 0 0 100 75 100 0 50 25 0 0 0 0 50 
C8 2 50 0 50 0 0 100 100 100 0 0 100 0 0 50 100 50 
C9 2 50 0 50 0 100 0 0 50 0 50 0 0 100 100 100 0 
C10 1 100 100 100 100 100 100 0 100 100 0 0 100 100 100 0 0 
                  
Total      61                 
Average 51 35 54 20 24 57 18 52 30 29 21 26 23 25 43 34 
 
 
C1: Sporadic impairments with possible slight excess of visuoperceptual & language impairments 
(VOSP6 & BC.Index) 
C2: Processing speed and grammar reception impairment (SDMT & TROG) 
C3: Verbal recall, processing speed and naming impairments (SRTD, SDMT & VOSP 2) 
C4: Verbal learning and memory (with or without visual cognition impairments) (SRT) 
C5: Verbal memory and counting (SRT & VOSP 8) 
C6: Language and naming impairments (WLGT, VOSP 2 & 3, TROG & BC.Index) 
C7: Verbal memory and processing speed (SRT, SDMT, PASAT, WLGT) 
C8: Processing speed, position discrimination and grammar reception (SDMT, PASAT, WLGT, 
VOSP6 & TROG) 
C9: Space perception (SPARTD, BORB 2 & 5) and grammar reception (TROG) 
C10: Global impairment 
 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC– Consistent Long 
Term Retrieval, SRTD – Delayed Retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART– items correct at learning 
stage, SPARTD– items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – Position of 
Gap Matching Task, TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – 





Cluster two (C2: 2/61 = 3.3%) indicated impairments on one of the processing speed tests and one 
language test, and cluster three (2/61 = 3.3%) patients had impairments on one of processing speed 
tests, verbal recall and naming. Since in these clusters the patients failed only one test per domain 
but not the others, the clinical validity of such classification was unclear and these clusters could be 
considered either artefacts, or parts of cluster one. 
Cluster four (7/61 = 11.5%) was one of the clearest clusters and the patients in it had a core 
impairment of verbal memory. 
Cluster five (5/61 = 8.2%) grouped patients with difficulties counting cubes and remembering words, 
with or without additional impairments. The value of this distinction is also unclear.  
The individual in cluster six (1/61 = 1.6%) had a clear impairment of language and failed only the 
tasks of word and sentence generation, grammar comprehension and picture naming.  
Cluster seven (4/61 = 6.6%) individuals had a core impairment of verbal memory and processing 
speed. The four individuals in this cluster fit the cognitive profile of impairment measured by the 
BRBN battery. 
Cluster eight (2/61 = 3.3%) represented individuals who had impairments in processing speed, 
position discrimination, and reception of grammar. It may be that clusters eight and seven were parts 
of the same entity that represents individuals with processing speed impairments with or without 
additional problems (possibly the additional problems that are caused or mediated by impairments 
of processing speed). 
Cluster nine (2/61 = 3.3%) represented individuals with difficulties in space perception with an 
additional impairment of grammar reception.  
Cluster ten (1/61 = 1.6%) contained an outlier case with impairments on multiple tasks across all 





III. Demographic and clinical characteristics of pwMS in each subject-cluster in 
phase I 
 
The demographic and clinical data of patients in each cluster is presented in Table 5.9.  
From inspecting the characteristics of individuals in cluster one, no clear excess of specific clinical 
or demographic variables emerged. Patients in this cluster therefore appeared to represent the typical 
MS cohort with the classic pathological view of a widely distributed multifocal inflammatory 
disorder of the CNS. 














































































































































































2 5 (2) 6 (0) 6 (0) 6 
MS modifying 
treatment 
23% 0% 50% 28.6% 20% 100% 25% 0% 0% 100% 
Antidepressant 
use 
31% 0% 50% 14.3% 20% 0% 100% 50% 50% 100% 
 
Note. The descriptive data presented in this table was collected at phase I 
Abbreviations: ACE-R – Addenbrooke’s Cognitive Examination – Revised, NART – National Adult 




Although clusters two and three did not seem to be much different in terms of cognition, and in the 
previous section I speculated that they might even be from the same entity, differences were seen in 
their clinical characteristics. Cluster two grouped SPMS patients who were younger, less educated 
and more depressed, and cluster three grouped RRMS patients that were older with less neurological 
disability and shorter MS duration. This could be used to argue that if clusters one, two and three 
represented the same group in terms of cognition, then the patients from clusters two and three could 
be considered being at the opposite ends of the spectrum in terms of demographic and clinical 
characteristics, with cluster one in-between. 
Cluster four appears to include all types of patients and there seemed to be no specific excess of 
clinical or demographic variables. Similarly, cluster five did not show clear excess for any clinical 
or demographic characteristics. These individuals may belong to cluster four and thus could be 
grouped as patients with core verbal memory difficulties with additional (potentially unrelated) 
impairments in spatial awareness or other domains.  
The language impairments and low performance on the ACE-R test of the individual in cluster six 
could potentially be caused by his low education, and not factors related to MS. 
The cognitive impairments (verbal memory and processing speed) of patients in cluster seven could 
potentially be side-effects of their antidepressant medication. By not finding any major differences 
in terms of clinical or demographic variables between the individuals in clusters seven and eight, the 
possibility remains that that these two clusters form parts of the same entity and represent core 
impairments of processing speed potentially caused by anti-depressant uptake. 
The two patients in cluster nine seem to exhibit cognitive impairments that could not be explained 
by clinical or demographic factors, and thus potentially could be indicative of posterior lesions or 
posterior atrophy. 
Cluster ten represents an outlier case with aggressive MS. At phase I this woman with SPMS has had 
MS for only six years, but her neurological disability and cognitive dysfunction had progressed 
profoundly and she seemed to be doing much worse than other patients.  
107 
 
IV. The dimensionality of Phase I study population. Summary 
 
From analysing the dimensionality of the phase I cohort it was found that the MS population is highly 
heterogeneous in respect to the dimensionality of their cognitive impairments. Speculations could be 
made about the best ways to group the patients, however, they do not yield a clear answer. 
5.4.2.   The dimensionality of the phase II study population  
After exploring the dimensionality of the phase I cohort the next step was to investigate whether the 
cluster solution for the population dataset of impairments simplified three years later at phase II. This 
in turn would answer the question whether our MS population starts as highly heterogeneous and 
then gradually becomes more homogeneous over time. Therefore the same cluster analysis 
methodology was therefore repeated on the same 61 pwMS at phase II.  
I. Number of subject-clusters in the phase II dataset 
 
The number of clusters for grouping the phase II was selected by examining the values of the 
Calinski-Harabasz pseudo-F statistic. As it can be seen from Table 5.10, the F-statistic was the 
highest when the sample was broken down into two clusters. Therefore the two cluster model was 










Table 5.10. Determination of the optimal number of clusters in the hierarchical cluster analysis of 
patient data at phase II 
 














Table 5.10. indicates that the Calinski-Harabasz pseudo-F supports a two cluster solution. 
 
Figure 5.2. Dendrogram of hierarchical cluster analysis using average linkage model of patient 
data at phase II. 
 


















































































































































































































































































































































II. Neuropsychological characteristics of pwMS in subject-clusters at phase II 
 
The frequencies of cognitive impairments for each test by subject-cluster are shown in Table 5.11 
(individual performance of each patient can be seen in Appendix F). An interpretative view of the 
cluster solution follows: 
The largest cluster (C1: 45/61 = 73.8%) showed impairments that appeared to occur scattered across 
cognitive abilities, consistent with the classic pathological view of a widely distributed multifocal 
inflammatory disorder of the CNS.  
Cluster two (C2: 16/61 = 26.2%) showed core impairments of processing speed and verbal memory 
with or without visuoperceptual impairment. 
Table 5.11. Frequencies (%) of patients failing each test in each subject-cluster at phase II 






























































































                                    
1 45 11 4 13 9 16 27 31 7 9 9 4 11 4 16 9 4 
2 16 100 88 88 31 13 100 88 6 31 44 50 38 25 31 25 0 
                 
Total       
61 
                 
Average  56 46 51 20 15 64 60 7 20 27 27 25 15 24 17 2 
 
C1: Sporadic impairments (with possible slight excess of processing speed impairments) 
C2: Verbal memory and processing speed impairments with or without impairments in 
visuoperceptual functions 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC– Consistent Long 
Term Retrieval, SRTD – Delayed Retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART– items correct at learning 
stage, SPARTD– items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – Position of 
Gap Matching Task, TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – 




III. Demographic and clinical characteristics of pwMS in each subject-cluster at 
phase II 
The analysis of demographic and clinical characteristics of the patients from the two clusters is 
presented in Table 5.12. The main difference between the two clusters was that cluster one had more 
RRMS, and cluster two had more SPMS patients in them.  Naturally, consistent with the differences 
between these two MS types, the patients in cluster two had longer MS duration, although this 
difference did not reach statistical significance. The patients in cluster two also tend to have higher 
frequencies of being on antidepressant medication. 
Table 5.12. Demographic and clinical characteristics of pwMS in each subject-cluster at phase II.  
Test C1 (n=45) C2 (n=16) Difference 
Age 49.39 (9.32) 52.27 (9.06) 
U=267, 
p=0.272 
Gender (% female) 47% 63% p = 0.243 
Years of education 13.52 (3.2) 11.93 (2.76) 
U=225.5, 
p=0.102 
Premorbid ability (NART 
score) 
114.2 (10.44) 112.31 (8.86) 
U=304.5, 
p=0.362 
Dementia (ACE-R <82) 7% 25% p = 0.062 
BDI-II depression score 14.57 (9.58) 17.73 (8.42) 
U=235.5, 
p=0.099 
MS disease course 
29% PPMS, 16% SPMS, 
55% RRMS 
19% PPMS, 56% SPMS, 
25% RRMS 
p=0.006 
Disease duration (years) 11.6 (4.72) 16.13 (10.32) 
U=254.4, 
p=0.226 
EDSS score 4.98 (1.91) 5.47 (1.51) 
U=293, 
p=0.494 
MS modifying treatment 53% 56% p = 0.771 
Antidepressant use 29% 56% p = 0.031 
Note. The descriptives presented in this table were collected at phase II, except for the NART, which 
was collected at baseline. The between-group comparisons were performed using the Mann-
Whitney U-test for interval data and Fisher’s exact test for frequency data 
Abbreviations: ACE-R – Addenbrooke’s Cognitive Examination – Revised, NART – National Adult 




IV. The dimensionality of phase II study population. Summary 
From analysing the dimensionality of the phase II cohort it appeared that the heterogeneity of the 
cohort in respect to their cognitive impairment diminishes with time, and the profiles of cognitive 
performance tend to become more homogeneous at phase II.  
5.4.3. The dimensionality of the study population with respect to longitudinal 
change in cognitive impairments 
As it can be seen from the analyses in section 5.3.1. and section 5.4.2. earlier in this chapter, the 
cluster analyses have yielded different results when employed at phase I and at phase II. From this it 
can be assumed that there have been time-related changes in the dimensionality of the study 
population. In the following section the temporal changes in MS-related cognitive deficits were 
examined by using the cluster analysis to group the patients based on the trajectory of their 
longitudinal changes. This was carried out to identify individuals whose cognitive deficits have 
progressed, remained the same, or improved over the period of three years.  
I. Number of clusters 
The cluster analysis was employed in order to group the pwMS based on their longitudinal changes 
in cognitive test performance. Based on the F-statistic (Table 5.13) we found that four trajectories of 




Table 5.13. Determination of the optimal number of clusters in the hierarchical cluster analysis of 
patient longitudinal change in their cognitive performance between phases I and II 
 














Table 5.13. indicates that the Calinski-Harabasz pseudo-F supports a four cluster solution. 
Figure 5.3. Dendrogram of hierarchical cluster analysis model of longitudinal trajectories of 
change in patient performance on cognitive tests between phases I and II 
 











































































































































































































































































































































Longitudinal change in impairment
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Table 5.14. Neuropsychological characteristics for the four subject-cluster solution for longitudinal 
change. Frequencies (%) of three different trajectories of change on the cognitive tests are 
presented 












SRTL 13 78 9 
SRTC 11 87 2 
SRTD 17 79 4 
SPART 6 88 6 
SPARTD 7 84 9 
SDMT 2 81 17 
PASAT 0 69 31 
WLGT 15 79 6 
VOSP2 4 87 9 
VOSP3 7 84 9 
VOSP6 24 70 6 
VOSP8 13 74 13 
BORB2 6 90 4 
BORB5 0 87 13 
TROG 9 91 0 
BC.Index 33 63 4 
 












SRTL 0 67 33 
SRTC 0 67 33 
SRTD 0 67 33 
SPART 0 33 67 
SPARTD 0 100 0 
SDMT 0 100 0 
PASAT 0 67 33 
WLGT 67 33 0 
VOSP2 0 67 33 
VOSP3 0 33 67 
VOSP6 0 33 67 
VOSP8 0 67 33 
BORB2 33 67 0 
BORB5 0 67 33 
TROG 0 0 100 





Table 5.14. (continued) 













SRTL 0 0 100 
SRTC 0 0 100 
SRTD 0 0 100 
SPART 0 100 0 
SPARTD 0 100 0 
SDMT 0 0 100 
PASAT 0 0 100 
WLGT 0 100 0 
VOSP2 0 100 0 
VOSP3 0 100 0 
VOSP6 0 33 67 
VOSP8 33 33 33 
BORB2 0 67 33 
BORB5 33 67 0 
TROG 0 100 0 
BC.Index 33 67 0 
 













SRTL 0 0 100 
SRTC 0 0 100 
SRTD 0 0 100 
SPART 0 100 0 
SPARTD 0 100 0 
SDMT 0 100 0 
PASAT 0 100 0 
WLGT 100 0 0 
VOSP2 0 0 100 
VOSP3 0 100 0 
VOSP6 100 0 0 
VOSP8 0 0 100 
BORB2 0 0 100 
BORB5 0 100 0 
TROG 0 100 0 
BC.Index 0 100 0 
 
C1: New impairments develop on tasks of processing speed (SDMT and PASAT) and one of the 
visuoperceptual tests (BORB5). Practice effect on many tasks (especially language) is observed. 
C2: Progression of deficits in grammar reception (TROG) with or without additional deficits 
C3: Progression of deficits in verbal memory and processing speed with or without progression of 
deficits in spatial awareness 
C4: Progression of deficits in verbal memory and visuoperceptual tests 
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I. Neuropsychological characteristics longitudinal change in subject-clusters of 
pwMS 
 
Individual changes in subject-clusters for each patient can be seen in the Appendix F. An 
interpretative view of the cluster solutions follows: 
The largest cluster (C1: 54/61 = 88.5%) shows a pattern of impairments emerging or resolving across 
cognitive abilities, although a tendency for emerging impairments in information processing speed 
is observed. A practice effect is also observed, but mainly on tasks involving language (sentence and 
word generation, reception of grammar, and verbal memory).  
Cluster two (C2: 3/61 = 4.9%) shows emergence of impairments in grammar reception (TROG) with 
or without additional deficits. 
Cluster three (C3: 3/61 = 3.3%) shows emergence of impairments in verbal memory and processing 
speed with or without progression of deficits in spatial awareness. 
Cluster four (C4: 1/61 = 1.6%) shows an individual whose deficits progressed in verbal memory 
and visuoperceptual cognition. 
II. Demographic and clinical characteristics of pwMS in each subject-cluster 
 
The demographical and clinical descriptives of the individuals from each cluster representing the 
four trajectories of longitudinal change can be seen in Table 5.15. From inspecting the characteristics 
of individuals in cluster one, no clear excess of specific clinical or demographic variables emerged. 
This group therefore appeared to represent a typical cohort of pwMS. 
Clusters two, three and four could be considered to form one cluster of changes relevant only to 
patients with SPMS. It could be considered, that the cognitive changes experienced by patients with 





Table 5.15. Demographic and clinical characteristics of pwMS from each of the four subject-
clusters representing the four trajectories of longitudinal change between performance in phase I 
and phase II 
Test C1 (n=54) C2 (n=3) C3 (n=3) C4 (n=1) 




Gender (% female) 50% 67% 67% 100% 










Dementia (ACE-R <82) 7% 67% 0% 100% 






MS disease course 
29% PPMS, 17% 







Disease duration (years) 12.22 (5.96) 
23.67 
(14.5) 
9.67 (3.79) 18 
EDSS score 4.94 (1.85) 5.67 (0.57) 6.67 (1.16) 7 
MS modifying treatment 54% 67% 67% 0% 
Antidepressant use 32% 67% 67% 0% 
Note. The descriptives presented in this table were collected at phase II, except for the NART, 
which was collected at phase I 
Abbreviations: ACE-R – Addenbrooke’s Cognitive Examination – Revised, NART – National Adult 
Reading Test, BDI-II – Beck’s Depression Inventory 2nd Ed., EDSS – Expanded Disability Status Scale 
 
III. Longitudinal changes in the dimensionality of the study population. Summary   
Four clusters of longitudinal change in the dimensionality of cognitive impairments were observed, 
and the patients developed new deficits or showed improvement in all cognitive domains. Patients 





5.5. Chapter summary 
In Chapter Five from analysing the dimensionality of cognitive impairments in MS, several 
tendencies have emerged. 
First, the cognitive deficits were seen to be prevalent in all cognitive domains and tests (none were 
spared), and initially they appeared heterogeneous on individual basis, although with MS progression, 
and development of new impairments in information processing speed and visuoperceptual functions, 
had the tendency to become more homogenous. 
Second, there was also a reduction in the dimensionality of the MS population with respect to their 
pattern of cognitive impairments over time. At phase I the patients classified into multiple groups 
based on their performance, indicative of the many ways in which cognitive deficits start. However, 
three years later (at phase II), only two clusters were present; this showed that with acquirement of 
new deficits the patients became more homogeneous in the expression of their cognitive symptoms.  
The analyses performed in this chapter would imply that MS affects individuals by initially causing 
a small set of domain-specific impairments (that differ between patients), and later evolves into (a 
larger) multi-domain set of impairments (that has more commonalities between patients). Most 
commonly the new deficits were in the information processing speed domain, however, besides that 
there seemed to be no clear pattern for new deficit acquirement, as it appeared that the deficits that 
the patients picked up have been sporadic. Our analyses suggest that in MS the cognitive deficits 
slowly accumulate, leading to development of major problems with longer disease duration. 
Through these analyses we were unable to identify a group of individuals who suddenly flipped into 
progression and whose cognitive functioning had changed globally. Instead the analyses indicated 
that the cognitive deficits have been acquired (and lost) mostly at random (with only very slight 
predisposition towards new impairments on information processing speed). Moreover, it could be 
speculated that some individuals with SPMS may have a slightly different course of progression of 
cognitive deficits, but the results do not support any definite conclusions regarding differences in the 






Chapter Six. The trajectory, extent, and predictors of cognitive change 
in pwMS 
 
6.1.      Chapter overview 
From analysing the dimensionality of cognitive impairment in chapter five I found that during the 
span of 3 years each patient has improved on some tests, and deteriorated on the others. However, 
the previous chapter investigated only dimensionality without addressing the magnitude of cognitive 
change in each domain. This chapter was dedicated to the investigation of the longitudinal change in 
cognition associated with MS, and identification of factors that are related to better or poorer 
cognitive outcome. 
The chapter begins with an analysis of distribution of controls’ scores at phases I and II of the study 
in search for systematic differences in changes of performance that could be attributable to variables 
not related to MS. Then the main analysis revolved around the variation of patients’ change in each 
cognitive domain, and the extent to which the change could be predicted by clinical and demographic 
variables, and cognitive reserve. 
6.2.        Methods 
6.2.1.      Participants 
For the analyses of the trajectory and extent of longitudinal change the data from the participants 
who underwent both phase I and phase II assessments was used (23 controls and 82 pwMS). However, 
for further analyses that required averaging the raw scores on the tests in order to establish 
standardized scores of domain-specific change, only the performance of pwMS with full data on all 




6.2.2.      Procedure 
I.         The trajectory and extent of cognitive change 
Prior to running any analyses on the change in patients’ performance, I needed to have an estimation 
of how much variation in longitudinal change is normal. This approach takes into account that not 
only patients change in their performance, but controls do as well, and that age-related deterioration 
on certain tasks, and practice effect on others were expected. Moreover, it was acknowledged that 
because the phase I and phase II assessments were performed by separate researchers, there was a 
chance for systematic differences in administration. Therefore in order to control for all these sources 
of normal variation I started this chapter by analysing the change in performance exhibited by healthy 
controls. 
a)      Control change 
The comparisons of control means between the performances at phase I and at phase II were 
presented in the previous chapter, Table 5.1. From that table we could see how much the controls 
have changed on each individual test, but the amount of change in raw numbers didn’t allow true 
appreciation of the change in one test in relation to another. For example, a change in 1 point on 
VOSP 8 (where the maximum score is 10 points) represented a much larger change than a change in 
1 point on BORB 5 (where the maximum score is 40 points). Therefore to estimate the true magnitude 
of how much the control performance varied from phase I to phase II on each test, the raw scores on 
all of the test items were converted into percentages. This conversion also allowed a better 
appreciation of the relative difficulty of each cognitive test, as the tests that were difficult for all 
participants would have lower values when converted into percentages, and easy tests with ceiling 
effect where the values approached 100% would also be easier to identify.  
First the difference between the performance on the phase I and phase II tests was calculated for the 
controls by subtracting phase I performance percentage from the phase II performance percentage. 
By calculating the performance differences this way, it was made sure that a positive difference 
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between the baseline and follow-up represented improvement, while a negative difference 
represented deterioration in performance.  
b)       Patient change 
After analysing the trajectory and extent of the control change, the next step was to investigate how 
much the patients have changed in the three years between the phase I and phase II assessments. 
Again, this procedure was performed after converting the raw data into percentages to allow for 
comparison of the extent of change among the different tests. In this chapter I aimed to analyse not 
only the extent of how much the patients have changed, but also the trajectory of their change, since 
I expected both decline (due to MS progression) and improvement (due to practice effect) to be 
observed. The patient change was calculated in the same way as the control change, i.e. by subtracting 
phase I performance percentage from the phase II performance percentage. 
c)      Comparison of the trajectory and extent between control and patient change 
The change in performance between control and patient participants was compared using the Mann-
Whitney U-test. A non-parametric test was chosen to employ as ceiling effect was expected on some 
of the cognitive tests, resulting in little variation in performance. 
II.  Standardization of change 
The natural tendency to experience changes in performance due to factors not related to MS needed 
to be taken into account later on when analysing the patient data in order to avoid overestimations or 
underestimations of deterioration. For example, on the tests where the controls performed worse at 
follow-up extra caution was needed for not overestimating the decline, as part of the decline observed 
in patients may be caused by other than MS-related factors. In addition, on tests where the controls 
showed practice effect, extra caution was needed for not underestimating the impairments. For 
example, if a patient appeared not to have changed, this could potentially indicate that the MS-related 
decline may be masked by practice effect, and the real change might be underestimated. These 
considerations have led to justification of a novel approach for further data analysis in order to adjust 
for factors related to healthy cognitive ageing, practice effect, and systematic differences in 
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administration. By running the following procedures it was attempted to account for those systematic 
effects. 
The z-score approach was chosen to employ since standardizing the variables allows comparing each 
patient outcome with that found in the reference control population. This enabled to account for 
normal variation in performance, expressed by normal deterioration related to cognitive ageing, and 
to improvement, related to practice effect. In addition, by choosing to convert the raw performance 
scores to z-scores I attempted to adjust for systematic bias in administration, so that the items where 
controls showed systematic change (improvement or deterioration) wouldn’t need to be eliminated. 
This way the effects of all of these confounding factors were subtracted, so that when later 
investigating the change in patient performance it would be ascertained that the observed changes 
represent solely the MS-related change.  
a)      Z-score approach for standardizing scores of longitudinal change 
The score standardization procedure employed in this study was adapted (with making a few changes 
to accommodate for the longitudinal study design) from the Multiple Sclerosis Functional Composite 
(MSFC) manual (Cutter et al., 1999). MSFC is a clinical outcome assessment scale widely used in 
everyday clinical practice (Cutter, et al., 1999). The authors of MSFC manual suggest converting 
raw scores on tests to z-scores (standardizing) to allow comparison of performance on tests with 
different units of measurement. Since the focus of this project was investigation of relative change, 
and not investigation of raw performance scores, therefore the raw values of performance on the test 
items were converted into z-scores to allow comparison of changes in performance on tests with 
different units of measurement 
The control data was standardized by converting the raw scores of change into z-scores.  
Individual Z-score = (raw score of individual’s change – average raw control change) / SD of raw 
control change 
The standardization procedure of the scores of change in patient performance was also based on the 
performance of the reference control group (Table 6.2.)  using the same formula. 
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b)      Establishing domain-specific change 
After calculating the standardized scores of change, the next step as suggested by the creators of the 
MSFC, was to average the z-scores of change for each domain to allow for evaluating the domain-
specific change. 
Implicit in this approach was the idea that patients who deteriorate or improve on several component 
(domain) measures would have an overall larger change than patients who change on only one of the 
measures. 
However, in order to allow averaging, it was necessary to establish that the tests in each domain did 
measure the same functions. Two tests were considered to measure the same cognitive function if 
they correlated. Correlations among the tests from a cognitive domain would allow averaging their 
scores, however, if the tests were found not to correlate, they were considered to measure separate 
functions. For the correlational analyses Spearman’s correlation coefficient was chosen to employ. 
The values of patient change on each test were averaged to create standardized scores of change in 
five cognitive domains: verbal memory, visuospatial memory, processing speed, visuoperceptual and 
language. 
III.      Predictors of patient change in each cognitive domain 
In this chapter when analysing the trajectory of longitudinal changes in performance I’ve expected 
to observe more than one trajectory of change. I hypothesized that the patients could be classified 
into those who improved, remained the same, and those who deteriorated in their performance on 
each cognitive domain. The next step was to investigate the factors that could potentially explain 
why some patients have changed in their performance more than others. However, the factors that 
potentially play a role in longitudinal changes in cognition were considered to vary and to be specific 





a)    Influence of clinical predictors of patient change in each cognitive domain 
In order to investigate the effect that MS-related factors have on cognition I chose to run separate 
multiple linear regression models for each cognitive domain. In each of the five models I’ve put the 
z-scores of patient change averaged for each domain as criterion variables, and the clinical variables 
as predictor variables. All values from the clinical variables were collected during the follow-up 
(phase II) assessment.   
The regression model employed to investigate the effect of MS-related variables on cognitive change 
in each domain is presented: 
Z-score of change = α + β1 (MS type) + β2 (disease duration) + β3 (neurological disability) + β4 
(Number of relapses in-between assessments) + β5 (depressive symptomology) + β6 (DMT uptake) + 
β7 (antidepressant uptake) 
I acknowledge that models with seven predictors and 61 observations lack power to run a multiple 
linear regression analysis (Green, 1991). Therefore for each domain only those predictor variables 
that had a relationship with the criterion variables were left in each of the models. 
b)    Influence of demographic and cognitive reserve predictors on performance changes 
in cognitive domains 
Having analysed the role that MS-related variables play in predicting the average change in each of 
the cognitive domains, the next step was to investigate to what extent cognitive changes could be 
explained by factors unrelated to MS, such as demographic and cognitive reserve variables. 
In order to investigate the effect that MS-unrelated factors have on cognition I again chose to run 
separate multiple linear regression models for each cognitive domain. In each of the five models I 
had put the z-scores of patient change (averaged for each domain) as criterion variables, and 
demographic and cognitive reserve variables as predictor variables. All values from the demographic 
and cognitive reserve variables were collected during the follow-up assessment, except again for the 
NART IQ score, which was collected at baseline. 
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The regression model employed to investigate the effect of MS-unrelated variables on cognitive 
change in each domain was proposed: 
Z-score of change = α + β1 (demographic factors) + β2 (reserve factors) 
The demographic factors included age and gender. The cognitive reserve factors included years of 
education, premorbid intelligence (NART IQ score), premorbid leisure activities score, number of 
languages spoken, current employment status and exercise. Therefore having included all of those 
variables, the full regression model of MS-unrelated predictors for change in each cognitive domain 
was presented: 
Z-score of change = α + β1 (age) + β2 (gender) + β3 (years of education) + β4 (premorbid 
intelligence) + β5 (premorbid leisure activities) + β6 (number of languages) + β7 (employment 
status) + β8 (exercise) 
As in the previous section, I acknowledge that regression models with eight predictors and 61 
observations do not have sufficient power to yield reliable results (Green, 1991). Therefore for each 
domain only the predictor variables that correlated with the criterion variables were left in each of 
the models. 
6.3.      The trajectory and extent of cognitive change 
I began the result analysis of this chapter by investigating the differences in performance between 
phases I and II to determine the longitudinal change. The distributions of performance scores at phase 
I and at phase II of control and patient participants can be seen in Appendix G. Since a large number 
of tests showed ceiling effect and the majority of distributions have been dramatically negatively 
skewed in both control and patient populations, it was chosen for the further analyses of the trajectory 
and extent of longitudinal change to employ non-parametric tests. 
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6.3.1.       How much change is normal - distribution of control scores in phases I 
and II 
As it can be seen from the Appendix G, overall the controls have exhibited similar distributions of 
performance scores at phases I and II. However, upon closer visual inspection it can be seen that on 
some tests a positive shift in the distribution was observed (SPART, SPARTD, WLGT and VOSP2), 
and on some other tests a negative shift in distribution was observed (SRTC, VOSP6, VOSP8, 
BORB5 and BC.Index).  
Although this observation indicated that in the time period of 3 years the controls have improved on 
some tests, and deteriorated on the others, these differences in distributions of scores were only 
statistically significant for the VOSP6 and BC.Index items. This could imply that on those tests in 
general the controls have participated worse at follow-up, and that trend was evident for the whole 
control sample. Therefore it could be assumed that the VOSP6 and BC.Index test items are highly 
sensitive to cognitive ageing, or that there has been systematic bias in the administration of those 
tests to the whole sample. 
Having analysed the overall trends of change in the control sample, the next step was to investigate 
the extent of individual changes in performance. The distribution of control scores in percentages in 
phases I and II can be seen in Table 6.1.  
From analysing the changes in control performance both slight deterioration and practice effect were 
observed. It appears that it is normal for heathy controls to improve on some tests and deteriorate on 
others up to 8 per cent in this longitudinal study. This could also be part of the normal fluctuation as 
people do not perform exactly equally each time they are tested. On average the practice effect was 
most evident for the visuospatial memory, naming and processing speed tests, while the decrease 
related to cognitive ageing was most evident for the verbal recall, visuoperceptual and language items.  
Having examined the trajectory and extent of control change, the next step was to investigate whether 




Table 6.1. Longitudinal change in control scores (in %) on the cognitive test items at phase I and 
phase II (n=23) 
 Phase I Phase II Average 
SRTL 71.12 (17.29) 71.12 (16.31) No change 
SRTC 57.08 (20.36) 57.27 (19.26) No change 
SRTD 82.61 (17.75) 77.17 (19.34) 5% decrease 
SPART 69.8 (16.52) 76.38 (14.03) 7% increase 
SPARTD 73.04 (18.2) 80.43 (24.58) 7% increase 
SDMT 66.24 (8.46) 70.25 (8.86) 4% increase 
PASAT 79.32 (21.17) 84.49 (10.92) 5% increase 
WLGT 70.97 (13.82) 77.56 (16.46) 7% increase 
VOSP2 77.39 (10.68) 83.04 (11) 6% increase 
VOSP3 93.48 (6.29) 92.39 (7.37) 1% decrease 
VOSP6 99.13 (2.45) 91.52 (5.92) 8% decrease 
VOSP8 99.13 (2.88) 96.52 (5.73) 3% decrease 
BORB2 91.3 (4.35) 91.16 (6.16) No change 
BORB5 92.83 (5.85) 90.54 (5.59) 2% decrease 
TROG 97.02 (3.76) 96.3 (3.68) 1% decrease 
BC.Index 41.67 (4.58) 34.06 (7.56) 7% decrease 
 
Table 6.1. shows that variations in the performance on the cognitive tests were observed. The 
controls tend to improve on the tests of visuospatial memory, information processing speed and 
naming, and deteriorate on tests measuring verbal recall, visuoperceptual cognition, and 
spontaneous speech. 
Note. For the tests where the maximum value is unknown (SDMT and WLGT), the highest value 
from the control and patient samples (both phases) was used to create the 100% score. 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – Delayed Retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART – items correct at learning 
stage, SPARTD – items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – Position of 
Gap Matching Task, TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – 




6.3.2.       Distribution of patient scores in phases I and II 
As it can be seen from the Appendix G, overall the patients have exhibited similar patterns of changes 
in distributions of performance at phases I and II as the controls. On most of the tests the distributions 
at phase I and II were no different, and as in the control sample, improvement on VOSP2, and 
deterioration on VOSP6 was observed. 
However, not only similarities, but differences could be indicated as well. While the controls showed 
overall improvement on both items of visuospatial memory (SPART and SPART D), the patients, 
however, showed only minimal improvement on SPART and a significant deterioration on SPARTD. 
The controls have showed a negative shift in distribution on SRTC, and BC.Index, but this was not 
observed in the patient sample. 
Another interesting aspect was that at phase II more patients had very low scores on the PASAT, and 
a second peak at low values could potentially indicate that a subgroup of patients emerged who found 
PASAT to be very difficult at phase II, but not at phase I. 
From analysing the patient performance (Table 6.2.) both improvements and deteriorations in 
performance were observed. On average, the patients have slightly improved on tests of verbal and 
visuospatial learning, and verbal recall. Most notable deteriorations in performance were observed 
on the test of sustained attention, and on a visuospatial test of position discrimination. 
To summarize, it can be noted, that the trajectory of longitudinal change was different for the patient 
and control participants. The next step was to investigate to whether there were differences in the 
extent of change as well.   
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Table 6.2. Longitudinal change in patient scores (in %) on the cognitive test items at phase I and 
phase II (n = 82).  
 Phase I Phase II Average change 
SRTL 45.49 (22.40) 48.78 (23.21) 3% increase 
SRTC 31.60 (23.03) 35.19 (23.29) 4% increase 
SRTD 51.34 (25.49) 52.67 (27.63) 1% increase 
SPART 58.90 (17.48) 64.23 (16.58) 5% increase 
SPARTD 63.58 (21.81) 61.67 (26.01) 2% decrease 
SDMT 54.88 (14.45) 53.60 (16.41) 1% decrease 
PASAT 61.21 (29.35) 51.71 (35.52) 10% decrease 
WLGT 59.52 (14.22) 61.72 (18.41) 2% increase 
VOSP2 73.33 (13.97) 73.05 (16.52 No change 
VOSP3 88.12 (10.11) 85.37 (12.32) 3% decrease 
VOSP6  97.06 (5.55)  86.89 (10.57) 10% decrease 
VOSP8 98.12 (91.98) 91.98 (13.64) 6% decrease 
BORB2 86.67 (6.94) 86.75 (7.06) No change 
BORB5 88.48 (6.91) 86.99 (8.79) 1% decrease 
TROG 94.46 (5.25) 94.38 (5.64) No change 
BC.Index 52.20 (16.14) 52.99 (12.78) No change 
 
Table 6.1. shows that both increases and decreases in the performance on the cognitive tests were 
observed. The patients tend to improve on the tests of verbal memory and visuospatial learning, 
and deteriorate on tests measuring sustained attention and visuospatial cognition. 
Note. For the tests where the maximum value is unknown (SDMT and WLGT), the highest value 
from the control and patient samples (both phases) was used to create the 100% score 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – Delayed Retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART – items correct at learning 
stage, SPARTD – items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – Position of 
Gap Matching Task, TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – 
Index of ratio of picture variables to number of words). 
 
6.3.3.      Comparison of the extent of the control and patient change 
As it can be seen from Table 6.3., the pattern of longitudinal change in performance was not uniform, 
with the patients and controls exhibiting differing trajectories of change. On some tests the patients 
have improved in their performance more than the controls (verbal memory); on some tests the 
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patients have deteriorated more than the controls (spatial cognition); on several tests the controls 
have improved while the patients have deteriorated (processing speed); and on some tests the controls, 
but not the patients have deteriorated (language).  
 
Table 6.3. Comparison of longitudinal changes in performance between control and patient 
participants 
 Controls (n = 23) Patients (n = 82) Difference 
SRTL 0.00 (14.42) 3.00 (20.86) U = 888.50, p = 0.803 
SRTC 0.19 (15.74) 3.23 (20.28) U = 869.00, p = 0.686 
SRTD -5.43 (16.01) 0.94 (18.94) U = 754.50, p = 0.185 
SPART 7.65 (12.73) 5.02 (16.69) U = 581.00, p = 0.569 
SPARTD 7.39 (19.36) -1.95 (26.51) U = 674, p = 0.081 
SDMT 4.43 (6.71) -1.31 (9.99) U = 586.50, p = 0.020 
PASAT 4.70 (17.00) -8.21 (24.94) U = 654.50, p = 0.066 
WLGT 6.59 (13.03) 2.20 (13.21) U = 788.00, p = 0.228 
VOSP2 5.65 (9.81) 0.54 (13.58) U = 688.50, p = 0.066 
VOSP3 -1.09 (7.38) -2.50 (12.35) U = 843.00, p = 0.535 
VOSP6 -7.61 (5.81) -10.38 (11.62) U = 783.50, p = 0.349 
VOSP8 -2.61 (6.19) -6.25 (13.91) U = 851.00, p = 0.543 
BORB2 -0.14 (5.55) 0.00 (7.73) U = 880.50, p = 0.820 
BORB5 -2.28 (6.39) -1.20 (8.51) U = 750.00, p = 0.263 
TROG -0.83 (2.66) -0.06 (0.82) U = 710.50, p = 0.300 
BC.Index -11.77 (9.40) 0.79 (19.99) U = 448.00, p = 0.004 
 
Table 6.3. shows that on the majority of tests the patients and the controls exhibit the same 
trajectory and similar extent of change. Different trajectories of change were observed on tasks 
measuring verbal and visual recall, information processing speed and spontaneous speech. The 
extent of change was statistically significantly different on the SDMT and BC Index items. 
Note. Comparisons were performed with the Mann Whitney U-test. Positive values indicate 
improvement; negative values indicate deterioration in performance 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – Delayed Retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART – items correct at learning 
stage, SPARTD – items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – Position of 
Gap Matching Task, TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – 




However, these differences reach significance only in two tests: the controls seem to show practice 
effect on an information processing speed task, while the patients show deterioration; and the controls 
show deterioration on a spontaneous speech task while the patients show no change. 
On most tests the patients seemed to express similar patterns of change as the controls, attributable 
to practice effect, cognitive ageing, and administration differences between the phases. However, on 
four tests (SPARTD, SDMT, PASAT, VOSP8) the patients have deteriorated much more, and on 
one test (BC.Index) the patients have improved much more, with these differences being statistically 
significant. This could potentially indicate that MS could be associated with a more rapid decline on 
spatial awareness and processing speed. However, the improvement expressed by patients on the BC 
test could be an artefact, as due to progression of upper limb motor disability, more patients were 
allowed to perform it this task orally at phase II, whereas all controls have performed in writing at 
both phases.  
In addition, I found a statistically significant difference in the distribution of BC.Index between 
phases I and II in the control sample, with healthy participants performing better at baseline. This 
could also be explained by administration differences between the researchers at phases I and II. 
Since there is no time limit for the BC test, different researchers may give more or less time to 
complete the task, or use verbal or non-verbal cues to encourage or discourage providing more text. 
Since the calculation of the BC.Index item is dependent on the total number of words provided, the 
differences in controls’ BC.Index could potentially be explained by how much of text they have 
actually written. At phase I the 22 controls provided an average of 55.23 (SD 19.26) words, and at 
phase II the same people provided an average of 65.14 (SD 25.25) words, but however, this difference 
was not statistically significant (t(42) = -1.464, p = 0.151, 2-tailed). 
6.3.4.       Standardization of change in domain scores 
Having standardized the change in performance for each participant on each test the next step was to 
establish the standardized scores of change in the cognitive domains. This was done by averaging 
the values of all the tests in each cognitive domain individually for each patient. However, in order 
to allow averaging, it was necessary to establish that the tests in each domain did measure the same 
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functions. Two tests were considered to measure the same function if they correlated and this would 
allow averaging their scores, but if they didn’t correlate, they were considered to measure separate 
functions. 
I. Correlations among the tests in each cognitive domain 
In order to determine whether the items in the cognitive domains were measuring similar functions 
it was decided to examine the correlation matrices of the raw values on each test for each domain at 
both phases (Tables 6.4 – 6.8).  
Table 6.4. Correlations among the test items in the verbal memory domain. Phase I and phase II 
patients with full data (n = 61) 
  SRTL SRTC 
Phase I 
   
SRTC r = 0.890, p < 0.001  
SRTD r = 0.733, p < 0.001 r = 0.742, p < 0.001 
    
Phase II SRTC r = 0.992, p < 0.001  
SRTD r = 0.888, p < 0.001 r = 0.889, p < 0.001 
   
 
Note. Correlations adjusted for multiple comparisons (Bonferroni α level 0.017) 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – Delayed Retrieval) 
 
 
Table 6.5. Correlations among the test items in the visuospatial memory domain. Phase I and 
phase II patients with full data (n = 61) 
  SPARTD 
Phase I 
  
SPART r = 0.753, p < 0.001 
  
Phase II SPART r = 0.724, p < 0.001 
  
 
Abbreviations: SPART – 10/36 Spatial Recall Test (SPART– items correct at learning stage, SPARTD 





Table 6.6. Correlations among the test items in the processing speed domain. Phase I and phase II 
patients with full data (n = 61) 
  SDMT PASAT 
Phase I 
   
PASAT r = 0.577, p < 0.001  
WLGT r = 0.544, p < 0.001 r = 0.496, p < 0.001 
Phase II 
   
PASAT r = 0.629, p < 0.001  
WLGT r = 0.577, p < 0.001 r = 0.443, p < 0.001 
    
 
Note. Correlations adjusted for multiple comparisons (Bonferroni α level 0.017) 
Abbreviations: SDMT – Symbol Digits Modalities Test, PASAT – Paced Auditory Serial Addition 
Test, WLGT – Category Animal Fluency task. 
 
 
Table 6.7. Correlations among the test items in the visuoperceptual domain. Phase I and phase II 
patients with full data (n = 61) 
  VOSP2 VOSP3 VOSP6 VOSP8 BORB2 
Phase I 
      
VOSP3 r = 0.347, p 
= 0.006 
    
VOSP6 r = - 0.100, 
p = 0.444 
r = 0.036, p 
= 0.784 
   
VOSP8 r = 0.201, p 
= 0.121 
r = - 0.018, 
p = 0.889 
r = -0.186, 
p = 0.151 
  
BORB2 r = 0.032, p 
= 0.808 
r = - 0.103, 
p = 0.430 
r = 0.013, p 
= 0.918 
r = 0.090, p 
= 0.490 
 
BORB5 r = 0.321, p 
= 0.012 
r = 0.045, p 
= 0.731 
r = 0.066, p 
= 0.614 
r = 0.340, p 
= 0.007 
r = 0.544, 
p < 0.001 
Phase II 
      
VOSP3 r = 0.556, 
p< 0.001 
    
VOSP6 r = 0.167, p 
= 0.199 
r = 0.335, p 
= 0.008 
   
VOSP8 r = 0.363, p 
= 0.004 
r = 0.270, p 
= 0.035 
r = 0.141, p 
= 0.277 
  
BORB2 r = 0.186, p 
= 0.151 
r = 0.094, p 
= 0.471 
r = 0.450, 
p < 0.001 
r = 0.172, p 
= 0.184 
 
BORB5 r = 0.552, 
p < 0.001 
r = 0.309, p 
= 0.016 
r = 0.361, p 
= 0.004 
r = 0.456, 
p < 0.001 
r = 0.393, 
p = 0.002 
       
 
Note. Correlations adjusted for multiple comparisons (Bonferroni α level 0.003). 
Abbreviations: VOSP – Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, 
VOSP3 – Object Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) 
BORB – Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – 
Position of Gap Matching Task. 
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Table 6.8. Correlations among the test items in the language domain. Phase I and phase II 
patients with full data (n = 61) 
  BC.Index 
Phase I 
  
TROG r = - 0.105, p = 0.422 
  
Phase II TROG r = - 0.260, p = 0.043 
  
Abbreviations: TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – Index of 
ratio of picture variables to number of words). 
 
From analysing the relationships among the test items, I found that the tests in verbal memory, 
visuospatial memory, and processing speed domains were highly inter-correlated, meaning that they 
measure the same (or very similar) functions. However, this pattern was less visible in 
visuoperceptual and language domains.  
The tests in the visuoperceptual domain could be considered inter-correlated, but the significance of 
those relationships diminished after adjusting for multiple comparisons. In addition, the lack of inter-
correlations could be explained by lack of variance, as many of the visuoperceptual tests had a strong 
ceiling effect. Therefore it was decided that even though these tests didn’t exhibit such high inter-
correlations as in the memory and processing speed domains, that could be explained by the lack of 
variance, and thus it was concluded that the z-scores of change on the visuoperceptual domain could 
be averaged for further analyses. 
Similarly as in the visuoperceptual domain, the tests in the language domain reached significance 
only in half of the correlations, and only at phase II. This could be interpreted in two ways. The first 
way to interpret was that at phase II the ceiling effect in TROG was slightly less evident, allowing 
for more variation in performance. This could explain why the two tests correlated only at phase II, 
and would treat phase I non-significant relationship as an artefact. The second possible interpretation 
was that these two tests measured different aspects of language: the TROG assessed grammar 
comprehension, and BC.Index item assessed spontaneous speech. It could be that these two tests 
were not correlated because they measured very different functions of the same domain, and therefore 
required different capabilities to perform them. However even though they measured different 
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functions, expression and comprehension are both important parts of the language domain. 
Considering these two interpretations I chose to average the z-scores in the language domain as well, 
as this was also consistent with the conservative approach used throughout this project. In this 
instance averaging the language domain decreased the chances of picking up artefacts and making 
the type I error, which could potentially occur if the two items were analysed separately. 
II. Calculating standardized scores of change in cognitive domains 
The values of patient change on each test were averaged to create standardized scores of change in 
five cognitive domains: verbal memory, visuospatial memory, processing speed, visuoperceptual, 
and language. The averaged z-scores of domain change for each patient can be seen in Appendix G. 
As can be seen from Figure 6.1., on each cognitive domain both improvement and deterioration were 
observed. 
However, on some cognitive domains the patients exhibited more deterioration than improvement 
(processing speed and visuoperceptual), and on other domains they exhibited more improvement 
than deterioration (verbal memory and language).  
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Figure 6.1. Distributions of criterion variables for linear regression models for patient participants 
(n=61). All criterion variables were in z-scores and included average change in verbal memory, 
visuospatial memory, processing speed, visuoperceptual and language domains 
 Mean (SD) Shapiro-Wilk test Distribution 
Verbal memory 0.218 (1.131) W = 0.979, p = 0.394 
 
Visuospatial memory -0.276 (1.094) W = 0.980, p = 0.429 
 
Processing speed -0.542 (0.933) W = 0.945, p = 0.008 
 
Visuoperceptual -0.196 (0.754) W = 0.944, p = 0.007 
 
Language 0.778 (0.940) W = 0.927, p = 0.001 
 
Note. The vertical line represents no change. 
137 
 
6.4.      Predictors of patient change in each cognitive domain 
In section 6.2. of this chapter I’ve established that the patients have changed in their performance in 
more than one trajectory – there were patients who improved, remained the same, and those who 
deteriorated in their performance in each cognitive domain. The next step was to investigate the 
factors that could potentially explain why some patients have changed in their performance more 
than others. However, those factors that play a role in cognitive changes can vary, and can also be 
specific for each cognitive domain. 
6.4.1.      MS-related predictors 
In order to investigate the effect that MS-related factors have on cognition I chose to run separate 
multiple linear regression models for each cognitive domain. In each of the five models I’ve put z-
scores of patient change averaged for each domain as criterion variables, and clinical variables as 
predictor variables. The averaged z-scores of domain change were deemed suitable to be criterion 
variables in a linear regression model, as they had a wide range and appeared to be sufficiently 
normally distributed after visual inspection (Figure 6.1.) 
I. Influence of time interval in-between assessments on clinical variables 
Before continuing with any further analyses it was necessary to determine whether any links could 
be identified between the MS-related variables and the time intervals in-between assessments. 
Namely, whether longer duration in-between the phase I and phase II assessments correlated with 
any of the clinical variables. As it can be seen from Table 6.4., none of the clinical variables were 




Table 6.9. Correlations between clinical predictor variables and the time interval in-between 
assessments for patient participants (n=61) 
 Interval in-between assessments (years) 
Predictor variables 
 
MS type r = 0.097, p = 0.348 
MS duration r = - 0.034, p = 0.715 
EDSS r = - 0.034, p = 0.728 
Number of relapses r = - 0.035, p = 0.738 
BDI-II r = 0.102, p = 0.265 
DMT uptake r = 0.163, p = 0.135 
Antidepressant uptake r = 0.070, p = 0.526 
 
Table 6.4. indicates that none of the clinical variables were linked to the time interval in-between 
assessments 
Note. For all analyses Kendall Tau correlations were employed 
Abbreviations: EDSS – Expanded Disability Status Scale, BDI-II – Beck’s Depression Inventory 2nd Ed., 
DMT – Disease modifying treatment 
 
II.  Preliminary investigation of relationships between potential predictor and criterion 
variables 
For the following analyses of linear relationships between predictor and criterion variables the non-
parametric tests were  chosen to employ for all numeric variables (MS duration, EDSS, number of 
relapses, BDI-II score), as the assumption of bivariate normality could be justified only for criterion, 
but not predictor variables in this sample. The distributions of MS-related variables can be seen in 
Figure 6.2.  
Kendall’s Tau correlation was chosen to employ since it has been shown to be less sensitive to error 
and to work better with smaller sample sizes than other measures of linear relationships (Bonett & 
Wright, 2000). For categorical variables I used comparisons of mean (ANOVA for MS type, and 
Mann Whitney U-test for DMT and antidepressant uptake) to establish associations between 




Figure 6.2. Distributions of clinical predictor variables for patient participants (n=61) 
a) Distributions of numeric predictor variables 
Variable Mean (SD) Shapiro-Wilk test Distribution 
Disease duration (years) 12.59 (6.91) W = 0.849, p < 0.001 
 
EDSS 5.19 (1.86) W = 0.945, p = 0.01 
 
Number of relapses 1.33 (3.68) W = 0.877, p < 0.001 
 
BDI – II 15.12 (9.38) W = 0.394, p < 0.001 
 
b) Frequencies of categorical predictor variables 
Variable Frequency 
MS type 16 (26%) PPMS, 18 (30%) SPMS, 27 (44%) RRMS 
DMT 27 (44%) no, 34 (56%) yes 
Antidepressants 39 (64%) yes, 22 (36%) no 
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Abbreviations: EDSS – Expanded Disability Status Scale, BDI-II – Beck’s Depression Inventory 2nd 
Ed., DMT – Disease modifying treatment 
As it can be seen from Table 6.5., the changes in each cognitive domain were associated with 
different clinical variables. The change in verbal memory domain was linked to the levels of 
neurological disability and depressiveness. The change in visuospatial memory didn’t seem to be 
linked to any of the MS-related variables. The change in processing speed was linked to the MS type 
only. The change in visuospatial domain was linked to neurological disability, MS type and DMT. 
The change in the language domain was linked to the level of depressiveness.  
Table 6.10. Relationships between clinical predictor and criterion (average change in a domain) 
variables for patient participants  










     
MS duration r = - 0.123,  
p = 0.177 
r = 0.164, 
p = 0.072 
r = - 0.140,  
p = 0.123 
r = - 0.001,  
p = 0.315 
r = - 
0.069,  
p = 0.446 
EDSS r = - 0.227,  
p = 0.018 
r = - 0.047, 
p = 0.629 
r = - 0.078,  
p = 0.419 
r = - 0.226,  
p = 0.019 
r = 0.103,  
p = 0.283 
Number of relapses r = - 0.163,  
p = 0.108 
r = - 0.074,  
p = 0.466 
r = 0.077,  
p = 0.447 
r = 0.107,  
p = 0.293 
r = - 
0.019,  
p = 0.848 
BDI-II r = -0.304,  
p = 0.001 
r = - 0.071,  
p = 0.428 
r = - 0.094,  
p = 0.295 
r = 0.068,  
p = 0.447 
r = -
0.181,  
p = 0.042 
MS type F = 2.594,  
p = 0.083 
F = 2.258,  
p = 0.114 
F = 5.184, 
p = 0.008 
F = 14.264,  
p < 0.001 
F = 1.844,  
p = 0.167 
DMT uptake U = 394,  
p = 0.345 
U = 372,  
p = 0.206 
U = 411,  
p = 0.486 
U = 286,  
p = 0.012 
U = 421,  
p = 0.581 
Antidepressant 
uptake 
U = 293,  
p = 0.074 
U = 346,  
p = 0.339 
U = 329,  
p = 0.221 
U = 364, 
p = 0.500 
U = 240,  
p = 0.294 
Table 6.5. shows that the changes in each cognitive domain were associated with different clinical 
variables. The change in verbal memory domain was linked to the levels of neurological disability 
and depressiveness. The change in visuospatial memory didn’t seem to be linked to any clinical 
variables. The change in processing speed was linked to MS type only. The change in 
visuoperceptual domain was linked to neurological disability, MS type and DMT. The change in the 
language domain was linked to the level of depressiveness.  
Note. Kendall Tau correlations for numeric variables, ANOVA for MS type, and Mann-Whitney U-
test for medication uptake comparisons were employed 
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Abbreviations: EDSS – Expanded Disability Status Scale, BDI-II – Beck’s Depression Inventory 2nd 
Ed., DMT – Disease modifying treatment 
Based on these preliminary investigations of the relationships between predictor and criterion 
variables, different criterion variables were selected to enter into each multiple linear regression 
model. 
6.4.2.     Verbal memory 
Based on the presented associations (Table 6.5.), the following model for the changes in verbal 
memory domain was proposed: 
Z-score of change in verbal memory = α + β1 (EDSS) + β2 (BDI-II) 
Before running this model the predictor variables were checked for multicollinearity. EDSS and BDI-
II were not correlated (r = 0.147, p = 0.134, Kendall Tau, 2-tailed). Durbin-Watson test values 
indicated that there was no autocorrelation (d = 1.725), and it was concluded that it was safe to 
proceed with the multiple linear regression model (Durbin & Watson, 1950).  
When average change in verbal memory was predicted it was found that both EDSS score (Beta = - 
0.278, p = 0.023) and BDI-II score (Beta = - 0.317, p = 0.010) were significant predictors. The overall 
model fit was R2adj.  = 0.212, p = 0.001. As it can be seen from Figure 6.3, deterioration in 





Figure 6.3. Linear relationship between the effects of neurological disability and depressiveness 




Figure 6.3. shows that higher EDSS and BDI-II scores predict negative change in performance on 
verbal memory tests.  





6.4.3.    Visuospatial memory 
Since the average change in the visuospatial memory domain was not shown to be linked to any of 
MS related variables (Table 6.5.), there was not enough justification to support running a linear 
regression model. 
6.4.4.    Processing speed 
Based on the associations presented in Table 6.5., the following model for the longitudinal changes 
in processing speed was proposed: 
Z-score of change in processing speed = α + β1 (MS type) 
In order to include the 3-level MS type variable (RRMS, PPMS, SPMS) into the linear regression 
model, dummy coding was used, and RRMS was used as a baseline category to which PPMS and 
SPMS were compared. Durbin-Watson test values indicated that there was no autocorrelation (d = 
1.744) thus it was considered suitable to proceed with the linear regression model. 
When the average change in processing speed was predicted it was found that progressive MS types 
had a negative effect. This indicated that patients with progressive types of MS suffer from poorer 
outcome on the processing speed tests. However, PPMS (Beta = - 0.276, p = 0.039) had a smaller 
effect than SPMS (Beta = - 0.813, p = 0.003). The overall model fit was R2adj. = 0.152, p = 0.008, 










Figure 6.4. Linear relationship between MS type and change in processing speed domain 
 
Figure 6.4. shows that progressive MS types were associated with decrease in processing speed 
Abbreviations: RRMS – Relapsing-remitting MS, PPMS – Primary progressive MS, SPMS – Secondary 
progressive MS 
 
6.4.3.       Visuoperceptual domain 
The associations presented in Table 6.5. justified running the following linear regression model for 
predicting average change in the visuoperceptual domain: 
Z-score of change in visuoperceptual domain = α + β1 (MS type) + β2 (DMT uptake) 
In this model again dummy coding was used for the MS type variable as it had three levels (RRMS, 
PPMS and SPMS), and RRMS was used as a baseline category. Fort the DMT uptake variable there 
were two categories (not taking and taking DMT drugs), and not taking DMT drugs was used as a 
baseline category. Durbin-Watson test values indicated that there was no autocorrelation (d = 1.702). 
The overall model fit was R2adj.  = 0.374, p < 0.001, and a visual representation of this model can be 




Figure 6.5. Linear relationship between MS type and DMT uptake as predictor variables for change 
in visuoperceptual domain 
 
 
Figure 6.5. shows that SPMS type was associated with decrease in performance, but using DMT was 
associated with better performance on visuoperceptual tests 
Abbreviations: RRMS – Relapsing-remitting MS, PPMS – Primary progressive MS, SPMS – Secondary 
progressive MS, DMT – disease modifying treatment 
 
When the average change in the visuoperceptual domain was predicted, it appeared that progressive 
MS type had a negative effect, while adhering to DMT had a positive effect. Comparing to RRMS, 
SPMS was predictive of deterioration in the visuoperceptual domain (Beta = - 0.544, p < 0.001), 
while PPMS appeared to have very limited effect (Beta = - 0.013, p = 0.908). In addition, it was 
shown that taking DMT drugs had a positive effect, and could be associated with improvement in 
performance on visuoperceptual tests (Beta = 0.327, p = 0.05), although this effect was borderline 
significant.  
Adherence to DMT and MS type were not related (X2 (2) = 4.206, p = 0.122), although a higher 




6.4.6.       Language 
 
Based on the findings in Table 6.5., it was decided to include only the level of depressiveness as a 
sole predictor variable into the regression model predicting the average longitudinal change in the 
language domain: 
Z-score of change in language domain = α + β1 (BDI-II score) 
For this model the Durbin-Watson test value indicated that there was no autocorrelation (d = 2.085). 
When the average change in the language domain was predicted, BDI-II score had a statistically 
significant effect (Beta = - 0.278, p = 0.030), indicating that higher BDI-II scores were predictive of 
decrease in performance on the language tests. The overall model fit was R2adj. = 0.077, p = 0.030, 
and a visual representation of the model can be seen in Figure 6.6.  
Figure 6.6. Linear relationship between levels of depressiveness as predictor variable for change in 
language domain 
 
Figure 6.6. shows that higher BDI-II scores were predictive of decrease in performance on language 
tests. 




          6.4.7.       MS-related predictors of domain-specific cognitive change. Summary 
In this section I’ve identified that changes in performance on verbal memory, processing speed, 
visuoperceptual and language domains could be to some extent predicted by different MS-related 
variables, but, however, the change in performance on tests from visuospatial memory domain could 
not. 
In the verbal memory domain higher EDSS and BDI-II scores predicted deterioration in performance. 
This indicated that in our sample neurological disability and level of depressiveness were predictive 
of poorer performance on the verbal memory tests. 
From analysing the regression model with the change in processing speed performance as the 
criterion variable, it was found that progressive MS types were associated with decrease in processing 
speed. In the span of 3 years both PPMS and SPMS patients tend to decrease in their performance 
on tests of processing speed more than RRMS patients. 
In the visuoperceptual domain it appeared that SPMS type and DMT uptake were associated with 
decrease in performance on visuoperceptual tests. Here the SPMS type was statistically significantly 
more linked to decrease in performance on visuoperceptual tests that other MS subtypes. This 
analysis had also indicated that patients who use DMT tend to have a better outcome on the 
visuoperceptual tests than those who don’t take DMT drugs. However, this finding was borderline 
significant and therefore should be proceeded with caution.  
In the language domain higher BDI-II scores were predictive of decrease in performance on the 
language tests. This indicated that individuals who were more depressed tend to deteriorate in their 
performance on the language tests. 
To conclude, clinical variables do have an effect on cognition, but different variables affect different 
cognitive domains. This could potentially explain confounding findings from previous studies that 
related changes in cognition to different clinical factors (Table 1.1.). The discrepancy of findings 
linking cognitive deterioration to different clinical and non-clinical variables in previous research 
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could be potentially explained by which tests those studies have employed, i.e. which cognitive 
domains were assessed. 
6.5.       Demographic and cognitive reserve predictors of patient changes in 
each cognitive domain 
 
After analysing the effect that the MS-related variables have on longitudinal changes in performance 
on each of the cognitive domains, the next step was to investigate whether the demographic and 
cognitive reserve variables help explain some of the changes as well. In this section I aimed to explore 
whether age, gender, premorbid IQ, premorbid leisure activities, years of education, exercise, 
employment status and the number of languages spoken could help predict the longitudinal changes. 
I. Correlations between predictor and criterion variables 
As before, I acknowledge that models with eight predictors and 61 observations did not have 
sufficient power to run a multiple linear regression analysis (Green, 1991). Therefore for each 
domain only the predictor variables that had linear relationship with the criterion variables were left 
in each of the models. 
For these analyses Kendall’s Tau correlation test was chosen to employ for all numeric variables 
(age, years of education, NART IQ score, premorbid leisure activities score, and number of 
languages), as the assumption of bivariate normality could not be justified for predictor variables in 
this sample (Figure 6.7.). For categorical variables (gender, employment status and exercise) I used 
non-parametric comparisons of mean (Mann-Whitney U-test).  
As it can be seen from Table 6.6., the changes in performance on four cognitive domains (verbal 
memory, visuospatial memory, processing speed and language) weren’t associated with demographic 
and cognitive reserve variables. A potential link between change in visuoperceptual domain, age and 
employment was identified, and these two predictors were used to include into the model. The change 






Figure 6.7. Distributions of demographic and cognitive reserve predictor variables for linear 
regression models for patient participants (n=61) 
 
a) Distributions of numeric variables 
Variable Mean (SD) Shapiro-Wilk test Distribution 
Age (years) 49.98 (9.32) 
W = 0.983, p = 
0.601 
 
Years of education 
13.05 (3.15) 
W = 0.916, p = 
0.001 
 
NART premorbid IQ 
113.53 
(10.20) 
W = 0.928, p = 
0.002 
 
Premorbid leisure 20.03 (4.36) 
W = 0.987, p = 
0.804 
 
Number of languages 
spoken 
1.33 (0.66) 




b) Frequencies of category variables 
Variable Frequency 
Gender 32 (52%) female, 29 (48%) male 
Exercise 33 (54%) no, 28 (46%) yes 
Employment 27 (44%) no, 34 (56%) yes 
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Table 6.11. Correlations between predictor (demographic and reserve) and criterion (average 
change in a domain) variables for patient participants (n=61) 










     
      
Demographic      
      
Age r = - 0.063, 
p = 0.417 
r = - 0.103,  
p = 0.198 
r = - 0.138,  
p = 0.079 
r = - 0.169,  
p = 0.033 
r = - 0.004,  
p = 0.963 
Gender U = 371,  
p = 0.179 
U = 419, 
 p = 0.516 
U = 464,  
p = 0.999 
U = 379,  
p = 0.220 
U = 445,  
p = 0.784 
      
Reserve       
      
Years of 
education 
r = 0.018,  
p = 0.828 
r = 0.018,  
p = 0.829 
r = 0.038,  
p = 0.651 
r = 0.137,  
p = 0.103 
r = 0.045,  
p = 0.614 
NART premorbid 
IQ 
r = - 0.096,  
p = 0.218 
r = - 0.006,  
p = 0.941 
r = - 0.044,  
p = 0.574 
r = 0.110,  
p = 0.168 
r = 0.084,  
p = 0.319 
Premorbid 
leisure activities 
r = - 0.019,  
p = 0.832 
r = 0.015,  
p = 0.871 
r = 0.091,  
p = 0.312 
r = 0.017,  
p = 0.851 
r = 0.055,  
p = 0.540 
Number of 
languages 
r = - 0.175,  
p = 0.091 
r = 0.038, 
p = 0.715 
r = 0.060,  
p = 0.561 
r = - 0.036,  
p = 0.728 
r = 0.033,  
p = 0.753 
Employment 
status 
U = 354,  
p = 0.260 
U = 369.5,  
p = 0.371 
U = 351,  
p = 0.241 
U = 148,  
p < 0.001 
U = 393,  
p = 0.589 
Exercise U = 352,  
p = 0.111 
U = 381,  
p = 0.241 
U = 365,  
p = 0.160 
U = 451,  
p = 0.874 
U = 377,  
p = 0.219 
 
Table 6.6. indicates that in general the change in performance on cognitive tests wasn’t associated 
with demographic and reserve variables. A link between change in visuoperceptual domain, age 
and employment needed to be further investigated. 
Note. Kendall Tau correlations for numeric variables, Mann-Whitney U-test for binary variables. 
 
6.5.1.     Visuoperceptual domain 
Based on the presented associations (Table 6.6.) the following model for the changes in 
visuoperceptual domain was proposed: 
Z-score of change in verbal memory = α + β1 (age) + β2 (employment status) 
For the employment status variable there were two categories (not employed and currently employed), 
and not employed was used as a baseline category.  
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Before running this model the predictor variables were checked for multicollinearity. Age and 
employment status were found to be negatively correlated (r = - 0.239, p = 0.027, Kendall Tau, 2-
tailed). However, it was considered to assume that older people in our sample have retired due to 
older age and lost their employment this way. But after checking that assumption I found that out of 
the 39 (of 61) unemployed patients only four were above the retirement age of 65 years. Therefore it 
was concluded that the unemployment in this sample represented retirement due to MS, and not due 
to reaching retirement age. Durbin-Watson test values indicated that there was no autocorrelation (d 
= 1.725). 
When average change in visuoperceptual domain was predicted it was found that being employed 
was the only significant predictor (Beta = 0.812, p = <0.001), and that age had no significant effect 
(Beta = 0.001, p = 0.946). The overall model fit was R2adj.  = 0.244, p < 0.001. As it can be seen from 
Figure 6.8, deterioration in performance on visuoperceptual tests was linked to being unemployed. 
Figure 6.8. Linear relationship between employment status and change in visuoperceptual 
domain 
 
Figure 6.8. indicates that being unemployed was shown to be the sole predictor of deterioration 
visuoperceptual domain 
This analysis indicated that impairments in visuoperceptual domain could cause participants 
problems at work and eventually lead to unemployment.  
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6.5.2. Demographic and cognitive reserve predictors of domain-specific change. 
Summary 
 
In this section I’ve identified that changes in performance on verbal memory, visuospatial memory, 
processing speed and language domains couldn’t have been predicted by demographic and cognitive 
reserve factors. The change in performance on tests from visuoperceptual domain could be predicted 
by employment status, but however, the directionality of this relationship was unclear. It could either 
be that continuing to be employed stimulated cognitive abilities required for performing 
visuoperceptual tests, but it could also be that failure to perform functions assessed by 
visuoperceptual tests resulted in failure in performing work-related tasks (such as reading or 
identifying numbers) therefore resulting in patients losing their jobs.  
Besides this, it can be concluded that cognitive reserve factors didn’t have an effect on longitudinal 
change in cognitive performance. It may be that cognitive reserve factors have an effect on the overall 
ability, but not on the rate of change – if an impairment in cognitive function develops, it progresses 
at the same rate for everyone, high or low premorbid ability. 
6.6.      Chapter summary 
In this chapter I’ve identified the trajectory, extent and predictors of cognitive change in MS. To 
begin with, I found is that there was no clear pattern of what trajectory and extent the change takes, 
and from what can be inferred from our sample, there was also no single predictor for cognitive 
change, as the impairments on different domains were linked to different MS-related variables. 
From analysing the trajectories of change I’ve shown that both pwMS and healthy controls exhibited 
changes in performance on the cognitive tests. Both controls and pwMS showed increased and 
decreased performance, and the extent of the changes differed depending on a cognitive test. In this 
chapter I’ve produced a standardized way to estimate the amount of change, and this method was 
shown to allow comparisons of longitudinal change across the cognitive domains. By standardizing 
the scores with reference to control performance I have accounted for variation that could have been 
caused by cognitive ageing, practice effect, and differences in test administration. 
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From analysing the predictors of cognitive change I’ve identified that the change on each cognitive 
domain could be predicted by different MS-related variables. The change in verbal memory domain 
was linked to the levels of neurological disability and depressiveness. The change in visuospatial 
memory didn’t seem to be linked to any clinical variables. The change in processing speed was linked 
to MS type only (SPMS, and to lesser extent PPMS). The change in visuoperceptual domain was 
linked to neurological disability, MS type and DMT. The change in the language domain was linked 
to the levels of depressiveness.  
In contrast to the effect of clinical variables, the demographic and cognitive reserve variables did not 
have predictive value on the cognitive change. The only exception was the change in visuoperceptual 
domain, where poorer performance was found to be associated with unemployment. However, the 

















Chapter Seven. Self-perception of cognitive change in pwMS 
7.1.      Chapter overview 
From analysing the longitudinal change in Chapter Six it was found that both improvements and 
deteriorations in performance were observed in this patient sample, and that they had been caused by 
multiple factors. The subsequent step was to investigate whether the patients themselves were aware 
of the trajectory and extent of their cognitive change, and the factors that have had an effect on those 
estimations.  
The first attempt was to replicate the findings from the previous studies on insight where the patients 
had been assessed solely with the BRBN battery (composed of tests assessing verbal memory, 
visuospatial memory, processing speed, attention and verbal fluency). Then the findings on the self-
perception of cognitive difficulties in performance on the BRBN battery were compared to the tests 
which haven’t been studied before in this context in MS, namely the visuoperceptual and language 
tests.  
Since it is common for healthy adults to exhibit some level of inaccuracies in their estimations, the 
patient self-estimates of longitudinal change in cognition were compared not only to their actual 
performance, but also to that exhibited by the reference control population. 
7.2.       Methods 
7.2.1. Participants 
For all of the analyses in this chapter only the participants with full data on all cognitive assessments 
were chosen to employ. This way it was controlled that all participants had gone through the exactly 
same tests and therefore provided their cognitive performance self-estimates for the same 
assessments, allowing for valid between-domain comparisons. 
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For the analyses comparing the actual change with the perceived change, the scores from 61 patient 
and 15 controls were used. For further analyses of the predictors of self-perceptions of longitudinal 
change, only the demographic and disease data from the patient participants was used. 
7.2.2. Data format 
In this chapter only the self-perceptions of longitudinal change in performance have been analysed. 
In order to address the doubts regarding the reliability of collecting the self-awareness data for phase 
I at phase II, we have further investigated the patient and control abilities to estimate their 
performance at phase II in the supplementary analysis (Appendix I). However, since no major 
discrepancies have been observed between the patients’ and controls’ abilities to estimate their 
cognitive performances, it was considered safe to continue with the analyses of self-perceptions of 
longitudinal change. 
I.     Actual change in performance 
The actual change in performance on the three groups of tests (the BRBN battery, visuoperceptual 
and language) was analysed as z-scores as had been done in Chapter Six.  
The standardized values of change on the language and visuoperceptual tests for the patient and 
control participants were employed from Chapter Six, section 6.3.4. and can be seen in Appendix H. 
The standardized values of change on the BRBN battery were calculated separately by averaging the 
standardized values of change in performance on its component test items: SRTL, SRTC, SRTD, 
SPART, SPARTD, SDMT, PASAT, and WLGT. In the previous chapters these test items were used 
to produce the domain scores for verbal memory, visuospatial memory, and processing speed. 
These cognitive tests comprising the BRBN battery are widely employed in MS research and 
impairments on the functions assessed by them are considered to represent a classical view on MS-
related cognitive impairment. Even though the BRBN battery includes tests that assess multiple 
cognitive domains (verbal memory, visuospatial memory, processing speed, attention, and category 
naming), it was decided to study patient self-perception of cognitive change on this battery as a whole, 
to allow comparison with previous work on insight in MS. The previous studies (such as 
Christodoulou et al., 2005; Sherman, Rapport, & Ryan, 2008; Julian, Merluzzi, & Mohr, 2007; 
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Carone, Benedict, Fishman, & Weinstock-Guttman, 2005) have all used solely the BRBN battery to 
assess cognitive deficits in MS, and collect data on awareness of these deficits. The estimates of self-
awareness of longitudinal change for the visuoperceptual and language domains were collected 
separately, as the insight into the deficits on these cognitive domains have never been studied before 
in MS. 
II. Perceived change in performance 
The estimates of perceived change in performance were collected on three groups of cognitive tests: 
the BRBN battery, and the visuoperceptual and language tests. Two types of estimates were collected 
– the self-estimation of perceived levels of performance at phase I, and the self-estimation of 
perceived levels of performance at phase II. The participants had provided both of these measures at 
phase II, therefore the self-estimates of performance at phase I were collected retrospectively. 
The self-estimates of longitudinal change in cognition were calculated using the following formula:  
Self-estimate of longitudinal change = Self-estimate of perceived performance at phase II – Self-
estimate of perceived performance at phase I 
By calculating the self-estimates of perceived longitudinal change in cognition this way, the positive 
differences indicated perceived improvement, and the negative differences indicated perceived 
deterioration in performance. Since the range for both estimations (at phase I and at phase II) were 
on a scale from 0 to 100, theoretically the values of self-estimations of longitudinal change would 
range from [– 100] to [+ 100], and the further they were from 0, the larger the perceived change. 
7.2.3.      Group differences in actual change in performance 
First the standardized scores of the amount of actual change between the patient and control 
participants were compared with the aim of investigating any differences that could be found between 
the patients and controls in how much they have actually changed on the three groups of cognitive 
tests. All comparisons were performed with the Mann-Whitney U-test. The dependent variables were 
the changes in performance on the BRBN tests, the visuoperceptual tests and the language tests; and 
the independent variable was being a patient or a control. 
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As a next step the amount of the actual change in performance on the three groups of tests was also 
compared for the patient and control samples separately. I wanted to know whether there have been 
differences in the amount of change between the three groups of tests. Namely, this way I’ve tested 
whether the participants have changed on some of the groups of tests more than on others. Those 
analyses were performed with the Related-Samples Friedman’s analysis of variance by ranks twice, 
first for the patient participants, then separately for the control participants. 
7.2.4.      Group differences in the perceived changes in performance 
After estimating the amounts of the actual change, I wanted to know whether there have been 
differences between the self-estimates of perceived change. The result analysis was conducted in the 
same manner, but this time the differences in self-estimates of change instead of the actual change 
were analysed. 
First I’ve compared the self-estimates of change between the patient and control participants. I 
wanted to know whether there were any differences between the patients and the controls in how 
much they have thought that they have changed on the three groups of tests. As has been done with 
comparisons of actual change, the comparisons of perceived change were performed with the Mann-
Whitney U-test. The dependent variables were the perceived changes in performance on the BRBN 
tests, the visuoperceptual and the language tests; and the independent variable was being a patient or 
a control. 
The perceived change on the three groups of tests was also compared for the patient and control 
samples separately. I wanted to know whether there have been differences in the amount of perceived 
change between the three groups of tests. These analyses were performed with the Related-Samples 
Friedman’s analysis of variance by ranks twice, first for the patient participants, then separately for 
the control participants. 
7.2.5.      Relationship between the actual and the perceived change in performance 
Having analysed the actual changes and the perceived changes in performance separately, the next 
step was to investigate the relationship between the self-estimated and the actual longitudinal changes 
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in cognition. This was done separately for each group of cognitive tests in both patients and controls, 
first by visually inspecting the trajectories of the actual longitudinal change and the perceived change, 
and then by running multiple correlations between those measures. Kendall Tau correlation was 
employed due to small sample sizes and non-normal distribution in the control cohort.  
7.2.6.        Predictors of perceived change 
Previous studies have identified that about 60% of pwMS believe that they have developed cognitive 
difficulties. I wanted to know what makes some patients believe that their performance on the 
cognitive tests has changed. The next step was to investigate the factors considered to be related to 
perceiving changes in cognitive abilities in the patient population.  
The following multiple linear regression model for the patient participants was devised: 
 
Perception of longitudinal change in patients = α + β1 (executive functioning) + β2 (depressive 
symptomology) + β3 (neurological disability) + β4 (Number of relapses in-between assessments) + 
β5 (MS impact) 
In this model it was predicted that poor executive functioning would be associated with 
underestimating the actual change. However, higher scores on the depression, MS impact, 
neurological disability scales, and more relapses in-between assessments, would be associated with 
perceived decline in cognitive functioning in all groups of tests. I anticipated these factors to have 
similar predictive values in all three models, on all three groups of cognitive tests. 
In this model the executive functioning was measured by the WLGT test, the depressiveness was 
measured with the BDI-II scale, and the neurological disability was measured with the EDSS scale. 
MS impact was measured with the MSIS-29 scale, and the number of relapses in-between the 
assessments was noted for the RRMS and SPMS participants (n=45). 
I do acknowledge that the WLGT is a category naming task that is considered to be a test of executive 
functioning in some of the studies, but not on the others. However, since no other better suitable test 
of executive functioning had been included into the phase I battery, it was decided to proceed with 
WLGT as an indicator of executive functioning in this model. 
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7.3.       Results 
In this chapter the z-scores of change on the individual BRBN battery, visuoperceptual and language 
tests were averaged to produce the values of actual change for each groups of tests for both patient 
and control participants. As it can be seen from the data presented in Appendix H, both patient and 
control participants weren’t exactly accurate in their estimations of their personal performance. 
7.3.1.       Actual changes in performance 
I.      Comparison of the change in performance scores between the patients and controls 
First I’ve compared the standardized scores of the actual change between the patient and control 
participants. I wanted to know whether there have been differences between how much the patients 
and the controls have actually changed on the groups of cognitive tests. 
As it can be seen from Figure 7.1., both controls and patients have exhibited improvements and 
deteriorations in their performances on all groups of tests. No differences between the patients and 
the controls were found in the patterns of longitudinal change in their performance on the BRBN and 
visuoperceptual tests. 
The main difference was on the change in performance on the language tests, where more controls 
than patients have deteriorated. The difference in patient and control distributions on the change in 
performance on the language tests was statistically significant (Kolmogorov-Smirnov Z = 1.744, p = 
0.005). This needs to be taken into account when analysing the predictors of change in language 
performance, as the patients could be considered unchanged in their performance in comparison to 
the reference control group, who for some reason have deteriorated. 
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Figure 7.1. Comparison of standardized scores of actual change in performance between control 
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p = 0.007 
   
 
Figure 7.1. shows that the controls and patients have showed similar patterns of longitudinal 
change in their performance on the BRBN and visuospatial tests. On the language tests the controls 
have deteriorated more than the patients 
Note. Group comparisons were performed using the Mann-Whitney U-test 






II.      Comparison of change in performance scores between the different groups of tests 
In this section I’ve investigated the differences in how much the participants have actually changed 
between the three different groups of tests. First I have separately looked into the differences between 
the changes in performance on the three groups of tests for the control participants, to understand 
whether there have been any changes in performance that could potentially be attributable to other 
factors not related to MS, such as healthy cognitive ageing, practice effect, normal fluctuation in 
performance, or systematic differences in administration between researchers at phase I and phase II. 
As it can be seen from the Table 7.1, the controls had shown similar patterns of change on the three 
groups of cognitive tests. This indicated that the differences that were observed between the patient 
and control participants on the change in language tests (Figure 7.1) were because the patients had 
improved on them, and the controls have in fact performed the same. 
However, there have been differences between how much the patients have changed on the three 
groups of cognitive tests. The patients have on average deteriorated on the BRBN and 
visuoperceptual tests, and improved on the language tests, and this difference was statistically 
significant.  
 
Table 7.1. Comparison of the standardized scores of change for patient and control participants on 
the three groups of cognitive tests 
Cognitive tests Controls (n=15) Patients (n=61) 
   
BRBN battery 0.09 (0.32) -0.20 (0.73) 
Visuoperceptual -0.10 (0.49) -0.20 (0.75) 
Language 0.03 (0.80) 0.78 (0.94) 
   
Difference F(2) = 1.600, p = 0.449 F(2) = 43.672, p < 0.001 
 
Table 7.1. shows that on average the controls haven’t changed in their performance on all three 
groups of cognitive tests, while the patients have on average deteriorated on the BRBN and 
visuoperceptual tests, and improved on the language tests 
Note. The differences between the groups of cognitive tests were compared using the Related-
Samples Friedman’s analysis of variance by ranks 




A visual representation of the differences in standardized scores of changes between performance at 
phase I and performance at phase II on the three groups of cognitive tests will be discussed later on 
in this chapter, and can be seen in Figure 7.3. 
III.     Actual change in performance. Summary 
After analysing the longitudinal changes in cognitive performance it was found that the controls have 
shown non-different amount of change on all three groups of tests. The patients have deteriorated on 
the on the BRBN and visuoperceptual, but not on the language tests. This indicated that the 
differences that were observed between the patient and control participants on the change in language 
tests were because the patients had improved on them, and the controls have performed the same at 
both phases. 
7.3.2.   Perceived change in performance 
 I.         Comparison of perceived change in performance between the patients and 
controls 
The next step was to investigate the patterns of how the patients and the controls have thought that 
they have changed. The comparison of estimations of patients’ and controls’ longitudinal change can 
be seen in Figure 7.2.  
I found that the patients and the controls estimated their changes in a similar manner on the BRBN 
and language tests. On the BRBN tests both patients and controls more often thought that they have 
deteriorated, and on the language tests both patients and controls mainly thought that they haven’t 
changed. However, on the visuoperceptual tests the patients perceived that they have deteriorated, 
while the controls perceived that their performance hadn’t changed.  
The average score of patients estimations of their change in the visuopeceptual domain was lower 
(Mann-Whitney U = 624.5, p = 0.025), and the difference between the distributions of patient and 
control estimation scores on the visuoperceptual tests was close to being statistically significant 




Figure 7.2. Comparison of self-perception of change between control and patient participants 
 
Cognitive tests  Difference 






U = 473.5,  






U = 624.5,  






U = 543,  
p = 0.223 
   
 
Figure 7.2. shows that the patients and the controls have perceived their changes similarly on the 
BRBN and language tests, but on the visuoperceptual tests the patients thought that they have 
deteriorated more than the controls 
Note. Positive values indicate perceived improvement, negative values indicate perceived 
deterioration, and values around 0 indicate perceived stability of cognitive function. The differences 
between the control and patient estimations were compared using the Mann-Whitney U-test 







II.        Comparison of perceived change in performance on the different groups of tests 
On average, the patients have thought that they have deteriorated in their performance on all groups 
of cognitive tests; however, on some groups of tests they perceived to have deteriorated more than 
on others (F (2) = 23.47, p < 0.001). Most deterioration was perceived on the BRBN items (Figure 
7.3). This tendency was also observed in the control sample, but the differences did not reach 
significance due to small control sample size. 
Table 7.2. Comparison of self-perception of longitudinal change on the three groups of cognitive 
tests for patient and control participants 
Cognitive tests Controls (n=15) Patients (n=61) 
   
BRBN -13.73 (18.57) -13.16 (14.19) 
Visuoperceptual -2.07 (8.41) -6.98 (10.44) 
Language -0.40 (8.41) -2.74 (9.82) 
   
Difference F (2) = 3.24, p = 0.197 F (2) = 23.47, p < 0.001 
 
Table 7.2. indicates that both controls and patients have thought that they have deteriorated on 
the BRBN items more than on the visuoperceptual and language items. 
Note. Positive values indicate perceived improvement, negative values indicate perceived 
deterioration, and values around 0 indicate perceived stability of cognitive function. The differences 
between the groups of cognitive tests were compared using the Related-Samples Friedman’s 
analysis of variance by ranks. 
Abbreviations: BRBN – Brief-Repeatable Battery of Neuropsychological test 
 
III.       Perceived change. Summary 
Both controls and patients have thought that they have deteriorated on the BRBN items more than 
on the visuoperceptual and language items. The patients and the controls estimated their changes 
similarly on the BRBN and language tests, but on the visuoperceptual tests the patients thought that 





7.3.3.       Relationships between actual and perceived change in performance 
The next step was to investigate the trends of how the participants thought that they changed are in 
comparison to the trends of how they have actually changed.  
I. Comparison of trends exhibited by patients and controls 
The comparison between the actual and the perceived changes in performance was done by visual 
examination of the patterns of perceived and actual change in the control and patient samples (Figure 
7.3.). 
Figure 7.3. A visual representation of the differences between actual and perceived changes in 
performance on the three groups of tests for control (n=15) and patient (n=61) participants 
 
Actual change Perceived change 
  
Error Bars: 95% CI 
Figure 7.3. shows that both patients and controls tend to underestimate their performance on all 
tests. A general tendency of participants to think that they have deteriorated was observed 
Note. The actual change is presented in standardized scores. Positive values of perceived change 
indicate perceived improvement, negative values indicate perceived deterioration, and values 
around 0 indicate perceived stability of cognitive function.  
Abbreviations: BRBN – Brief-Repeatable Battery of Neuropsychological test 
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As it can be seen from Figure 7.3., both patients and controls tend to underestimate their performance 
on all tests. In other words, a general tendency to think that they have deteriorated was observed. As 
on average all participants have thought that they have deteriorated.  
II. Correlations between the actual and the perceived longitudinal change 
The next step was to investigate the relationship between the actual and the perceived changes in 
performance on the individual level, accounting for individual trajectories of change.  
The first analysis included running multiple correlations between the measures of actual longitudinal 
change and the perceived change. As it can be seen from Table 7.3., the patients tend to be more 
accurate than the controls in estimating the trajectory of their cognitive change.  
Table 7.3. Correlations between actual change and perceived longitudinal change 
 
Cognitive  tests Controls (n=15) Patients (n=61) 
   
BRBN battery r = 0.049, p = 0.803 r = 0.313, p = 0.001 
Visuoperceptual r = - 0.095, p = 0.652 r = 0.259, p = 0.005 
Language r = 0.041, p = 0.839 r = 0.097, p = 0.323 
   
 
Table 7.3. shows that the patients have been more accurate in perceiving their cognitive changes 
on the BRBN battery and visuoperceptual tests 





Figure 7.4. Relationships between actual change and perceived change on the three groups of 
cognitive tests 
 
Tests Controls (n=15) Patients (n=61) 











Figure 7.4. shows that there was no relationship between the actual and the perceived change in 
control performance on all groups of tests, and on patient performance on the language tests. 
However, the patients showed some degree of accuracy in perceiving their change on the BRBN 
battery and visuoperceptual tests. 








III. Comparison between the actual and the perceived change in performance. 
Summary 
 
A general tendency for both patient and control participants to underestimate their performance was 
observed on all cognitive tests. However, when compared to controls, the patients have been more 
accurate in perceiving their cognitive changes on the BRBN battery and visuoperceptual tests. There 
was no relationship between the actual and perceived change in control performance on all tests, and 
on patient performance on the language tests. Moreover, the patients were considered to show some 
level of accuracy in perceiving their change on the BRBN battery and visuoperceptual tests. This 
could be due to the fact that all participants think that they have deteriorated, when in reality only 
the patient participants have. 
7.3.4.     Predictors of perceived change 
As it can be seen from previous analyses earlier in this chapter, the patient and control participants 
tend to perceive that they have deteriorated, regardless of what the actual change in performance was. 
It appeared that it was of no importance if the participants have actually improved, remained the 
same or deteriorated, the majority of them have thought that they have deteriorated. 
The next step was to investigate what makes the patient participants think that they have changed. 
This was examined by running multiple linear regression analyses with the perceived change as the 
criterion variable and measurements of executive functioning, depressive symptomology, 
neurological disability, MS impact, and number of relapses in-between assessments as predictor 
variables.  
I. Analysis of univariate normality of criterion variables 
The first step before running multiple linear regression analyses was to check for univariate normality 
of the criterion variables. As it can be seen in Figure 7.5., the Shapiro-Wilk statistics indicated that 
all of the criterion variables haven’t been normally distributed. However, upon visual inspection it 
was decided that the distributions were sufficiently normal, as all of them were unimodal with no 
extreme skew. Therefore it was decided to proceed with running the linear regression models. 
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Figure 7.5. Distributions of criterion variables for linear regression models of perceived change for 
patient participants 
 
Cognitive tests Mean (SD) Shapiro-Wilk test Distribution 
BRBN battery -13.16 (14.19) 
W = 0.947,  
p = 0.011 
 
Visuoperceptual -6.98 (10.44) 
W = 0.931,  
p = 0.002 
 
Language -2.74 (9.82) 
W = 0.752,  
p < 0.001 
 
Note. All criterion variables were in percentages of change. Positive values of perceived change 
indicate perceived improvement, negative values indicate perceived deterioration, and values 
around 0 indicate perceived stability of cognitive function. The vertical line represents no 
perceived change.  
Abbreviations: BRBN – Brief-Repeatable Battery of Neuropsychological test 
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II. Analyses of the relationships between the criterion and predictor variables 
 
Before running the linear regression models it was necessary to identify the predictor variables 
worthy of including, as due to small sample sizes (61 patients) and insufficient power I could not 
include more than two predictor variables for the patient models. 
This was done by examining the relationships between the criterion and predictor variables, and only 
those predictor variables that were shown to be related to the criterion variables were included in the 
multiple linear regression models. 
The distributions of the predictor variables can be seen in Figure 7.6. It should be noted that there 
have been high numbers of patients with EDSS scores of 6 and zero relapses. Therefore the results 
of those predictors should be interpreted with caution. 
As it can be seen from Table 7.4, the perceived changes on BRBN tests were associated with 
executive functioning, neurological disability and MS impact. The perceived changes on the 
visuospatial tests were associated with executive functioning. No relationships were found with the 
perceived change on language tests, but this was potentially caused by lack of actual change, as the 





Figure 7.6. Distributions of clinical predictor variables used in linear regression models to 
determine their effects on perceived change in performance for patient participants 
 




WLGT 20.02 (5.20) 
W = 0.960,  
p = 0.045 
 
EDSS 5.19 (1.86) 
W = 0.945,  
p = 0.01 
 
Number of relapses (only for 
RRMS and SPMS patients 
(n=45)) 
1.33 (3.68) 
W = 0.877,  
p < 0.001 
 
BDI - II 15.12 (9.38) 
W = 0.394,  
p < 0.001 
 
MSIS-29 82.97(25.99) 
W = 0.962,  
p = 0.056 
 
Abbreviations: WLGT – Category animal fluency test, EDSS – Expanded Disability Status Scale, BDI-
II – Beck’s Depression Inventory 2nd Ed., MSIS-29 – Multiple Sclerosis Impact Scale. 
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Table 7.4. Correlations between predictor and criterion variables in models of perceived change 
in performance on groups of cognitive tests for patient participants 
 
Predictor variables BRBN battery Visuoperceptual Language 
WLGT r = 0.298, p = 0.002 r = 0.199, p = 0.039 r = 0.060, p = 0.550 
EDSS r = - 0.247, p = 0.011 r = -0.054, p = 0.586 r = -0.169, p = 0.101 
Number of relapses r = 0.061, p = 0.561 r = -0.022, p = 0.836 r = -0.070, p = 0.528 
BDI-II r = -0.062, p = 0.508 r = -0.119, p = 0.212 r = 0.042, p = 0.673 
MSIS-29 r = -0.200, p = 0.030 r = -0.088, p = 0.351 r = -0.132, p = 0.180 
 
Table 7.4. shows that the perceived changes on BRBN tests were associated with executive 
functioning, neurological disability and MS impact. The perceived changes on the visuoperceptual 
tests were associated with executive functioning 
Note. The relationships were examined employing the Kendall Tau correlation 
Abbreviations: WLGT – Category animal fluency test, EDSS – Expanded Disability Status Scale, BDI-
II – Beck’s Depression Inventory 2nd Ed., MSIS-29 – Multiple Sclerosis Impact scale 
 
Based on the findings presented in Table 7.4. it was proceeded with running a multiple linear 
regression model with three predictor variables for the perceived change on the BRBN tests, and a 
simple linear regression model with sole predictor for the perceived change on the visuoperceptual 
tests. It was decided not to continue with further analyses to explain perceived changes on the 
language tests. 
I. Linear regression analyses to investigate the predictors of perceived change in 
performance on the cognitive tests 
 
a) BRBN tests 
 
Based on the presented associations (Table 7.4.), the following linear regression model was proposed 
in order to identify the predictors of perceived change in performance on the BRBN tests. 
Self-awareness of longitudinal change on BRBN tests= α + β1 (executive functioning) + β2 
(neurological disability) + β3 (MS impact) 
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Before running this model the predictor variables were checked for multicollinearity. WLGT did not 
correlate with EDSS (r = -0.113, p = 0.231, Kendall Tau, 2-tailed) and MSIS-29 (r = -0.152, p = 
0.093, Kendall Tau, 2-tailed). However, EDSS and MSIS-29 scores were moderately correlated (r = 
0.444, p < 0.001, Kendall Tau, 2-tailed). This auto-correlation was expected, as neurological 
disability is the major factor contributing to MS impact.  
However, even though much of EDSS and MSIS-29 variance was shown to overlap, these two factors 
could not be considered equal, as physical disability is not the sole predictor of MS impact. Emotional, 
sleep, and quality of life factors are also components of the MSIS-29, and I believe that they play a 
significant role as well in perceiving changes in cognitive functioning. 
Instead of excluding one of these variables out of the equation it was decided to run two equations 
instead, in one of them including WLGT and EDSS, and in another including WLGT and MSIS-29, 
with the aim of identifying the model with a better fit. 
The following two models are presented below: 
Self-awareness of longitudinal change on BRBN tests= α + β1 (executive functioning) + β2 
(neurological disability) 
and 
Self-awareness of longitudinal change on BRBN tests= α + β1 (executive functioning) + β2 (MS 
impact) 
 
For the first model with WLGT and EDSS as predictor variables the Durbin-Watson test values 
indicated that there was no autocorrelation (d = 1.765), and it was concluded that it’s safe to proceed 
with the multiple linear regression model. 
When perceived change on the BRBN tests was predicted it was found that both WLGT score (Beta 
= 0.325, p = 0.006) and EDSS score (Beta = - 0.362, p = 0.002) were significant predictors. The 
overall model fit was R2adj.  = 0.256, p < 0.001 (Figure 7.7). 
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Figure 7.7. The effects of executive functioning, neurological disability, and MS impact on the 




Figure 7.7. shows that executive dysfunction, neurological disability, and MS impact were 
predictive of perceived deterioration in performance on BRBN tests 
Abbreviations: BRBN – Brief-Repeatable battery of neuropsychological tests, WLGT – Category 
animal fluency task, EDSS – Expanded Disability Status Scale 
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For the second model with WLGT and MSIS-29 as predictor variables the Durbin-Watson test values 
indicated that there was no autocorrelation (d = 1.829), and it was concluded that it’s safe to proceed 
with the multiple linear regression model. 
When perceived change on the BRBN tests was predicted it was found that both WLGT score (Beta 
= 0.338, p = 0.006) and EDSS score (Beta = - 0.270, p = 0.026) were significant predictors. The 
overall model fit was R2adj.  = 0.198, p = 0.001.  
From running both of these models it can be concluded that executive dysfunction, neurological 
disability, and MS impact are predictive of perceived deterioration in performance on BRBN tests, 
although neurological disability could be considered to be a better predictor of perceived decline than 
MS impact. 
b) Visuoperceptual tests 
 
Based on the presented associations (Table 7.4.), the following linear regression model was proposed 
in order to identify the predictors of perceived change in performance on the visuoperceptual tests. 
Self-awareness of longitudinal change on visuoperceptual tests= α + β1 (executive functioning) 
When perceived change on the visuoperceptual tests was predicted it was found that the WLGT score 
(Beta = 0.251, p = 0.030) was a significant predictor. The overall model fit was R2adj.  = 0.062, p = 
0.030. A visual representation of the relationship between WLGT and perceived change on 










Figure 7.8. The effects of executive functioning on the perceived change in performance on the 
visuoperceptual tests for patient participants 
 
Figure 7.8. shows that executive dysfunction was predictive of perceived deterioration in 
performance on the visuoperceptual tests 
Abbreviations: WLGT – Category animal fluency task 
 
7.3.5.      Predictors of perceived change. Summary 
From running linear regression analyses I’ve found that executive dysfunction, neurological 
disability, and MS impact were predictive of perceived deterioration in performance on BRBN tests, 
and that executive dysfunction was the sole predictor of perceived deterioration in performance on 




7.4.       Chapter summary 
After analysing the longitudinal changes in cognitive performance it was found that the controls have 
equally deteriorated on all three groups of tests. The patients have deteriorated on the on the BRBN 
and visuoperceptual, but not on the language tests. This indicated that the differences that were 
observed between the patient and control participants on the change in language tests were because 
the patients had improved on them, and the controls have performed the same at both phases. 
Both controls and patients have thought that they have deteriorated on the BRBN items more than 
on the visuoperceptual and language items. The patients and the controls estimated their changes 
similarly on the BRBN and language tests, but on the visuoperceptual tests the patients thought that 
they have deteriorated more than the controls. 
A general tendency for both patients and controls to underestimate their changes in performance was 
observed on all cognitive tests. However, when compared to controls the patients have been more 
accurate in perceiving their cognitive changes on the BRBN battery and visuoperceptual tests. This 
could be due to the fact that all participants think that they have deteriorated, when in reality only 
the patient participants have. There was no relationship between the actual and perceived change in 
control performance on all tests, and on patient performance on the language tests. However, the 
patients were accurate in perceiving their change on the BRBN battery and visuoperceptual tests.  
From running linear regression analyses I’ve found that executive dysfunction, neurological 
disability, and MS impact were predictive of perceived deterioration in performance on BRBN tests, 
and that executive dysfunction was the sole predictor of perceived deterioration in performance on 
the visuospatial tests.  
The analyses performed in this chapter have fulfilled the chapter aim of investigating the patients’ 
self-estimates of the trajectory and extent of their cognitive change, and identifying the factors that 





Chapter Eight.  Discussion 
8.1.       Purpose of the study and chapter overview 
The aim of this study was to investigate the longitudinal changes in cognition in MS, by analysing 
the pattern of how MS-related cognitive decline starts and spreads, and the role that the clinical and 
non-clinical variables play on developing new cognitive deficits. In addition, this study was the first 
to systematically examine the patients’ perception of cognitive decline in MS samples, and related 
their self-perception of change to the actual longitudinal changes in performance on 
neuropsychological tests. This project has successfully addressed the aims and answered the research 
questions raised in the introduction. 
In this chapter the results from the longitudinal study were explained. The main body of the 
discussion chapter was composed of two parts, the first part corresponding to the interpretation of 
the study findings, and the second part was allocated for critical evaluation of the methodology, 
clinical application of the results, and guidelines for future research. 
8.2.       Interpretation of the findings  
8.2.1.       Dimensionality of cognitive impairment 
The first aim of this project was to investigate the dimensionality of MS-related cognitive impairment. 
It was hypothesized that MS affects all cognitive domains, although independently and not 
necessarily at the same frequency. Another hypothesis for longitudinal changes was made as well, 
where it was predicted that the pattern of cognitive deficits would become more homogeneous over 
time at the population level, reflecting increasing multidimensionality at the individual level. 
This study has successfully addressed the two aims. Based on the analyses of prevalence of cognitive 
deficits in Chapter Five it was shown that indeed as predicted the cognitive deficits can be observed 
in all cognitive domains and that no functions were spared. With respect to the longitudinal 
examination, the cognitive deficits initially appear heterogeneous on individual basis, although with 
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MS progression, and development of new impairments (mainly in the areas of information processing 
speed and visuoperceptual functions) the individual patterns of deficits had the tendency to become 
more homogenous. This indicated a reduction in the dimensionality of the MS population with 
respect to their pattern of cognitive impairments over time. At phase I the patients classified into 
multiple groups based on their performance, indicative of the many ways in which cognitive deficits 
start (apparently in random and typically isolated cognitive impairments). However, three years later 
(at phase II), only two clusters were present; this showed that with acquirement of new deficits the 
patient cohort had become more homogeneous in their expression of their cognitive symptoms. These 
results remained unchanged after addressing missing observations using the multiple imputation 
technique (Appendix E). 
These findings would imply that MS affects individuals by initially causing a small set of domain-
specific impairments (that differ between patients), and later evolves into (a larger) multi-domain set 
of impairments at the individual level. Therefore it can be concluded that both hypotheses about the 
dimensionality of MS related cognitive impairment were supported in this study. 
These findings tend to contradict those reported by previous studies that argued that in pwMS 
cognitive deficits start in certain cognitive functions and then spread to other cognitive functions 
(such as Denney et al., 2008; Morrow et al., 2009; Glanz et al., 2012). From the results of this study 
it appears that the cognitive deficits that the pwMS pick up are sporadic in their nature, and could 
not be narrowed down into particular patterns of how they emerge. However, my longitudinal 
analyses suggested that the cognitive deficits in pwMS slowly accumulated, spreading into 
processing speed and visuoperceptual domains, leading to development of major problems with 
longer disease duration.  
However, besides the duration of MS, it seemed that there was no other reason for new deficit 
acquirement and the population becoming more homogeneous. Besides some individuals with SPMS 
who were in general much worse off than the rest of the sample (e.g. individuals with EDSS score 
of 8 and above), I could not identify a group of individuals who suddenly flipped into progression 
and exhibited severe cognitive decline. Again this contradicts previous literature that claim that 
specific groups of pwMS can be identified (such as ‘cognitively impaired’ and ‘cognitively 
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unimpaired’) at baseline, and that those groupings could be predictive of future cognitive decline 
(Schwid et al., 2007; Deloire et al., 2010; Kujala et al., 1997). This was not observed in this sample. 
This study can be deemed suitable for assessing the dimensionality of cognitive deficits in pwMS 
due to several reasons. Firstly, in my battery I’ve included measurements of a broad range of 
cognitive functions, while in previous research the test batteries employed were heavily weighted 
towards memory, attention and processing speed functions. Secondly, I had investigated all three MS 
types in my sample, and their recruitment rates were reflective of the overall PPMS, SPMS and 
RRMS prevalence in MS population. This implies that the results of this study can be generalizable 
to the overall MS population, when the results from most previous studies can only be generalizable 
to certain subsamples of pwMS. Moreover, in this project I managed to secure high follow-up rates, 
therefore the results of longitudinal changes in domain-specificity can be deemed representative as 
well.  
After having analysed the longitudinal changes in the dimensionality of cognitive deficits in pwMS 
the next step was to try to explain what causes them. 
8.2.2.       Predictors of cognitive change 
The second aim of the study was to examine the predictors of longitudinal change in cognition in 
pwMS. It was hypothesized that age, gender, pre-morbid IQ (involving pre-morbid cognitive leisure 
and educational exposure), affective comorbidity, and drugs, would all have an effect on the 
longitudinal changes in cognitive functioning. This hypothesis was tested by running separate linear 
regression models (Chapter Six) to investigate whether these factors have an effect on cognitive 
changes in five groups of cognitive tests: verbal memory, visuospatial memory, processing speed, 
visuoperceptual and language. The research aims could be considered to have been addressed 
successfully and interestingly it was found that the factors that influenced cognitive decline were 
specific for each of the cognitive domains. 
The change in verbal memory domain was linked to the levels of neurological disability and 
depressiveness. The change in visuospatial memory didn’t seem to be linked to any clinical variables. 
The change in processing speed was linked to MS type only (SPMS, and to a lesser extent PPMS). 
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The change in visuoperceptual domain was linked to neurological disability, MS type and MS 
modifying medication. The change in the language domain was linked to the level of depressiveness. 
It appears that the heterogeneity of causes of MS-related cognitive decline reported by previous 
studies could be explained by which cognitive tests were used during their assessments, as decline 
in performance on different tests was explained by different clinical variables in this study. However, 
summing up, neurological disability, MS type and levels of depressiveness were the most common 
predictors of change in cognitive functioning. These findings have been thoroughly described 
elsewhere (Patti et al., 1998; Amett, 2005; Amato et al., 2010).  
The MS modifying medication had an effect only on one group of cognitive tests, and this could be 
because the way in how the drugs affect cognition is still unclear. Depending on the individual and 
on the actual drug, the disease modifying drugs may have no effect, a deleterious effect, and an 
advantageous effect on cognition. This could potentially explain the lack of clarity of the MS 
modifying treatment effect on cognitive changes in this sample. 
In contrast to the effect of clinical variables, the demographic and cognitive reserve variables did not 
seem to have predictive value on the cognitive changes. Once again this could be used to question 
the arguments found in the literature that some individuals with MS are more robust to cognitive 
decline than others (Deloire et al., 2010; Camp et al., 2005; Kujala et al., 1997). 
I. Potential explanations of why some of expected effect was not found 
Even though based on the previous literature this model was expected to explain the longitudinal 
changes in cognition, several potential explanations for why some of the predictor factors did not 
have an effect on our dataset were identified. 
In the model it was expected that in pwMS age adds pathology (plus interacts with comorbidity) and 
the effects of age would tend to intertwine with the effects of disease duration. Even though it was 
expected for older age to have an effect on the brain function, in our sample there were also 
individuals with late onset MS (older age fewer years with MS) who had relatively good cognitive 
outcome, and individuals with early onset MS (younger age but more years with MS) who had worse 
cognitive outcome. This could potentially explain why no effect of age was observed in our sample. 
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However, the findings may be different if everyone in our sample was followed up from the point of 
diagnosis, as the participants in this study have had very variable age and duration of MS. 
Even though previous literature has reported that men are more likely to experience cognitive decline, 
in this study no specific effect of gender was found. There is some literature on gender-based 
differences in specific cognitive functions, such as men performing better at tasks of information 
processing speed and visuospatial functions, and women performing better on memory tasks 
(Halpern, 2013); and it could be that the gender-specific effects of MS could have been masked by 
these differences in abilities. 
The lack of effect of premorbid functioning in this dataset did not support the hypotheses, and this 
could have been caused by several reasons. To begin with, as has been mentioned in the introduction, 
cognitive reserve related compensation is reported to be most beneficial at earliest stages of MS and 
may, however, fail with progression of damage (Amato et al., 2013). As this study included 
participants with variable durations of MS, it may be that there could have been more effect of 
premorbid reserve on some patients than the others. However, this question was not analysed in more 
detail as the primary goal was to keep consistency in the methodology of predictor analysis, and 
therefore to run the same analyses for all of the predictor variables. This way it was allowed for 
comparisons between the effects of different predictors to be made. 
The second reason why no effect of premorbid intelligence was observed could be because the 
measurements of pre-morbid IQ employed in clinical research could be considered to be able to give 
only a limited indication of the actual pre-morbid performance. The tests of premorbid functioning 
are tests of semantic storage and were created for neuropsychological assessments of groups of 
patients with more homogeneous locations of brain pathology (such as AD or FTD), whereas due to 
heterogeneity of brain lesion locations in MS samples, some pwMS may be more in advantage than 
others when performing on the tests of premorbid intelligence. This could in part explain the lack of 
effect of premorbid abilities on longitudinal change in cognitive functioning observed in this sample.  
In this study the protective effect of physical exercise may have been limited, as the means of 
collecting such information in this study may have been overly simplistic. The methodology of 
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collecting information about exercising employed in this study was coded binary as ‘0’ ‘no exercise’ 
and ‘1’ ‘exercising’. Since many types of physical exercise exist (from easy to strenuous) an 
argument can be raised about the level of their comparability. It could be that choosing to code the 
levels of exercise on a 5-point or 7-point Likert scale rather than binary could be considered to have 
been a more suitable approach for this study. Moreover, the other reason why no link between 
exercising and cognitive change was observed could be because the ability to exercise was masked 
by the levels of neurological disability, as in some cases the physical disability resulting from chronic 
MS progression (such as dizziness or tremor) may be the cause preventing some individuals from 
engaging in exercise more than others. Therefore it could be considered, that the relationship is 
actually the other way round from what was expected, and that in this instance when working with 
MS samples, exercising could be regarded as a derivative from the progression of the disease, rather 
than from personality traits such as health-consciousness or positivism. 
To sum up, out of the many potential predictor variables studied, in this study the longitudinal 
changes in cognitive functioning seemed to be linked only to the levels of neurological disability and 
depressiveness, and to some extent to MS type and MS modifying treatment uptake. The other 
hypothesized predictor variables seemed to have no effect on the cognitive decline. The next step 
was to investigate whether the patients themselves were aware of their longitudinal changes in 
cognition, and what factors had influence on making them perceive that their cognitive functioning 
has deteriorated. 
8.2.3.     Self-perception of change 
The third aim of this project was to investigate the patients’ perception of their deficit progression. 
This aim was successfully fulfilled by comparing the patients’ actual changes in performance with 
their perceived changes. 
A general tendency for both patients and controls to underestimate their performance was observed 
on all groups of cognitive tests. However, when compared to controls the patients have been more 
accurate in perceiving their cognitive changes on the BRBN battery and visuoperceptual, but not the 
language tests. This could be due to the fact that all participants have thought that they have 
deteriorated, when in reality only the patient participants have. Moreover, since in this project the 
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pwMS have been shown to perceive their changes similarly to the controls, it could be argued that 
the tendency observed in frontal-executive disorders (such as FTD) where the patients underestimate 
or fail to acknowledge their deficits, was not observed in MS. 
In this study the factors that had an effect of self-estimations of perceived change for BRBN tests 
were executive dysfunction, neurological disability, and MS impact. Executive dysfunction was the 
sole predictor of perceived deterioration in performance on the visuoperceptual tests, and none of the 
factors were predictive of perceived change on the language tests.  
However, it could be considered that the observed predictive value of executive functioning could 
have been to some extent influenced and inflated by the choice of the test used to assess the executive 
functions, indicating that the WLGT may not have been the most suitable variant for this purpose. 
WLGT is considered to be a category naming test, and not all of the sources of previous literature 
accept it as a measure of executive functioning (Phillips, 1997). Nonetheless, since the original phase 
I battery did not include a more suitable measure of executive functions, for the purposes of this 
study it was chosen to employ the closest equivalent of an executive function assessment. 
As hypothesized, the proposed model had the best fit for the BRBN items, and could be considered 
unsuitable for the visuoperceptual and language items. This could be because the model was built 
based on the previous literature where all the previous work on the awareness of deficits in MS has 
been conducted employing the BRBN battery tests. It can be considered that separate models should 
be built for the perception of visuoperceptual and language difficulties, and that could include 
measurements of visual or contrast acuity for visuoperceptual functions, and speech or vocabulary 
measurements for language functions. It can be assumed that those measurements would be more 
predictive of perceived decline on the visuoperceptual and language abilities. 
I. Controls and insight 
Even though the focus of this investigation was around self-evaluations in the patient cohort, however, 
through additional analyses we found that the controls had the tendency to underestimate their 
performance when evaluated cross-sectionally at phase II. This was an important observation as so 
far we did not find any work concentrating on the phenomenon of the under-estimations of their 
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cognitive performance of the general population. The only published work that we could find on the 
general population was in relation to estimating self-worth, rather than evaluating cognitive 
performance, which is an entirely different concept. Only one study has measured self-estimations 
of cognitive performance in healthy adults (although only used them as controls as their focus was 
on FTD, CBD and PSP patients) and that study has also reported that the controls had the tendency 
to underestimate their performance (O’Keefe et al., 2010). That study had also employed composite 
scores and similar statistical methods to ours to define accuracy of self-estimations. However, besides 
stating the finding, they did not emphasize on it or try to explain it. What they observed O’Keefe et 
al. called ‘normal estimations’ rather than ‘underestimation’, and they didn’t look into them 
separately, just as a reference point for comparison in their analyses of patient estimations. 
Therefore it could be concluded that the general population do not represent the perfect reference 
point for comparisons, as they exhibit a natural tendency to underestimate their own performance. 
Therefore future studies comparing self-estimations between groups of people should take that into 
account. Moreover, this phenomenon needs to be explained and investigated in more detail in future 
work, as interpretation of self-estimations in the control sample is not as straightforward concept as 
it had been thought. Only the understanding of the causes behind underestimations in healthy self-
evaluations could lead to a better understanding of the impaired self-evaluations and insight deficits 
in the patient samples. 
II. PwMS and insight 
In this study we found that the patient participants showed a similar pattern as the controls in 
estimating their performance at phase II, and as a group did not exhibit clear deficits in insight 
common to other neurological conditions that involve damage to the frontal cortex (O’Keefe et al., 
2010). In general, we found that those pwMS who had cognitive deficits were able to identify their 
presence and their degree on all groups of cognitive tests, and, similarly as the healthy controls, they 
had a tendency to underestimate their performance. This trend was more evident on BRBN and 
visuoperceptual tests, and less evident on language tests, where both patients and controls provided 
estimations of a wide range of levels of accuracy. Moreover, there was a subgroup of pwMS that 
overestimated their performance, and that small subgroup could be defined by poorer scores on 
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frontal-executive tests. Therefore it can be concluded that even though pwMS exhibited deficits on 
tests of frontal-executive functions, they, as a group, were not prone to awareness disorders and were 
overall able to evaluate their performance with the same level of accuracy as the controls. Future 
studies could compare pwMS to other neurological conditions that exhibit frontal-executive 
problems (FTD, MND, PSP, CBD, etc.) as our study has shown that even though frontal-executive 
dysfunction is linked to higher levels of awareness deficits, but it is not the sole predictor of 
disordered insight. Therefore it can be concluded that there is basis for other variables that cause 
awareness problems, or, perhaps, the degree of frontal-executive deficits was much milder in our MS 
sample than it was in previous insight studies into other disorders. Moreover, it could also be that the 
awareness deficits develop only once frontal-executive problems have reached a certain threshold, 
which could explain the lack of linear relationship between the variables. 
In this study we found that pwMS were generally accurate in estimating their current cognitive status, 
therefore it should be safe to assume that in clinical practice, when evaluating cerebral functions as 
part of EDSS, the patients should be considered accurate in their reports of cognitive functioning (or 
at least no major discrepancies were shown in this study to support otherwise). However, since pwMS 
could be considered accurate in their cognitive estimations, in both research and clinical practice it 
could be beneficial to supplement the EDSS with Multiple Sclerosis Neuropsychological 
Questionnaire (MSNQ; Benedict et al., 2003). MSNQ is a short 15-item self-report screening 
measure of neuropsychological functioning that includes questions addressing cognitive domains 
often disrupted in MS. MSNQ could be a particularly useful instrument if the investigator is 
interested in collecting more information about multiple cognitive functions, and this could be done 
both at baseline and at follow-up in order to evaluate longitudinal change, either as part of an 
observational or an interventional study. Due to it’s multidimensionality the MSNQ would yield a 
more detailed report of perceived cognitive functioning than that currently collected via EDSS. 
Moreover, the MSNQ is a well-validated measure that also gives insight into the partner’s or carer’s 
perspective of the patient’s cognitive status, therefore overall could be considered to be a superior 
method for collecting self-estimations to that which has been used in this study. 
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In our study, however, we found that as a group the patients were accurate not only when estimating 
their cognition cross-sectionally, but also when estimating the longitudinal change. This contrasts 
previous findings from one study where pwMS have been found to not be fully aware of their current 
cognitive deficits (or not report them reliably) when examined cross-sectionally, however, when 
examined longitudinally, pwMS were found to be accurate in their reports of perceived levels of 
cognitive change (Christodoulou et al., 2005). Interestingly, in their study the authors report 
overestimations, and not underestimations of performance, which is surprising to some extent, as 
their study had employed the same cognitive tests (BRBN battery). However, the method of 
collecting the awareness data selected for that study was different – in their study the 5-item 
Perceived Deficits Questionnaire and a 2-item memory and attention/concentration questionnaires 
were used to assess self-perceived cognitive impairment. Estimating one’s level of cognitive deficits 
is a highly subjective task, prone to be affected by how the question is formulated. Therefore it could 
be concluded that the discrepancy of findings on awareness between this study and previous research 
could be explained by the methodology behind awareness data collection. 
From the analysis of self-estimations of performance at phase II we found that overall, similarly as 
the controls, the patients were prone to underestimate their performance, although there was a range 
in accuracy, including a number of patients who have over-estimated their performance. This has 
been reported by another study that investigated the self-perception of cognitive deficits in MS, 
which has shown that the pwMS could be classified according to whether they overestimated or 
underestimated their cognitive ability (Carone, Benedict, Fishman, & Weinstock-Guttman, 2005). 
However, instead of comparing the patients’ self-reports to their actual performance, that study 
compared them to informant ratings (usually those of a spouse or a family member). In their study, 
compared to underestimations,  overestimations of performance were linked to lower levels of 
depression and conscientiousness, and greater degrees of cognitive impairment, euphoric behavioural 
disinhibition, and unemployment (Carone, Benedict, Fishman, & Weinstock-Guttman, 2005). This 
is in line with our findings, which showed that in the very few cases that exhibited overestimations, 
they were associated with higher levels of MS impact and neurological disability, but not depression. 
This highlights the behavioural consequences of insight deficits in a subsample of MS patients, and 
invites to further study insight focusing on the peculiarities of this small group of pwMS.  
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8.2.4.      MS type and cognition 
The following section revolves around the generalizability and implications this work has in terms 
of understanding cognition in different types of MS. Our findings are compared to those of previous 
studies with the aim of understanding the cognitive features associated with progressive and 
relapsing-remitting courses of MS. 
I. Differences in performance of MS subgroups on cognitive tests 
Studies comparing the cognitive profiles of patients with three types of MS have been quite recent 
(Denney, Sworowski and Lynch, 2005). Historically the more common practice has been to compare 
RRMS to chronic progressive patients (combining PPMS and SPMS subtypes together). Typically, 
in those studies patients with chronic progressive MS are found to have a more pronounced cognitive 
impairment than those with relapsing-remitting disease (Beatty et al., 1988, Beatty et al., 1989, 
Kujala et al., 1995).  
In the few studies where patients with PPMS and SPMS have been distinguished, most investigators 
have reported greater overall cognitive impairment in those with SPMS (D’Amico et al., 2016; 
Huijbregts et al., 2006), athough others argued that PPMS and SPMS patients couldn’t be 
differentiated by their neuropsychological performance once matched for disease duration and 
disability (Foong et al., 2000).  
In our study we found that the SPMS patients showed worse overall cognitive performance, and had 
failed the cognitive tests more often than the RRMS and PPMS patients on all cognitive domains. 
Regarding the differences between the RRMS and PPMS, in general these two groups of patients 
had exhibited very similar cognitive profiles. In those cases where there had been any differences 
between these subtypes at phase I, they disappeared when re-assessed three years later at phase II. In 
our study no crude differences between these subtypes were found, only minor, where PPMS showed 
slightly more deficits on information processing speed and visuospatial memory tasks. 
Other studies report similar tendencies with the mildest cognitive impairments in RRMS, slightly 
more common impairments in PPMS and most prevalent and global, multi-domain cognitive 
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impairments in SPMS (Beatty et al., 1989; Comi et al., 1995; Filippi et al., 1994; Huijbregts et al., 
2006; Ruet et al., 2013). However, it should be taken into consideration that those studies did not 
investigate all three groups of patients together using the same tests. Even though these findings have 
been shown to some extent elsewhere, in this study we were able to show them all in one cohort and 
with the same tests administered to everyone. 
There had been attempts in previous research to explain poorer cognitive performance in SPMS 
patients. SPMS can be considered a more advanced stage of MS, one that might be expected to be 
present with greater cognitive impairment. Such patients have a prior history of relapsing disease 
that has subsequently devolved to a progressive course. In contrast, PPMS patients have no prior 
history of relapsing disease and therefore a comparison between them and relapsing patients does 
not necessarily entail a difference in chronicity (Denney et al., 2005). Overall RRMS patients are 
relatively better off, which is not surprising as they are, on the average, characterised by younger age 
and shorter disease duration. 
However, the differences between the MS subtypes observed in this and in earlier studies were shown 
to be robust in a very recent study, where after controlling for age, sex, disability level, disease 
duration, and education level, patients with SPMS were at least twofold more frequently impaired 
than patients with late RRMS in information processing speed, executive functions, verbal fluency, 
verbal episodic memory, working memory, and visuospatial construction (Planche et al., 2016). This 
illustrates that the pattern of differences between MS subtypes observed in this study has been shown 
to be robust. Even after removing the effects of potential confounding variables the SPMS remained 
the most cognitively impaired subgroup of pwMS. 
Little research has been done in order to investigate the differences among the MS subtypes in each 
cognitive domain. In the following sections our findings from each cognitive domain on group 






II. Language  
In our study we found language impairments to be rare in pwMS. At phase I only three and at phase 
II none of the 82 pwMS studied had exhibited problems in the language domain. The language 
impairments remained rare even after accounting for the missing observations. 
The three patients that had failed both of the language tests at phase I were all SPMS type. However, 
when studied separately, the SPMS patients had a higher tendency to fail the test of reception of 
grammar (TROG), but not the test of spontaneous language production (BCT). Of those who failed 
the TROG, 7 were SPMS (19% of SPMS sample), 2 were PPMS (8% of PPMS patients), and 3 were 
RRMS (6% of RRMS sample). Of those who had failed the BCT, 3 were SPMS (8% of SPMS 
sample), 5 were PPMS (19% of PPMS sample), and 9 were RRMS (18% of RRMS sample). Even 
though it has been shown with this study that isolated deficits on a task measuring spontaneous 
language production appear more common in PPMS and RRMS patients, however, they do not tend 
to form a more global language deficit, as they do in SPMS. Moreover, for the RRMS and PPMS 
patients the deficits on the BCT to some extent might have been an artefact caused by the flawed 
methodology of BCT administration and scoring (as explained in more detail later on in the 
discussion). 
Language cognition has not been extensively studied in MS samples. Most of previous research 
revolves around information processing speed, memory and attention functions; however, the few 
studies that have investigated language deficits in MS have shown similar results to ours. In their 
study Mackenzie & Green (2009) have also shown that chronic progressive MS patients exhibit 
patterns of global deterioration in the language domain, encompassing both expression and 
comprehension. In their study Mackenzie & Green have studied the chronic progressive MS patients 
as a group, thus they did not compare the performance of PPMS with those with SPMS. Therefore 
our study has added to their findings that more global deterioration in language, as a result of global 
cognitive decline, is present in SPMS patients and not in PPMS patients. 
The assessment battery employed in Mackenzie & Green’s study contained tests that measured only 
the language functions. In our study we have studied language in relation to other cognitive functions. 
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We found that language deficits do exist, but not as isolated deficits, as they were shown to emerge 
only in combination with other cognitive difficulties. It could be considered that impairments in 
language are a result not only of dysarthria (Mackenzie & Green, 2009), but also of a more global 
cognitive decline, both associated with SPMS course. It could be speculated that the language 
impairments in MS patients tend to predominantly be caused by initial learning, memory and 
information processing problems, rather than by isolated language deficits. 
Our findings contradict those observed by Connick et al. (2013) who, by studying people with 
progressive MS, had identified two independent dimensions of cognitive impairment in MS: frontal-
executive dimension (attention, verbal fluency, recall), and posterior dimension (language and 
visuospatial functions). Connick et al. further report that language and visuospatial deficits account 
for 14% and 11% respectively of the total cognitive impairment in MS; and for 55% and 45% 
respectively of the variance not explained by fronto-executive impairments. Connick et al. have 
reported that language and visuospatial impairments formed independent deficits, a finding which 
was opposite from what we have observed in our study. By reporting isolated language dysfunction 
in both PPMS and SPMS groups, Connick et al. hypothesized that language and visuospatial 
impairments may be typical of cognitive dysfunction in progressive MS, where deficits due to 
randomly distributed focal white matter lesions are minimal and that the specific language and 
visuospatial deficits could in fact be attributed to mechanisms of neurodegeneration associated with 
progressive MS (Connick et al., 2013). So far this, together with the studies by Grossman (1995) and 
Mackenzie & Green (2009), have been the only studies that emphasised the need to assess language 
functions in pwMS and even suggested including language assessments into routine clinical 
assessments of people with progressive MS. 
We believe that the reason behind different findings and therefore different conclusions between our 
study and that of Connick et al. was different methodologies employed to study cognition and 
different statistical techniques used for inferential statistics. In their study Connick et al. had 
employed the factor analysis on the ACE-R data, therefore it could be considered that, even though 
the aim was to investigate the dimensionality of cognitive impairment in MS, with that statistical 
technique, they were actually measuring the dimensionality of the instrument itself (ACE-R) and not 
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the dimensionality of the patient performance on it. Factor analysis is a common technique in 
psychometric studies used to evaluate the instruments to unravel how the individual items within the 
instrument group together. Since Connick et al. had performed a factor analysis on the ACE-R 
component items, therefore they had analysed what underlying functions the ACE-R measured. And 
indeed, the ‘frontal executive domain’ as they called it, or attention, learning and recall items, do 
account for 58% of the ACE-R test, and the language and visuospatial items comprise 42% of ACE-
R (26 points and 16 points of 100 on ACE-R respectively). It could be argued that by using a factor 
analysis as a statistical technique Connick et al. have shown only how much of the ACE-R battery is 
comprised of items assessing which cognitive functions, and that their results could not be used to 
make inferences about cognitive profiles of MS patients. I believe that if replicated on healthy 
controls, the factor analysis would yield the exact same results, therefore their findings can only be 
used to make inferences about the dimensionality of the instrument, and not the study cohort. I 
believe that the dimensionality analysis presented in Chapter Five of this thesis could be considered 
a more suitable approach than a factor analysis to study cognitive profiles of MS patients, and that 
our findings in the language domain could be considered a more true representation of the 
dimensionality and cognitive profiles of pwMS than those from the Connick et al.’s study using the 
factor analysis. Therefore we did not support Connick et al’s reasoning that language and visuospatial 
impairments could be indicative of neurodegeneration processes or characteristic to progressive MS. 
III. Visuoperceptual functions 
In our study we have shown the visuoperceptual impairments to be more common than language 
impairments among pwMS. Overall, 20% of pwMS at phase I and 55% of patients at phase II had 
some deficits with visuoperceptual performance, with or without additional deficits in other domains. 
This indicated that overall with disease duration more patients had accumulated deficits in the 
visuoperceptual domain. 
In our study we found that, differently from the language where the deficits in that domain were 
indicative of a more cognitive global decline, in our sample the pwMS have also exhibited isolated 
impairments in the visuoperceptual domain. At phase I 7% of pwMS had isolated visuoperceptual 
impairment, compared to only 3% who had isolated visuoperceptual impairment at phase II. This 
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indicated that in some cases visuoperceptual problems may represent an initial symptom in the 
beginning of MS that gradually with disease duration spread into other domains. This would be in 
line with the pattern of MS symptoms observed in the clinical practice, where a portion of patients 
experience visual perception symptoms early in their MS. In our study we have shown that in MS 
visuoperceptual deficits can occur individually and even as the first symptom, as well as accompany 
other cognitive symptoms in a more global cognitive decline. 
At phase I 16% of the SPMS patients, 18% of RRMS and 4% of PPMS patients failed the 
visuoperceptual cognitive domain. These individuals remained impaired on the visuoperceptual tests 
at phase II, while accumulating additional deficits in other cognitive domains. The three patients who 
had failed visuoperceptual tests at baseline, but not at follow-up were RRMS patients, and it could 
be speculated that their phase I performance may have been indicative of a relapse that was not 
present again during re-testing at follow-up. At phase II 22% of SPMS, 25% of RRMS and 23% of 
PPMS patients had failed the visuoperceptual domain, which was indicative that more pwMS 
developed visuoperceptual deficits with disease duration. Even though from analysing phase I data 
it seemed that the visuoperceptual impairments were more prevalent in the RRMS and SPMS, at 
phase II it was found that these deficits were equally distributed among all subtypes of MS. 
Our findings at phase I were in line with the previous research that investigated visuoperceptual 
deficits comparing different types of MS. However, we have failed to reproduce the same pattern as 
described elsewhere at phase II. 
Gaudino and colleagues (2001) have demonstrated similar findings to our phase I findings in their 
study, although they had used tests that measured visuoperception as well as visuospatial memory 
(therefore less pure reflections of visuoperception function, as ‘contaminated’ by involvement of 
memory functions). According to Gaudino et al., the specificity of visual perception and acquisition 
deficits to the RRMS and SPMS subtypes highlights the possibility of an increased susceptibility to 
visuospatial deficits with a disease course involving relapses and remissions. This was recently 
shown again by Planche et al. (2016) where the differences between RRMS/SPMS and PPMS 
remained even after controlling for age, gender, disability level, disease duration, and education level. 
Gaudino et al. further reasoned, referencing the work by Fischer et al. (1998), that since SPMS is 
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marked by initial RRMS disease course followed by progression, therefore the underlying disease 
pathology could be considered the same in these two MS subtypes, perhaps with specificity for 
decline in visuoperceptual recognition and learning functions. Despite these differences in the initial 
acquisition of visuospatial information, in their study disease course did not differentially affect the 
rate of forgetting, with no significant differences noted with regard to recall of newly learned 
information (Gaudino et al., 2001). They concluded that RRMS and SPMS are more prone to deficits 
when initially processing visuoperceptual information, and that their visuoperceptual problems could 
be the reason for memory problems, as the patients who exhibit deficits when initially processing 
visual information have more problems remembering it. However, we have only managed to observe 
these patterns at phase I, but not at phase II, therefore the generalizability of the above reasoning by 
Gaudino et al. should be considered with caution. 
Moreover, when comparing our results to those of Gaudino et al., it is important to consider the 
different methodologies employed. In our study we have selected the visuoperceptual tests that 
captured a much wider array of visual cognition functions than those in Gaudino et al.’s battery. Our 
battery included tests assessing visual stimuli identification (recognition of what the object is), 
visuospatial functions (apprehension of spatial relationships among the objects) and analysis of other 
visual characteristics of the objects (size, length, orientation). Our visuoperceptual assessment was 
more thorough and included a larger domain of visuoperceptual functions, which can be concluded 
that the findings presented by Gaudino et al. can be generalizable only to visuospatial perception and 
memory. Therefore an alternative interpretation should be considered in order to model other 
visuoperceptual functions, especially later on in disease progression, as has been shown with our 
phase II results. 
IV. Memory 
In this study the two types of memory, verbal and visuospatial, were studied separately. We found 
verbal memory deficits to be more common, with 33% of pwMS failing verbal memory domain at 
phase I, and 34% at phase II. With regard to MS subtype, at phase I 27% of PPMS, 27% of SPMS 
and 20% of RRMS failed the verbal memory domain; and at phase II 19% of PPMS, 32% of SPMS 
and 22% of RRMS failed the verbal memory domain. As it can be seen, the SPMS patients have 
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consistently exhibited more frequent verbal memory deficits. Moreover, even though at phase I 
PPMS had similar frequencies of verbal memory impairments, at phase II SPMS patients were 
noticeably more commonly impaired than the other MS subtypes. It could be hypothesized that the 
reason behind these findings was that in our sample PPMS patients have had MS for a shorter amount 
of time, therefore had participated in fewer assessments and thus were less familiar with cognitive 
tests during the baseline assessment. This reasoning could potentially explain why the PPMS patients 
had overall, as a group shown higher frequencies of verbal memory impairment at baseline than at 
follow-up. 
Now regarding the visuospatial memory, on these tests the patients had substantially lower 
prevalence of impairment in our sample. Only 5% of pwMS had failed the visuospatial memory 
domain at phase I, and 10% at phase II. It can be seen that even though the prevalence of impairment 
on visuospatial memory was much lower than that of verbal memory, it had a similar tendency where 
with time more patients had acquired visuospatial memory deficits. With regard to MS subtypes, at 
phase I 4% of PPMS, 5% of SPMS, 2% of RRMS failed the visuospatial memory tests, and at phase 
II 8% of PPMS, 14% of SPMS and 2% of RRMS failed the visuospatial memory tests. It can be 
noted that even though earlier in their MS (at phase I) the three groups of patients seemed to exhibit 
similar frequencies of visuospatial memory deficits, with disease duration (at phase II) the SPMS 
showed a tendency to develop more impairments in the visuospatial memory domain. This 
observation was in line with the previous finding regarding verbal memory, and it can be concluded, 
that even though some proportion of all MS patients fail these tests, the patients with the SPMS 
course were the most prone to memory problems (both verbal or visuospatial). 
 Our findings have partially replicated those reported by Gaudino and colleagues (2001) who have 
looked into group differences on verbal and visuospatial memory in different subtypes of MS using 
the same tests as in our study (CVLT and SPART). Their study showed qualitative differences 
between all three MS subtypes: PPMS and SPMS had more problems with verbal new learning than 
RRMS patients, and SPMS and RRMS patients had more difficulties with visuospatial new learning 
than PPMS patients (Gaudino et al., 2001). We have shown that among all subtypes SPMS had the 
most pronounced verbal and visuospatial memory deficits, however, we have shown limited support 
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for their finding regarding differences between PPMS and RRMS. In our data PPMS had more 
impairments on verbal memory only at phase I but not at phase II; and we have shown that not only 
the RRMS were not more likely to show more visuospatial memory deficits than PPMS at neither 
baseline nor follow-up assessments. Indeed, we have shown that the opposite was true in our data – 
the progressive MS types were more likely to show deficits on visuospatial memory tests than RRMS 
patients. 
Gaudino et al. explain their findings regarding group differences among people with different types 
of MS in that PPMS and SPMS result in significantly greater deficits with regard to acquisition of 
new verbal information, with the SPMS showing a significantly higher failure rate (Gaudino et al., 
2001). Even though we have replicated the higher frequencies of impairments in the verbal memory 
domain, and have associated that with SPMS, however, in our study we did not observe any 
differences between verbal learning and verbal recall at neither of the phases. Therefore our memory 
data does not support such interpretation and limits the generalizability of Gaudino et al.’s findings. 
An alternative interpretation by Litvan et al. (1988) suggest that patients with MS may suffer from 
multiple memory impairment that occur at different stages of a theoretical memory system. PwMS 
are reported to have trouble processing information at the level of the articulatory loop, in retrieving 
verbal information from long-term storage and in rapidly processing verbal information. In summary, 
Litvan et al. state that pwMS have memory deficits primarily because of a deficit in a component of 
the working memory system, and slowed information processing speed. This is consistent with 
previous work noting a relation between memory performance and information processing abilities 
in MS (DeLuca et al., 1994). 
The mechanism behind the memory problems in pwMS is further explained from a neuroanatomical 
perspective. Since knowledge representation is stored in gray matter, then patients whose primary 
CNS pathologic condition is in white matter should be expected to demonstrate cognitive deficits in 
components on an information-processing system that are responsible for transmitting information 
from the gray matter for activation or rehearsal purposes (Litvan et al., 1988). Litvan and colleagues 
further reason that if impaired articulatory loop was accepted as the reason behind memory deficits 
in pwMS, then controlling for encoding by forcing pwMS to encode deeply verbal information, or 
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by involving semantics, should aid in their long-term recall. They further elaborate that pwMS have 
been shown to make fewer mistakes and have higher accuracy of performance once they are given 
more time to process the information (Litvan et al., 1988). This again strengthens the assumption that 
memory deficits are inseparable from information processing speed deficits in pwMS. 
V. Information processing speed 
16% of patients in our sample had failed the information processing speed domain at phase I, 
compared to 29% of patients who failed at phase II. Overall in our sample there was a tendency for 
more patients to acquire information processing speed deficits with progression of their MS. 
A split analysis of the different subgroups of MS at phase I has shown that 8% of PPMS, 24% of 
SPMS and 4% of RRMS patients failed the information processing speed domain. However, at phase 
II 19% of PPMS, 35% of SPMS and 10% of RRMS patients had exhibited deficits. It can be noted 
that information processing deficits occur in all groups of pwMS and increase in their frequency over 
time, and with higher predisposition towards the SPMS group. The differences between MS types 
were the highest for information processing speed in our study, indicating that this deficit was most 
notably associated with SPMS course, more so than the impairments on other cognitive domains. 
This finding was in line with previous research that showed that general slowing occurred in all MS 
subtypes with higher slowing rates for the SPMS and PPMS subtypes, and RRMS patients seem to 
hold a position halfway between the controls and the PPMS/SPMS group (De Sonneville et al., 2002). 
Not only have we observed that SPMS patients exhibit processing speed impairments more 
frequently, but in our study we also noted that their deficits have been more severe than those of 
PPMS or RRMS patients. This was not in line with a finding described by Foong et al. (2000) who 
reported little difference in the proportion of PPMS and SPMS patients who had severe cognitive 
impairment in their sample. The results by Foong and colleagues could be considered limited due to 
their small sample size (12 PPMS and 13 SPMS patients), while in our study the sample size was 
double of theirs for PPMS and triple for SPMS (50 RRMS, 26 PPMS and 37 SPMS). Therefore based 
on our findings the profiles of performance on information processing speed tasks should be 
considered different for SPMS and PPMS patients. 
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In MS information processing speed so far has been most extensively studied by De Sonneville and 
colleagues in their 2002 paper. In their study they argue that slowed information processing speed in 
MS is a result of not a single deficit, but of multiple deficits. To begin with, De Sonneville et al. 
argue that the information processing speed deficits exhibited by pwMS revolve not only around 
slowed times of giving a response, but also that pwMS tend to demonstrate slowed response speed 
compared to controls when they simply have to detect the mere presence of a stimulus. Moreover, 
when higher cognitive demands were imposed in the more complex tasks, differences in speed 
between controls and MS patients tend to increase dramatically. MS patients were more susceptible 
to distraction than controls: speed of performance deteriorated disproportionately in the presence of 
distractors. MS patients slowed down much more after making an error that controls, the extent of 
this delay suggesting an interruption of the ongoing process rather than an adequate adjustment, 
underscoring the existence of executive control weaknesses (De Sonneville et al., 2002). Therefore 
as shown by De Sonneville and colleagues, there are many reasons for poorer performance on the 
information processing speed tasks in pwMS. 
As MS is known to cause problems with fine motor control and motor slowing as well as 
psychomotor slowing, the dissociation between their effects on slowed performance on cognitive 
tests has been the focus of several previous studies. Such dissociation is particularly important as 
SPMS patients tend to exhibit higher levels of both, and in order to successfully measure each of 
them separately, adequate measurement tools need to be employed. 
Inordinate increase of reaction time in pwMS with task complexity suggest a slowing of mental 
processing independent of motor slowing (Archibald & Fisk, 2000; Rao, Aubin-Faubert & Leo, 
1989), but others have failed to find this interaction (Litvan et a., 1988). Such inconsistencies in 
findings might be explained by many factors such as differences in tasks, severity of the disease, 
disease course, disease duration, and cognitive status of MS patients, or different statistical approach 
(De Sonneville et al., 2002).  
Moreover, the influence of physical disability on performance on information processing speed tasks 
can also manifest through impaired vision, slowing of eye movement, sensory motor slowing and 
hand dexterity problems (De Sonneville et al., 2002). 
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Besides neurological disability, previous research has suggested that fatigue also tends to be 
associated with poorer performance on speed of information processing tests and needs to be 
controlled for during cognitive assessments as well (Denney et al., 2004). So far this has been 
successfully addressed only in one study by employing not only a healthy control group, but a clinical 
control group as well. In their study rheumatoid arthritis (RA) was selected as a clinical control 
because it is an autoimmune disease resulting in physical disability (although with no known 
involvement of the CNS); with comparable symptoms of pain and fatigue that might impact 
performance on cognitive tests; and these patients often take similar types of medication as pwMS 
(e.g. anti-inflammatories; immunosupressants) with potential side effects upon cognitive 
performance (Denney et al., 2005). In Denney et al’s study (2005) slowing in the speed of 
information processing was characteristic only to MS patients, and RA performed no differently from 
the controls on tests of processing speed. This could be used to conclude that once the confounding 
variables (pain, fatigue, physical disability, medication) are accounted for, the core processes 
underlying cognitive slowing can be attributed only to MS CNS pathology (Denney et al., 2005). 
Future studies should consider not only enrolling a healthy control group, but also a clinical control 
group, such as RA, in order to dissociate among the many factors that contribute to poorer 
performance on information processing speed tests by MS group. 
In our study the De Sonneville et al’s (2002) multi-causal model presented earlier could be an 
explanation of why so many MS patients have performed so poorly on the PASAT test, with a 
significant number of patients only collecting the minimal score of zero. As shown by the findings 
presented by De Sonneville and colleagues, too many time constraints make the task too difficult for 
the pwMS to engage in (2002), therefore by not being able to engage in the task those with processing 
speed deficits are doomed to fail the task before they can even begin performing it. Too many time 
constraints in the PASAT test (new number every three seconds), make the patients distracted by 
their own mistakes, following which they cannot engage again with performing the test. As we have 
seen in our practice, and as was explained by De Sonneville’s work, even though the PASAT is 
considered to be the standard measurement of information processing speed in MS, it is in fact a 
really poor measurement, as the nature of MS deficits doesn’t allow the patients to successfully 
engage in the task, resulting in the non-informative scores of zero. The only patients that can engage 
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and therefore attempt to perform it are those that don’t have the information processing speed deficits. 
Therefore by administering the PASAT on pwMS with information processing speed impairments 
their ability does not get successfully measured, and all that administering this test does is it only 
confronts the patients with their limitations and gets them frustrated and upset about the level of their 
abilities. Thus the PASAT could be argued to only be deemed suitable to measure attentional deficits 
on a limited sample of MS patients – those who are early in their MS and have good numerical ability 
(higher education levels). Other patients, because of their deficits, cannot successfully engage in 
performing this test. Limited application sample makes the use of PASAT in intervention studies 
limited, and more appropriate measurements of information processing speed should be considered. 
Hence keeping all of the considerations regarding multiple causes of poorer performance on the 
information processing speed tests (De Sonneville et al., 2002) in mind, an appropriate test of 
information processing speed should have only the stimulus exposure time pre-determined and allow 
patients to respond at their leisure. Preferably to facilitate the administration such test should also be 
not confounded by patient’s physical disability, such as the ability to move the arms or give fast 
verbal responses. Moreover, to ensure adequate interpretation, the information processing speed tests 
should have no involvement of other cognitive processes, such as memory or executive functions; 
something that the commonly used  SDMT and PASAT tests had been criticized for (Piccinin & 
Rabbitt, 1999). Such confounder-free assessment would be particularly important if we consider that 
deteriorating processing speed has the potential to be considered a biomarker of MS-related CNS 
disease (Hoffman et al., 2007). Therefore developing information processing speed tests that are free 
of all problems associated with SDMT and PASAT is particularly important. 
A potential candidate test has been developed and used in research involving cognitive ageing (Penke 
et al., 2010; Penke et al., 2012) and neurological diseases such as Parkinson’s disease (Shipley et al., 
2002), and CNS malignancy (Scotland et al., 2012). The Visual Inspection Time (VIT) test involves 
patients making simple decisions about a stimulus presented on the computer screen, with the 
duration of stimulus exposure being varied by the experimenter. This way the time for how long the 
participants see the stimulus is controlled and since the respondents can respond at their leisure the 
responses are not confounded by the time it takes the patients to move their arms or give verbal 
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responses. Our own pilot data supports VIT feasibility in MS, with evidence of clear disease-specific 
signal (Pettit, 2015). We believe that the VIT test can act as a suitable candidate to be used instead 
of PASAT and SDMT in further research as it free of disability confounders associated with PASAT 
and SDMT, is a more suitable measure for patients that have attention deficits (aforementioned 
problems with PASAT), easy to explain and well tolerable in neurological samples (Pettit, 2015).  
In this study we have also shown that processing speed is one of the main cognitive deficits and an 
indicator of MS progression. Further research is needed to make any conclusions regarding the 
causality, but our findings did not contradict those presented by De Soneville and colleagues (2002) 
who had previously discussed that disruption in information processing speed may be considered the 
underlying cause for other cognitive impairments. In their study De Sonneville et al. have shown that 
processing speed is substantially correlated with SPMS type, disease duration and disability, which 
they then explained by CNS pathology.  
Moreover, if we assume that the information processing speed is the underlying deficit behind other 
deficits in other cognitive domains, then a test that reliably measures information processing speed 
could be considered the ideal candidate to be the potential output variable as an indicator of disease 
progression or as a measure of the efficacy of treatment. More research needs to be done in order to 
investigate how likely the information processing speed is to represent a biomarker for MS 
progression and the extent to which it is independent from other MS symptoms. However, based on 
our pilot study using the VIT test (Pettit, 2015), it can be considered likely. 
Previous research into processing speed shows that once given unlimited time to perform the task, 
the pwMS were still slower, but this time did not differ in accuracy of processing from controls, 
suggesting the importance of using time strategies in planning everyday life and job activities to 
compensate for or alleviate MS-related speed handicaps (Demaree et al., 1999; De Sonneville et al., 
2002). Seeing our results in the light of those presented by De Sonneville and colleagues we raise a 
question - could it be that by measuring other cognitive functions (such as the number of words 
retrieved on a verbal memory task or the number of words in a category listed on a verbal fluency 
task) we are actually measuring the outcome of deficits in concentration abilities, but not the domain-
specific deficits themselves? Could it be that concentration and information processing speed, rather 
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than other deficits hinder performance on other cognitive domains? More work for dissociation 
among memory problems and problems with information processing speed and attention are needed 
to disentangle among the causes for cognitive deficits in MS. Future work might consider focusing 
on replicating our study but with patients performing all the tests twice – first with limited time and 
the second time with unlimited time. It would be worthwhile to study how different settings of time 
given for performance might influence the cognitive outcome. Such study would yield results that 
could help build successful compensation and cognitive rehabilitation strategies to compensate for 
MS-related cognitive limitations by using time strategies to cope with daily life requirements and job 
activities. 
8.2.5.      Causes for cognitive impairment in MS 
Even though there seems to be consensus in the literature that the SPMS type is associated with more 
prominent cognitive impairment, however, no clear explanation for what causes the cognitive deficits 
in MS has been presented. There have been attempts to name the specific profile of MS cognitive 
impairment as subcortical disconnection dementia (Piras et al., 2003), with it’s distinctive features 
of reduced information processing speed causing intellectual slowing, attentional problems, 
impairment in abstract reasoning, problem solving, and memory dysfunction. The causes for 
subcortical disconnection dementia condition have been attributable to the interruption of the neural 
connections among cortical associative areas as well as between cortical and subcortical structures 
as a consequence of demyelination and axonal degeneration (Piras et al., 2003). 
The biological cause for the distinctive profile of subcortical disconnection dementia could be 
explained by myelin breakdown which slows neural conduction along an axon and therefore slowing 
problem solving speed (Peters, 1996) and that nerves with thinner myelin sheaths are slower and less 
accurate in signal processing (Miller, 1994). In clinical practice this is considered to be represented 
by MRI abnormalities and the size and number of lesions (Thompson et al., 1990).  
However, finding evidence to support the reasoning behind subcortical disconnection dementia 
theory is not so easy as previous studies have shown that increased MRI lesions do not correlate with 
the clinical course of the disease and cognitive deficit evolution (Piras et al., 2003; Foong et al., 
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2000). This was well illustrated by Dominik Meier (Brigham & Women’s Hospital, Boston), based 
on a time-series analysis of 24 brain MRI scans taken in a man with RRMS over 12 months. Dominik 
Meier has shown that throughout a span of one year numerous WMH grow and shrink, as if the 
disease is active, however, according to the clinical measures, the patient was stable during that year. 
This observation has been referred to as the so-called clinic-radiological paradox - abnormal spots 
on MRI often don’t manifest in physical or cognitive symptoms (Barkhof, 2002), and physicians 
cannot always trace symptoms to a particular spot on a scan (Chen, 2012). This is further illustrated 
in a systematic review by Mollison et al. (under review) where correlations as low as r = - 0.30 
between cognitive performance and white matter lesion burden have been reported. 
Moreover, previous research indicate that the severity of cognitive impairment cannot be fully 
explained by the extent of abnormalities detected on conventional MRI images, and that other 
pathological abnormalities such as normal-appearing white matter are likely to be involved (Foong 
et al., 2000). Interestingly Meier et al. (2007) have shown that the extent of brain white matter lesions 
were not only not predicting functional degeneration, but also found that smaller lesions appeared 
disproportionally more damaging than larger lesions, with lesions in progressive MS smaller and of 
shorter activity than in RRMS. It has been further hypothesized that nonfocal, diffuse changes in the 
MS brain, especially axonal loss and mitochondrial dysfunction, prove better correlates of disability 
than total lesion load and have been associated with disease progression (Stadelmann, 2011). A 
neurodegenerative component of pathology is increasingly recognised in all forms of MS, but may 
be particularly salient to the progressive phase (Stadelmann et al., 2011; Stadelmann, 2011). 
Thus, cognitive dysfunction could be related to disease peculiarity and not the time course and there 
could be several causes behind cognitive deficits (Piras et al., 2003). Although inflammation and 
neurodegeneration co-exist throughout the disease, they assume shifting prominence dependent upon 
the clinical stage, with neurodegeneration assuming greater pathogenic significance in patients with 
progressive disease (Reynolds et al., 2011). The mechanistic relationship between these components 
of the disease biology remains debated (Stadelmann et al., 2011); however, the relative lack of focal 
inflammatory white matter disease in PPMS compared to SPMS suggests that differences observed 
between these MS subtypes could be explained by contribution of multifocal inflammation (Connick 
et al., 2013). It could be argued that the poorer cognitive performance of the SPMS patients observed 
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in this study could be associated with the complex interactions behind both inflammatory and 
degenerative processes particular to this subtype of MS. 
8.3.      Evaluation of study methodology 
As part of this research project not only I’ve attempted to answer the three research questions 
(dimensionality, predictors and perception of change), but I also tried to address the methodological 
problems that exist in many longitudinal studies. These methodological caveats tend to play a major 
role in representability of the results and in comparability of the findings among different 
longitudinal studies. In this section I address two of methodological aspects that I tried to ensure 
throughout my project – test battery optimization and recruitment (sample representativeness). 
8.3.1.        Test battery optimization 
The phase II battery optimization procedure has served several purposes in this study. To begin with, 
the optimization procedure has helped shorten the follow-up assessment while ensuring that the test 
battery coverage remains intact.  Moreover, since novel fields of interest have emerged in the time 
span from the development of the phase I battery to the implementation of the follow-up assessment, 
it was necessary to incorporate the additional questionnaires to capture the new data of interest. This 
is especially important when working with clinical samples such as MS where individuals tire 
quickly (thus it’s very expensive to administer time-consuming assessments that are redundant or not 
sensitive), and where individuals are highly heterogeneous in their symptoms (thus a wide range of 
domains needs to be evaluated). 
To begin with, pragmatic considerations identified through feedback from phase I participants on the 
tolerability of the assessment schedule indicated that the phase I assessment was too long and that an 
unchanged assessment schedule was likely to impact negatively on recruitment to phase II. In order 
for the results of the longitudinal study to be reliable I needed to do everything in my power to ensure 
high recruitment rates. And indeed, making the phase II test battery twice shorter by removing 
redundant or insensitive items has undeniably increased the follow-up recruitment rates and the 
overall patient satisfaction with the study. Especially since pwMS tend to tire quickly, at this stage 
an assessment of over three hours would have been unbearable and would have resulted in lower 
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recruitment rates. It is also important to note, however, that the changes made did not affect any other 
test parameters, such as the test setting and sequence, and that all attempts were undertaken to ensure 
that the results from the phase I and phase II would be comparable.  
It is important to note that to the best of my knowledge this longitudinal study so far has been the 
first to optimize its assessment battery to adjust for the participants’ feedback. Most longitudinal 
studies in MS have a few tests and low coverage, but even studies with a wide selection of tests and 
high coverage (such as Morrow et al., 2009; Strober et al., 2014) didn’t report critically evaluating 
their tools.  
I believe that the attempt to optimize the phase II battery has led to higher follow-up recruitment 
rates in this study than those reported by other longitudinal studies in MS. I believe that this has been 
a strong methodological aspect which has highly benefited the representativeness of my follow-up 
sample and that this practice should be considered to be employed in future longitudinal studies. In 
addition, I would strongly suggest other researchers to aim to optimize their test batteries prior to 
each of the follow-up assessments to make their assessments still comparable to the previous ones, 
while responding to the advances of the latest developments in the field. 
8.3.2.         Sample representativeness 
This section includes a discussion of follow-up recruitment rates, and the characterization and 
representativeness of the study cohort. 
This study had high recruitment rates (over 70% for both patients and controls), which can be 
considered high in comparison to the follow-up rates of other longitudinal studies in MS (Table 1.2., 
Chapter One). Not only this study had high recruitment rates to be deemed representable of the 
patient sample, but it also had high follow-up rates and was representable of the control sample. Few 
longitudinal studies in MS have recruited controls, and if they did, their follow-up rates haven’t been 
presented in the write-up. I consider it to be important to discuss not only the patients’, but the 
controls’ follow-up recruitment rates as well, as not having a representative sample yields results that 
are difficult to generalize and interpret.  
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Moreover, this study allowed the participants to have the assessments administered at the 
convenience of their own homes, which in turn has helped secure higher recruitment rates by 
involving the individuals with severe neurological disability, and also those with full-time 
employment or other responsibilities (such as inflexible schedule, lack of transportation or having 
nowhere to leave the children) to be able to take part in research. Without the researcher having to 
come to their house for assessment, these individuals would not have been able to participate, 
resulting in lower representativeness of the follow-up sample. 
One major disadvantage of the longitudinal study design is that we can only generalize the findings 
of the individuals who come back for follow-up assessments, with the data of those who don’t come 
back being lost. There are several reasons why participants do not come back for follow-up 
assessments. To begin with, they may be feeling too ill or have their neurological disability 
progressed to the point where it’s difficult to move. Besides the physical reasons, the individuals 
who don’t come back may have high levels of depression, more cognitive disability, etc., which, due 
to higher drop-out rates, remain uncaptured in many longitudinal studies. Therefore it could be 
considered that the studies with lower follow-up recruitment rates are indeed studying the 
longitudinal changes of those individuals who have lower levels of disability or depression, just 
because such samples are more convenient to approach, making them easier to study. Only by 
ensuring high recruitment rates I can be certain that the findings of this study can be generalizable to 
all pwMS, not only those who are least affected, highly motivated, and have the time and means to 
make their way to the hospital buildings for clinical visits.  
Moreover, these arguments imply that the longitudinal studies which do not allow the re-assessments 
to be performed at patient homes, underestimate the true progression of MS symptoms. This brings 
me to the next issue – the generalizability of findings from longitudinal studies in MS. If other studies 
don’t perform actions to accommodate for patients who have progressed (optimizing the battery and 
allowing the assessments to be administered at patient homes) then those studies are limited to 
including only the patients with less severe courses of MS. This could imply that such studies indeed 
monitor not the progression of MS, but instead the life of the ‘survivors’, i.e. of the individuals with 
the most benevolent courses of MS who have their lives least affected. Indeed, providing with 
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research conditions tolerable only for the relatively healthy patients results in research findings 
applicable only to a subsample, instead of all of the patients with MS. 
Accommodating for the individuals whose MS has severely progressed and making the research 
settings more tolerable for them was one of the strong methodological aspects of this study, allowing 
to provide with results more indicative of the actual situation in MS progression than previous 
longitudinal studies. This was an achievement; however, even with doing so, in this study the follow-
up data from about one in four participants was still not captured. This indicates that in the future 
there is potential for more to be done in order to increase the appeal of participation in the follow-up 
assessments for the participants, and to ensure better representativeness of the dataset and 
generalizability of the findings. 
8.3.3.      Clinical applications of study findings 
This section was allocated for the clinical application of this study’s findings. Here I identified the 
most sensitive and specific cognitive tests for administration for pwMS during regular 
neuropsychological assessments, and for tracking symptom progression.  
To begin with, from analysing the trajectory of change I’ve shown that both pwMS and healthy 
controls have exhibited changes in performance on the cognitive tests, the direction of which not 
always being negative. Upon temporal evaluation both controls and pwMS showed increased and 
decreased performances, and the trajectory and extent of those changes differed depending on a 
cognitive test. Taking that into account, the tests that can be considered most suitable for picking up 
MS-related deficits should be sensitive (those that pwMS fail at baseline but even more at follow-up) 
and specific (controls don’t fail them). On those tests the pwMS should exhibit only one trajectory 
of change, representing development of new impairments attributable only to the progression of MS.  
The suitability of the tests for use in clinical practice was investigated by inspecting the true 
frequencies of pwMS failing each cognitive task (percentage of pwMS minus percentage of controls). 
The tests, arranged in the order from the most sensitive and specific to the least at phases I and II can 
be seen in Figure 8.1. 
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Figure 8.1. True frequencies (%) of pwMS failing each cognitive task at phases I and II 
a) True frequencies at phase I 
 
b) True frequencies for phase II 
 
Note. True frequencies were calculated by subtracting the percentage of controls from the percentage 
of pwMS that failed the test 
Abbreviations: SRT – Selective Reminding Test (SRTL– Long Term Storage, SRTC – Consistent Long Term 
Retrieval, SRTD – Delayed Retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced Auditory 
Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART– items correct at learning stage, SPARTD– 
items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – Visual Object and Space 
Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object Decision Task, VOSP6 – Position 
Discrimination Task, VOSP8 – Cube Counting Task,) BORB – Birmingham Object Recognition Battery 
(BORB2 – Line Length Matching Task, BORB5 – Position of Gap Matching Task, TROG – Test of Reception 






















As it can be seen from Figure 8.1., different items were the most sensitive and specific to MS-related 
cognitive impairment at phases I and II. At phase I the items of verbal memory, spontaneous speech, 
and visual information processing speed have topped the list. However at phase II, the items of 
visuospatial memory, and only then followed by verbal memory, were highest on the list. Moreover, 
the conclusion about which tests should be advised to be used in everyday clinical practice is even 
more difficult, as some of the items that were quite sensitive at phase I, had lost their sensitivity at 
phase II (such as TROG and PASAT). Therefore it can be concluded that, even though cognitive 
impairment in MS should be regarded as a multidimensional construct and for thorough assessments 
tests measuring visuoperceptual and language abilities should be included as well, for quick 
screening at everyday clinical practice the BRBN battery (without the PASAT) can be considered to 
be the most suitable instrument. In this study the PASAT has been shown to be a problematic test, 
with its instructions being too difficult to comprehend not only to the pwMS but to the control 
participants as well.  
Based on the results of this study, administering the whole BRBN battery should be regarded as a 
sufficient examination of neuropsychological changes in pwMS. However, even though proposed by 
some authors, narrowing down the examination to administration only of SDMT as a sole component 
of BRBN is not enough, as administrating only the SDMT (especially as has been shown in Figure 
8.1. b) would not suffice in picking up the MS-related deficits. 
Moreover, part of the reason why the SPART test was shown to be so sensitive to impairment at 
phase II could be because performing it involves hand movement and hand-eye coordination, 
functions that tend to deteriorate together with MS progression. It could be suggested that an 
approach is needed to make the SPART test more applicable to be administered on individuals with 
upper limb paralysis, as in this study three patients were unable to perform the task due to inability 
to move their hands; although their visuospatial memory was considered to be unaffected. 
In this study the 2SD cut-off was employed and, due to the reference group that was used, the cut-
off values produced for the majority of BRBN tasks were higher than those proposed by the test 
authors. Therefore even though these cut-off values were more representative of our reference control 
group, as a consequence these tests became more sensitive (and less specific) to detect cognitive 
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problems in the MS sample. It could possibly be that the suitability of the BRBN battery tests to 
detect MS-related cognitive impairment observed in this study might have been inflated by the way 
the cut-off values were calculated. 
8.3.4.       Definition of impairment 
This section of the discussion centres around the complex issue of definition of cognitive impairment 
and how I believe that it was successfully dealt with in this study. This aspect is important as by 
being thorough in how one defines impairment results in the reliability of the findings, and the 
clinical application of the results. In this study the impairments were defined separately for each test 
item and for each phase of the study. Moreover, specific definition for cognitive domain failure was 
created to address the dimensionality of cognitive impairments. I believe that the approaches 
employed in this study were successful and resulted in greater validity of the study findings. 
One of the advantages of this study was that separate cut-off scores for impairment definition were 
created for the phase I and phase II assessments. These adjustments produced differing cut-off values 
for the majority of the cognitive tests (eleven of sixteen), and although small differences between 
cut-offs for most of the items, for some items the differences were quite significant (e.g. 20-point 
(out of 60) increase in PASAT cut-off). I believe that by adjusting the cut-offs I managed to avoid 
systematic differences in test administration, practice effect, and healthy cognitive ageing. To my 
knowledge no other longitudinal study up to date has re-adjusted their cut-offs in order to redefine 
the normal range of performance. This is very important in future longitudinal research, since, as has 
been shown by this study, both patients and healthy controls tend to vary in their performance.  
This study has attempted to capture that normal fluctuation, and make attempts to incorporate that 
variation into the result analysis in order not to over-estimate the variation in performance exhibited 
by the patient participants. This attempt as illustrated in this study should encourage other 
longitudinal researchers to consider external factors not related to MS, such as practice effect, healthy 
cognitive ageing and systematic differences in test administration, prior to running their result 
analyses; as accounting for these external sources of variation could potentially help explain the 
heterogeneity of findings from the longitudinal studies into cognitive changes in MS. 
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In this study an approach was chosen to define impairment on a domain when a patient failed at least 
two tests within a domain. The motivation behind this approach was that it was less sensitive than 
failing at least one test, but definitely more specific, while allowing comparable application across 
all tested domains. I believe that this approach has led to valid findings especially since the domains 
have an unequal number of cognitive tests in them. Moreover, this approach has also minimized the 
chance of picking up false positives, where the patients might have failed one test in a domain 
because they didn’t understand the task or due to fatigue. Being more conservative and avoiding such 
false positives is also an important aspect since this study could be considered experimental in that 
some of the tests employed here (majority of visuoperceptual tests and language tests) have never 
before been used in MS. Therefore I believe that by using this approach I have managed to capture 
the domain-specificity of MS impairment while maintaining a good balance on the trade-off between 
sensitivity and specificity, therefore avoiding both the type I and type II errors. 
          8.3.5.       Reference control group 
One of the strongest aspects of this project was that not only I managed to collect a representative 
patient sample, but that I also managed to collect and follow-up a corresponding control group. This 
group of participants was well-matched to the patients in terms of age, gender and education, and in 
majority was comprised of patients family members and friends, thus they were comparable in terms 
of their background and cognitive reserve to the patient group. I managed to ensure that my control 
group differed from the patient group only in one aspect – they didn’t have MS. Moreover, the 
follow-up recruitment rates were the same for patient and control samples therefore it can be 
concluded that there had been no systematic differences between individuals showing up for follow-
up between these two groups. Therefore it can be safe to infer that all the differences found in 
longitudinal changes in cognition between these two groups could be attributable to factors caused 
solely by MS. 
By having a reference control group I managed to account for the effects such as normal fluctuation 
in performance, cognitive ageing, practice effect, and systematic differences in administration 
between the phases. To the best of my knowledge, no longitudinal study of cognitive changes in MS 
up to date has accounted for all of those effects. Therefore for the aforementioned reasons future 
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longitudinal studies in MS should ensure that matched control samples should followed as well, and 
that their recruitment is controlled with the same rigour as that of the patients.  
8.3.6. Other strengths and weaknesses of the work 
In our study we have demonstrated a finding which could be of interest to other researchers planning 
to perform repeated assessments on pwMS, either through an observational or interventional 
longitudinal study design. The weaknesses of this work would be associated with some of the tests 
chosen, and the strengths of this work would be associated with the methodology for the analysis of 
longitudinal change. 
Even though language deficits are rare in MS and were not expected to be picked up at a frequent 
level, however, it could be argued that other language tests could have been better candidates for 
including into the assessment battery rather than the BCT that had been selected for this study. As it 
was noted in Chapter Six, the patients have exhibited no change on the BCT, but the controls have 
exhibited a dramatic 7% drop in their performance on the BCT from phase I to phase II. This 
discrepancy was inconsistent with the profile of deterioration in cognitive performance shown on 
other tests where both controls and patients have deteriorated (visuoperceptual items). On those items 
the patients have deteriorated to a similar or to a higher extent than the controls, and therefore on 
those items that decrease in performance was linked to the effects of cognitive ageing or development 
of age-related eye problems. However, with regard to the BCT, only the controls have deteriorated, 
but not the patients, and since both groups had been matched for age, we searched for an alternative 
explanation behind this observation. 
One candidate for a potential explanation of why the controls but not the patients had performed 
worse at follow-up than at baseline could be related to the nature of the BCT administration. While 
other cognitive tests were highly structured and during administration were presented in a question-
and-answer format, the BCT administration could be considered the most unstructured of all of the 
tasks performed. In this task the participants are asked to describe the activity taking place in the 
stimulus picture. No other guidelines are given – the participants respond at their leisure and decide 
themselves the contents, the length and the style of their descriptions. Therefore the way that the task 
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is presented allows each participant to understand its requirements in their own way. This had 
resulted in a vast range of the number of words written by each participant, some of them producing 
one sentence descriptions with others producing a full page of text with hundreds of words. Currently 
this task has been shown by previous literature as a suitable candidate to pick up language problems 
in an individual patient, however, in order for the BCT to be used in the future for cross-sectional 
comparisons more structure should be introduced into this task allowing for more comparable results 
between individuals.  
However, thinking in retrospect, having considered this limitation of the BCT, it is still unclear 
whether there could be a more structured way to measure spontaneous speech. In our study the 
language domain had good coverage, and was comprised of tests measuring both language 
comprehension and language production. Future researchers might wish to consider alternative ways 
how to measure spontaneous language production in a more structured manner that would be less 
affected by individual interpretations and that would allow comparison to an individual’s 
performance on other, more structured tests. 
Other potential sources for limitations in a longitudinal project could be centred around practice 
effect and controlling for it. We believe, that by using the methodology employed in this study we 
have managed to avoid those limitations, and turn them into the strengths of this study. The method 
for quantification and individual analysis of longitudinal change in performance employed in this 
study centred around using the healthy controls as a reference point. The reasoning behind that was 
that this way the items with the most practice effect could be identified by analysing the changes in 
performance in the control group, and then controlled for by incorporating average control change 
into the analysis of the average patient change for each item. This way we have controlled for not 
only the practice effect, but also for the effects of cognitive ageing and administrative differences if 
there had been any.  
For example, there were several items where the controls had exhibited practice effect. The controls 
showed better performance at phase II than at phase I on visuospatial memory (SPART), information 
processing speed (SDMT, PASAT, WLGT), and naming (VOSP2) tasks. This was not a surprising 
finding as practice improves performance on memory tasks, even though in this study we aimed to 
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control for that by employing alternative versions of the BRNB battery tests. Moreover, having done 
the naming task for the second time, many participants had reported remembering doing it the first 
time and managed to recognise several of the stimulus materials from three years ago. The increased 
performance of the control group on the information processing speed task indicated that by 
performing it for the second time they already knew how to perform it, and spent less time trying to 
understand the requirements of the task, or maybe even remembered performance strategies acquired 
during the phase I assessment.  
The patients, however, had demonstrated an increase (though slightly smaller) in performance on the 
verbal fluency, visuospatial learning (but a decrease on visuospatial retrieval), no change on the 
naming task, and deterioration on the information processing speed tasks (SDMT and PASAT). Only 
by incorporating the average change in the control group we have managed to show that the ‘no 
change’ on the naming task actually indicated emergence of mild deficits in the patient group, as, 
compared to the controls who have improved on this task, the patients had performed worse. While 
the age matched controls have shown that it is normal to remember some of the stimuli from three 
years ago during re-assessment, the patients as a group have failed to exhibit this pattern. Therefore 
if we hadn’t incorporated the average change of controls into our methodology of estimating change, 
we would have overlooked that emerging deficit and treated it as unchanged performance.  
This illustration was particularly evident for the information processing speed tests in our study. 
While the patients had exhibited mild deterioration on these items (1% decrease on SDMT and 10% 
decrease on PASAT), the controls showed improved performance (4% increase in SDMT and 5% 
increase in PASAT), indicative of practice effect. Therefore by incorporating the average change of 
the controls into our methodology, we have adequately inflated the deterioration exhibited by patients 
(from 1% decrease to 5% decrease on SDMT and from 10% decrease to 15% decrease on PASAT). 
This is particularly important, as since the SDMT and PASAT are the most commonly used tests in 
research, it could be considered that other studies which did not employ this methodology and did 
not account for practice effect exhibited by controls, tended to underestimate the actual deterioration 
in patient performance on the information processing speed tasks. Although it is a well established 
finding that information processing speed tends to deteriorate in MS, it could be considered that the 
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actual extent of deterioration reported by previous studies could have been underappreciated. Again 
this stresses the importance of employing reference control groups in longitudinal studies in order to 
correctly estimate the amount of cognitive change, especially on the often studied information 
processing speed domain. 
The results of our 3-year follow-up study showed that on some of the tasks the control participants 
had a tendency to perform better at follow-up, therefore indicating that those patients who had 
exhibited non-different performance on those tests, had actually deteriorated, even though that 
deterioration was masked as lack of improvement. These findings are in line with those of another 
2-year follow-up which showed that PPMS and SPMS subtypes were associated with lack of 
improvement compared to controls and RRMS on the PASAT and SDMT, but not on other tasks of 
the BRBN (Huijbregts et al., 2006). They also conclude that future longitudinal studies should 
consider that lack of improvement with practice in progressive MS on the SDMT and PASAT 
indicates a short-term manifestation of cognitive deterioration (Huijbregts et al., 2006), rather than 
no change.  
8.4.        Chapter summary and study conclusions 
This project has been the first representative attempt to study domain-specificity, predictors, and 
perception of longitudinal change in cognitive impairment in MS. No MS study up to today has had 
such high coverage of functions assessed and overall sample representativeness. The richness of this 
study data and high follow-up percent, allowed us to be confident of the study findings and to ensure 
their generalizability. With this project not only we’ve provided an answer about the domain 
specificity of MS impairment, but also related it to a rich dataset of other measures of interest – 
demographic, clinical, and cognitive reserve variables. In addition, not only we’ve investigated the 
actual change in performance, but we’ve also analysed the patients’ own perspective into their 
longitudinal change, which has never been done before in MS in this way.  
The results regarding the domain-specificity of MS-related cognitive performance have been 
discussed extensively with regard to MS subtype and other causes behind cognitive symptom 
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development. The strengths and weaknesses of the work have been addressed, and suggestions for 
future research and clinical practice have been made. 
We believe that the questioning of methodologies behind the data collection and analysis was one of 
the strongest aspects of this project. By doing so we’ve addressed the issue of why different 
longitudinal studies in MS have yielded different results, and contributed to the better understanding 
of such a heterogeneous condition. By attempting to be methodologically precise we believe that we 
have managed to show evidence of controlling for such external factors as natural variation in 
performance, cognitive ageing, practice effect, and administration differences, by utilizing a very 
representative control group, and accounting for their variance when calculating the standardized 
scores of change. 
Due to the aforementioned reasons, this study could be considered to be a useful resource to 
researchers who aim to investigate the progression of cognitive deficits in MS longitudinally. We 
believe that this study could be of interest not only to those who specialize in cognitive functioning 
in MS, but also to those who question the methods employed in clinical research to define 






















Appendix A. Normative values of phase I tests 
 
Table 1. Published cut-off values for each test used to define cognitive impairment. MS-
specific cut-off norms are indicated in bold 






SRTL * < 29years 38;  
30-39years 33;  
40-49 years 32; 
50-59years 33;  
60-69years 23;  
70-79years 17. 
** 32 




* <29years 34;  
30-39years 27; 








19, >60years 3 
*(Larrabee, Trahan, & 
Levin, 2000) 
**(Boringa et al., 
2001) 
***(Rao, 1990) 
SRTC * <29years 30;  
30-39years 21;  
40-49 years 19; 
50-59years 22;  
60-69years 13;  
70-79years 9 
** 16 
* <29years 25; 
30-39years 13; 
40-49 years 12; 
50-59years 16; 
60-69years 6;  
70-79years 2 
** 9 
*(Larrabee, et al., 
2000) 
**(Boringa et al., 
2001) 
SRTD *18-29years 11; 
30-39years 8; 






30-39years 7;  





*(Larrabee et al., 
2000) 
**(Boringa et al., 
2001) 








*(Sheridan et al., 
2006) 




Garg, Munschauer, & 
Benedict, 2007) 













SPART 16 14 (Boringa et al., 2001) 
10/36 SPARTD 5 4 (Boringa et al., 2001) 
 
WLGT (60s) *<59 years 14, 
>60 years 10 
**11 
*<59 years 12, 
>60 years 8 
**8 
*(Tombaugh, Kozak, 
& Rees, 1999) 
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VOSP2 **15 *<50 years 16, 





& Millis, 1997) VOSP3 **15 *<50 years 16, 
>50 years 15; 
** 14 
VOSP5 **9 * 8 
** 9 
VOSP6 **18 * 18 
** 17 
VOSP7 **8 *7 
** 7 






 BORB2 NA NA  
BORB3 NA NA  
BORB4 NA NA  
BORB5 NA NA  
 TROG Bishop: 15 of 20 items passed (Bishop, 1982) 




Bschor reports that healthy 
individuals typically come up with 
an average of 88.2 (SD=56.9) 
words, and on average 20.2 (SD=8) 
picture variables. 
(Bschor et al., 2001) 
 PPT 22 21 (Hulst, 2012) 
 KDT 22 21 (Hulst, 2012) 
 TTT 22 21 (Hulst, 2012) 
 GNT 15 13 (Warrington, 1997) 
 MPNWDS 46 46 (Rewaj, 2013) 
 Orchard test 9 9 (Hulst, 2012) 
 SPMS 27 26 (Hulst, 2012) 
 
Abbreviations: pwMS – people with MS, YoE – years of education, SRT – Selective Reminding Test 
(SRTL – Long Term Storage, SRTC – Consistent Long Term Retrieval, SRTD – delayed retrieval), SDMT 
– Symbol Digits Modalities Test, PASAT – Paced Auditory Serial Addition Test, SPART – 10/36 Spatial 
Recall Test (SPART – items correct at learning stage, SPARTD– items correct at delayed recall), WLGT 
– Category Animal Fluency task, VOSP – Visual Object and Space Perception Battery (VOSP2 – 
Silhouette Naming Task, VOSP3 – Object Decision Task, VOSP5 - Dot Counting Test, VOSP6 – Position 
Discrimination Task, VOSP7 – Number Location Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB3 – Size 
Matching Task, BORB4 – Line Orientation Matching Task, BORB5 – Position of Gap Matching Task, 
GNT – Graded Naming Test, TROG – Test of Reception of Grammar, MPNWDS – Minimal Pairs Non-
Words Task, TTT – Tomato and Tuna Test, PPT – Pyramids and Palm Trees Test, KDT – Kissing and 
Dancing Test, BC – Boston Cookie Test (BC.Index – Index of ratio of picture variables to number of 





Appendix B. Normality of distributions of phase I variables 
 
Table 1. Exploration of normality of distributions of phase I variables 
 
Note. Explorations of normality were performed with Shapiro-Wilk test  
Abbreviations: PwMS – people with MS, SRT – Selective Reminding Test (SRTL – Long Term Storage, 
SRTC – Consistent Long Term Retrieval, SRTD – delayed retrieval), SDMT – Symbol Digits Modalities 
Test, PASAT – Paced Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART – items 
correct at learning stage, SPARTD– items correct at delayed recall), WLGT – Category Animal 
Fluency task, VOSP – Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, 
VOSP3 – Object Decision Task, VOSP5 - Dot Counting Test, VOSP6 – Position Discrimination Task, 
VOSP7 – Number Location Task, VOSP8 – Cube Counting Task,) BORB – Birmingham Object 
Recognition Battery (BORB2 – Line Length Matching Task, BORB3 – Size Matching Task, BORB4 – 
Line Orientation Matching Task, BORB5 – Position of Gap Matching Task, GNT – Graded Naming 
Test, TROG – Test of Reception of Grammar, MPNWDS – Minimal Pairs Non-Words Task, TTT – 
Tomato and Tuna Test, PPT – Pyramids and Palm Trees Test, KDT – Kissing and Dancing Test, BC – 
Boston Cookie Test (BC.Index – Index of ratio of picture variables to number of words), SPMT – 
Sound – Picture Matching Task. 
 
 
 PwMS (n=108) Controls (n=33) 
Test N W p N W p 
SRTL 107 0.978 0.071 29 0.922 0.182 
SRTC 107 0.954 0.001 29 0.949 0.469 
SRTD 107 0.970 0.044 29 0.744 0.001 
SDMT 106 0.992 0.867 28 0.940 0.348 
PASAT 105 0.924 <0.001 29 0.763 0.001 
SPART 105 0.969 0.039 29 0.941 0.360 
SPARTD 105 0.949 0.002 29 0.948 0.459 
WLGT 108 0.980 0.216 32 0.906 0.099 
VOSP2 105 0.950 0.002 31 0.894 0.064 
VOSP3 105 0.845 <0.001 31 0.888 0.052 
VOSP5 105 0.326 <0.001 29 0.273 <0.001 
VOSP6 105 0.583 <0.001 31 0.405 <0.001 
VOSP7 105 0.618 <0.001 31 0.591 <0.001 
VOSP8 105 0.410 <0.001 30 0.398 <0.001 
BORB2 103 0.939 0.001 30 0.960 0.666 
BORB3 103 0.923 <0.001 30 0.949 0.467 
BORB4 102 0.858 <0.001 30 0.920 0.166 
BORB5 102 0.881 <0.001 30 0.878 0.037 
TROG 101 0.872 <0.001 29 0.788 0.002 
BC.Index 90 0.992 0.886 27 0.976 0.922 
PPT 104 0.903 <0.001 28 0.797 0.003 
KDT 104 0.901 <0.001 28 0.782 0.002 
TTT 103 0.769 <0.001 28 0.762 0.001 
GNT 101 0.881 <0.001 29 0.829 0.007 
MPNWDS 100 0.598 <0.001 27 0.794 0.002 
Orchard test 97 0.410 <0.001 25 0.405 <0.001 
SPMT 102 0.848 <0.001 25 0.815 0.004 
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Figure 1. Histograms of distribution of pwMS’ performance scores at phase I on individual test 
variables with a superimposed normative curve 
 
1. BRBN items: SRTL, SRTC, SRTD, SPART, SPARTD, SDMT, PASAT, WLGT. Phase I patients (n 
= 108) 
 
SRTL SRTC SRTD 
   
SPART SPARTD SDMT 
   
PASAT WLGT  
  
 
        
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – delayed retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART – items correct at learning 









2. Visuoperceptual items: VOSP2, VOSP3, VOSP5, VOSP6, VOSP7, VOSP8, BORB2, BORB3, 
BORB4, BORB5. Phase I patients (n = 108) 
 
VOSP2 VOSP3 VOSP5 
   
VOSP6 VOSP7 VOSP8 
   
BORB2 BORB3 BORB4 
   
BORB5   
 
  
Abbreviations: VOSP – Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, 
VOSP3 – Object Decision Task, VOSP5 - Dot Counting Test, VOSP6 – Position Discrimination Task, 
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VOSP7 – Number Location Task, VOSP8 – Cube Counting Task,) BORB – Birmingham Object 
Recognition Battery (BORB2 – Line Length Matching Task, BORB3 – Size Matching Task, BORB4 – 
Line Orientation Matching Task, BORB5 – Position of Gap Matching Task 
 
3. Language items: TROG, BC.Index, PPT, KDT, TTT, GNT, MPNWDS, Orchard test, SPMT. 
Phase I patients (n = 108) 
 
TROG BC.Index PPT 
   
KDT TTT GNT 
   
MPNWDS Orchard test SPMT 
   
Abbreviations: GNT – Graded Naming Test, TROG – Test of Reception of Grammar, MPNWDS – 
Minimal Pairs Non-Words Task, TTT – Tomato and Tuna Test, PPT – Pyramids and Palm Trees Test, 
KDT – Kissing and Dancing Test, BC – Boston Cookie Test (BC.Index – Index of ratio of picture 





Figure 2. Histograms of distribution of controls’ performance scores at phase I on individual test 
variables with a superimposed normative curve 
 
1. BRBN items: SRTL, SRTC, SRTD, SPART, SPARTD, SDMT, PASAT, WLGT. Phase I controls (n 
= 29) 
 
SRTL SRTC SRTD 
   
SPART SPARTD SDMT 
   
PASAT WLGT  
  
 
        
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – delayed retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART – items correct at learning 









2. Visuoperceptual items: VOSP2, VOSP3, VOSP5, VOSP6, VOSP7, VOSP8, BORB2, BORB3, 
BORB4, BORB5. Phase I controls (n = 29) 
 
VOSP2 VOSP3 VOSP5 
   
VOSP6 VOSP7 VOSP8 
   
BORB2 BORB3 BORB4 
   





Abbreviations: VOSP – Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, 
VOSP3 – Object Decision Task, VOSP5 - Dot Counting Test, VOSP6 – Position Discrimination Task, 
VOSP7 – Number Location Task, VOSP8 – Cube Counting Task,) BORB – Birmingham Object 
Recognition Battery (BORB2 – Line Length Matching Task, BORB3 – Size Matching Task, BORB4 – 
Line Orientation Matching Task, BORB5 – Position of Gap Matching Task 
 
3. Language items: TROG, BC.Index, PPT, KDT, TTT, GNT, MPNWDS, Orchard test, SPMT. 
Phase I controls (n = 29) 
 
TROG BC.Index PPT 
   
KDT TTT GNT 
   
MPNWDS Orchard test SPMT 
   
Abbreviations: GNT – Graded Naming Test, TROG – Test of Reception of Grammar, MPNWDS – 
Minimal Pairs Non-Words Task, TTT – Tomato and Tuna Test, PPT – Pyramids and Palm Trees Test, 
KDT – Kissing and Dancing Test, BC – Boston Cookie Test (BC.Index – Index of ratio of picture 
variables to number of words), SPMT – Sound – Picture Matching Task. 
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Figure 3. Histograms of logarithmically transformed VOSP5, VOSP6, VOSP7, VOSP8, TROG, TTT, 
MPNWDS, SPMT and Orchard test variables. Phase I patients (n = 108) 
 
LN VOSP5 LN VOSP6 LN VOSP7 
   
LN VOSP8 LN TROG LN TTT 
   
LN MPNWDS LN SPMT LN Orchid test 
   
Abbreviations: LN – natural logarithmic transformation, VOSP – Visual Object and Space Perception 
Battery (VOSP5 - Dot Counting Test, VOSP6 – Position Discrimination Task, VOSP7 – Number 
Location Task, VOSP8 – Cube Counting Task), TROG – Test of Reception of Grammar, MPNWDS – 







Table 2. Properties of the distributions of the logarithmically transformed items. Phase I patients 
(n = 108) 
 
Item Skewness (SE) Shapiro-Wilk Test 
LN(VOSP5) -3.851 (0.236) W = 0.300, p < 0.001 
LN(VOSP6) -4.012 (0.236) W = 0.536, p < 0.001 
LN(VOSP7) -3.870 (0.236) W = 0.553, p < 0.001 
LN(VOSP8) -4.817 (0.236) W = 0.346, p < 0.001 
LN(TROG) -1.199 (0.240) W = 0.866, p < 0.001 
LN(TTT) -2.749 (0.238)  W = 0.664, p < 0.001 
LN(MPNWDS) -3.452 (0.241) W = 0.561, p < 0.001 
LN(SPMT) -1.830 (0.239) W = 0.816, p < 0.001 
LN(Orchard test) -4.826 (0.245) W = 0.394, p < 0.001 
 
Abbreviations: Visual Object and Space Perception Battery (VOSP5 – Dot Counting Test, VOSP6 – 
Position Discrimination Task, VOSP7 – Number Location Task, VOSP8 – Cube Counting Task,) TROG 
– Test of Reception of Grammar, TTT – Tomato and Tuna Test, MPNWDS – Minimal Pairs Non-Words 









Appendix C. Validity of phase II tests 
 
Table 1. Evidence of validation of tests in the phase II battery 
Test Validation 
sample 
Functions assessed, or sensitivity to 
lesions in brain areas 
Validation study 
EDSS 572 male MS 
patients 
Pyramidal, Cerebellar, Brainstem, 
Sensory, Bowel and bladder, Visual and 
Cerebral (mental) functions 
(Kurtzke, 1970) 
ACE-R 241 subjects  
(AD 67, FTD 55, 
LBD 20; mild MCI 
36; controls 63 
 
Dementia screening (Mioshi, et al., 
2006) 
SRT Right (n = 20) and 
left (n = 22) 
temporal lobe 
epilepsy patients 
and controls (n = 
49) 
Verbal memory and in particular 
wordspan, correlated best with left 
temporal lobe abnormalities 
(Bell, Fine, Dow, 
Seidenberg, & 
Hermann, 2005) 
SPART 82 MS patients Visuospatial memory and delayed 
recall , Correlates with parietal lesion 
load 
(Lazeron et al., 
2005) 
SDMT 82 MS patients Sustained attention and concentration 
Correlates with frontal, parietal and 
temporal lesion load 
(Lazeron, et al., 
2005) 
PASAT 82 MS patients Sustained and divided attention and 
information processing speed 
correlates with subcortical brain 
systems and white matter tract 
atrophy; Correlates with frontal, 
parietal and temporal lesion load 
(Lazeron, et al., 
2005) 
WLGT 31 studies with 
1,791 participants 
Correlates moderately high with focal 
frontal (r=.54) and temporal (r=.61) 
injuries 
(Henry & Crawford, 
2004; Ross, 2003) 
VOSP2 150 controls, and 
55 right- and 52 
left- hemisphere 
lesion cases 




VOSP3 150 controls, and 
55 right- and 52 
left- hemisphere 
lesion cases 




VOSP6  200 controls, and 
74 right- and 75 
left- hemisphere 
lesion cases 




VOSP8 200 controls, and 












Functions assessed, or sensitivity to 
lesions in brain areas 
Validation study 
BORB2 and BORB5  Right hemisphere lesion group is 
slightly worse at length location, and 
more noticeably worse at location 
discrimination than left-hemisphere 
lesioned patients. Results suggest 
general right-hemisphere 
specialization for visual processing. 
(Riddoch & 
Humphreys, 1993) 
TROG 70 controls Grammatical comprehension (Bishop, 1982) 
Boston Cookie Theft 
Test (BCT) 
34 patients with a 
degree of severity 
of aphasia ranging 
from slight to 
severe 
Broca’s Aphasia, posterior left 








RR (n = 28), SP (n = 
6), and PP (n = 2). 
Cognitive reserve (Sumowski et al., 
2010) 
BDI-II Meta-analysis of 
26 studies 
Depression (Beck, Steer, & 
Carbin, 1988) 
MSIS-29 233 patients Correlations with The 59 item 
Functional Assessment of Multiple 
Sclerosis (FAMS), the Medical 
Outcomes Study 36 item Short-Form 
Health Survey (SF-36), and the 12 item 
General Health Questionnaire (GHQ-
12) provide evidence for the 
convergent and discriminant validity of 
MSIS-29 as a measure of the physical 





Abbreviations: ACE-R – Addenbrooke’s Cognitive Examination – Revised, BDI-II – Beck’s Depression 
Inventory 2nd Ed., MSIS-29 – 29 item Multiple Sclerosis Impact Scale, EDSS – Expanded Disability 
Status Scale, SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – delayed retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART– items correct at learning 
stage, SPARTD– items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – Position of 
Gap Matching Task, TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – 
Index of ratio of picture variables to number of words), MS – multiple sclerosis, AD – Alzheimer’s 





Appendix D. Dimensionality of cognitive impairments of each 
individual 
 
Table 1. Phase I ten subject-cluster solution. In this matrix the rows represent the 61 pwMS, and 
the columns represent individual cognitive tests. 
0 
 Normal. Represents performance above the cut-off score, defined by 2SD below the Phase I 
(n=29) control mean 
1 
 Impaired. Represents performance below the cut-off score, defined by 2SD below the Phase I 
(n=29) control mean 
 




























































































1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 
1 2 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 
1 3 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 
1 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
1 6 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 
1 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
1 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 11 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 
1 12 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 
1 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 15 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 
1 16 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 17 0 1 1 0 0 0 0 0 0 0 1 0 0 0 1 0 
1 18 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 
1 19 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 
1 20 0 1 0 0 1 0 0 0 0 0 1 0 0 0 0 1 
1 21 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
1 22 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 
1 23 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 
1 24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
1 25 0 0 1 0 0 1 0 0 0 0 1 0 0 0 0 0 
1 26 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 



































































































1 28 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 1 
1 29 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 
1 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 31 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
1 32 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 33 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 34 0 0 1 0 0 1 0 0 0 0 1 0 0 0 0 0 
1 35 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
2 36 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 0 
2 37 1 0 0 0 0 1 0 1 0 0 0 0 0 0 1 0 
3 38 0 0 1 0 0 1 0 0 1 0 0 0 0 0 0 1 
3 39 0 0 1 1 0 1 0 0 1 0 0 1 0 0 0 0 
4 40 1 1 1 1 0 1 0 0 0 0 1 0 0 0 0 0 
4 41 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 
4 42 1 1 0 0 0 0 0 0 0 1 1 0 0 0 0 0 
4 43 1 1 1 0 0 0 0 0 0 0 1 0 1 0 0 0 
4 44 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 
4 45 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0 1 
4 46 1 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 
5 47 1 1 1 0 1 1 0 0 0 0 0 1 0 0 0 0 
5 48 1 0 1 0 0 0 0 0 0 0 0 1 0 0 1 1 
5 49 1 0 1 0 0 0 0 1 0 1 0 1 0 0 0 1 
5 50 0 0 1 0 1 0 0 0 0 0 0 1 0 0 0 0 
5 51 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 
6 52 0 0 0 0 0 0 0 1 1 1 0 0 0 0 1 1 
7 53 1 1 1 0 0 1 1 1 0 0 1 0 0 0 0 0 
7 54 0 1 1 0 0 1 0 1 0 1 0 0 0 0 0 1 
7 55 1 1 0 0 0 1 1 1 0 1 0 0 0 0 0 1 
7 56 1 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 
8 57 1 0 1 0 0 1 1 1 0 0 1 0 0 0 1 1 
8 58 0 0 0 0 0 1 1 1 0 0 1 0 0 1 1 0 
9 59 1 0 1 0 1 0 0 1 0 1 0 0 1 1 1 0 
9 60 0 0 0 0 1 0 0 0 0 0 0 0 1 1 1 0 
10 61 1 1 1 1 1 1 0 1 1 0 0 1 1 1 0 0 
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Table 2. Phase II two subject-cluster solution. In this matrix the rows represent the 61 pwMS, and 
the columns represent individual cognitive tests. 
0  
Normal. Represents performance above the cut-off score, defined by 2SD below the Phase 
II (n=23) control mean 
1  
Impaired. Represents performance below the cut-off score, defined by 2SD below the 
Phase II (n=23) control mean 
 




























































































1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 2 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 
1 3 0 0 0 1 1 0 0 0 1 0 0 1 0 1 1 0 
1 4 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 
1 5 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 
1 6 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 
1 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 8 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 
1 9 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 11 0 0 0 0 0 1 1 0 0 0 1 0 1 1 1 0 
1 12 1 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 
1 13 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
1 14 0 0 0 0 0 0 1 0 0 1 0 0 1 0 0 0 
1 15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 16 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 
1 17 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 
1 18 0 0 0 0 0 1 1 0 0 1 0 0 0 0 0 0 
1 19 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 21 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 23 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 25 0 0 0 0 0 1 1 1 1 0 0 0 0 0 1 0 
1 26 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 27 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 28 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 29 0 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 
1 30 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 































































































1 32 1 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 
1 33 0 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 
1 34 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 
1 35 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 36 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 
1 37 0 0 0 0 0 1 1 0 0 1 1 0 0 1 1 0 
1 38 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 
1 39 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 40 0 0 1 0 0 1 1 0 0 0 0 0 0 0 0 0 
1 41 0 0 0 0 1 0 1 0 0 0 0 1 0 1 0 1 
1 42 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 43 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
1 44 0 0 0 0 0 1 1 0 1 0 0 1 0 1 0 0 
1 45 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
2 46 1 1 1 1 0 1 1 0 0 1 0 1 0 0 0 0 
2 47 1 1 1 1 1 1 1 0 1 1 1 1 0 1 1 0 
2 48 1 1 1 0 0 1 1 0 0 0 1 0 0 0 0 0 
2 49 1 1 1 0 0 1 1 1 0 0 1 0 1 1 0 0 
2 50 1 1 1 0 0 1 1 0 0 0 0 1 0 0 0 0 
2 51 1 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 
2 52 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 
2 53 1 1 1 0 0 1 1 0 1 1 0 0 0 0 0 0 
2 54 1 0 1 0 0 1 1 0 1 1 0 0 0 0 0 0 
2 55 1 0 0 0 0 1 1 0 0 0 1 0 0 0 0 0 
2 56 1 1 1 1 0 1 1 0 0 0 1 1 0 0 1 0 
2 57 1 1 1 0 0 1 1 0 1 0 0 1 1 1 1 0 
2 58 1 1 1 0 0 1 1 0 0 0 1 0 1 0 0 0 
2 59 1 1 0 0 0 1 1 0 0 1 0 0 1 1 0 0 
2 60 1 1 1 0 0 1 0 0 0 1 1 1 0 0 0 0 




Table 3. Four subject-cluster solution for longitudinal change. The rows represent 61 pwMS and the 
columns represent individual cognitive tests.   
-1 
Resolved impairment. Represents cases that had performed below the cut-off at Phase I, but 
above the cut-off at Phase II. The cut-off scores were defined for the Phase I and Phase I 
assessments as performance below 2 SD below control mean. 
0 
Unchanged. Represents cases that performed identically (either above or below the cut-off) 
both at Phase I and Phase II.  
1 
New impairment. Represents cases that had performed above the cut-off at Phase I, but below 
the cut-off at Phase II. 


























































































1 1 0 0 0 0 0 0 0 0 0 0 -1 0 0 0 0 -1 
1 2 0 0 0 0 0 0 1 0 0 1 -1 1 0 0 0 0 
1 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 4 -1 0 -1 1 0 0 0 -1 1 -1 0 1 -1 0 0 0 
1 5 1 0 1 0 0 0 0 0 0 0 -1 0 0 0 0 0 
1 6 -1 -1 -1 -1 0 0 0 0 0 0 0 0 0 0 0 0 
1 7 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 
1 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -1 
1 9 -1 -1 -1 0 -1 0 0 0 0 0 0 -1 0 0 0 0 
1 10 1 0 -1 0 0 -1 0 0 -1 0 0 0 0 0 0 -1 
1 11 0 0 0 0 0 0 0 0 0 0 -1 0 0 0 0 -1 
1 12 -1 0 -1 0 0 0 0 -1 0 0 0 0 1 1 0 -1 
1 13 0 1 0 0 0 0 0 0 0 0 0 -1 0 1 -1 -1 
1 14 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
1 15 0 0 0 0 0 0 1 0 0 1 0 0 1 0 0 -1 
1 16 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 17 -1 -1 0 0 0 0 1 0 0 -1 -1 1 0 0 0 0 
1 18 0 0 0 0 0 0 1 1 0 0 -1 0 0 0 0 0 
1 19 0 0 0 0 0 1 1 0 0 1 -1 0 0 0 -1 0 
1 20 0 0 0 0 0 1 1 1 0 0 0 0 0 1 0 0 
1 21 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 23 0 0 1 0 0 0 0 0 0 0 0 -1 0 0 0 0 
1 24 0 0 0 0 0 0 0 -1 0 0 -1 1 0 0 0 0 
1 25 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 26 1 -1 -1 0 0 0 0 0 0 0 -1 0 0 0 -1 0 
1 27 0 0 0 0 0 0 0 0 0 0 -1 0 0 0 0 0 
1 28 0 0 0 0 0 1 1 0 0 -1 0 0 0 0 0 -1 
































































































1 30 0 -1 0 0 -1 0 0 0 0 0 -1 0 0 0 0 -1 
1 31 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -1 
1 32 -1 0 0 0 0 0 0 1 1 0 -1 0 0 0 0 0 
1 33 0 0 0 0 1 0 0 -1 0 0 0 0 0 0 0 -1 
1 34 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -1 
1 35 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 -1 
1 36 1 0 0 0 0 0 0 0 0 0 -1 0 0 0 0 0 
1 37 0 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 
1 38 1 0 0 0 0 0 1 -1 1 0 0 0 0 0 0 -1 
1 39 0 0 0 0 0 1 1 -1 1 0 0 -1 0 0 0 -1 
1 40 0 0 0 -1 1 0 0 0 -1 0 0 -1 0 0 0 0 
1 41 0 -1 0 0 0 0 0 -1 0 -1 1 0 0 0 0 -1 
1 42 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -1 
1 43 0 0 0 -1 -1 1 0 0 0 0 0 0 0 0 0 -1 
1 44 0 0 0 0 0 0 1 0 0 0 1 0 0 1 0 0 
1 45 0 0 -1 0 0 1 0 0 0 0 0 0 0 0 0 0 
1 46 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 47 0 0 0 0 -1 1 1 0 0 0 0 -1 0 0 0 0 
1 48 0 0 0 0 0 0 1 0 0 0 0 1 -1 0 -1 1 
1 49 0 0 0 0 0 0 0 0 0 0 0 0 -1 0 0 0 
1 50 0 0 -1 0 0 1 1 0 0 1 0 0 0 1 0 0 
1 51 0 0 -1 0 0 0 0 0 0 0 0 0 0 0 0 1 
1 52 0 0 0 0 0 1 0 0 0 1 1 0 0 0 0 0 
1 53 -1 0 0 0 0 0 1 -1 1 0 0 1 0 1 -1 0 
1 54 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
2 55 0 0 0 0 0 0 1 -1 0 1 1 0 -1 0 1 0 
2 56 0 0 1 1 0 0 0 -1 0 0 1 1 0 0 1 0 
2 57 1 1 0 1 0 0 0 0 1 1 0 0 0 1 1 0 
3 58 1 1 1 0 0 1 1 0 0 0 1 0 0 0 0 0 
3 59 1 1 1 0 0 1 1 0 0 0 0 -1 0 -1 0 -1 
3 60 1 1 1 0 0 1 1 0 0 0 1 0 1 0 0 0 







Appendix E. Dimensionality analyses with multiple imputation 
 
1. Section Aim 
The aim of the following insert was to rerun the Chapter Five dimensionality analyses (sections 5.3. 
and 5.4.), but this time with the data from the 21 pwMS with missing observations included. This 
supplementary analysis investigated the robustness of the dimensionality analyses conducted in 
Chapter Five, and it was also used to determine whether the Chapter Five results might have been 
biased towards the more healthy individuals (i.e. those without missing data). 
2. Methods 
 
2.1.  Design 
Just like the analyses in Chapter Five, this insert addressed the issue of disentangling whether the 
cognitive impairment in pwMS could be considered more of a unidimensional or multidimensional 
construct, and the longitudinal pattern of changes in domain-specificity of individual cognitive 
impairments. 
In this supplementary insert the dimensionality analyses were carried out following the same 
methodology as presented in the methods section of Chapter Five. However, in this appendix, in 
addition to complete case analysis, subjects with missing observations were included as well. 
2.2.  Dealing with missing data 
The cluster analysis method tends to assume the absence of missing data and is only able to include 
the observations for which every variable was measured. There are two ways how such analyses can 
be performed – as complete case analyses (excluding all participants with any missing observations) 
or by performing imputation to fill in the missing observations. Both methods of handling missing 
data have their strengths and weaknesses, therefore in order to address the aim of this thesis all cluster 
analyses have been performed twice – first as complete cases analyses (Chapter Five), and the second 




2.2.1. Complete cases analysis 
In the complete case analyses (Chapter Five) all cases with missing observations were excluded by 
performing list-wise deletion. If the missingness mechanism is missing completely at random 
(MCAR), a complete case analysis is sensible, although it may well not use all the available 
information in the data. However, in our study the cause of missingness was not MCAR since we 
were able to identify the source of missingness (Figures 2-4 in Results section). Therefore if the 
missingness mechanism is not MCAR, as was in our study, some authors argue that list-wise deletion 
might not be the most sensible approach (Carpenter & Kenward, 2007).  
2.2.2. Imputation 
The second way of dealing with missing observations is performing imputation to appropriately use 
all the information present in a dataset with missingness, therefore avoiding the biases, inefficiencies, 
and incorrect uncertainty estimates that can result from dropping all partially observed cases from 
the analysis. In social sciences missing data is most commonly dealt with ad-hoc methods of 
imputation, such as mean/mode/median imputation, however, they have been reported to lead to 
serious biases in variances and covariances (Honaker, King & Blackwell, 2015).  
Another common way of dealing with missing data is Last Observation Carried Forward (LOCF), 
where for each patient their subsequent missing responses are set equal to their last observed response. 
However, this approach is not fit for studies where longitudinal change is expected as it decreases 
the sensitivity to detect the actual change (false negative). LOCF also does not help deal with missing 
observations at phase I, as it was the patient’s first visit, and there are no previous values to carry 
forward. Moreover, the LOCF method has received much criticism, since it is neither valid under 
general assumptions nor based on statistical principles, and, according to Carpenter and Kenward, it 
is not a sensible method, and should not be used (2007). The group of patients who complete, but 
who share similar characteristics and responses to a specific patient prior to withdrawal, will usually 
give a better estimate of the distribution of the missing values than the last response before the patient 
withdrew (Carpenter & Kenward, 2007). 
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Multiple imputation (MI) is a general method that incorporates the uncertainty into the imputation 
process. One of the main reasons to use MI is the fact that all relevant data-collection information, 
both observed and unobserved, can be incorporated into the imputation. MI is comprised of three 
stages: imputation stage, in which the missing data are imputed; analysis stage, in which each 
complete data set is analysed using a complete-data technique; and the last stage, in which the results 
from the analysis are combined in order to yield a final result that combines the uncertainty in the 
data and the uncertainty due to missing values (Harel & Zhou, 2007). Multiple imputation has been 
shown to reduce bias and increase efficiency compared to list-wise deletion, ad-hoc methods of 
imputation, and LOCF methods (Honaker, King & Blackwell, 2015). 
2.3. Multiple imputation 
 
2.3.1. Imputation method 
The R package ‘Amelia II’ performs MI to data with missing values by employing expectation-
maximization with bootstrapping (EMB) algorithm (Figure 1) (Honaker & King, 2010; Honaker, 
King & Blackwell, 2015). 
 
Figure 1. Amelia II schematic approach to multiple imputation with the expectation-maximization 





The expectation-maximization (EM) algorithm (Dempster, Laird & Rubin, 1997) is a general-
purpose computational approach to finding the mode of the posterior. In their original form the EM 
estimates cannot be used to create MI, as the estimates do not reflect the fact that they have been 
estimated from a finite sample. In order to solve this, Amelia II first takes m bootstrap samples, and 
applies the EM-algorithm to each of these bootstrap samples (Figure 1). The m estimates of means 
and variances will now be different. The first set of estimates is used to draw the first set of imputed 
values by a form of regression analysis, the second is used to calculate the second set of imputed 
values, and so on. The bootstrapping creates samples based on the distribution, and the EM-algorithm 
fits those samples on the original data. The decision for which value will be put in place of the 
missing value is made by regression. The imputed value is calculated as the predicted value plus a 
random draw from the residual distribution (King, Tomz and Wittenberg, 2000). 
MI involves imputing m values for each missing cell in the data matrix and creating m ‘completed’ 
data sets. Across these completed data sets, the observed values are the same, but the missing values 
are filled in with a distribution of imputations that reflect the uncertainty about missing data. After 
imputation with Amelia II’s EMB algorithm, all statistical methods can be applied that would have 
been used if there had been no missing values to each of the m data sets, and the results from m 
analyses can be combined in interpretation. For the purposes of this study, the program default of 
m=5 has been used, i.e. five new imputed datasets were created for each analysis. 
2.3.2. Imputation assumptions 
The imputation model in Amelia II assumes that the data are missing at random (MAR) and not 
missing completely at random (MCAR). This assumption means that the pattern of missingness only 
depends on the observed data, not the unobserved data. For such data multiple imputation is deemed 
suitable, once the reasons for missingness are included into the EMB model.  
The second MI assumption is that the complete data (that is, both observed and unobserved) are 
multivariate normal, so all information about the relations in the data can be summarized by just 
mean and covariances. When data are incomplete, Amelia II uses the EM algorithm to find corrected 
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estimates of the means and covariances (Little & Rubin, 2002). However, there is also evidence that 
this model works as well even with categorical or mixed data (Schafer & Olsen, 1998). 
2.3.3. Imputation methodology 
For the MI as a prior all unobserved values on cognitive tests were set as positive (minimum value 
of 0) and the highest logical value on that variable for all phases and all participants was set as a 
maximum. 
All imputations were performed on continuous data; only after imputation the variables were 
transformed into binary format (‘0’ not impaired and ‘1’ impaired) based on the same thresholds as 
had been done in Chapter Five (Table 5.2). 
2.4. Dimensionality analysis 
In this supplementary insert the dimensionality analyses were carried out following the same 
methodology as presented in the methods section of Chapter Five. 
This insert starts with an attempt to investigate the domain-specificity of cognitive disturbances. The 
second but linked analysis revolved around identification of potential subgroups (clusters) of 
individuals (within the study population) who display distinct patterns of cognitive impairments 
and/or cognitive change. The dimensionality of the phase I and phase II datasets were analysed 
separately, then later the differences between phase I and phase II dimensionality were analysed as 
a third (longitudinal change) dataset.  
 All analyses with MI have been be performed five times as five MI datasets, as per recommendations 






3.1. Participant data completeness 
Of the 82 patients with both phase I and phase II data, 21 had missing observations on at least one of 
the sixteen cognitive variables at either phase I or at phase II (Table 1). In Chapter Five analyses 
these individuals were removed by performing list-wise deletion, however, in this insert, these 
individuals were included. This was done after attributing the causes of missingness, therefore 
properly managing the missing data. 
Table 1. Cognitive data completeness at phases I and II 
 Missing observations 
 Phase I Phase II 
   
SRTL 1/82 1/82 
SRTC 1/82 1/82 
SRTD 1/82 1/82 
SPART 1/82 4/82 
SPARTD 1/82 4/82 
SDMT 3/82 1/82 
PASAT 9/82 16/82 
WLGT 0/82 0/82 
VOSP2 2/82 0/82 
VOSP3 2/82 1/82 
VOSP6 2/82 3/82 
VOSP8 2/82 1/82 
BORB2 3/82 1/82 
BORB5 3/82 3/82 
TROG 3/82 1/82 
BC.Index 12/82 2/82 
   
Table 1 shows that the PASAT and BC.Index (at phase I) variables had the highest numbers of 
missing observations. Missing observations on other variables were minimal. 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – Delayed Retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART– items correct at learning 
stage, SPARTD– items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – Position of 
Gap Matching Task, TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – 





On both phases there had been high numbers of missing observations on the PASAT test (11% phase 
I and 19.5% phase II). This indicated that the instructions of the PASAT test had been too difficult 
for many patients to understand, and because they didn’t know how to perform the test, these pwMS 
ended up not doing it at all.  
The high number of missing observations on the BC test at phase I (14.6%) were because this test 
was added to the study battery later on, after the study had already started. For the most part, the 
missing observations indicated the individuals that were the first ones to join the phase I study.  
The individual patterns of missing data for phase I can be seen in Figure 2; for phase II in Figure 3; 




Figure 2. Missingness map of the phase I cognitive dataset (n=82).  
Note. Missing values are in tan and observed values are in red. The columns represent the variables 
and the rows represent individual patients. The variables are arranged in the order from most to 
least missing values from left to right. The rows are in random order. 
Figure 2 shows that at phase I the pattern of missing observations was not random, as there were 
three individuals with high numbers of missing observations on many of the variables. All other 
patients with missing observations had data missing on the BC.Index and PASAT variables. 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – Delayed Retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART– items correct at learning 
stage, SPARTD– items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – Position of 
Gap Matching Task, TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – 







Figure 3. Missingness map of the phase II cognitive dataset (n=82).  
Note. Missing values are in tan and observed values are in red. The columns represent the variables 
and the rows represent individual patients. The variables are arranged in the order from most to 
least missing values from left to right. The rows are in random order. 
Figure 3 shows that at phase II there was one individual with most of the data missing, a few 
individuals with some data missing on the visuoperceptual tests, and the majority of missing 
observations were on the PASAT tests. 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – Delayed Retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART– items correct at learning 
stage, SPARTD– items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – Position of 
Gap Matching Task, TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – 





Figure 4. Missingness map of the phases I and II cognitive datasets (n=82).  
Note. Missing values are in tan and observed values are in red. The columns represent the variables 
and the rows represent individual patients. The variables are arranged in the order from most to 
least missing values from left to right. The rows are in random order. The number at the end of the 
name each variable on the x-axis indicates at which phase that data was collected (e.g. PASAT.I was 
collected at phase I, and PASAT.II was collected at phase II).  
Figure 4 shows that just a few patients had missing data on the same variables on both phases (e.g. 
PASAT I and PASAT II; BORB5 I and BORB5 II). There was one individual who was unable to perform 
many of the items on both phases; one individual who had visuoperceptual data missing at phase 
I, but not phase II; and one individual who had memory data missing at phase I, but not phase II. 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – Delayed Retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART– items correct at learning 
stage, SPARTD– items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – Position of 
Gap Matching Task, TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – 
Index of ratio of picture variables to number of words). 
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At phase I it seemed that the data was not MCAR – several certain individuals had more missing data 
than others (Figure 2). Specifically, two individuals had completed all but the visuoperceptual tests, 
and one individual had missing data on all but the VOSP items. Besides these two cases, the 
remaining individuals had data missing only on the BC test and PASAT. 
At phase II again the data was not MCAR (Figure 3), as it can be seen that most individuals had data 
missing on the PASAT test. A few patients had data missing on the visuoperceptual tests, and only 
one individual had a large number of observations missing, having completed only the VOSP2 and 
WLGT tests. 
As it can be seen from Figure 4, just a few individuals had missing data on the same variables at both 
phases. One patient had many missing observations due to physical limitations, however, for that 
specific participant more observations were missing at follow-up than at baseline. This patient’s MS 
had severely progressed, limiting her to a totally helpless bed patient who was unable to communicate 
effectively (phase I EDSS=8; phase II EDSS=9.5).  
The PASAT was the only test that had large numbers of unobserved values on both phases. This 
indicated that the individuals with unobserved PASAT values were unable to understand it’s 
instructions during both assessments, and that the missing values were specific to the test, rather than 
to the administration protocol differences between the phases I and II. 
As has been shown in Table 1 and Figures 2-4, in this study the missing observations can be 
considered to be missing at random (MAR), and not missing completely at random (MCAR), as the 
sources of all missingness can be explained in this study. The main sources of missingness were 
inability to move the hands for missing SPART observations; complicated instructions and cognitive 
difficulties in understanding instructions for PASAT; visual problems for missing values on some of 
the visuoperceptual items; the order of recruitment for BC Test missing data at phase I; etc. Therefore 





3.2.   Individuals with complete and missing data 
Using the MI method the missing values were imputed for 21 individuals. 
In order to investigate whether there had been any systematic differences between individuals with 
complete and missing data, their clinical and demographic characteristics were examined. 
Table 2. Demographic and clinical characteristics of the individuals with complete and missing data 





     
Age  50.23 (9.18) 53.30 (9.69) U = 750,  
p = 0.125 
 
Gender (%)   53% Female, 47% male 55% female, 45% male X2 = 0.039,  




 13.05 (3.15) 12.11 (2.85) U = 455,  




 89% not impaired,  
11% impaired 
85% not impaired,  
15% impaired 
X2 = 0.173,  
p = 0.678 
 
BDI-II  15.25 (9.22)  15.32 (10.66) U = 577.50,  
p = 0.982 
 
MSIS-29  82.97 (25.99) 85.16 (28.71) U = 602,  
p = 0.799 
 
MS course (%)  26% PPMS, 30% SPMS, 
44% RRMS 
14% PPMS, 48% SPMS, 
38% RRMS 
X2 = 2.602,  
p = 0.272 
 
Disease duration  12.58 (6.81) 17.85 (9.92) U = 793,  
p = 0.032* 
 
EDSS  5.16 (1.83) 5.80 (2.33) U = 703.50,  
p = 0.282 
 
Note. Data for comparison of demographic and clinical characterisics was collected at phase II. 
Comparisons were performed using the Mann-Whitney U-test for interval and ordinal data, and 
Pearson’s Chi Square test for frequency data 
Table 2 shows that in general, there had been no differences between the patients with complete 
observations and those with some missing data, however, the missing observations were 
associated with longer MS duration 
Abbreviations: ACE-R – Addenbrooke’s Cognitive Examination – Revised, BDI-II – Beck’s Depression 




As it can be seen from Table 2, the only differences between the pwMS with complete data (n=61) 
and missing data (n=21) were in the disease duration, therefore it appears that the participants who 
had missing observations have had MS for longer. However, such difference was not unexpected, as 
the reason why the data was not collected had in part to do with the patients’ more severe MS 
symptoms (such as visual problems or tremor); and the longer someone has had MS, the more likely 
they were to develop more symptoms that may have interfered with cognitive testing. 
Besides the duration of MS, there were no other differences between the patients included in the 
Chapter Five analyses, and those who were not. 
3.3.  Imputation 
This study has met all of the assumptions necessary for MI, therefore it was proceeded with imputing 
the missing values. 
In order to improve the accuracy of MI, it was considered to run the imputation procedures separately 
for the phase I and phase II data sets. First, in order to better predict performance of severely disabled 
individuals, it was decided to include the EDSS scores among the information variables into both 
data sets. Moreover, since the BC.Index missing values occurred at baseline, they could be partially 
predicted by follow-up data values. Therefore for phase I, in order to have better accuracy for 
BC.Index data imputation, in addition to EDSS scores, the BC.Index scores from phase II were also 
included among the information variables. 
However, since the PASAT and the BC.Index items had the most missing observations, in further 
dimensionality analyses it was important to keep in mind that these items had the most data ‘created’ 
therefore their results should be interpreted with caution. 
3.4.  The dimensionality of cognitive impairments 
The result analysis of this chapter begins with an attempt to investigate the pattern in which the 
cognitive functions are affected by MS. First the dimensionality of cognitive impairments of phase I 
and phase II datasets was analysed separately, then later the dimensionality of emerging and 
resolving deficits as a third longitudinal dataset was studied. 
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3.4.1. Domain-specificity of impairments at phase I 
The first step was to investigate the pattern of domain deficits at phase I. This analysis of 
dimensionality allowed to explore two elements – the cumulative burden of impairments (i.e. were 
they predominantly single-domain, or multi-domain), and the pattern of impairments (i.e. was there 






Table 3. The pattern of domain deficits for pwMS at phase I. Complete case analysis (n=61) and 
multiple imputation (m=5; n=82) 
Cognitive domain Number of items in each domain 
Minimum number of tests to fail to be 
considered impaired on each domain 
Verbal memory 3 (SRTL, SRTC, SRTD) 2 / 3 
Visuospatial memory 2 (SPART, SPARTD) 2 / 2 
Processing speed 3 (SDMT, PASAT, WLGT) 2 / 3 
Visuoperceptual 6 (VOSP2, VOSP3, VOSP6, VOSP8, BORB2, BORB5) 2 / 6 




Domain unaffected. Represents performance below cut-off on one or less tests in that domain.  
1 
 
Domain impaired. Represents performance below cut-off on two or more tests in the domain.  






































































































































on only one 
domain 









0 1 0 0 0 2 (3%) 2 (2%) 2 (2%) 2 (2%) 2 (2%) 
2 
(2%) 
0 0 1 0 0 1 (2%) 2 (2%) 2 (2%) 2 (2%) 2 (2%) 
2 
(2%) 
0 0 0 1 0 4 (7%) 8 (10%) 7(9%) 7 (9%) 8 (10%) 
8 
(10%) 




1 1 0 0 0       
1 0 1 0 0 4 (7%) 5 (6%) 5 (6%) 5 (6%) 5 (6%) 
5 
(6%) 
1 0 0 1 0 4 (7%) 6 (7%) 6 (7%) 7 (8%) 5 (6%) 
6 
(7%) 
1 0 0 0 1 1 (2%) 1 (1%) 2 (2%) 1 (1%) 1 (1%) 
2 
(2%) 
0 1 0 0 1       
0 0 1 1 0 1 (2%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 
1 
(1%) 
0 0 1 0 1       






1 1 1 0 0       
1 1 0 1 0       
1 1 0 0 1       
1 0 1 1 0       






1 1 1 1 0 1 (2%) 2 (2%) 2 (2%) 2 (2%) 2 (2%) 
2 
(2%) 
1 1 1 0 1       
Global 
impairment 
1 1 1 1 1       
Table 3 shows that at phase I around half of the patients had no cognitive domains failed, a quarter had one 




As it can be seen from Table 3, at phase I the profiles of patients with complete cases were non-
different from those with imputed data. However, the sole minor difference can be observed in the 
prevalence of patients without any impairments – there were slightly less individuals with no 
impairments among the patients with missing data, although this difference was quite small (approx. 
6%). 
Again, as had been shown in Chapter Five, at phase I the patients tend to fail all of the cognitive 
domains, although the impairments on verbal memory items were the most common. Besides that 
there seemed to be no over-representation of a particular combination, suggesting that cognitive 
deficits at phase I could indeed be considered multidimensional. At phase I most patients failed only 
one or two cognitive domains, and only a few patients could be considered more globally impaired 
having failed three or four cognitive domains.  
To sum up, at phase I the findings from the imputed samples were non-different from those presented 
in the complete case analysis in Chapter Five. 
3.4.2. Domain-specificity of impairments at phase II 
The next step was to investigate whether the MI has caused any differences in the dimensionality of 
cognitive impairments at phase II. Again, at phase II the MI data had the same dimensionality as the 
complete case analysis data, except that after MI more patients have had severe global impairments 
(Table 4). These were the only cases that had been missed with the complete case analysis. Besides 
that, no differences were found between the complete case and MI data dimensionality analyses at 
phase II.  
In phase II patients had developed more multi-dimensional deficits, as more patients have failed three 
or more cognitive domains than in phase I.  
At phase II the multidimensional impairments had similar patterns – these patients were more likely 
to have failed verbal memory, processing speed and visuoperceptual groups of tests. The patients 
who had failed four cognitive domains had also had the same pattern with an additional impairment 




Table 4. The pattern of domain deficits for pwMS at phase II. Complete case analysis (n=61) and 
multiple imputation (m=5; n=82) 
Cognitive domain Number of items in each domain 
Minimum number of tests to fail to be 
considered impaired on each domain 
Verbal memory 3 (SRTL, SRTC, SRTD) 2 / 3 
Visuospatial memory 2 (SPART, SPARTD) 2 / 2 
Processing speed 3 (SDMT, PASAT, WLGT) 2 / 3 
Visuoperceptual 6 (VOSP2, VOSP3, VOSP6, VOSP8, BORB2, BORB5) 2 / 6 




Domain unaffected. Represents performance below cut-off on one or less tests in that domain.  
1 
 
Domain impaired. Represents performance below cut-off on two or more tests in the domain.  





























































































































on only one 
domain 
1 0 0 0 0 3 (5%) 5 (6%) 5 (6%) 5 (6%) 5 (6%) 
5 
(6%) 
0 1 0 0 0 3 (5%) 3 (4%) 3 (4%) 3 (4%) 3 (4%) 
3 
(4%) 
0 0 1 0 0 7 (11%) 10 (12%) 10 (12%) 10 (12%) 9 (11%) 
10 
(12%) 
0 0 0 1 0 2 (3%) 5 (6%) 5 (6%) 5 (6%) 4 (5%) 
4 
(5%) 




1 1 0 0 0   1 (1%)         
1 0 1 0 0 3 (5%) 3 (4%) 5 (6%) 5 (6%) 5 (6%) 
4 
(5%) 
1 0 0 1 0 2 (3%) 3 (4%) 3 (4%) 3 (4%) 3 (4%) 
3 
(4%) 
1 0 0 0 1             
0 1 1 0 0       1 (1%)   
1 
(1%) 
0 1 0 1 0 1 (2%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 
1 
(1%) 
0 1 0 0 1             
0 0 1 1 0 3 (5%) 5 (6%) 5 (6%) 6 (7%) 7 (8%) 
7 
(8%) 
0 0 1 0 1             




1 1 1 0 0 1 (2%) 2 (2%) 1 (1%) 1 (1%) 1 (1%) 
1 
(1%) 
1 1 0 1 0             
1 1 0 0 1             
1 0 1 1 0 8 (13%) 9 (11%) 8 (10%) 8 (10%) 8 (10%) 
9 
(11%) 
1 0 1 0 1             
1 0 0 1 1             




1 1 1 1 0 1 (2%) 4 (5%) 3 (4%) 3 (4%) 3 (4%) 
3 
(4%) 
0 1 1 1 1             
Global 
impairment 
1 1 1 1 1             
Table 4 shows that at phase II less than half of pwMS were considered to be cognitively spared; around 15% 




3.4.3. Dimensionality of temporal change in cognitive impairments  
In the previous analyses the patterns were shown of how cognitive impairments group in pwMS at 
two separate phases of the assessment. However, what was left unexplained was how stable those 
impairments were, and what was the pattern of their longitudinal development. 
The dimensionality of change was analysed in two ways and separate steps were taken to investigate 
the impairments that emerge, and the impairments that resolve. This was done in order to explore 
whether any patterns of domain-specificity of evolving or resolving impairments could be observed.  
Several measures were undertaken in order to avoid the effect of potential artefacts in the 
dimensionality analysis that could potentially limit the generalizability of the findings. I identified a 
possibility that there could also be individuals that show patterns of both emerging and resolving 
impairments in the same domain, but on different tests. Because of this reason it was chosen to define 
longitudinal change on a cognitive domain when there were at least two observations on two separate 
tests in the same direction, following the same reasoning as per definition of impairment in Table 3 
and Table 4. This adjustment made the analyses of longitudinal change more conservative, especially 
on the domains that have fewer tests in them and was shown to be successful in Chapter Five in 
reducing the risk of Type I error. 
I. Dimensionality of emerging impairments 
The first part of longitudinal analyses of changes in dimensionality of cognitive impairment revolved 
around identification of evolving impairments. These were the instances where a patient has 
performed at norm at phase I, but below the cut-off at phase II (Table 5). In majority, the MI datasets 
showed similar patterns as the complete case analysis. Around half of patients did not develop any 
new domain impairments, at least none that could get picked up by this conservative definition.  
However, there have also been differences between the complete case and MI analyses. In the 
complete case analysis almost all of the newly developed domain impairments were uni-dimensional, 
with emerging impairments in processing speed and visuoperception most prominent.  
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In the analysis of the dimensionality of emerging deficits in the MI datasets, there have been a few 
patients who have suddenly developed more global impairments with emerging deficits in two or 
three domains.  
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Table 5. Dimensionality of developing impairments. The pattern of acquired deficits for pwMS in 
each domain between phase I and phase II is presented. Complete case analysis (n=61) and multiple 
imputation (m=5; n=82) 
Cognitive domain Number of items in each domain 
Minimum number of items to develop 
new impairments on to be considered 
having emerging impairments on each 
domain 
Verbal memory 3 (SRTL, SRTC, SRTD) 2 / 3 
Visuospatial memory 2 (SPART, SPARTD) 2 / 2 
Processing speed 3 (SDMT, PASAT, WLGT) 2 / 3 
Visuoperceptual 6 (VOSP2, VOSP3, VOSP6, VOSP8, BORB2, BORB5) 2 / 6 








Domain impaired. Represents performance below cut-off on two or more tests in the 
domain.  

















































































































on only one 
domain 
1 0 0 0 0 2 (3%) 4 (5%) 4 (5%) 4 (5%) 4 (5%) 4 (5%) 
0 1 0 0 0 2 (3%) 3 (4%) 3 (4%) 3 (4%) 3 (4%) 3 (4%) 


















9 (11%) 9 (11%) 





1 1 0 0 0  3 (4%)     
1 0 1 0 0 1 (2%) 2 (2%) 2 (2%) 2 (2%) 2 (2%) 2 (2%) 
1 0 0 1 0 1 (2%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 
1 0 0 0 1       
0 1 1 0 0   2 (2%) 2 (2%) 2 (2%) 2 (2%) 
0 1 0 1 0       
0 1 0 0 1       
0 0 1 1 0 3 (5%) 5 (6%) 3 (4%) 3 (4%) 4 (5%) 5 (6%) 
0 0 1 0 1       





1 1 1 0 0  1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 
1 1 0 1 0       
1 1 0 0 1       
1 0 1 1 0  1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 
1 0 1 0 1       
1 0 0 1 1       
0 1 1 1 0  1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 
0 1 1 0 1       





1 1 1 1 0       
1 1 1 0 1       
1 1 0 1 1       
1 0 1 1 1       
0 1 1 1 1       
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Table 6. Dimensionality of resolving impairments. The pattern of resolving deficits for pwMS in 
each domain between phase I and phase II is presented. Complete case analysis (n=61) and 
multiple imputation (m=5; n=82) 
Domain Number of tests in each domain 
Minimum number of tests to improve on 
to be considered having resolving 
impairments on each domain 
Verbal memory 3 (SRTL, SRTC, SRTD) 2 / 3 
Visuospatial memory 2 (SPART, SPARTD) 2 / 2 
Processing speed 3 (SDMT, PASAT, WLGT) 2 / 3 
Visuoperceptual 
6 (VOSP2, VOSP3, VOSP6, VOSP8, BORB2, 
BORB5) 
2 / 6 




Impairments resolve. I.e. impaired at phase I and non-impaired at phase II 
0 
 
New impairments that emerge or remain stable.  























































































































No recovery 0 0 0 0 0 
 51 
(84%) 















0 1 0 0 0  1 (2%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 
0 0 1 0 0             
0 0 0 1 0  2 (3%) 5 (6%) 5 (6%) 6 (7%) 4 (5%) 6 (7%) 
0 0 0 0 1  1 (2%) 1 (1%) 3 (4%) 1 (1%) 1 (1%) 2 (2%) 
Recovery on 
two domains 
1 1 0 0 0       1 (1%) 1 (1%) 1 (1%) 
1 0 1 0 0             
1 0 0 1 0  2 (3%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 
1 0 0 0 1  1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 
0 1 1 0 0            
0 1 0 1 0             
0 1 0 0 1             
0 0 1 1 0             
0 0 1 0 1             




1 1 1 0 0             
1 1 0 1 0             
1 1 0 0 1             
1 0 1 1 0             
1 0 1 0 1             
1 0 0 1 1             
0 1 1 1 0             
0 1 1 0 1             




1 1 1 1 0             
1 1 1 0 1             
1 1 0 1 1             
1 0 1 1 1             






1 1 1 1 1             
Table 5 shows that around half of the patients don’t develop new impairments in the time interval 
between phase I and phase II. About a third of patients have developed new impairments on one 
domain, 10% on two domains, and it was very unlikely to suddenly develop multidimensional 
impairments in 3 year follow-up. 
Table 6 shows that for the majority of patients the impairments exhibited at phase I didn’t resolve. 
Around 20% of patients had impairments resolved on one domain, with most improvement seen 
on verbal memory. Very small numbers of patients showed recovery on two domains indicating 
that a multidimensional recovery is highly unlikely. 
 
II. Dimensionality of resolving impairments 
 
The vast majority of patients did not improve on any of the cognitive domains, and if they did, they 
mostly improved on only one domain (Table 6). This was consistent to both complete cases and MI 
datasets. Therefore it could be considered, that in general, the changes between phases I and II were 
not random, instead, a trend for acquiring new impairments was observed, with most of new 
problems emerging on visuoperceptual and information processing speed tests. 
3.4.4. Dimensionality of cognitive impairments. Summary 
From analysing the domain-specificity of cognitive impairments it was found that all cognitive 
domains can be affected in MS, although not at the same frequencies. The majority of individuals 
from the phase I MS sample had deficits only on one cognitive domain, however, with when re-
assessed three years later they became impaired on more cognitive domains, with emerging deficits 
on visuoperceptual and information processing speed tests being most prominent. 
From the comparison of complete cases and MI datasets it can be summarised that in general both 
methods of data analysis have provided similar results, however, the MI datasets included slightly 
more patients with more global impairments and smaller prevalence of patients without any 
impairments; which was expected as physical disability caused by more severe disease progression 
had interfered with collection of cognitive data. 
In the analysis of the dimensionality of emerging deficits in the MI datasets, there have been a few 
patients who have suddenly developed more global impairments with emerging deficits in two or 
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three domains. The progression profiles exhibited by these three individuals represented a more 
severe deterioration and had not been present in the initial complete case analyses in Chapter Five. 
3.5.  The dimensionality of the phase I study population 
After completing the analysis of the dimensionality of cognitive impairments, the next step was to 
investigate the dimensionality of the study cohort in order to address the emerging patterns of 
grouping the pwMS based on their performance. With this analysis we aimed to understand whether 
certain groups of patients that share similar patterns of cognitive performance could be identified. 
Again, all cluster analyses were performed in total of six times – first as the complete cases analysis, 
as had been done in Chapter Five, then five times with all MI datasets.  
As had been done in Chapter Five, the subject-cluster analyses were first performed on the phase I 
datasets, then on the phase II datasets, and then finally on the datasets of longitudinal change. 
3.5.1. Subject-clusters in the phase I dataset 
First we examined the phase I dataset to find the optimum number of clusters of patients based on 
their cognitive performance. We separately sought to identify the most suitable number of clusters 





Table 7. Determination of the optimal number of clusters in the hierarchical cluster analysis of 
patient data at phase I (n=82) 

















        
2  3.39 6.66 5.53 6.06 4.78 6.14 
3  3.59 5.19 4.57 5.14 4.20 4.90 
4  5.28 3.98 3.61 4.23 3.99 4.44 
5  4.6 3.60 4.01 3.74 3.52 3.86 
6  4.22 7.17 3.65 3.44 3.11 3.42 
7  4.72 7.08 3.29 3.24 3.02 5.71 
8  6.22 6.60 3.60 3.38 3.64 5.48 
9  6.29 6.18 3.44 3.51 5.97 5.66 
10  6.33 6.51 5.60 3.48 6.27 5.78 
11  6.15 6.92 5.80 6.07 6.45 6.52 
12  5.9 6.70 5.78 5.72 6.67 6.69 
13  6.1 6.71 6.18 6.09 6.62 6.40 
14  5.65 6.90 6.04 5.97 6.76 6.74 
15  5.61 6.72 5.84 5.74 6.87 6.52 
        
 
Table 7 shows that there were no clear optimum number of clusters in the phase I dataset. The 
complete case analysis and the five MI datasets suggested that the number of clusters ranged in-
between six and fifteen. 
 
 
According to the Caliński-Harabasz cluster stopping criterion, there is no one clear optimum number 
of clusters at phase I data. Depending on the dataset (complete cases or the five MI), the number of 
subject-clusters for the phase I sample ranged between six and fifteen. Moreover, as can be seen from 
the Table 8 and the dendrograms (Figure 5), in each clustering solution the clusters were not equal 
in their sizes. In each solution there tended to be one largest cluster that grouped around half of 
patients, leaving small numbers of patients in the remaining clusters. This pattern with half of patients 
in cluster one, and with another half distributed in the remaining (five to fourteen) clusters, was 
present in all six datasets. 
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Table 8. Number of individuals in each subject-cluster solution at phase I (n=82) 













        
1  35 (57%) 48 (59%) 41 (50%) 41 (50%) 38 (46%) 40 (49%) 
2  2 (3%) 27 (33%) 4 (5%) 16 (20%) 3 (4%) 4 (5%) 
3  2 (3%) 2 (2%) 13 (16%) 8 (10%) 4 (5%) 5 (6%) 
4  7 (12%) 2 (2%) 3 (4%) 2 (2%) 6 (7%) 1 (1%) 
5  5 (8%) 2 (2%) 6 (7%) 3 (4%) 3 (4%) 3 (4%) 
6  1 (2%) 1 (1%) 4 (5%) 3 (4%) 5 (6%) 2 (2%) 
7  4 (7%)  2 (2%) 1 (1%) 6 (7%) 8 (10%) 
8  2 (3%)  1 (1%) 1 (1%) 4 (5%) 7 (9%) 
9  2 (3%)  3 (4%) 1 (1%) 4 (5%) 4 (5%) 
10  1 (2%)  2 (2%) 2 (2%) 2 (2%) 1 (1%) 
11    1 (1%) 1 (1%) 1 (1%) 2 (2%) 
12    1(1%) 1 (1%) 2 (2%) 2 (2%) 
13    1 (1%) 2 (2%) 2 (2%) 1 (1%) 
14      1 (1%) 2 (2%) 
15      1 (1%)  
        
Table 8 shows that at phase I around half of patients shared similar patterns of cognitive 




Figure 5. Dendrogram of hierarchical cluster analysis using average linkage model of phase I 
patient data. The horizontal line is shown to represent where the optimal cluster cut falls in each 
analysis 
a) Phase I, Complete cases (n=61). Ten-cluster solution
 
b) Phase I, Imputation 1 (n=82). Six-cluster solution
 




d) Phase I, Imputation 3 (n=82). Thirteen-cluster solution
 
e) Phase I, Imputation 4 (n=82). Fifteen-cluster solution 
 




After splitting the phase I patients into groups, the next step was to investigate the cognitive profiles 
of the individuals in each cluster. As it can be seen from Table 9, all of the phase I datasets (complete 
cases and all imputations) have yielded similar results. At phase I half of the patients (Cluster One) 
showed low frequencies of impairments that appeared to be scattered across cognitive abilities, 
consistent with the classic pathological view of a widely distributed multifocal inflammatory disorder 
of the CNS. The other clusters had high frequencies, but, depending on the cluster, those high 
frequencies were on different tests. This indicated groups of patients with more severe problems in 





Table 9. Frequencies (%) of patients failing each test in each cluster at phase I 
 
a) Phase I, Complete cases (n=61). Ten-cluster solution 




















































































                   
C1 35 0 6 14 6 9 6 6 3 0 3 29 9 3 3 6 31 
C2 2 50 0 0 0 0 
10
0 



















71 43 0 43 0 0 0 14 57 0 29 0 0 14 
C5 5 80 40 
10
0 
0 40 20 0 20 0 20 0 
10
0 
0 0 20 40 












C7 4 75 
10
0 






0 50 25 0 0 0 0 50 














C9 2 50 0 50 0 
10
0 


































Average                 
C2-
10 
26 69 54 65 19 19 58 19 42 15 27 27 27 19 15 31 31 
 
 
b) Phase I, Imputation 1 (n=82). Six-cluster solution 



















































































                   
C1 48 8 2 15 4 8 10 6 13 2 13 21 13 6 4 15 38 
C2 27 78 78 74 15 7 67 7 26 0 15 52 15 15 4 19 22 









0 0 50 0 0 0 50 
C4 2 50 0 50 0 
10
0 






















































Average                 
C2-
6 




c) Phase I, Imputation 2 (n=82). Thirteen-cluster solution 




















































































                                    
C1 41 0 2 15 5 7 10 5 5 0 7 27 5 10 0 2 29 
C2 4 25 0 0 0 0 
10
0 




C3 13 92 92 77 31 0 38 0 8 0 8 69 8 15 8 23 15 
C4 3 67 67 
10
0 
0 67 33 0 0 0 0 0 
10
0 
0 0 0 0 
C5 6 67 83 33 0 0 
10
0 
0 50 0 50 0 0 33 0 0 50 
C6 4 75 0 75 0 0 25 0 25 0 25 25 
10
0 
0 25 50 
10
0 









0 0 50 0 0 0 50 

























0 0 67 0 0 0 33 33 
C10 2 50 0 50 0 
10
0 


















































































Average                 
C2-
13 





d) Phase I, Imputation 3 (n=82). Thirteen-cluster solution 




















































































                                    




81 56 19 13 63 0 19 0 13 31 19 19 0 6 6 
C3 8 50 50 
10
0 
0 0 75 25 38 0 0 
10
0 
13 0 0 63 13 













0 67 0 0 0 0 33 0 33 0 
10
0 
0 33 33 
10
0 
C6 3 33 
10
0 
67 0 0 
10
0 
33 67 0 67 0 0 33 0 0 
10
0 

















0 0 0 
10
0 




























C10 2 50 0 50 0 
10
0 














































































Average                 
C2-
13 





e) Phase I, Imputation 4 (n=82). Fifteen-cluster solution 




















































































                                    
C1 38 0 3 8 5 8 5 8 5 0 3 21 5 8 0 3 32 














83 0 83 0 0 0 0 33 17 0 17 0 33 
C5 3 67 67 
10
0 
0 67 33 0 0 0 0 0 
10
0 




80 40 0 0 0 0 0 0 20 80 20 40 0 0 0 
C7 6 33 50 
10
0 
0 0 67 0 17 0 0 
10
0 
17 0 0 67 0 
C8 4 50 
10
0 
50 0 0 
10
0 






50 25 0 25 
10
0 
0 75 0 0 0 0 25 0 25 0 









0 0 50 0 0 0 50 




























0 0 0 50 50 
C13 2 50 0 50 0 
10
0 





























































Average                 
C2-
15 





f) Phase I, Imputation 5 (n=82). Fourteen-cluster solution 




















































































                                    
C1 40 0 3 3 5 10 5 5 5 0 8 23 8 10 0 3 33 
C2 4 50 0 0 0 0 
10
0 
25 25 0 25 0 0 25 0 75 0 
C3 5 20 40 
10
0 
0 0 80 0 0 0 0 
10
0 
20 0 0 60 0 


















0 67 0 0 0 0 33 0 33 0 
10
0 
0 33 33 
10
0 















88 38 25 
10
0 




86 57 14 0 0 0 0 0 14 71 29 29 14 0 0 
C9 4 50 
10
0 
50 0 0 
10
0 
0 50 0 75 0 0 25 0 0 
10
0 





























C12 2 50 0 50 0 
10
0 





















































50 0 0 0 50 
Average                 
C2-
14 
42 73 59 68 20 15 66 10 34 15 24 41 25 17 15 32 32 
Table 9 shows that at phase I around half of pwMS had multifocal impairments, and half had 
predominantly verbal memory and processing speed impairments (SDMT only), accompanied with 
or without additional deficits on VOSP6. This was consistent across all imputations and the 





Table 9 shows dissociation between scattered impairments in Cluster One, indicative of widely 
distributed multifocal inflammatory disorder of the CNS; and other clusters with more pronounced 
damage. Some of the clusters grouped together patients with more damage on some tests but not the 
others, however, that distinction was unclear. Only once the remaining clusters that grouped together 
around half of patients and phase I were merged together, a pattern of deficits emerged with 
predominantly verbal memory and processing speed impairments (SDMT only), accompanied with 
or without additional deficits on VOSP6. This was consistent across all imputations and the complete 
case analysis. 
 
Table 10. Comparison of MS types between Cluster One and the remaining clusters at phase I (n=82) 






     
Complete case analysis 
(n=61) 
35 26% PPMS, 23% SPMS, 
51% RRMS 
26 27% PPMS, 32% SPMS, 
41% RRMS 
Imputation 1 48 24% PPMS, 29% SPMS, 
47% RRMS 
34 22% PPMS, 42% SPMS, 
36% RRMS 
Imputation 2 41 27% PPMS, 19% SPMS, 
54% RRMS 
41 20% PPMS, 49% SPMS, 
31% RRMS 
Imputation 3 41 27% PPMS, 22% SPMS, 
51% RRMS 
41 20% PPMS, 46% SPMS, 
34% RRMS 
Imputation 4 38 29% PPMS, 18% SPMS, 
53% RRMS 
44 18% PPMS, 48% SPMS, 
34% RRMS 
Imputation 5 40 28% PPMS, 18% SPMS, 
54% RRMS 
42 19% PPMS, 50% SPMS, 
31% RRMS 
Table 10 shows that at phase I the majority of participants in Cluster One were RRMS, and in other 
clusters the majority of pwMS were SPMS. These differences in MS type prevalence were more 
pronounced in the MI datasets. 





Therefore in all further analyses it was considered to merge the remaining clusters and compare them 
against the Cluster One. As it can be seen from Table 10, the two halves of participants had differed 
in the prevalence of MS subtypes. The ‘Multifocal’ cluster, or Cluster One, was largely comprised 
of the RRMS patients, and the other clusters with more pronounced verbal memory and processing 
speed impairments, were comprised largely of SPMS patients. 
3.5.2. Subject-clusters in the phase II dataset 
After having examined the subject-clusters in phase I, the next step was to investigate the 
dimensionality of the phase II cohort, and whether there had been any changes in the groupings of 
patients based on their cognitive profiles. 
 
Table 11. Determination of the optimal number of clusters in the hierarchical cluster analysis of 
patient data at phase II (n=82) 

















        
2  23.01 11.43 23.21 8.52 2.53 11.44 
3  14.06 16.34 13.07 5.44 13.38 6.96 
4  12.54 12.34 11.02 11.24 11.30 11.08 
5  10.7 10.94 9.41 9.06 9.59 9.63 
6  9.39 9.28 8.18 8.08 8.31 9.85 
7  - 9.04 7.97 7.84 8.40 8.92 
8  7.65 8.44 8.15 7.39 8.55 8.13 
9  7.22 8.18 7.87 7.33 8.17 8.35 
10  8.19 7.51 7.47 7.71 7.72 7.83 
11  8.04 7.04 7.00 7.40 7.17 7.38 
12  - 6.82 6.58 7.00 6.88 6.93 
13  7.23 6.97 6.31 6.63 6.54 6.65 
14  7.16 6.78 6.04 6.40 6.23 6.54 
15  - 6.59 5.81 6.15 5.98 7.37 
        
Table 11 shows that the complete cases and all five MI datasets had yielded non-different 




According to the Caliński-Harabasz cluster stopping criterion, all analyses suggest mainly the two 
or three cluster solutions in the phase II datasets. This indicated that the clustering solution at phase 
II was more stable than at phase I, as all datasets (complete cases and all MIs) yielded similar 
grouping solutions. Therefore it could be considered that the results from the complete cases analysis 
were more robust at phase II than they were at phase I. 
Again, as can be seen from the Table 12 and the dendrograms (Figure 6), in each clustering solution 
the clusters were unequal in their sizes. All solutions suggested one large cluster that contained the 
majority of patients, and then one or more other smaller clusters that had much less participants in 
them (1 to 26%). 
 
Table 12. Number of individuals in each subject-cluster solution at phase II (n=82) 













        
1  45 (74%) 61 (74%) 61 (75%) 61 (74%) 60 (73%) 76 (93%) 
2  16 (26%) 16 (20%) 21 (25%) 16 (20%) 21 (26%) 6 (7%) 
3   5 (6%)  1 (1%)  1 (1%)  
4     4 (5%)   
        
Table 12 shows that in all subject-cluster solutions there was a one larger cluster with three 
quarters of pwMS and the remaining quarter was distributed among one to three small clusters. 
The results from all six datasets were similar, except for imputation 5 that has offered a much 




Figure 6. Dendrograms of hierarchical cluster analysis using average linkage model of patient data 
at phase II. The horizontal line is shown to represent where the optimal cluster cut falls in each 
analysis 
a) Phase II, Complete cases (n=61). Two-cluster solution 
 
b) Phase II, Imputation 1 (n=82). Three-cluster solution 
 
 



















































































































































































































































































































































d) Phase II, Imputation 3 (n=82). Four-cluster solution 
 
e) Phase II, Imputation 4 (n=82). Three-cluster solution 
 




After determining the most appropriate numbers of clusters for each dataset, the next step was to 
explore the cognitive profiles of the patients in the large subject-cluster, and then to compare them 
to the profiles of the patients in the smaller subject-clusters. 
 
Table 13. Frequencies (%) of patients failing each test in each subject-cluster at phase II 
a) Phase II Complete Case analysis (n=61) 





























































































                                    
C1 45 11 4 13 9 16 27 31 7 9 9 4 11 4 16 9 4 
C2 16 100 88 88 31 13 
10
0 
88 6 31 44 50 38 25 31 25 0 
                 
 
b) Phase II Imputation 1 (n=82) 
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86 91 48 29 
10
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86 24 38 48 53 43 29 34 34 0 





c) Phase II Imputation 2 (n=82) 





























































































                                    
C1 61 16 5 16 10 15 36 38 10 11 16 7 15 8 18 10 3 
C2 21 100 86 90 43 29 
10
0 
90 24 38 48 43 43 29 33 33 0 
                 
d) Phase II Imputation 3 (n=82) 































































































                                    
C1 61 18 5 16 8 11 38 39 10 10 16 8 13 8 15 8 3 
C2 16 100 94 94 31 13 
10
0 
94 19 25 38 31 38 31 19 19 0 































Average                 
C2-
4 
21 95 86 86 43 24 95 86 24 43 48 38 48 28 38 38 0 
                 
e) Phase II Imputation 4 (n=82) 






























































































                                    
C1 60 17 5 15 10 13 35 37 10 12 17 5 15 7 18 10 3 
C2 21 95 86 90 43 19 
10
0 
90 19 33 43 43 38 29 29 29 0 






















Average                 
C2-
3 
22 91 82 90 41 18 
10
0 
90 18 36 46 46 41 32 32 32 0 
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e) Phase II Imputation 5 (n=82) 































































































                                    











83 17 67 50 67 83 33 67 100 0 
                 
Table 13 shows that at phase II the participants again could be split into two groups based on their 
cognitive profiles. The first larger cluster with three quarters of patients showed multifocal widely 
distributed deficits. However, the remaining patients in other clusters exhibited a more progressive 
cognitive impairment, with deficits in verbal memory and processing speed being most 
predominant. 
 
As it can be noted from the Table 13, at phase II the patients could be grouped into two distinct 
groups. The larger cluster that contained approximately three quarters of the patients was similar to 
the larger group at phase I – it included patients with widely distributed impairments without a 
coherent pattern. However, what was different at phase II from phase I, was that at phase II the 
second largest cluster could be clearly defined by problems with verbal memory (SRT) and 
information processing speed (SDMT and PASAT) with or without additional problems. It appears 
that in the three years between phase I and phase II assessments the sample had become more 
homogeneous. It had formed into two groups of patients, those with mild scattered impairments, and 
those with a more progressive pattern. This profile was consistent among all datasets – the complete 
cases and all five MIs. 
Although in phase I the more progressive clusters grouped together deficits on many domains, at 
phase II the more progressive patients were more homogeneous, with major problems settling on 





Table 14. MS types in each subject-cluster at phase II (n=82) 




MS Types Size 
(n)  
MS Types 
     
Complete case 
analysis (n=61) 
45 29% PPMS, 16% SPMS, 
55% RRMS 
16 19% PPMS, 56% SPMS, 
25% RRMS 
Imputation 1 61 26% PPMS, 21% SPMS, 
52% RRMS 
21 14% PPMS, 71% SPMS, 
14% RRMS 
Imputation 2 61 26% PPMS, 21% SPMS, 
52% RRMS 
21 14% PPMS, 71% SPMS, 
14% RRMS 
Imputation 3 61 25% PPMS, 21% SPMS, 
54% RRMS 
21 19% PPMS, 71% SPMS, 
10% RRMS 
Imputation 4 60 27% PPMS, 20% SPMS, 
53% RRMS 
22 14% PPMS, 71% SPMS, 
14% RRMS 
Imputation 5 76 25% PPMS, 29% SPMS, 
46% RRMS 
6  100% SPMS 
Table 14 shows that the more impaired on memory and processing speed were mainly SPMS 
patients 
Abbreviations: PPMS – Primary Progressive MS, SPMS – Secondary Progressive MS, RRMS – 
Relapsing-Remitting MS 
 
As it can be seen from Table 14, the more impaired memory and processing speed group were mainly 
comprised of SPMS patients, with their cognitive profile more indicative of progressive disease 
course. 
3.5.3. Subject-clusters of the trajectory of longitudinal change  
As it can be seen from the analyses in section 3.5.1. and section 3.5.2. earlier in this appendix, the 
cluster analyses have yielded slightly different results when employed at phase I and at phase II. This 
was consistent across all datasets (complete cases and the five MIs). This has allowed to assume that 
there have been time-related changes in the dimensionality of the study population. To address this 
in the following section the temporal changes in MS-related cognitive deficits were examined by 
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using the cluster analysis to group the patients based on the trajectory of their longitudinal changes. 
This was carried out to identify individuals whose individual cognitive deficits have progressed, 
remained the same, or improved over the period of three years.  
As it can be seen from Table 15, each dataset (complete cases and the five MIs) has yielded a different 
grouping solution. Depending on the dataset, the numbers of groups have varied between four and 
fourteen. This indicated that the subject-clustering solutions provided by the longitudinal analysis 
were not robust, and should be interpreted with caution. 
Moreover, the Calinski-Harabasz pseudo-F indexes were very similar for all subject-cluster solutions 
in all datasets, most of them were around 3 or 4 in values; when in comparison to phase II, where 
these indexes were 5 to 23. Since the differences between Calinski-Harabasz Pseudo-F indexes were 
so minimal, this has again showed that the results from the subject-clustering solutions of 




Table 15. Determination of the optimal number of clusters in the hierarchical cluster analysis of 
longitudinal change in their performance between phases I and II (n=82) 

















        
2  
2.4 
2.98 2.28 2.63 3.59 2.39 
3  4.06 3.48 3.13 2.37 2.90 3.19 
4  4.23 4.42 3.52 2.96 3.37 3.49 
5  3.66 3.74 3.21 3.56 3.88 3.63 
6  4.22 3.99 2.91 3.60 3.88 3.59 
7  3.84 3.88 3.66 4.14 3.63 3.98 
8  3.63 3.66 3.63 3.80 3.38 3.69 
9  3.83 4.08 3.47 3.59 3.68 3.53 
10  3.61 3.84 3.70 3.80 3.47 3.68 
11  3.65 3.92 3.67 3.76 3.84 3.50 
12  3.52 3.79 3.73 3.59 3.92 3.34 
13  3.46 3.61 3.55 3.96 3.73 3.56 
14  3.41 3.48 3.78 3.64 3.62 3.41 
15  - 3.73 3.69 3.58 3.86 3.67 
        
Table 15 shows that there was no consensus among the datasets for the optimum number of 
subject-clusters. Depending on a dataset (complete cases or the five MIs) the number of clusters 




Table 16. Number of individuals in each subject-cluster solution at phase II 













        
C1  54 (89%) 72 (88%) 55 (67%) 67 (82%) 58 (71%) 67 (82%) 
C2  3 (5%) 6 (7%) 4 (5%) 5 (6%) 3 (4%) 3 (4%) 
C3  3 (5%) 3 (4%) 3 (4%) 2 (2%) 5 (6%) 2 (2%) 
C4  1 (2%) 1 (1%) 2 (3%) 3 (4%) 1 (1%) 3 (4%) 
C5    4 (5%) 3 (4%) 3 (4%) 3 (4%) 
C6    1 (1%) 1 (1%) 1 (1%) 3 (4%) 
C7    3 (4%) 1 (1%) 2 (2%) 1 (1%) 
C8    3 (4%)  3 (4%)  
C9    1 (1%)  2 (2%)  
C10    1 (1%)  1 (1%)  
C11    1 (1%)  1 (1%)  
C12    1 (1%)  2 (2%)  
C13    2 (2%)    
C14    1 (1%)    
        
Table 16 showed that in all datasets Cluster One had grouped the majority of participants, with 






Figure 7. Dendrograms of hierarchical cluster analysis model of longitudinal trajectories of change 
in patient performance on cognitive tests between phases I and II (n=82).  
a) Longitudinal Change, Complete Case Analysis (n=61). Four-cluster solution 
 
b) Longitudinal Change, Imputation 1. Four-cluster solution 
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d) Longitudinal Change, Imputation 3. Seven-cluster solution 
 
e) Longitudinal Change, Imputation 4. Twelve-cluster solution 
 





In all datasets (complete cases and five MIs) there was a clear one large cluster with the majority of 
patients. This large subject-cluster has grouped together the patients that had mostly unchanged, with 
similar frequencies of resolved impairments and new impairments on all cognitive tests (Table 17). 
However, in the smaller clusters a shift could be observed towards acquiring more new impairments 
and much less resolved impairments, indicative of a faster and more progressive cognitive 
deterioration. The emerging impairments were most evident on the verbal memory (SRT) and 
information processing speed items (SPART and PASAT), and could also be seen, but to a lesser 
extent on some of the visuoperceptual items. This pattern was consistent across all datasets of 
longitudinal change. Therefore to show this contrast in further analyses all the smaller clusters were 
merged into one in order to contrast them to the largest C1 in each dataset. After investigating the 
patterns of longitudinal changes of the patients in the many small clusters, no clear differences were 




Table 17. Neuropsychological characteristics for the subject-cluster solutions for longitudinal 
change for each dataset. Frequencies (%) of three different trajectories of change on the cognitive 
tests are presented 
a) Complete Case Analysis (n=61). Four-cluster Solution 
  Cluster One (n=54)  Other Clusters (n=7) 








         
SRTL  13 78 9  0 29 71 
SRTC  11 87 2  0 29 71 
SRTD  17 79 4  0 29 71 
SPART  6 88 6  0 71 29 
SPARTD  7 84 9  0 100 0 
SDMT  2 81 17  0 57 43 
PASAT  0 69 31  0 43 57 
WLGT  15 79 6  43 57 0 
VOSP2  4 87 9  0 71 29 
VOSP3  7 84 9  0 71 29 
VOSP6  24 70 6  14 29 57 
VOSP8  13 74 13  14 43 43 
BORB2  6 90 4  14 57 29 
BORB5  0 87 13  0 71 14 
TROG  9 91 0  0 57 43 
BC. 
Index 
 33 63 4  0 86 0 





b) Imputation 1 (n=82). Four-cluster Solution 
  Cluster One (n=72)  Other Clusters (n=10) 








         
SRTL  13 79 8  10 40 50 
SRTC  15 82 3  10 30 60 
SRTD  17 81 3  0 40 60 
SPART  6 83 11  10 60 30 
SPARTD  7 82 11  0 80 20 
SDMT  1 79 19  10 60 30 
PASAT  0 65 35  0 10 90 
WLGT  12 78 10  30 70 0 
VOSP2  3 83 14  0 80 20 
VOSP3  7 78 15  0 70 30 
VOSP6  22 74 4  30 20 50 
VOSP8  11 71 18  20 60 20 
BORB2  8 85 7  20 50 30 
BORB5  0 86 14  20 70 10 
TROG  10 87 3  0 60 40 
BC. 
Index 
 33 64 3  20 80 0 





c) Imputation 2 (n=82). Fourteen-cluster solution.  
  Cluster One (n=55)  Other Clusters (n=27) 








         
SRTL  9 86 6  18 52 30 
SRTC  9 87 4  26 52 22 
SRTD  11 85 4  26 52 22 
SPART  7 86 7  4 74 22 
SPARTD  7 82 11  4 81 15 
SDMT  2 82 16  0 74 26 
PASAT  0 75 25  0 18 82 
WLGT  5 84 11  33 63 4 
VOSP2  4 89 7  0 67 33 
VOSP3  0 85 15  18 67 15 
VOSP6  24 73 4  30 48 22 
VOSP8  13 82 5  11 48 41 
BORB2  4 91 5  26 56 18 
BORB5  0 89 11  4 70 26 
TROG  7 93 0  11 70 19 
BC. 
Index 
 25 73 2  41 55 4 





d) Imputation 3 (n=82). Seven-cluster solution 
  Cluster One (n=67)  Other Clusters (n=15) 








         
SRTL  10 81 9  27 40 33 
SRTC  15 82 3  20 40 40 
SRTD  18 78 4  7 60 33 
SPART  7 85 7  7 60 33 
SPARTD  9 82 9  0 87 13 
SDMT  1 81 18  0 73 27 
PASAT  0 66 34  0 20 80 
WLGT  10 81 9  33 60 7 
VOSP2  3 87 10  7 60 33 
VOSP3  4 81 15  13 67 20 
VOSP6  22 72 6  40 33 27 
VOSP8  12 78 10  13 40 47 
BORB2  4 88 8  33 47 20 
BORB5  0 87 13  13 67 20 
TROG  7 91 2  20 53 27 
BC. 
Index 
 30 69 1  20 73 7 





e) Imputation 4 (n=82). Twelve-cluster solution 
  Cluster One (n=58)  Other Clusters (n=24) 








         
SRTL  5 88 7  33 38 29 
SRTC  5 91 3  38 38 25 
SRTD  7 88 5  33 46 21 
SPART  5 86 9  12 63 25 
SPARTD  5 86 9  12 75 12 
SDMT  2 77 21  4 75 21 
PASAT  0 64 36  0 33 67 
WLGT  10 79 10  25 71 4 
VOSP2  3 88 9  0 67 33 
VOSP3  3 83 14  12 67 21 
VOSP6  24 69 7  25 58 17 
VOSP8  12 81 7  12 46 42 
BORB2  3 93 3  21 54 25 
BORB5  0 90 10  4 71 25 
TROG  7 93 0  12 67 21 
BC.Index  31 67 2  29 67 4 





f) Imputation 5 (n=82). Seven-cluster solution 
  Cluster One (n=67)  Other Clusters (n=15) 








         
SRTL  10 81 9  27 40 33 
SRTC  12 85 3  27 33 40 
SRTD  15 81 4  20 47 33 
SPART  6 85 9  13 6 27 
SPARTD  6 81 13  13 80 7 
SDMT  2 79 19  7 73 20 
PASAT  0 64 36  0 20 80 
WLGT  10 79 10  33 67 0 
VOSP2  3 85 12  7 67 27 
VOSP3  5 82 13  13 67 20 
VOSP6  22 72 6  33 40 27 
VOSP8  12 78 10  13 33 53 
BORB2  7 87 6  20 60 20 
BORB5  0 87 14  7 73 20 
TROG  7 91 1  3 53 33 
BC.Index  36 63 1  13 80 7 
         
Table 17 showed that in all longitudinal datasets (complete cases and five MI) the profile for change 
of individuals in the large cluster was sporadic. However, the other participants that fell into the 
remaining three to thirteen subject-clusters, exhibited a more progressive accumulation of new 
impairments, mainly on the information processing speed items. 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – Delayed Retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART– items correct at learning 
stage, SPARTD– items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – Position of 
Gap Matching Task, TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – 




Table 18. Clinical characteristics in each subject-cluster of longitudinal change (n=82) 
 ‘Multifocal’ change 
cluster (C1) 





Types Size (n)  Types  
      
Complete case 
analysis (n=61) 
54 29% PPMS, 17% 
SPMS, 54% 
RRMS 
7 100% SPMS X2 = 18.89,  
p < 0.001 
Imputation 1 72 26% PPMS, 26% 
SPMS, 47% 
RRMS 
10 90% SPMS, 10% 
RRMS 
X2 = 15.89,  
p < 0.001 
Imputation 2 55 29% PPMS, 22% 
SPMS, 49% 
RRMS 
27 11% PPMS, 59% 
SPMS, 23% 
RRMS 
X2 = 11.57, 
p = 0.003 
Imputation 3 67 27% PPMS, 27% 
SPMS, 46% 
RRMS 
15 7% PPMS, 67% 
SPMS, 27% 
RRMS 
X2 = 8.95,  
p = 0.011 
Imputation 4 58 26% PPMS, 21% 
SPMS, 53% 
RRMS 
24 17% PPMS, 67% 
SPMS, 17% 
RRMS 
X2 = 16.51,  
p < 0.001 
Imputation 5 67 27% PPMS, 24% 
SPMS, 49% 
RRMS 
15 7% PPMS, 80% 
SPMS, 13% 
RRMS 
X2 = 17.17, p 
< 0.001 
       
Table 18 showed that the smaller clusters contained much more patients with SPMS 
Note. The comparison of frequencies was done with Pearson Chi-Square test 






After comparing the two groups of patients (large relatively unchanged Cluster One and the 
remaining clusters with pwMS that deteriorated), it was found that those who have deteriorated had 
predominantly SPMS course (Table 18). These individuals were also older, had longer disease 
duration, more neurological disability, higher levels of depression and disease impact; but none of 
those differences reached statistical significance. Therefore it can be concluded that the main factor 
which has caused progression of cognitive symptoms and new deficit acquirement was the MS course. 
However, since the clustering solutions in this instance were not robust, the dimensionality of the 
datasets of longitudinal change should be interpreted with caution. 
3.5.4. Dimensionality of the study population. Summary 
In the second half of this appendix the dimensionality of the study cohort was investigated by using 
the cluster analysis method. It was found that the study population had a tendency to become more 
homogeneous over time, emphasizing the differences between the more progressive MS course. 
At phase I around half of patients had multifocal impairments, and half exhibited a pattern of more 
pronounced verbal memory and visual information processing speed impairments. At phase II the 
more progressive patients had developed more deficits on the information processing speed tasks. 
From analysing the datasets of longitudinal change it can be seen that the newly emerging deficits 
were mainly in the information processing speed domain, and had affected predominantly the SPMS 
patients. However, since the clustering solutions hadn’t been robust, these findings should be 
interpreted with caution. 
3.6.   Section summary 
The analyses with multiple imputation (MI) presented in this appendix have supported the complete 
cases analyses performed in Chapter Five.  
In this appendix it was found that both the analyses of the dimensionality of cognitive impairments 
in pwMS, and the analyses of the dimensionality of the study cohort, have yielded similar results for 
the complete cases and the MI datasets. This has shown that the findings presented in Chapter Five 
were robust and that the conclusions drawn about the dimensionality of cognitive impairments in MS 
had not been specific only to the subgroup of patients who had complete data. 
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However, it should be noted that the MI technique has helped us identify three additional patients 
with more severe global impairments among those with missing data who had been previously 
excluded from the complete cases analysis. This indicated that those individuals had initially been 
excluded because their missing data was caused by their advanced MS, which, besides motor 
symptoms, had also included the more advanced cognitive symptoms. We acknowledge that these 
three individuals with severe MS had been underrepresented in the Chapter Five analyses, however, 
they were rare cases which explained less than 4% of the total variance, and did not affect the overall 
results. 
Rerunning the Chapter Five analyses on the five MI datasets has shown that the clustering solutions 
were the most robust for the phase II datasets. Due to the lack of clear numbers of clustering solutions, 
the clustering patterns for phase I and for longitudinal data were explained better once the large 
clusters with the majority of patients were contrasted against the many small clusters. The small 
clusters had included the patients whose cognitive symptoms were more progressive, and most 
commonly the progression was expressed by worsening verbal memory and information processing 
speed, and to a lesser extent by worsening visuoperceptual functions. The observed associations 
between SPMS course and developing deficits in the information processing speed and memory 







Appendix F. Distributions of performance scores at phases I and II 
 
Figure 1. The distribution of controls’ performance scores on each item at phases I and II 
 



















































Note. The solid line represents distribution of scores at phase I and the dashed line represents 
distribution of scores at phase II. 
 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – Delayed Retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART– items correct at learning 
stage, SPARTD– items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – Position of 
Gap Matching Task, TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – 





Table 1. Comparisons of distribution of controls’ scores on cognitive tests between phase I and 
phase II.  
 
Cognitive test Difference between score distributions 
SRTL (N=23) D = 0.174, p = 0.877 
SRTC (N=23) D = 0.13, p = 0.99 
SRTD (N=23) D = 0.217, p = 0.649 
SPART (N=17) D = 0.235, p = 0.734 
SPARTD (N=23) D = 0.391, p = 0.059 
SDMT (N=22) D = 0.273, p = 0.386 
PASAT (N=22) D = 0.182, p = 0.86 
WLGT (N=23) D = 0.348, p = 0.124 
VOSP2 (N=23) D = 0.348, p = 0.124 
VOSP3 (N=23) D = 0.087, p = 0.999 
VOSP6 (N=23) D = 0.652, p < 0.001*** 
VOSP8 (N=23) D = 0.217, p = 0.649 
BORB2 (N=23) D = 0.13, p = 0.99 
BORB5 (N=23) D = 0.358, p = 0.124 
TROG (N=21) D = 0.19, p = 0.841 
BC.Index (N=22) D = 0.591, p < 0.001 *** 
Note. Comparisons were performed using 2-sample Kolmogorov – Smirnov test, 2-sided 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – Delayed Retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART– items correct at learning 
stage, SPARTD– items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – Position of 
Gap Matching Task, TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – 






Figure 2. The distributions of patients’ scores on each test item at phases I and II 
 


















































Note. The solid line represents distribution of scores at phase I and the dashed line represents 
distribution of scores at phase II. 
 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – Delayed Retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART– items correct at learning 
stage, SPARTD– items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – Position of 
Gap Matching Task, TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – 
Index of ratio of picture variables to number of words). 
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Table 2. Comparisons of distributions of patient scores on cognitive tests between phase I and 
phase II  
 
Cognitive test Difference between score distributions 
SRTL (N=80) D = 0.099, p = 0.824 
SRTC (N=80) D = 0.136, p = 0.444 
SRTD (N=80) D = 0.074, p = 0.979 
SPART (N=75) D = 0.16, p = 0.292 
SPARTD (N=77) D = 0.143, p = 0.412 
SDMT (N=79) D = 0.114, p = 0.684 
PASAT (N=80) D = 0.15, p = 0.329 
WLGT (N=82) D = 0.098, p = 0.83 
VOSP2 (N=80) D = 0.137, p = 0.436 
VOSP3(N=80) D = 0.175, p = 0.172 
VOSP6 (N=78) D = 0.603, p < 0.001 *** 
VOSP8 (N=81) D = 0.225, p = 0.035 * 
BORB2 (N=79) D = 0.025, = 0.999 
BORB5 (N=77) D = 0.117, p = 0.669 
TROG (N=79) D = 0.038, p = 0.999 
BC.Index (N=69) D = 0.174, p = 0.248 
Note. The comparisons were performed with 2-sample Kolmogorov – Smirnov test, 2-sided 
Abbreviations: SRT – Selective Reminding Test (SRTL – Long Term Storage, SRTC – Consistent Long 
Term Retrieval, SRTD – Delayed Retrieval), SDMT – Symbol Digits Modalities Test, PASAT – Paced 
Auditory Serial Addition Test, SPART – 10/36 Spatial Recall Test (SPART– items correct at learning 
stage, SPARTD– items correct at delayed recall), WLGT – Category Animal Fluency task, VOSP – 
Visual Object and Space Perception Battery (VOSP2 – Silhouette Naming Task, VOSP3 – Object 
Decision Task, VOSP6 – Position Discrimination Task, VOSP8 – Cube Counting Task,) BORB – 
Birmingham Object Recognition Battery (BORB2 – Line Length Matching Task, BORB5 – Position of 
Gap Matching Task, TROG – Test of Reception of Grammar, BC – Boston Cookie Test (BC.Index – 




Appendix G. Standardized scores of longitudinal change 
Table 1. Averaged z-scores of individual patient (n=61) change for each domain 
 
Averaged z-score Definition 
> 3 great improvement 
1.5 to 3 moderate improvement 
0.5 to 1.5 mild improvement 
-0.5 to 0.5 No change 
-1.5 to -0.5 mild deterioration 
-3 to -1.5 moderate deterioration 
< -3 severe deterioration 
 
ID Verbal memory Visuospatial memory Processing speed Visuoperceptual Language 
1 -0.13 -0.11 -0.38 0.22 0.74 
2 0.52 -0.62 -2.11 -0.95 0.74 
3 0.24 -1.01 -1.51 -1.7 -0.68 
4 0.5 -0.23 -0.35 -0.32 1.68 
5 1.17 -0.1 -0.04 -0.38 1.2 
6 -1.49 -1.26 0.5 0.38 0.74 
7 1.57 2.11 -0.55 -0.59 1.21 
8 -0.36 -0.61 -0.6 0.02 2.16 
9 -1.71 -2.3 -1.34 0.18 1.2 
10 -2.57 -0.48 -2.55 -0.44 0.73 
11 0.01 0.81 -0.35 -0.42 1.68 
12 -1.07 -0.36 0.09 -0.43 0.26 
13 2.16 0.03 -0.64 -0.21 0.26 
14 0.77 0.15 -1.06 -0.19 1.66 
15 -1.27 0.68 -1.82 0.23 2.61 
16 0.13 -1.4 -4.1 -0.58 -0.21 
17 0.16 -1.01 -0.65 -0.25 0.73 
18 -0.22 0.81 0.4 0.02 1.2 
19 -0.38 -0.36 -0.62 0.35 0.72 
20 0.47 -1.28 0.46 0.19 0.25 
21 0.63 0.81 -0.89 0.03 1.19 
22 1.05 -0.23 1.1 0.83 2.61 
23 1.63 -2.57 -1.07 0.94 0.73 
24 -0.08 -1.4 -1.34 0.63 -0.65 
25 0.31 0.04 -0.82 0.78 1.2 
26 1.72 1.19 0.25 -0.03 1.68 
27 0.3 0.95 0.93 0.52 1.21 
28 -0.1 1.07 -1.36 0.14 1.67 
29 -0.86 -1.53 -1.73 0.38 -0.19 




  Verbal memory Visuospatial memory Processing speed Visuoperceptual Language 
31 -1.37 1.07 0.07 0.51 0.74 
32 -0.12 -0.48 -0.17 -0.33 0.74 
33 -0.48 -1.01 -0.14 -0.63 1.2 
34 0.01 -1.52 -0.32 -0.32 0.73 
35 -0.3 0.56 -0.57 -0.67 0.74 
36 0.03 -1.79 -0.99 0.02 0.75 
37 0.49 0.04 -0.22 0.31 0.74 
38 1.52 0.03 0.84 -0.2 0.27 
39 2.14 0.03 0.41 1.03 -0.21 
40 1.14 1.07 -0.19 -0.6 1.22 
41 -0.84 -1.91 0.27 0.16 -2.57 
42 0.24 1.08 -1.93 -1.69 0.72 
43 -0.37 -2.18 -0.43 -0.18 0.25 
44 -0.09 0.42 -0.07 -0.29 1.2 
45 -1.65 2.23 -1.31 0.66 -0.67 
46 -1.94 -0.36 0.49 -1.59 0.73 
47 0.42 -0.23 0.04 -0.52 2.6 
48 0.43 -0.1 -1.51 0.82 0.72 
49 -0.55 -0.36 -1.02 -1.73 0.25 
50 0.32 -1.53 -2.03 -1.47 -0.22 
51 1.79 -0.23 -0.64 0.24 0.72 
52 -0.52 0.28 -0.71 -0.48 1.2 
53 0.39 0.03 0.43 -2.41 1.68 
54 -0.72 -1.14 -0.51 -0.83 -1.63 
55 0.44 0.69 -0.96 -0.32 -0.22 
56 -0.31 -1.66 -0.49 -1.7 2.62 
57 2.43 0.42 0.4 -0.02 0.27 
58 2.8 1.19 -0.69 0.91 0.71 
59 0.51 -1.4 0.41 0.4 0.75 
60 2.67 0.55 0.56 0.53 0.74 







Appendix H. Standardized scores of actual change, and scores of 
perceived change for each individual 
Table 1. Patient (n=61) actual and perceived change for each group of cognitive tests  
Averaged z-score Definition 
> 3 great improvement 
1.5 to 3 moderate improvement 
0.5 to 1.5 mild improvement 
-0.5 to 0.5 No change 
-1.5 to -0.5 mild deterioration 
-3 to -1.5 moderate deterioration 
< -3 severe deterioration 
 
  Actual change (z-scores) Perceived change (%) 
ID BRBN battery Visuoperceptual Language BRBN battery Visuoperceptual Language 
1 -0.21 0.22 0.74 -15 0 0 
2 -0.74 -0.95 0.74 -50 -15 -5 
3 -0.76 -1.7 -0.68 -50 -27 -30 
4 -0.03 -0.32 1.68 0 0 -10 
5 0.34 -0.38 1.2 -5 -10 -10 
6 -0.75 0.38 0.74 -25 0 -5 
7 1.04 -0.59 1.21 -5 -5 5 
8 -0.52 0.02 2.16 -10 -10 0 
9 -1.78 0.18 1.2 -20 0 -5 
10 -1.87 -0.44 0.73 -27 -30 -15 
11 0.16 -0.42 1.68 -5 -5 -5 
12 -0.45 -0.43 0.26 10 10 0 
13 0.52 -0.21 0.26 -15 -20 0 
14 -0.05 -0.19 1.66 -10 -30 0 
15 -0.8 0.23 2.61 -45 15 10 
16 -1.79 -0.58 -0.21 -20 -15 0 
17 -0.5 -0.25 0.73 0 -10 0 
18 0.33 0.02 1.2 -5 -20 0 
19 -0.45 0.35 0.72 -25 -5 -10 
20 -0.12 0.19 0.25 -10 -10 0 
21 0.18 0.03 1.19 -10 -5 0 
22 0.64 0.83 2.61 -10 5 0 
23 -0.67 0.94 0.73 -10 0 -10 
24 -0.94 0.63 -0.65 -20 -5 0 




  Actual change Perceived change 
ID BRBN battery Visuoperceptual Language BRBN battery Visuoperceptual Language 
26 1.05 -0.03 1.68 0 -10 0 
27 0.73 0.52 1.21 20 0 0 
28 -0.13 0.14 1.67 -25 -30 -40 
29 -1.37 0.38 -0.19 -10 0 0 
30 -0.79 0.33 1.68 -10 0 0 
31 -0.08 0.51 0.74 -5 -10 0 
32 -0.26 -0.33 0.74 -8 0 0 
33 -0.54 -0.63 1.2 0 0 0 
34 -0.61 -0.32 0.73 -15 0 0 
35 -0.1 -0.67 0.74 0 15 -5 
36 -0.92 0.02 0.75 0 -5 0 
37 0.1 0.31 0.74 -20 0 0 
38 0.8 -0.2 0.27 -20 0 -10 
39 0.86 1.03 -0.21 -8 -15 0 
40 0.67 -0.6 1.22 -10 -5 5 
41 -0.83 0.16 -2.57 -30 -25 -10 
42 -0.2 -1.69 0.72 -40 -20 30 
43 -0.99 -0.18 0.25 -20 10 0 
44 0.09 -0.29 1.2 -5 0 0 
45 -0.24 0.66 -0.67 -10 -25 -5 
46 -0.6 -1.59 0.73 -5 0 0 
47 0.08 -0.52 2.6 0 -10 -10 
48 -0.39 0.82 0.72 -5 -5 0 
49 -0.64 -1.73 0.25 -20 0 -10 
50 -1.08 -1.47 -0.22 -35 -9 -7 
51 0.31 0.24 0.72 -5 0 0 
52 -0.32 -0.48 1.2 -35 0 25 
53 0.28 -2.41 1.68 -30 -15 0 
54 -0.79 -0.83 -1.63 0 -10 0 
55 0.06 -0.32 -0.22 0 0 0 
56 -0.82 -1.7 2.62 -20 -15 0 
57 1.08 -0.02 0.27 0 0 0 
58 1.1 0.91 0.71 0 -10 0 
59 -0.16 0.4 0.75 -10 0 0 
60 1.26 0.53 0.74 10 -20 0 
61 0.6 -1.24 0.73 -25 -15 -25 
 
Note. The actual change is presented in standardized scores. Positive values of perceived change 
indicate perceived improvement, negative values indicate perceived deterioration, and values 
around 0 indicate perceived stability of cognitive function. 
Abbreviations: BRBN – Brief-Repeatable Battery of Neuropsychological tests. 
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Table 2. Control (n=15) actual and perceived change for each group of cognitive tests  
Averaged z-score Definition 
> 3 great improvement 
1.5 to 3 moderate improvement 
0.5 to 1.5 mild improvement 
-0.5 to 0.5 No change 
-1.5 to -0.5 mild deterioration 
-3 to -1.5 moderate deterioration 
< -3 severe deterioration 
 
  Actual change Perceived change 
Case BRBN battery Visuoperceptual Language BRBN battery Visuoperceptual Language 
1 0.29 -0.37 -0.02 10 0 7 
2 0.32 -0.68 -0.56 5 0 0 
3 0.55 -0.08 -0.46 -50 -10 0 
4 0.3 0.02 -0.53 0 0 0 
5 0.11 -1.07 -0.61 -20 0 -10 
6 -0.22 -0.33 -0.23 -25 5 -5 
7 0.13 0.21 1.14 -30 -10 -10 
8 -0.26 1.02 -0.14 -10 0 0 
9 0.51 0.11 1.15 -38 0 7 
10 -0.12 -0.41 0.2 -28 10 10 
11 0.16 0.19 -1.59 0 0 5 
12 -0.21 -0.34 0.83 0 0 -5 
13 0.3 0.44 1.06 7 1 2 
14 0.06 0.09 -0.48 0 0 0 
15 -0.64 -0.25 0.76 -27 -27 -7 
Note. The actual change is presented in standardized scores. Positive values of perceived change 
indicate perceived improvement, negative values indicate perceived deterioration, and values 
around 0 indicate perceived stability of cognitive function. 






Appendix I. Awareness of cognitive deficits in pwMS 
 
1. Section Aim 
The aim of the following insert was to rerun the Chapter Seven awareness analyses (section 7.3), but 
this time in search for cross-sectional differences in awareness of cognitive difficulties on the data at 
phase II, instead of focusing on self-perception of longitudinal change. 
This supplementary analysis investigated the relationships between actual cognitive performance and 
the patients’ own perception of how they performed on the cognitive tests at phase II. The separate 
but linked analysis revolved around investigation of the factors that may help explain the 
discrepancies between the actual and perceived cognitive deficits. The supplementary analyses 
performed in this insert were designed to yield a better understanding of whether the patients had 
been accurate in estimating their performance, and whether they had been capable to make 
assumptions about the amount of perceived longitudinal change. 
2. Methods 
2.1.   Participants 
For all cross-sectional analyses in this section only the participants with full data on all cognitive 
assessments at phase II were chosen to employ, the reason behind it was that the self-evaluation data 
had been collected only at phase II. By restricting the analyses to participants with full data at phase 
II it was controlled that all participants had gone through the exactly same tests and therefore 
provided their self-estimates of cognitive performance for the same assessments.  
Therefore for all of the cross-sectional analyses of the actual and the perceived performance, the 
scores of 63 patients and 23 controls were employed. For further analyses to investigate the predictors 




2.2.   Data format 
2.2.1. Actual performance at phase II 
The scores of actual performance at phase II were all converted to percentages. For the tests where 
the maximum value was unknown (SDMT, WLGT and BC.Index), the highest value from the control 
and patient samples was used to create the 100% score. The percentage values were calculated 
separately by averaging the scores of the component tests for each of these groups of tests: the BRBN 
battery, visuoperceptual and language tests.  
2.2.2. Perceived performance 
The estimates of perceived performance at phase II were collected on three groups of cognitive tests: 
the BRBN battery, and the visuoperceptual and language tests. Higher self-reported values indicated 
better perceived performance and the range of estimations at phase II was on a scale from 0 to 100. 
2.3.       Group differences in performance at phase II 
The scores of actual performance at phase II were converted to percentages and were then compared 
between the patient and control participants with the aim of investigating any differences that could 
be found between the patients and controls in how well they had performed at phase II on the three 
groups of cognitive tests. All comparisons were performed with the Mann-Whitney U-test. The 
dependent variables were the percentage scores of actual performance on the BRBN tests, the 
visuoperceptual tests and the language tests; and the independent variable was being a patient or a 
control. 
As a next step the actual performance at phase II on the three groups of tests was also compared for 
the patient and control samples separately. The aim of this analysis was to investigate whether there 
had been differences in actual performance between the three groups of tests. Namely, this way it 
was tested whether the participants had performed on some groups of tests better than on others. 
Those analyses were performed with the Related-Samples Friedman’s analysis of variance by ranks, 
first for the patient participants, then separately for the control participants. 
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2.4.       Group differences in perceived performance at phase II 
After analyzing the actual performance, the next step was to investigate whether there have been 
differences between the self-perceptions of performance at phase II. The analyses of perceived 
performance were conducted in the same manner as the analyses of actual performance, but this time 
the percentage of perceived rather than actual performance was analysed. 
First the self-estimates of performance at phase II between the patient and control participants were 
compared. It was done to investigate whether there wed been any differences between the patients 
and the controls in how well they thought that they had performed at phase II. The performance of 
the patients and the controls on all three groups of cognitive tests was compared using the Mann-
Whitney U-test. The dependent variables were the scores of perceived performance at phase II on 
the BRBN tests, visuoperceptual and language tests; and the independent variable was being a patient 
or a control. 
The perceived performance on the three groups of cognitive tests at phase II was also compared for 
the patient and control samples separately. This was done in order to investigate whether there had 
been any differences in the perceived performance between the three groups of cognitive tests at 
phase II. These analyses were performed with the Related-Samples Friedman’s analysis of variance 
by ranks twice, first for the patient participants, and then separately for the controls. 
2.5.      Relationship between the actual and the perceived performance at phase II 
Having analysed the actual performance and the perceived performance at phase II separately, the 
next step was to investigate the relationship between them. These analyses aimed to answer the 
question whether the participants were correct in estimating their own performance. This was done 
separately for each group of cognitive tests in both patients and controls. 
In the first set of analyses it was investigated how correct the participants were in estimating their 
performance. This was done by comparing the estimated performance to their actual performance 
using the Related Samples Wilcoxon Signed Rank Test.  
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In the second set of analyses we aimed to investigate the extent to which the actual and the perceived 
performance have been associated. It was chosen to run multiple correlations between the measures 
of actual and perceived performance. Spearman correlation was employed due to non-parametric 
distributions of both the actual and perceived scores in the patient and control cohorts. 
2.6.     Predictors of perceived performance 
The next step was to investigate the factors considered to be related to self-perception of cognitive 
performance at phase II in the patient population. The following multiple linear regression model for 
the patient participants was devised: 
Self-evaluation of cognitive performance = α + β1 (depression score) + β2 (neurological disability 
score) + β3(MS impact score) 
The linear regression model predicted that lower self-evaluations would be associated with higher 
levels of depression, neurological disability and MS impact. It was anticipated that these models 
would have similar predictive values on all groups of cognitive tests. 
In this model the depression was measured with the BDI-II scale, the neurological disability was 
measured with the EDSS scale, and the MS impact was measured with the MSIS-29 scale. All data 





In this chapter the percentage scores on the individual BRBN, visuoperceptual and language tests 
were averaged to produce the average values of performance for each group of tests for both patient 
and control participants. 
Table 1. Descriptives of actual and perceived performance on the groups of cognitive tests for 
patient and control participants 
  Patients (n=63)  Controls (n=23) 








         
BRBN  57% (15.73)  45% (22.71)  73% (10.51)  58% (19.41) 
Visuoperceptual  87% (5.67)  62% (17.78)  90% (5.43)  72% (12.94) 
Language  74% (17.78)  72% (16.56)  72% (5.34)  79% (10.85) 
         
Abbreviations: BRBN – Brief-Repeatable Battery of Neuropsychological tests 
 
As it can be seen in Table 1, there had been few inaccuracies in estimating the performance at phase 
II. Overall there had been a tendency to underestimate the cognitive performance for both groups of 
participants. 
3.1.  Group differences in actual performance at phase II 
 
First the actual performance was compared between the patient and control participants on the three 
groups of cognitive tests. This was done to investigate whether there had been differences between 
the patients and controls in how they’ve performed on the tests at phase II.  
As it can be seen from Figure 1, the controls had performed statistically significantly better than the 
patients on the BRBN and visuoperceptual tests at phase II. However, there had been no differences 
between the groups on the language tests. On average, the patients and the controls had performed 
the same on the language tests at phase II, but there was a wider range of scores in the patient group, 
indicative of presence of both the patients who performed very well and those who performed poorly. 
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Figure 1. Comparison of performance percentages between control and patient participants for 
each group of cognitive tests at phase II 
Group of 
tests 
 Difference   
                                              Controls                Patients  










U = 285.00,  
p < 0.001 
   













U = 456.00, 
p = 0.009 
    









U = 935.00, 
p = 0.060 
   
 
Figure 1 shows that the controls have performed statistically significantly better on BRBN and 
visuoperceptual tests than patients. There was no significant difference in the performance on the 
language tests between the groups at phase II. 
Note. Group comparisons were performed using the Mann-Whitney U-test 







3.2.    Group differences in perceived performance at phase II 
As the next step the self-evaluations of performance on the tests at phase II were compared between 
the groups. This was done in order to investigate whether there had been any differences in how well 
the patients and controls had thought that they had performed at phase II.  
As it can be seen from Figure 2, on average the controls thought that they had performed better than 
the patients, and this difference was statistically significant only on BRBN and visuoperceptual tests. 
The same tendency was observed on the language tests, even though the group differences did not 




Figure 2. Comparison of self-estimates of perceived performance between control and patient 
















U = 476.00,  
p = 0.015 












U = 487.00, 
p = 0.020 











U = 533.00, 
p = 0.060 
   
 
Figure 2 shows that on average the controls thought that they had performed better than the 
patients, and this difference was statistically significant only on BRBN and visuoperceptual, but not 
the language tests. 
Note. Group comparisons were performed using the Mann-Whitney U-test 
Abbreviations: BRBN – Brief Repeatable Battery of Neuropsychological tests 
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3.3.   Relationship between the actual and the perceived performance at phase 
II 
 
Having analysed the actual performance and the perceived performance at phase II separately, the 
next step was to investigate the relationship between them. These analyses aimed to answer the 
question whether the participants were correct in estimating their own performance.  
3.3.1. Perceived and actual performance in the control sample 
As it can be seen from Figure 3, the controls had a tendency to evaluate their performance worse 
than it actually was, and this difference was statistically significant on the BRBN and visuoperceptual 
tests. This means that overall the controls had thought that they performed the tasks around 58% and 
72% correct, when in reality they were on average 73% and 90% correct (Table 1). 
However, on the language tests the difference took an opposite direction as the controls had thought 
that they had performed better than they actually had; although this discrepancy was less often 
observed than those on BRBN and visuoperceptual tests.  
Overall the controls had a tendency to underestimate their performance on the BRBN and 
visuoperceptual tests, but to overestimate on the language tests. 
As it can be seen from Figure 4, the performance scores were linked to self-evaluation scores only 
on the BRBN battery tests. This was indicative that the estimations of performance on 
visuoperceptual and language tests were not related to the actual performance in the control sample. 










Controls (n=23) Difference 












Z = 33.00,  













Z = 2.00,  











Z = 218.00, 
p = 0.015 
   
 
Figure 3 shows that the controls had a tendency to underestimate their performance on the BRBN 
and visuoperceptual tests, but to overestimate on the language tests 
Note. The comparisons were performed using the Related Samples Wilcoxon Signed Rank Test. 




Figure 4. Relationships between actual and perceived performance on the three groups of cognitive 
tests at phase II 
Tests Controls (n=23) Patients (n=63) 









r = 0.471, p = 0.023 r = 0.689, p < 0.001 
  








r = 0.282, p = 0.192 r = 0.404, p = 0.001 
  







r = 0.074, p = 0.736 r = - 0.063, p = 0.621 
  
 
Figure 4 shows that the performance scores were linked to self-evaluation scores only on the BRBN 
battery for both groups of participants, and only for patients on the visuoperceptual tests. 
Note. The relationships were examined using the Spearman correlation coefficient 





3.3.2. Perceived and actual performance in the patient sample 
As it can be seen from Figure 5, the patients had exhibited a non-different pattern from the controls, 
as they also had a tendency to evaluate their performance worse than it actually was. This difference 
was statistically significant on the BRBN and visuoperceptual tests.  
However, on the language tests the patients had underestimated and overestimate their performance 
an equal amount of times, and with a similar degree of inaccuracies.  
As it can be seen from Figure 4, the performance scores were linked to self-evaluation scores only 
on the BRBN and visuoperceptual tests. This was indicative that the estimations of performance on 
language tests were not related to the actual performance in the patient sample. It could be argued 








Patients (n=63) Difference 













Z = 273.00,  













Z = 9.50,  











Z = 875.00, 
p = 0.363 
   
 
Figure 5 shows that the patients had a tendency to underestimate their performance on the BRBN 
and visuoperceptual tests. 
Note. The comparisons were performed using the Related Samples Wilcoxon Signed Rank Test. 




3.4.     Predictors of perceived performance 
As it can be seen from previous analyses earlier in this appendix, the patient and control participants 
tend to think that they have performed worse than they actually have on the BRBN and 
visuoperceptual, but not the language tests. Moreover, the actual performance and perceived 
performance were only correlated on the BRBN and visuosperceptual tests for the patient participants; 
and the perceived performance could not be fully explained by the actual performance only.  
The next step was to investigate the factors considered to be related to self-perception of cognitive 
performance at phase II in the patient population. The following analyses were devised in order to 
explain what other factors beside the actual performance influence the patients’ decision about 
whether they have performed well or poorly. 
This was examined by running a multiple linear regression model for the patient participants with 
the perceived performance as the criterion variable and measurements of depressive symptomology, 
neurological disability and MS impact as predictor variables. 
3.4.1. Analysis of univariate normality of criterion variables 
The first step before running multiple linear regression analyses was to check for univariate normality 
of the criterion variables. As it can be seen in Figure 6, the Shapiro-Wilk statistics indicated that most 
of the criterion variables haven’t been normally distributed. However, upon visual inspection it was 
decided that the distributions were sufficiently normal, as all of them were unimodal with no extreme 




Figure 6. Distribution of criterion variables for linear regression models of perceived performance 
at phase II for patient participants 
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3.3.2. Analysis of univariate normality of predictor variables 
As it can be seen from the distributions of the predictor variables in Figure 7, the Shapiro-Wilk 
statistics indicated that the EDSS and BDI-II variables haven’t been normally distributed. It was 
evident that a large number of patients had the EDSS scores of 6 and 6.5. However, upon visual 
inspection it was decided that the distributions were sufficiently normal, as all of them were unimodal 
with a sufficient range of scores. Therefore it was decided to proceed with including them into the 





Figure 7. Distribution of predictor variables for linear regression models of perceived performance 
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W = 0.950, 
 p = 0.012 
 
 
Abbreviations: EDSS – Expanded Disability Status Scale; MSIS-29 – 29-item Multiple Sclerosis Impact 




3.3.3. Predictors of perceived performance 
Prior to running the linear regression models it was necessary to identify the predictor variables 
worthy of inclusion, as due to small sample size (63 patients) and insufficient power it was not 
recommended to include more than two predictor variables for patient models.  
This was done by examining relationships between the criterion and predictor variables, and only 
those predictor variables that were shown to be related to the criterion variables were included in the 
multiple regression models. 
As it can be seen from Table 2, in our patient sample the perceived performance was mainly linked 
to MS impact. Neurological disability was only linked to perceived performance on the 
visuoperceptual and language tests, and levels of depression was not likely to have influence on the 
self-evaluations of perceived performance. 
 
Table 2. Correlations between predictor and criterion variables in models of perceived 
performance for patient participants at phase II 
Predictor variables BRBN battery Visuoperceptual Language 
    
EDSS r = -0.193, p = 0.130 r = - 0.300, p = 0.017 r = - 0.298, p = 0.018 
MSIS-29 r = - 0.280, p = 0.026 r = - 0.283, p = 0.025 r = - 0.270, p = 0.033 
BDI-II r = 0.008, p = 0.953 r = - 0.026, p = 0.841 r = 0.173, p = 0.176 
    
Table 2 shows that perceived performance was mainly linked to MS impact. Neurological disability 
was only linked to perceived performance on the visuoperceptual and language tests, and 
depressive symptomology was not linked to self-evaluations of performance on any domain. 
Note. The relationships were examined employing the Spearman correlation 
Abbreviations: EDSS – Expanded Disability Status Scale; MSIS-29 – 29-item Multiple Sclerosis Impact 





Based on the findings presented in Table 2 and Figures 6 and 7, it was decided to proceed with 
running multiple linear regression models with neurological disability and MS impact for perceived 
performance scores on visuoperceptual and language tests, and a simple linear regression model with 
MS impact as a sole predictor of perceived performance on the BRBN battery. 
I. Predictors of perceived performance on the BRBN battery tests 
When perceived performance on BRBN tests was predicted it was found that MS impact (Beta = - 
0.320, p = 0.011) was a significant predictor. The overall model fit was R2 = 0.102 (Figure 8). This 
indicated that patients with higher MSIS-29 scores thought that they had performed worse on the 
BRBN tests at phase II. 
 
Figure 8. The effect of MS impact on the perceived performance on the BRBN tests at phase II for 
patient participants 
 
Figure 8 shows that MS impact was predictive of perceived performance on BRBN tests at phase 
II. 






II. Predictors of perceived performance on the visuoperceptual tests 
Based on the presented associations (Table 2) it was decided to run a linear regression model with 
perceived performance on visuoperceptual tests as the criterion variable and neurological disability 
(EDSS score) and MS impact (MSIS-29 score) as predictor variables.  
Figure 9. The effects of neurological disability and MS impact on the perceived performance on the 
visuoperceptual tests at phase II for patient participants  
 
 
Figure 9 shows that MS impact had more impact on perceived performance than neurological 
disability on the visuoperceptual tests at phase II  
Abbreviations: EDSS – Expanded Disability Status Scale 
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When perceived performance on visuoperceptual tests was predicted it was found that neither 
neurological disability (Beta = -0.039, p = 0.815) nor MS impact (Beta = -0.214, p = 0.076) were 
significant predictors (Figure 9), even though the model itself had significant predictive power (R2 
adj = 0.102, p = 0.033).  
Since MS impact was the stronger predictor in this model, the model was rerun after excluding 
neurological disability, with MS impact as a sole predictor variable. In this model when perceived 
performance on visuoperceptual tests was predicted, it was found that the predictive value of the sole 
MS impact variable had slightly increased (Beta = -0.233, p = 0.009), and the model fit slightly 
improved (R2 = 0.106). 
This implied that patients with higher MS impact thought that they had poorer performance on 
visuoperceptual tests at phase II. Neurological disability had questionable predictive value. 
III. Predictors of perceived performance on the language tests 
When perceived performance on the language tests at phase II was predicted for patient participants, 
neither neurological disability (Beta = -0.205, p = 0.221) nor MS impact (Beta = -0.151, p = 0.0367) 
were significant predictors (Figure 10), even though the model itself had significant predictive power 
(R2adj = 0.107, p = 0.034). As both predictor variables had similar coefficients, it was decided not to 
further investigate their predictive power individually. This implied that patients with higher 
neurological disability and MS impact were only slightly more likely to give poorer estimates of their 




Figure 10. The effects of neurological disability and MS impact on the perceived performance on 
the language tests at phase II for patient participants  
 
 
Figure 10 shows that both higher neurological disability and MS impact were to some extent linked 
to lower perceived performance on the language tests 





4. Section summary  
In this section the awareness analyses of Chapter Seven had been rerun on the phase II data 
investigating the relationships between self-estimations and the actual cognitive performance, as well 
as the factors that influence self-estimations of performance on different groups of cognitive tests. It 
was found that overall the patients were able to report their level of cognitive difficulties with the 
same accuracy as the controls, which allows us to conclude, that the self-estimations of longitudinal 
change analysed in Chapter Seven had been reliable measures of perceived changes in performance.  
The results presented in this insert have shown that overall there had been a tendency to 
underestimate the cognitive performance for both groups of participants on the BRBN and 
visuoperceptual tests. On the language tests, however, the controls had slightly more often 
overestimated their performance, and the patients had both underestimated and overestimated their 
performance an equal amount of times, and with a similar degree of inaccuracies. On average, the 
patients and the controls had performed similarly on the language tests, but there has been a wider 
range of scores in the patient group, indicative of presence of both the patients who performed very 
well and those who performed poorly, while the performance of the controls was more uniform. This 
difference in performance could explain different profiles of self-estimations of performance on the 
language tests between the patient and control participants. 
In the subsequent analysis it was found that the performance scores were linked to self-evaluation 
scores only on the BRBN battery tests for the controls; and on the BRBN battery and visuoperceptual 
tests for the patients. This was indicative that the estimations of performance on language tests were 
not related to the actual performance neither in the patient nor in the control sample. It could be 
argued that the self-evaluations on those tests could be explained better by other variables, rather 
than the actual performance. 
 Upon further investigation of the variables linked to self-estimations of cognitive performance at 
phase II it was found that higher MS impact was linked to poorer perceived performance on all groups 
of cognitive tests. Besides MS impact, higher neurological disability was associated with poorer 
perceived performance on the visuoperceptual and language tests, but only in correlational but not 
regression analyses. These results could be used to conclude that cognitive impairments tend to affect 
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pwMS and be associated with higher MS impact, while the perception of visuoperceptual and 
language impairments could be in part linked to neurological disability, such as damage to the optic 
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